



Supporting Information

for

α,γ -Dioxygenated amides via tandem Brook rearrangement/ radical oxygenation reactions and their application to syntheses of γ -lactams

Mikhail K. Klychnikov, Radek Pohl, Ivana Císařová and Ullrich Jahn

Beilstein J. Org. Chem. **2021**, *17*, 688–704. doi:10.3762/bjoc.17.58

Experimental details and spectral data

Table of contents


1. Experimental procedures and analytical data	S2
2. X-Ray crystallography	S108
3. References	S110
4. ^1H and ^{13}C NMR spectra	S111

1. Experimental procedures and analytical data

General experimental conditions

Reactions not involving aqueous conditions were performed in flame-dried glassware under an argon atmosphere. Solvents and additives were dried prior to use according to standard procedures. TLC analyses were performed on POLYGRAM SIL G/UV254 plates. Chromatographic separations were carried out on silica gel 60 (Fluka, 230–400 mesh). IR spectra were measured on a Bruker ALPHA-FT-IR spectrometer as neat samples using an ATR device. The optical rotation was measured on an automatic polarimeter Autopol IV, Rudolph Research Analytical. ^1H and ^{13}C NMR spectra were recorded on Bruker Avance 400, 500, or 600 spectrometers at working frequencies of 400, 500, or 600 MHz for ^1H NMR spectra and 100.1, 125.7 or 150.9 MHz for ^{13}C NMR spectra. Connectivities were determined by ^1H - ^1H COSY and ^1H - ^{13}C HMBC experiments, ^1H - ^{13}C assignments were obtained from ^1H - ^{13}C HSQC measurements. The relative configurations were determined by H,H-ROESY experiments. *N,N*-Diallylamine (**S1**) and the epoxides **7a–f** are commercially available. Compounds benzyl-2-methylprop-2-en-1-amine (**S2**),¹ *N*-benzyl-3-methylbut-2-en-1-amine (**S3**),² (*S*)-*N*-(1-phenylethyl)prop-2-en-1-amine (**S4**),³ (*S*)-2-methyl-*N*-(1-phenylethyl)prop-2-en-1-amine (**S5**),⁴ (*S*)-*N*-(cyclopent-1-en-1-ylmethyl)-1-phenylethan-1-amine (**S6**),⁵ *N*-benzyl-1-(cyclohex-1-en-1-yl)methanamine (**S7**),² *N*-benzylcyclopent-2-en-1-amine (**S8**),⁶ (*R*)-*N*-benzylcyclohex-2-en-1-amine (**S9**),⁶ *N,N*-diallylacetamide (**11a**),⁷ *N*-allyl-*N*-methylacetamide (**11b**)⁸ were prepared according to the literature. Their spectral and physical data matched those reported.

(*S*)-*N*-Allyl-*N*-(1-(naphthalen-2-yl)ethyl)amine (**S10**):




n-Butyllithium (1.6 M in hexane, 11.0 mL, 17.5 mmol) was added to a stirred solution of (*S*)-1-(naphth-2-yl)ethyl-1-amine (3.0 g, 7.5 mmol) in THF (56 mL) at $-78\text{ }^{\circ}\text{C}$. After 40 min, a solution of allyl bromide (1.4 mL, 16.6 mmol) in dry THF (5 mL) was added dropwise and stirring was continued for 3 h. The reaction was quenched by saturated NH_4Cl solution and diluted with water (30 mL) and diethyl ether (50 mL). The organic layer was separated and the

aqueous phase was extracted with diethyl ether (3×20 mL). The combined organic layers were dried over MgSO_4 and filtered. The filtrate was evaporated and the crude product was purified by flash chromatography (gradient, hexanes/EtOAc + 1% Et_3N 20:1 to 4:1) to give 2.9 g (78%) **S10**.

[R_f (hexanes/EtOAc 1:1) = 0.44]; IR (film); ν [cm^{-1}]: 3336 (w), 3054 (w), 3010 (w), 2972 (m), 2924 (w), 2866 (w), 2816 (w), 1624 (w), 1601 (w), 1507 (w), 1452 (w), 1416 (m), 1370 (w), 1270 (w), 1177 (m), 1130 (w), 1062 (w), 1018 (w), 994 (m), 917 (w), 856 (m), 819 (s), 747 (s), 689 (w), 618 (w); MS (+ESI) m/z , (%): 212 (10, $[\text{M}+\text{H}^+]$), 155 (100, $[\text{M}-\text{CH}_2=\text{CHCH}_2\text{NH}]^+$); HRMS (+ESI) m/z [$\text{C}_{15}\text{H}_{18}\text{N}^+$]: calcd. 212.1434; found 212.1435; $[\alpha]_{\text{D}}^{20}$: -54.5 (c 1.016, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 1.45 (d, $J = 6.7$ Hz, 3H, CH_3), 1.52 (br. s, 1H, NH), 3.14 (dt, $J = 6.0, 1.5$ Hz, 2H, $\text{CH}_2\text{CH}=\text{}$), 3.99 (q, $J = 6.6$ Hz, 1H, CHCH_3), 5.06-5.18 (m, 2H, $\text{CH}=\text{CH}_2$), 5.92 (ddt, $J = 17.2, 10.1, 5.9$ Hz, 1H, $\text{CH}=\text{CH}_2$), 7.41-7.55 (m, 3H, ArH), 7.74 (s, 1H, ArH), 7.80-7.85 (m, 3H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 24.4 (q, CH_3), 50.4 (t, $\text{CH}_2\text{CH}=\text{}$), 57.8 (d, CHCH_3), 115.9 (t, $\text{CH}=\text{CH}_2$), 125.0 (d, CH_{Ar}), 125.4 (d, CH_{Ar}), 125.6 (d, CH_{Ar}), 126.1 (d, CH_{Ar}), 127.8 (d, CH_{Ar}), 127.9 (d, CH_{Ar}), 128.4 (d, CH_{Ar}), 133.0 (s, C_{Ar}), 133.6 (s, C_{Ar}), 137.1 (d, $\text{CH}=\text{CH}_2$), 143.0 (s, C_{Ar}).

***N*-Benzyl-*N*-(cyclopent-1-en-1-ylmethyl)amine (S11):**




A solution of 1-(bromomethyl)cyclopent-1-ene (4.1 g, 25.5 mmol) in MeCN (5 mL) was added to a solution of benzylamine (8.2 g, 76.6 mmol) and K_2CO_3 (4.2 g, 30.6 mmol) in MeCN (40 mL) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were dried over MgSO_4 and filtered. The filtrate was evaporated and the crude product was purified by flash column chromatography (hexane/EtOAc + 1% Et_3N 5:1 to 2:1) to give 3.6 g (75%) **S11**.

HRMS (+ESI) m/z [$\text{C}_{13}\text{H}_{18}\text{N}^+$]: calcd. 188.1434; found 188.1434.

The analytical data are in agreement with those in the literature.⁹

(S)-3-Methyl-N-(1-phenylethyl)but-2-en-1-amine (S12):




Prepared according to the procedure for **S11**, yield 2.3 g (73%).

[R_f (hexanes/EtOAc 2:1) = 0.26]; IR (film); ν [cm^{-1}]: 3334 (br), 3062 (w), 3025 (w), 2967 (m), 2926 (m), 2857 (w), 1492 (w), 1450 (m), 1375 (w), 1351 (w), 1302 (w), 1187 (w), 1116 (w), 1074 (w), 1055 (w), 1027 (w), 986 (w), 835 (w), 760 (m), 700 (s); MS (+ESI) m/z , (%): 212 (65, $[\text{M}+\text{Na}^+]$), 190 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{13}\text{H}_{20}\text{N}^+$]: calcd. 190.1596; found 190.1594; $[\alpha]_D^{20}$: -69.9 (c 1.000, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 1.22 (br. s, 1H, NH), 1.30 (d, J = 6.6 Hz, 3H, CHCH_3), 1.48 (s, 3H, $\text{CH}=\text{C}(\text{CH}_3)_2$), 1.65 (s, 3H, $\text{CH}=\text{C}(\text{CH}_3)_2$), 2.99 (d, J = 7.0 Hz, 2H, $\text{CH}_2\text{CH}=\text{}$), 3.73 (q, J = 6.6 Hz, 1H, CHCH_3), 5.20 (tquint, J = 7.0, 1.4 Hz, 1H, $\text{CH}=\text{C}(\text{CH}_3)_2$), 7.15-7.22 (m, 1H, ArH), 7.24-7.31 (m, 4H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 18.0 (q, $\text{CH}=\text{C}(\text{CH}_3)_2$), 24.5 (q, CHCH_3), 25.9 (q, $\text{CH}=\text{C}(\text{CH}_3)_2$), 45.4 (t, $\text{CH}_2\text{CH}=\text{}$), 123.3 (d, $\text{CH}=\text{C}(\text{CH}_3)_2$), 126.7 (d, CH_{Ar}), 127.0 (d, CH_{Ar}), 128.5 (d, CH_{Ar}), 134.4 (s, $\text{CH}=\text{C}(\text{CH}_3)_2$), 145.9 (s, C_{Ar}).

General procedure for preparation of amides 11:

Acetyl chloride (1.6 g, 20.5 mmol) was added to a stirred solution of amines **S1–S12** (17 mmol) and triethylamine (2.4 mL, 17 mmol) in dry dichloromethane (15 mL) at 0 °C. After 30 min, the reaction was quenched by saturated NH_4Cl solution. After diluting with water (20 mL) and dichloromethane (30 mL), the organic layer was separated and the aqueous was extracted with dichloromethane (3×10 mL). The combined organic layers were dried over MgSO_4 and filtered. The filtrate was evaporated and the crude product was purified by flash chromatography (gradient, hexanes/EtOAc 20:1 to 2:1) to give pure amides **11**.


***N*-Benzyl-*N*-(2-methylallyl)acetamide (11c):**



Prepared according to the general procedure, yield 3.4 g (98%) as a 1.7:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.46]; IR (film); ν [cm^{-1}]: 3032 (w), 2974 (w), 2939 (w), 1636 (s), 1497 (m), 1448 (s), 1404 (w), 1376 (w), 1322 (w), 1299 (w), 1267 (w), 1237 (w), 1208 (m), 1183 (m), 1049 (w), 1012 (w), 905 (m), 782 (m), 747 (m), 698 (s); MS (+ESI) m/z , (%): 226 (60, $[\text{M}+\text{Na}^+]$), 204 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{13}\text{H}_{18}\text{NO}^+$]: calcd. 204.1388; found 204.1390; ^1H NMR (400 MHz, CDCl_3): δ 1.69/1.70 (s, 3H, $\text{CH}_3\text{C}=\text{}$), 2.14/2.17 (s, 3H, CH_3CO), 3.70/3.98 (s, 2H, $\text{NCH}_2\text{C}=\text{}$), 4.48/4.58 (s, 2H, CH_2Ph), 4.73/4.83 (dsext, $J = 1.6, 0.8$ Hz/dquint, $J = 1.7, 0.9$ Hz, 1H, $\text{C}=\text{CH}_2$), 4.90/4.96 (sept, $J = 1.4$ Hz/quint, $J = 1.5$ Hz, 1H, $\text{C}=\text{CH}_2$), 7.14-7.42 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 20.2 (q, $\text{CH}_3\text{C}=\text{}$), 21.5/21.8 (q, CH_3CO), 48.2/50.7 (t, CH_2Ph), 50.4/53.1 (t, $\text{NCH}_2\text{C}=\text{}$), 111.6/112.5 (t, $\text{C}=\text{CH}_2$), 126.4/127.7 (d, CH_{Ar}), 127.5/128.4 (d, CH_{Ar}), 128.7/129.1 (d, CH_{Ar}), 137.7 (s, C_{Ar}), 139.8 (s, $\text{C}=\text{CH}_2$), 171.4/177.4 (s, $\text{C}=\text{O}$).

***N*-Benzyl-*N*-(3-methylbut-2-en-1-yl)acetamide (11d):**




Prepared according to the general procedure, yield 3.6 g (97%) as a 1.3:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.44]; IR (film); ν [cm^{-1}]: 2977 (w), 2929 (w), 1636 (s), 1492 (w), 1449 (m), 1415 (m), 1372 (w), 1354 (w), 1339 (w), 1301 (w), 1263 (w), 1204 (w), 1173 (w), 1055 (w), 1030 (w), 989 (w), 964 (w), 842 (w), 788 (w), 771 (w), 761 (m), 736 (w), 699 (m); MS (+ESI) m/z , (%): 240 (55, $[\text{M}+\text{Na}^+]$), 218 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{14}\text{H}_{20}\text{NO}^+$]: calcd. 218.1545; found 218.1548; ^1H NMR (400 MHz, CDCl_3): δ 1.54/1.70 (s, 3H, $\text{CH}=\text{C}(\text{CH}_3)_2$), 1.58/1.72 (s, 3H, $\text{CH}=\text{C}(\text{CH}_3)_2$), 2.13/2.17 (s, 3H, CH_3CO), 3.77/3.99 (d, $J = 6.8$ Hz/ $J = 6.6$ Hz, 2H, $\text{CH}_2\text{CH}=\text{}$), 4.47/4.56 (s, 2H, CH_2Ph), 5.06-5.11/5.14-5.19 (m, 1H, $\text{CH}=\text{C}(\text{CH}_3)_2$), 7.14-7.41 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.9/18.0 (q,

CH=C(CH₃)₂), 21.8/21.9 (q, CH₃CO), 25.8/25.9 (q, CH=C(CH₃)₂), 42.9/45.8 (t, CH₂CH=), 48.0/51.0 (t, CH₂Ph), 119.79/119.82 (d, CH₂CH=), 126.5/127.6 (d, CH_{Ar}), 127.4/128.3 (d, CH_{Ar}), 128.6/129.0 (d, CH_{Ar}), 136.1/136.6 (s, CH=C(CH₃)₂), 137.1/137.9 (s, C_{Ar}), 170.7/170.9 (s, C=O).


(S)-N-Allyl-N-(1-phenylethyl)acetamide (11e):



Prepared according to the general procedure, yield 3.4 g (98%) as a 2.7:1 mixture of rotamers.

HRMS (+CI) m/z [C₁₃H₁₈NO⁺]: calcd. 204.1388; found 204.1389; [α]_D²⁰: −162.7 (c 1.000, CHCl₃). The analytical data are in agreement with those in the literature.¹⁰


(S)-N-Allyl-N-(1-(naphthalen-2-yl)ethyl)acetamide (11f):



Prepared according to the general procedure, yield 4.3 g (99%) as a 3.1:1 mixture of rotamers.

[R_f (hexanes/EtOAc 2:1) = 0.44]; IR (film); ν [cm^{−1}]: 3055 (w), 2977 (w), 2936 (w), 1631 (s), 1406 (s), 1318 (w), 1259 (w), 1189 (m), 1032 (w), 963 (w), 920 (w), 821 (m), 749 (m), 630 (w), 602 (w); MS (+ESI) m/z, (%): 529 (20, [2M+Na⁺]), 276 (100, [M+Na⁺]); HRMS (+ESI) m/z [C₁₇H₁₉NONa⁺]: calcd. 276.1359; found 276.1362; [α]_D²⁰: −222.0 (c 1.009, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 1.61/1.73 (d, J = 7.1 Hz/J = 7.0 Hz, 3H, CHCH₃), 2.15/2.28 (s, 3H, CH₃CO), 3.47/3.59 (dd, J = 15.4, 6.4 Hz/J = 17.9, 5.2 Hz, 1H, CH₂CH=), 3.71/4.18 (dd, J = 17.9, 5.1 Hz/J = 15.4, 4.8 Hz, 1H, CH₂CH=), 4.95-5.10 (m, 2H, CH=CH₂), 5.25/6.28 (q, J = 6.9 Hz/J = 7.2 Hz, 1H, CHCH₃), 5.51-5.63/5.73-5.85 (m, 1H, CH=CH₂), 7.32-7.53 (m, 3H, ArH), 7.68/7.74 (s, 1H, ArH), 7.76-7.87 (m, 3H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 16.8/19.0 (q, CHCH₃), 22.4 (q, CH₃CO), 45.5/46.8 (t, CH₂CH=), 51.0/56.8 (d, CHCH₃), 116.2/116.6 (t, CH=CH₂), 125.1/125.8 (d, CH_{Ar}), 125.2/126.1 (d, CH_{Ar}), 126.3/126.4 (d, CH_{Ar}), 126.5/126.6 (d, CH_{Ar}), 127.69/127.73 (d, CH_{Ar}), 128.05/128.09 (d, CH_{Ar}), 128.3/128.7 (d, CH_{Ar}), 132.78/132.82 (s, C_{Ar}), 133.27/133.33 (s, C_{Ar}), 135.2 (d, CH=CH₂), 138.2/138.6 (s, C_{Ar}), 170.7/171.6 (s, C=O).


(S)-N-(3-Methylbut-2-en-1-yl)-N-(1-phenylethyl)acetamide (11g):



Prepared according to the general procedure, yield 3.9 g (99%) as a 2.9:1 mixture of rotamers.

[R_f (hexanes/EtOAc 2:1) = 0.23]; IR (film); ν [cm^{-1}]: 2974 (w), 2932 (w), 1637 (s), 1495 (w), 1447 (m), 1412 (m), 1377 (w), 1363 (w), 1333 (w), 1306 (w), 1259 (w), 1210 (w), 1170 (w), 1056 (w), 1029 (w), 988 (w), 965 (w), 843 (w), 786 (w), 770 (w), 760 (m), 732 (w), 700 (m), 595 (w); MS (+ESI) m/z , (%): 254 (40, $[\text{M}+\text{Na}^+]$), 232 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{15}\text{H}_{22}\text{NO}^+$]: calcd. 232.1701; found 232.1699; $[\alpha]_{\text{D}}^{20}$: -115.9 (c 1.000, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 1.51/1.52 (d, $J = 7.0$ Hz, 3H, CHCH_3), 1.53/1.64 (s, 3H, $\text{CH}=\text{C}(\text{CH}_3)_2$), 1.63/1.66 (s, 3H, $\text{CH}=\text{C}(\text{CH}_3)_2$), 2.12/2.23 (s, 3H, CH_3CO), 3.46/3.53 (dd, $J = 15.5, 6.0$ Hz/ $J = 17.3, 5.8$ Hz, 1H, $\text{CH}_2\text{CH}=\text{}$), 3.69/4.07 (dd, $J = 17.2, 6.2$ Hz/ $J = 15.4, 6.0$ Hz, 1H, $\text{CH}_2\text{CH}=\text{}$), 4.85-4.97/5.05-5.15 (m, 1H, $\text{CH}=\text{C}(\text{CH}_3)_2$), 5.10/6.09 (q, $J = 7.0$ Hz, 1H, CHCH_3), 7.25-7.41 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.7/17.9 (q, CHCH_3), 18.7 (q, $\text{CH}=\text{C}(\text{CH}_3)_2$), 22.2 (q, CH_3CO), 25.7 (q, $\text{CH}=\text{C}(\text{CH}_3)_2$), 41.1/42.7 (t, $\text{CH}_2\text{CH}=\text{}$), 50.9/56.4 (d, CHCH_3), 122.6/122.8 (d, $\text{CH}_2\text{CH}=\text{}$), 126.8/127.4 (d, CH_{Ar}), 127.6/127.7 (d, CH_{Ar}), 128.5/128.8 (d, CH_{Ar}), 133.7 (s, $\text{CH}=\text{C}(\text{CH}_3)_2$), 141.3 (s, C_{Ar}), 167.8 (s, $\text{C}=\text{O}$).

(S)-N-(2-Methylallyl)-N-(1-phenylethyl)acetamide (11h):




Prepared according to the general procedure, yield 3.6 g (97%) as a 3.8:1 mixture of rotamers.

[R_f (hexanes/EtOAc 2:1) = 0.38]; IR (film); ν [cm^{-1}]: 3030 (w), 2976 (w), 2936 (w), 1637 (s), 1495 (m), 1448 (s), 1404 (w), 1376 (w), 1322 (w), 1299 (w), 1267 (w), 1237 (w), 1208 (m), 1183 (m), 1049 (w), 1030 (w), 1009 (w), 965 (w), 902 (m), 787 (m), 742 (m), 699 (s); MS (+ESI) m/z , (%): 240 (45, $[\text{M}+\text{Na}^+]$), 218 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{14}\text{H}_{20}\text{NO}^+$]: calcd. 218.1467; found 218.1472; $[\alpha]_{\text{D}}^{20}$: -157.1 (c 1.000, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 1.49 (d, $J = 7.2$ Hz, 3H, CHCH_3), 1.63/1.69 (s, 3H, $\text{CH}_3\text{C}=\text{}$), 2.11/2.24 (s, 3H, CH_3CO),

3.33/3.43 (d, $J = 17.0$ Hz/ $J = 18.6$ Hz, 1H, $\text{CH}_2\text{C}=\text{}$), 3.61/4.26 (d, $J = 18.7$ Hz/ $J = 17.0$ Hz, 1H, $\text{CH}_2\text{C}=\text{}$), 4.67/4.81 (d, $J = 2.9$ Hz, 1H, $\text{C}=\text{CH}_2$), 4.79/4.90 (d, $J = 2.9$ Hz, 1H, $\text{C}=\text{CH}_2$), 5.14/6.11 (q, $J = 7.1$ Hz/ $J = 7.2$ Hz, 1H, CHCH_3), 7.23-7.41 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.7/18.7 (q, CHCH_3), 20.3/20.5 (q, $\text{CH}_3\text{C}=\text{}$), 22.0/22.3 (q, CH_3CO), 48.0/49.7 (t, $\text{CH}_2\text{C}=\text{}$), 51.2/56.7 (d, CHCH_3), 110.2/110.9 (t, $\text{C}=\text{CH}_2$), 126.4/127.3 (d, CH_{Ar}), 127.5 (d, CH_{Ar}), 128.4/128.7 (d, CH_{Ar}), 133.1/133.2 (s, C_{Ar}), 141.2/141.3 (s, $\text{C}=\text{CH}_2$), 171.9 (s, $\text{C}=\text{O}$).


(S)-N-(Cyclopent-1-en-1-ylmethyl)-N-(1-phenylethyl)acetamide (11i):



Prepared according to the general procedure, yield 3.4 g (83%) as a 3.2:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.34]; IR (film); ν [cm^{-1}]: 3030 (w), 2936 (w), 2846 (w), 1642 (s), 1495 (w), 1451 (m), 1411 (w), 1377 (w), 1362 (w), 1327 (w), 1311 (w), 1265 (w), 1210 (w), 1182 (w), 1057 (w), 1029 (w), 995 (w), 786 (w), 737 (w), 700 (m), 642 (w); MS (+ESI) m/z , (%): 266 (50, $[\text{M}+\text{Na}^+]$), 244 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{16}\text{H}_{22}\text{NO}^+$]: calcd. 244.1623; found 244.1622; $[\alpha]_{\text{D}}^{20}$: -132.5 (c 0.200, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 1.48/1.60 (d, $J = 7.1$ Hz, 3H, CHCH_3), 1.83 (quint, $J = 7.8$ Hz, 2H, H4), 2.05-2.09/2.15-2.20 (m, 2H, H5), 2.10/2.22 (s, 3H, CH_3CO), 2.23-2.30 (m, 2H, H3), 3.49/3.53 (d, $J = 18.0$ Hz/ $J = 16.6$ Hz, 1H, $\text{CH}_2\text{C}=\text{}$), 3.69/4.22 (d, $J = 18.0$ Hz/ $J = 16.6$ Hz, 1H, $\text{CH}_2\text{C}=\text{}$), 5.10/6.07 (q, $J = 7.2$ Hz, 1H, CHCH_3), 5.27-5.30/5.40 (m/quint, $J = 2.1$ Hz, 1H, H2), 7.20-7.39 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.9/18.8 (q, CHCH_3), 22.3/22.4 (q, CH_3CO), 23.5 (t, C4), 32.4 (t, C3), 33.6/33.8 (t, C5), 43.2/45.4 (t, $\text{CH}_2\text{C}=\text{}$), 51.2/56.6 (d, CHCH_3), 125.5/126.4 (d, C2), 126.7/127.4 (d, CH_{Ar}), 127.6/127.7 (d, CH_{Ar}), 128.4/128.8 (d, CH_{Ar}), 137.5/137.6 (s, C_{Ar}), 141.25/141.30 (s, C1), 171.60/171.63 (s, $\text{C}=\text{O}$).


***N*-Benzyl-*N*-(cyclopent-1-en-1-ylmethyl)acetamide (11j):**



Prepared according to the general procedure, yield 3.9 g (99%) as a 1.8:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.44]; IR (film); ν [cm^{-1}]: 3031 (w), 2928 (w), 2847 (w), 1645 (s), 1495 (w), 1469 (w), 1420 (m), 1359 (w), 1241 (m), 1170 (w), 1066 (w), 1029 (w), 986 (m), 944 (w), 821 (w), 774 (w), 733 (m), 700 (m), 600 (w); MS (+ESI) m/z , (%): 481 (15, $[2M+Na^+]$), 459 (15, $[2M+H^+]$), 252 (30, $[M+Na^+]$), 230 (100, $[M+H^+]$); HRMS (+ESI) m/z [$C_{15}H_{20}NO^+$]: calcd. 230.1539; found 230.1539; 1H NMR (400 MHz, $CDCl_3$): δ 1.86-1.98 (m, 2H, H4), 2.16/2.17 (s, 3H, CH_3CO), 2.19-2.27 (m, 2H, H3), 2.30-2.40 (m, 2H, H5), 3.82/4.09 (s, 2H, $NCH_2C=$), 4.49/4.59 (s, 2H, $\underline{CH}_2Ph$), 5.46/5.53 (quint, $J = 1.8 \text{ Hz}/J = 2.1 \text{ Hz}$, 1H, H2), 7.16-7.39 (m, 5H, ArH); ^{13}C NMR (101 MHz, $CDCl_3$): δ 21.6/21.7 (q, $\underline{CH}_3CO$), 23.5 (t, C4), 32.3/32.4 (t, C5), 33.3/33.5 (t, C3), 45.2/48.4 (t, $N\underline{CH}_2C=$), 48.2/50.9 (t, $\underline{CH}_2Ph$), 126.4/127.4 (d, CH_{Ar}), 127.5/127.6 (d, C2), 128.3 (d, CH_{Ar}), 128.6/129.0 (d, CH_{Ar}), 136.9/137.8 (s, C_{Ar}), 139.5/140.0 (s, C1), 171.0/171.1 (s, $C=O$).

***N*-Benzyl-*N*-(cyclohex-1-en-1-ylmethyl)acetamide (11k):**




Prepared according to the general procedure, yield 4.3 g (99%) as a 1.7:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.32]; IR (film); ν [cm^{-1}]: 2925 (m), 2857 (w), 2836 (w), 1644 (s), 1495 (w), 1468 (w), 1421 (m), 1359 (w), 1237 (w), 1177 (m), 1067 (w), 1030 (w), 985 (m), 921 (w), 802 (w), 732 (m), 699 (m), 628 (w), 604 (w); MS (+ESI) m/z , (%): 509 (15, $[2M+Na^+]$), 266 (100, $[M+Na^+]$), 244 (25, $[M+H^+]$); HRMS (+ESI) m/z [$C_{16}H_{21}NONa^+$]: calcd. 266.1515; found 266.1511; 1H NMR (400 MHz, $CDCl_3$): δ 1.52-1.68 (m, 4H, H4, H5), 1.81-1.86/1.87-1.91 (m, 2H, H6), 1.97-2.06 (m, 2H, H3), 2.15 (s, 3H, CH_3CO), 3.66/3.93 (s, 2H, $NCH_2C=$), 4.45/4.55 (s, 2H, $\underline{CH}_2Ph$), 5.44/5.52 (sept, $J = 1.5 \text{ Hz}/J = 1.7 \text{ Hz}$, 1H, H2), 7.14-7.39 (m, 5H, ArH); ^{13}C NMR (101 MHz, $CDCl_3$): δ 21.7/21.9 (q, $\underline{CH}_3CO$), 22.5 (t, C4), 22.6/22.7 (t, C5),


25.1/25.2 (t, C3), 26.39/26.43 (t, C6), 48.0/50.5 (t, $\underline{\text{C}}\text{H}_2\text{Ph}$), 50.7/53.6 (t, $\text{N}\underline{\text{C}}\text{H}_2\text{C=}$), 123.8/124.6 (d, C2), 126.4/127.6 (d, CH_{Ar}), 127.3/128.4 (d, CH_{Ar}), 128.6/129.0 (d, CH_{Ar}), 132.3/133.2 (s, C1), 137.0/137.9 (s, C_{Ar}), 171.2/171.3 (s, C=O).

***N*-Benzyl-*N*-(cyclopent-2-en-1-yl)acetamide (11l):**



Prepared according to the general procedure, yield 3.6 g (98%) as a 1.3:1 mixture of rotamers. $[\text{R}_f(\text{hexanes/EtOAc } 2:1) = 0.39]$; IR (film); ν [cm^{-1}]: 3063 (w), 3031 (w), 2939 (w), 2850 (w), 1644 (s), 1495 (w), 1413 (m), 1363 (w), 1328 (w), 1297 (w), 1264 (w), 1206 (w), 1178 (w), 1028 (w), 997 (w), 976 (w), 729 (m), 700 (m); MS (+ESI) m/z , (%): 238 (100, $[\text{M}+\text{Na}^+]$), 216 (30, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{14}\text{H}_{17}\text{NONa}^+$]: calcd. 238.1202; found 238.1199; ^1H NMR (400 MHz, CDCl_3): δ 1.49-1.58/1.59-1.68 (m, 1H, H5), 2.00/2.27 (s, 3H, CH_3), 2.21-2.39 (m, 3H, H5, H4), 4.38 (d, $J = 15.5$ Hz, 1H, $\underline{\text{C}}\text{H}_2\text{Ph}$)/4.40 (s, 2H, $\underline{\text{C}}\text{H}_2\text{Ph}$)/4.52 (d, $J = 15.5$ Hz, 1H, $\underline{\text{C}}\text{H}_2\text{Ph}$), 5.01-5.07/5.79-5.85 (m, 1H, H1), 5.52 (dd, $J = 5.7, 2.2$ Hz, 1H, H2), 5.92 (ddd, $J = 5.6, 4.6, 2.3$ Hz, 1H, H3), 7.14-7.22 (m, 2H, ArH), 7.24-7.29 (m, 2H, ArH), 7.31-7.37 (m, 1H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 22.4/22.6 (q, CH_3), 28.6/29.1 (t, C5), 31.5 (t, C4), 45.4/47.7 (t, $\underline{\text{C}}\text{H}_2\text{Ph}$), 60.8/65.2 (d, C1), 125.8/126.7 (d, CH_{Ar}), 127.2/127.3 (d, CH_{Ar}), 128.4/128.9 (d, CH_{Ar}), 130.2/130.4 (d, C2), 135.2/135.6 (d, C3), 138.8/139.6 (s, C_{Ar}), 170.9/171.9 (s, C=O).

***(R)*-*N*-Benzyl-*N*-(cyclohex-2-en-1-yl)acetamide (11m):**




Prepared according to the general procedure from enantiomerically enriched amine **S9** (85% ee, see p. S2), yield 3.9 g (99%, 85% ee) as a 1.9:1 mixture of rotamers. HRMS (+CI) m/z [$\text{C}_{15}\text{H}_{20}\text{NO}^+$]: calcd. 230.1545; found 230.1543; $[\alpha]_{\text{D}}^{20}$: +49.6 (c 0.498, CHCl_3).

The analytical data are in agreement with those in the literature.⁸

General procedure for the α -silylation of amides 11:

n-Butyllithium (1.6 M in hexane, 14.9 mL, 23.8 mmol) was added dropwise by syringe to a stirred solution of dry diisopropylamine (3.6 mL, 23.8 mmol) in anhydrous THF (30 mL) at $-78\text{ }^{\circ}\text{C}$. After 30 min, a solution of the amide **11** (21.6 mmol) in anhydrous THF (5 mL) was added dropwise and the mixture was stirred for 30 min. Then, TMSCl (3.3 mL, 22.7 mmol) was rapidly added at $-78\text{ }^{\circ}\text{C}$ and the mixture was stirred at this temperature for 1 h. The reaction was quenched by saturated NH_4Cl solution after diluting with water (30 mL) and diethyl ether (50 mL), the organic layer was separated and the aqueous was extracted with diethyl ether ($3 \times 10\text{ mL}$). The combined organic layers were dried over MgSO_4 and filtered. The filtrate was evaporated and the crude product was purified by flash chromatography (gradient, hexanes/EtOAc 20:1 to 5:1) to give α -trimethylsilylamides **8**.


N,N-Diallyl-2-(trimethylsilyl)acetamide (**8a**):



Prepared according to the general procedure, yield 3.4 g (76%).

[R_f (hexanes/EtOAc 1:1) = 0.57]; IR (film); ν [cm^{-1}]: 3081 (w), 2955 (w), 1627 (s), 1443 (m), 1415 (m), 1395 (m), 1282 (w), 1247 (s), 1195 (w), 1134 (w), 1104 (w), 1025 (w), 993 (w), 920 (m), 851 (s), 700 (w), 611 (w); MS (+ESI) m/z , (%): 234 (60, $[\text{M}+\text{Na}^+]$), 212 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{11}\text{H}_{22}\text{NOSi}^+$]: calcd. 212.1392; found 212.1396; ^1H NMR (400 MHz, CDCl_3): δ 0.10 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.94 (s, 2H, CH_2CO), 3.80 (d, $J = 5.4\text{ Hz}$, 2H, $\text{CH}_2\text{CH=}$), 3.95 (d, $J = 6.0\text{ Hz}$, 2H, $\text{CH}_2\text{CH=}$), 5.03-5.22 (m, 4H, CH=CH_2), 5.67-5.80 (m, 2H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ -0.8 (q, $\text{Si}(\text{CH}_3)_3$), 25.4 (t, CH_2CO), 47.6 (t, $\text{CH}_2\text{CH=}$), 50.1 (t, $\text{CH}_2\text{CH=}$), 116.7 (t, CH=CH_2), 117.1 (t, CH=CH_2), 133.1 (d, CH=CH_2), 133.9 (d, CH=CH_2), 172.6 (s, C=O).


***N*-Allyl-*N*-methyl-2-(trimethylsilyl)acetamide (8b):**



Prepared according to the general procedure, yield 4.1 g (70%) as a 1.3:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.23]; IR (film); ν [cm^{-1}]: 2955 (w), 1624 (s), 1419 (w), 1383 (m), 1278 (w), 1247 (m), 1136 (w), 1072 (m), 991 (w), 920 (w), 848 (s), 722 (w), 700 (w), 609 (w); MS (+ESI) m/z , (%): 208 (55, $[\text{M}+\text{Na}^+]$), 186 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_9\text{H}_{20}\text{NOSi}^+$]: calcd. 186.1314; found 186.1316; ^1H NMR (400 MHz, CDCl_3): δ 0.11/0.12 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.93/1.99 (s, 2H, CH_2CO), 2.89/2.90 (s, 3H, CH_3), 3.84/3.98 (d, $J = 5.0 \text{ Hz}/J = 6.1 \text{ Hz}$, 2H, $\text{CH}_2\text{CH=}$), 5.07-5.23 (m, 2H, CH=CH_2), 5.65-5.83 (m, 1H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ -0.8 (q, $\text{Si}(\text{CH}_3)_3$), 25.2/25.7 (t, CH_2CO), 33.5/36.0 (q, CH_3), 50.0/53.4 (t, $\text{CH}_2\text{CH=}$), 116.8/117.1 (t, CH=CH_2), 132.9/133.8 (d, CH=CH_2), 172.4/172.9 (s, C=O).


***N*-Benzyl-*N*-(2-methylallyl)-2-(trimethylsilyl)acetamide (8c):**



Prepared according to the general procedure, yield 4.2 g (75%) as a 1.4:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.53]; IR (film); ν [cm^{-1}]: 3066 (w), 3030 (w), 2954 (w), 1628 (s), 1495 (w), 1440 (m), 1395 (m), 1248 (m), 1204 (w), 1139 (w), 1119 (w), 1077 (w), 1051 (w), 1030 (w), 942 (w), 897 (w), 852 (s), 722 (w), 701 (m), 604 (w); MS (+ESI) m/z , (%): 573 (50, $[\text{M}+\text{Na}^+]$), 298 (100, $[\text{M}+\text{Na}^+]$), 276 (30, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{16}\text{H}_{25}\text{NOSiNa}^+$]: calcd. 298.1598; found 298.1595; ^1H NMR (400 MHz, CDCl_3): δ 0.13/0.15 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.70 (s, 3H, CH_3), 2.00/2.06 (s, 2H, CH_2CO), 3.65/3.98 (s, 2H, $\text{NCH}_2\text{C=}$), 4.45/4.57 (s, 2H, CH_2Ph), 4.74/4.83 (d, $J = 2.9 \text{ Hz}$, 1H, C=CH_2), 4.89/4.96 (d, $J = 2.9 \text{ Hz}$, 1H, C=CH_2), 7.16-7.39 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ -0.62/-0.59 (q, $\text{Si}(\text{CH}_3)_3$), 20.28/20.34 (q, CH_3), 25.4/25.8 (t, CH_2CO), 48.0/50.6 (t, CH_2Ph), 50.2/53.1 (t, $\text{NCH}_2\text{C=}$), 111.8/112.4 (t, C=CH_2), 126.5/127.6 (d, CH_{Ar}), 127.3/128.5 (d, CH_{Ar}), 128.6/129.0 (d, CH_{Ar}), 137.1/138.3 (s, C_{Ar}), 140.0/141.2 (s, C=CH_2), 173.1/173.3 (s, C=O).


***N*-Benzyl-*N*-(3-methylbut-2-en-1-yl)-2-(trimethylsilyl)acetamide (8d):**



Prepared according to the general procedure, yield 4.5 g (72%) as a 1.4:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.58]; IR (film); ν [cm^{-1}]: 2955 (w), 2867 (w), 1623 (s), 1495 (w), 1440 (m), 1397 (m), 1361 (w), 1245 (m), 1138 (w), 1112 (w), 1076 (w), 1033 (w), 943 (w), 846 (s), 772 (w), 733 (w), 699 (m), 625 (w), 603 (w); MS (+ESI) m/z , (%): 601 (20, $[2M+Na^+]$), 312 (100, $[M+Na^+]$), 290 (80, $[M+H^+]$); HRMS (+ESI) m/z [$C_{17}H_{27}NOSiNa^+$]: calcd. 312.1754; found 312.1752; 1H NMR (400 MHz, $CDCl_3$): δ 0.15/0.16 (s, 9H, $Si(CH_3)_3$), 1.55/1.59 (s, 3H, CH_3), 1.72/1.74 (s, 3H, CH_3), 2.03/2.06 (s, 2H, CH_2CO), 3.75/4.00 (d, $J = 6.8$ Hz/ $J = 7.0$ Hz, 2H, $CH_2CH=$), 4.44/4.58 (s, 2H, CH_2Ph), 5.09-5.13/5.14-5.18 (m, 1H, $CH=C(CH_3)_2$), 7.18-7.22 (m, 2H, ArH), 7.23-7.39 (m, 3H, ArH); ^{13}C NMR (101 MHz, $CDCl_3$): δ -0.73/-0.65 (q, $Si(CH_3)_3$), 17.9/18.0 (q, CH_3), 25.5/25.7 (t, CH_2CO), 25.81/25.83 (q, CH_3), 42.6/45.9 (t, $CH_2CH=$), 47.9/51.1 (t, CH_2Ph), 120.36/120.40 (d, $CH=C(CH_3)_2$), 126.6/127.5 (d, CH_{Ar}), 127.2/128.4 (d, CH_{Ar}), 128.5/128.9 (d, CH_{Ar}), 135.6/136.1 (s, $CH=C(CH_3)_2$), 137.5/138.5 (s, C_{Ar}), 172.7/172.8 (s, $C=O$).

***(S)*-*N*-Allyl-*N*-(1-phenylethyl)-2-(trimethylsilyl)acetamide (8e):**




Prepared according to the general procedure, yield 5.3 g (89%) as a 3.6:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.55]; IR (film); ν [cm^{-1}]: 3064 (w), 3030 (w), 2955 (w), 1623 (s), 1495 (w), 1431 (m), 1390 (m), 1315 (w), 1248 (m), 1209 (w), 1183 (w), 1096 (w), 985 (w), 918 (w), 854 (s), 787 (w), 744 (w), 700 (m), 622 (w); MS (+ESI) m/z , (%): 573 (10, $[2M+Na^+]$), 298 (100, $[M+Na^+]$); HRMS (+ESI) m/z [$C_{16}H_{25}NOSiNa^+$]: calcd. 298.1598; found 298.1593; $[\alpha]_D^{20}$: -124.1 (c 0.998, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$): δ 0.13/0.15 (s, 9H, $Si(CH_3)_3$), 1.47/1.62 (d, $J = 7.2$ Hz/ $J = 7.1$ Hz, 3H, CH_3), 1.96/2.15 (d, $J = 13.0$ Hz/ $J = 12.8$ Hz, 1H, CH_2CO),

2.01/2.15 (d, $J = 13.0$ Hz/ $J = 12.8$ Hz, 1H, CH_2CO), 3.40/3.55 (dd, $J = 15.6$, 6.5 Hz/ $J = 17.9$, 5.3 Hz, 1H, $\text{CH}_2\text{CH=}$), 3.66/4.25 (dd, $J = 17.9$, 5.3 Hz/ $J = 15.6$, 4.7 Hz, 1H, $\text{CH}_2\text{CH=}$), 4.99-5.07 (m, 2H, CH=CH_2), 5.10/6.14 (q, $J = 7.2$ Hz, 1H, CHCH_3), 5.55/5.76-5.89 (ddt, $J = 17.2$, 10.5, 5.3 Hz/m, 1H, CH=CH_2), 7.21-7.40 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ -0.6/-0.5 (q, $\text{Si}(\text{CH}_3)_3$), 16.9/19.6 (q, CH_3), 25.7/26.1 (t, CH_2CO), 45.6/46.7 (t, $\text{CH}_2\text{CH=}$), 50.8/56.7 (d, CHCH_3), 115.7/116.4 (t, CH=CH_2), 126.6/127.9 (d, CH_{Ar}), 127.4/127.5 (d, CH_{Ar}), 128.4/128.8 (d, CH_{Ar}), 135.8/135.9 (d, CH=CH_2), 141.5 (s, C_{Ar}), 173.4 (s, C=O).


(S)-N-Allyl-N-(1-(naphthalen-2-yl)ethyl)-2-(trimethylsilyl)acetamide (8f):



Prepared according to the general procedure, yield 6.6 g (95%) as a 4:1 mixture of rotamers.

[R_f (hexanes/EtOAc 2:1) = 0.68]; IR (film); ν [cm^{-1}]: 3056 (w), 2954 (w), 2895 (w), 1621 (s), 1431 (m), 1389 (m), 1315 (w), 1248 (m), 1190 (w), 1125 (w), 986 (w), 921 (w), 855 (s), 822 (m), 749 (m), 724 (w), 702 (w); MS (+ESI) m/z , (%): 673 (10, $[2\text{M}+\text{Na}^+]$), 348 (40, $[\text{M}+\text{Na}^+]$), 326 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{20}\text{H}_{28}\text{NOSi}^+$]: calcd. 326.1935; found 326.1933; $[\alpha]_D^{20}$: -184.7 (c 1.000, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 0.16/0.18 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.59/1.73 (d, $J = 7.1$ Hz/ $J = 7.0$ Hz, 3H, CH_3), 1.85/2.00 (d, $J = 13.0$ Hz/ $J = 13.2$ Hz, 1H, CH_2CO), 2.06/2.22 (d, $J = 13.0$ Hz/ $J = 13.2$ Hz, 1H, CH_2CO), 3.44/3.56 (dd, $J = 15.5$, 6.4 Hz/ $J = 17.7$, 5.4 Hz, 1H, $\text{CH}_2\text{CH=}$), 3.68/4.32 (dd, $J = 17.7$, 5.1 Hz/ $J = 15.5$, 4.6 Hz, 1H, $\text{CH}_2\text{CH=}$), 4.95-5.11 (m, 2H, CH=CH_2), 5.25/6.31 (q, $J = 7.1$ Hz, 1H, CHCH_3), 5.50-5.63/5.79-5.93 (m, 1H, CH=CH_2), 7.34-7.51 (m, 3H, ArH), 7.66/7.74 (s, 1H, ArH), 7.76-7.85 (m, 3H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ -0.6/-0.5 (q, $\text{Si}(\text{CH}_3)_3$), 16.9/19.6 (q, CH_3), 25.8/26.2 (t, CH_2CO), 45.6/46.7 (t, $\text{CH}_2\text{CH=}$), 50.8/56.8 (d, CHCH_3), 115.8/116.5 (t, CH=CH_2), 125.0/125.8 (d, CH_{Ar}), 126.0 (d, CH_{Ar}), 126.2/126.3 (d, CH_{Ar}), 126.6/126.9 (d, CH_{Ar}), 127.7 (d, CH_{Ar}), 128.0/128.1 (d, CH_{Ar}), 128.2/128.6 (d, CH_{Ar}), 132.7/132.8 (s, C_{Ar}), 133.3/133.4 (s, C_{Ar}), 135.8/135.9 (d, CH=CH_2), 138.9/139.1 (s, C_{Ar}), 173.0/173.5 (s, C=O).


(S)-N-(3-Methylbut-2-en-1-yl)-N-(1-phenylethyl)-2-(trimethylsilyl)acetamide (8g):



Prepared according to the general procedure, yield 5.7 g (88%) as a 3.9:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.67]; IR (film); ν [cm^{-1}]: 2954 (w), 2932 (w), 1623 (s), 1494 (w), 1449 (m), 1431 (w), 1393 (m), 1377 (m), 1333 (w), 1305 (w), 1248 (m), 1211 (w), 1172 (w), 1111 (w), 1095 (w), 1068 (w), 1029 (w), 983 (w), 855 (s), 785 (w), 720 (w), 700 (m), 618 (w); MS (+ESI) m/z , (%): 629 (10, $[2M+Na^+]$), 326 (100, $[M+Na^+]$), 304 (95, $[M+H^+]$); HRMS (+ESI) m/z [$C_{18}H_{29}NOSiNa^+$]: calcd. 326.1911; found 326.1908; $[\alpha]_D^{20}$: -96.7 (c 1.000, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$): δ 0.13/0.15 (s, 9H, $Si(CH_3)_3$), 1.47/1.60 (d, $J = 7.2$ Hz/ $J = 7.1$ Hz, 3H, $CHCH_3$), 1.50 (s, 3H, $CH=C(CH_3)_2$), 1.63 (s, 3H, $CH=C(CH_3)_2$), 1.92/1.99 (d, $J = 12.8$ Hz/ $J = 13.3$ Hz, 1H, CH_2CO), 1.97/2.13 (d, $J = 12.8$ Hz/ $J = 13.3$ Hz, 1H, CH_2CO), 3.42/3.48 (dd, $J = 17.5$, 6.1 Hz/ $J = 15.8$, 4.6 Hz, 1H, $CH_2CH=$), 3.61/4.17 (dd, $J = 17.5$, 6.2 Hz/ $J = 15.8$, 4.5 Hz, 1H, $CH_2CH=$), 4.85-4.91/5.10-5.14 (m, 1H, $CH=C(CH_3)_2$), 5.06/6.12 (q, $J = 7.1$ Hz/ $J = 7.0$ Hz, 1H, $CHCH_3$), 7.21-7.28 (m, 3H, ArH), 7.29-7.37 (m, 2H, ArH); ^{13}C NMR (101 MHz, $CDCl_3$): δ -0.6 (q, $Si(CH_3)_3$), 16.8/19.4 (q, $CHCH_3$), 17.9 (q, $CH=C(CH_3)_2$), 25.7 (q, $CH=C(CH_3)_2$), 25.8/26.8 (t, CH_2CO), 41.2/42.5 (t, $CH_2CH=$), 50.6/56.4 (d, $CHCH_3$), 123.3/123.4 (d, $CH=C(CH_3)_2$), 126.6/127.8 (d, CH_{Ar}), 127.3/127.4 (d, CH_{Ar}), 128.4/128.7 (d, CH_{Ar}), 133.0/133.1 (s, $CH=C(CH_3)_2$), 141.4/141.9 (s, C_{Ar}), 172.6/173.1 (s, $C=O$).

(S)-N-(2-Methylallyl)-N-(1-phenylethyl)-2-(trimethylsilyl)acetamide (8h):




Prepared according to the general procedure, yield 5.8 g (93%) as a 3.9:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.57]; IR (film); ν [cm^{-1}]: 3087 (w), 3031 (w), 2954 (w), 1625 (s), 1495 (w), 1449 (m), 1431 (m), 1388 (m), 1322 (w), 1248 (m), 1209 (w), 1186 (w), 1126 (w), 1097 (w), 1070 (w), 1047 (w), 1030 (w), 980 (w), 855 (s), 787 (w), 746 (w), 701 (m), 619 (w); MS (+ESI) m/z , (%): 601 (40, $[2M+Na^+]$), 312 (100, $[M+Na^+]$), 290 (25, $[M+H^+]$); HRMS

(+ESI) m/z [$C_{17}H_{27}NOSiNa^+$]: calcd. 312.1754; found 312.1752; $[\alpha]_D^{20}$: -106.4 (c 1.004, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$): δ 0.11/0.16 (s, 9H, $Si(CH_3)_3$), 1.44 (d, $J = 7.1$ Hz, 3H, $CHCH_3$), 1.59/1.69 (s, 3H, $CH_3C=$), 1.90/1.98 (d, $J = 13.2$ Hz/ $J = 13.3$ Hz, 1H, CH_2CO), 1.96/2.17 (d, $J = 13.2$ Hz/ $J = 13.3$ Hz, 1H, CH_2CO), 3.25/3.37 (d, $J = 16.8$ Hz/ $J = 18.7$ Hz, 1H, $CH_2C=$), 3.53/4.34 (d, $J = 18.7$ Hz/ $J = 16.8$ Hz, 1H, $CH_2C=$), 4.70/4.79 (d, $J = 1.9$ Hz, 1H, $C=CH_2$), 4.86 (d, $J = 1.9$ Hz, 1H, $C=CH_2$), 5.12/6.12 (q, $J = 6.9$ Hz/ $J = 7.1$ Hz, 1H, $CHCH_3$), 7.19-7.41 (m, 5H, ArH); ^{13}C NMR (101 MHz, $CDCl_3$): δ $-0.6/-0.5$ (q, $Si(CH_3)_3$), 16.9/19.3 (q, $CHCH_3$), 20.5/20.8 (q, $CH_3C=$), 26.1/26.4 (t, CH_2CO), 48.4/49.6 (t, $CH_2C=$), 51.1/56.8 (d, $CHCH_3$), 110.0/111.3 (t, $C=CH_2$), 126.5/127.9 (d, CH_{Ar}), 127.4/127.5 (d, CH_{Ar}), 128.4/128.8 (d, CH_{Ar}), 133.7 (s, C_{Ar}), 141.6/141.8 (s, $C=CH_2$), 173.66/173.74 (s, $C=O$).


(S)-N-(Cyclopent-1-en-1-ylmethyl)-N-(1-phenylethyl)-2-(trimethylsilyl)acetamide (8i):



Prepared according to the general procedure, yield 5.7 g (84%) as a 4.9:1 mixture of rotamers.

$[R_f$ (hexanes/EtOAc 3:1) = 0.54]; IR (film); ν [cm^{-1}]: 2952 (w), 2896 (w), 2846 (w), 1624 (s), 1495 (w), 1459 (m), 1430 (m), 1392 (w), 1375 (w), 1327 (w), 1310 (m), 1248 (w), 1210 (w), 1184 (w), 1140 (w), 1121 (w), 1096 (w), 1069 (w), 1029 (w), 985 (w), 855 (s), 787 (w), 700 (m), 622 (w); MS (+ESI) m/z , (%): 653 (10, $[2M+Na^+]$), 338 (100, $[M+Na^+]$), 316 (15, $[M+H^+]$); HRMS (+ESI) m/z [$C_{19}H_{29}NOSiNa^+$]: calcd. 338.1911; found 338.1909; $[\alpha]_D^{20}$: -82.3 (c 1.000, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$): δ 0.11/0.15 (s, 9H, $Si(CH_3)_3$), 1.45/1.60 (d, $J = 7.1$ Hz, 3H, $CHCH_3$), 1.76-1.89 (m, 2H, H4), 1.94/1.98 (d, $J = 13.1$ Hz, 1H, CH_2CO), 2.01/2.14 (d, $J = 13.1$ Hz, 1H, CH_2CO), 2.03-2.10 (m, 2H, H3), 2.18-2.30 (m, 2H, H5), 3.44/3.50 (d, $J = 15.4$ Hz/ $J = 18.0$ Hz, 1H, $CH_2C=$), 3.63/4.35 (d, $J = 18.0$ Hz/ $J = 15.4$ Hz, 1H, $CH_2C=$), 5.09/6.10 (q, $J = 7.2$ Hz, 1H, $CHCH_3$), 5.29-5.33/5.38 (m/quint, $J = 2.3$ Hz, 1H, H2), 7.20-7.38 (m, 5H, ArH); ^{13}C NMR (101 MHz, $CDCl_3$): δ $-0.58/-0.56$ (q, $Si(CH_3)_3$), 16.9/19.3 (q, $CHCH_3$), 23.47/23.50 (t, C4), 26.0/26.3 (t, CH_2CO), 32.36/32.42 (t, C5), 33.6/34.0 (t, C3), 43.4/45.1 (t, $CH_2C=$), 51.0/56.7 (d, $CHCH_3$), 125.1/126.5 (d, C2), 126.6/127.3 (d, CH_{Ar}), 127.4/127.9 (d, CH_{Ar}), 128.3/128.7 (d, CH_{Ar}), 141.5/141.7 (s, C1, C_{Ar}), 173.0/173.4 (s, $C=O$).


***N*-Benzyl-*N*-(cyclopent-1-en-1-ylmethyl)-2-(trimethylsilyl)acetamide (8j):**



Prepared according to the general procedure, yield 4.5 g (82%) as a 1.5:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.61]; IR (film); ν [cm^{-1}]: 3030 (w), 2952 (w), 2897 (w), 2847 (w), 1625 (s), 1495 (w), 1441 (m), 1397 (m), 1357 (w), 1247 (m), 1138 (w), 1113 (w), 1076 (w), 1044 (w), 1028 (w), 946 (w), 849 (s), 725 (w), 700 (m), 616 (w); MS (+ESI) m/z , (%): 625 (10, [2M+Na⁺]), 324 (100, [M+Na⁺]), 302 (25, [M+H⁺]); HRMS (+ESI) m/z [$\text{C}_{18}\text{H}_{27}\text{NOSiNa}^+$]: calcd. 324.1754; found 324.1758; ^1H NMR (400 MHz, CDCl_3): δ 0.13/0.14 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.82-1.98 (m, 2H, H4), 2.02/2.03 (s, 2H, CH_2CO), 2.17-2.26 (m, 2H, H3), 2.29-2.39 (m, 2H, H5), 3.76/4.08 (s, 2H, $\text{NCH}_2\text{C}=\text{}$), 4.45/4.58 (s, 2H, CH_2Ph), 5.45/5.52 (quint, $J = 1.7$ Hz/ $J = 1.9$ Hz, 1H, H2), 7.15-7.25 (m, 2H, ArH), 7.26-7.38 (m, 3H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ -0.64/-0.63 (q, $\text{Si}(\text{CH}_3)_3$), 23.5/23.7 (t, C4), 25.5/25.8 (t, CH_2CO), 32.36/32.43 (t, C5), 33.4/33.7 (t, C3), 44.9/48.4 (t, $\text{NCH}_2\text{C}=\text{}$), 48.0/50.9 (t, CH_2Ph), 126.5/127.6 (d, CH_{Ar}), 127.3/128.5 (d, CH_{Ar}), 127.39/127.43 (d, C2), 128.5/128.9 (d, CH_{Ar}), 137.2/138.5 (s, C_{Ar}), 139.8/140.5 (s, C1), 172.9/173.0 (s, C=O).

***N*-Benzyl-*N*-(cyclohex-1-en-1-ylmethyl)-2-(trimethylsilyl)acetamide (8k):**




Prepared according to the general procedure, yield 5.7 g (85%) as a 1.5:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.63]; IR (film); ν [cm^{-1}]: 3029 (w), 2927 (w), 2858 (w), 2836 (w), 1625 (s), 1495 (w), 1439 (m), 1398 (m), 1374 (w), 1359 (w), 1247 (m), 1137 (w), 1116 (w), 1076 (w), 1028 (w), 852 (w), 728 (w), 700 (m), 624 (w), 603 (w); MS (+ESI) m/z , (%): 653 (10, [2M+Na⁺]), 338 (15, [M+Na⁺]), 316 (100, [M+H⁺]); HRMS (+ESI) m/z [$\text{C}_{19}\text{H}_{30}\text{NOSi}^+$]: calcd. 316.2091; found 316.2089; ^1H NMR (400 MHz, CDCl_3): δ 0.12/0.14 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.53-

1.66 (m, 4H, H4, H5), 1.81-1.86/1.87-1.92 (m, 2H, H3), 1.98-2.06 (m, 2H, H6), 2.02/2.03 (s, 2H, CH₂CO), 3.61/3.93 (s, 2H, NCH₂C=), 4.42/4.55 (s, 2H, CH₂Ph), 5.44/5.52 (tt, *J* = 3.7, 1.7 Hz/*J* = 3.8, 1.7 Hz, 1H, H2), 7.15-7.25 (m, 2H, ArH), 7.26-7.37 (m, 3H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ -0.61/-0.60 (q, Si(CH₃)₃), 22.5 (t, C5), 22.6/22.7 (t, C4), 25.1/25.2 (t, C6), 25.6/25.9 (t, CH₂CO), 26.5/26.6 (t, C3), 47.8/50.4 (t, NCH₂C=), 50.5/53.6 (t, CH₂Ph), 123.8/124.7 (d, C2), 126.5/127.5 (d, CH_{Ar}), 127.2/128.5 (d, CH_{Ar}), 128.6/128.9 (d, CH_{Ar}), 132.6/133.7 (s, C1), 137.3/138.5 (s, C_{Ar}), 173.1/173.2 (s, C=O).


***N*-Benzyl-*N*-(cyclopent-2-en-1-yl)-2-(trimethylsilyl)acetamide (8l):**



Prepared according to the general procedure, yield 5.6 g (91%) as a 1.5:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.47]; IR (film); ν [cm⁻¹]: 3062 (w), 3030 (w), 2953 (w), 2853 (w), 1625 (s), 1496 (w), 1454 (m), 1435 (m), 1394 (m), 1365 (w), 1350 (w), 1326 (w), 1295 (w), 1249 (m), 1208 (w), 1179 (w), 1138 (w), 1076 (w), 1028 (w), 852 (s), 726 (m), 699 (m), 618 (w); MS (+ESI) *m/z*, (%): 310 (40, [M+Na⁺]), 288 (100, [M+H⁺]); HRMS (+ESI) *m/z* [C₁₇H₂₆NOSi⁺]: calcd. 288.1778; found 288.1776; ¹H NMR (400 MHz, CDCl₃): δ 0.10/0.17 (s, 9H, Si(CH₃)₃), 1.42-1.55/1.57-1.69 (m, 1H, H5), 1.87/2.11 (d, *J* = 13.5 Hz/*J* = 13.0 Hz, 1H, CH₂CO), 1.90/2.22 (d, *J* = 13.0 Hz/*J* = 13.5 Hz, 1H, CH₂CO), 2.17-2.44 (m, 3H, H4, H5), 4.34 (d, *J* = 15.4 Hz, 1H, CH₂Ph)/4.35 (s, 2H, CH₂Ph)/4.53 (d, *J* = 15.4 Hz, 1H, CH₂Ph), 4.99-5.06/5.82-5.88 (m, 1H, H1), 5.43-5.55 (m, 1H, H2), 5.79-5.95 (m, 1H, H3), 7.14-7.28 (m, 3H, ArH), 7.30-7.38 (m, 2H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ -0.69/-0.66 (q, Si(CH₃)₃), 26.1/26.7 (t, CH₂CO), 28.8/29.0 (t, C5), 31.4/31.5 (t, C4), 45.3/47.6 (t, CH₂Ph), 60.6/65.4 (d, C1), 126.0/127.1 (d, CH_{Ar}), 126.5/127.4 (d, CH_{Ar}), 128.2/128.8 (d, CH_{Ar}), 130.6/130.8 (d, C2), 134.9/135.1 (d, C3), 139.1/140.2 (s, C_{Ar}), 172.8/173.8 (s, C=O).

(R)-N-Benzyl-N-(cyclohex-2-en-1-yl)-2-(trimethylsilyl)acetamide (8m):




Prepared according to the general procedure, yield 5.0 g (76%) as a 2.1:1 mixture of rotamers.

[R_f (hexanes/EtOAc 3:1) = 0.59]; IR (film); ν [cm^{-1}]: 3028 (w), 2948 (w), 2863 (w), 1626 (s), 1496 (w), 1452 (m), 1431 (w), 1396 (w), 1361 (w), 1313 (w), 1294 (w), 1249 (m), 1224 (w), 1203 (w), 1172 (w), 1138 (w), 1116 (w), 1076 (w), 1055 (w), 1029 (w), 989 (w), 854 (s), 727 (m), 700 (m), 619 (w); MS (+ESI) m/z , (%): 324 (40, $[\text{M}+\text{Na}]^+$), 302 (100, $[\text{M}+\text{H}]^+$); HRMS (+ESI) m/z [$\text{C}_{18}\text{H}_{28}\text{NOSi}^+$]: calcd. 302.1940; found 302.1942; $[\alpha]_{\text{D}}^{20}$: +44.1 (c 0.503, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 0.11/0.17 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.29-1.43/1.52-1.58 (m, 1H, H6), 1.59-1.79 (m, 2H, H5), 1.80-1.85/1.89-1.92 (m, 1H, H6), 1.93-2.01 (m, 2H, H4), 2.03/2.09 (d, $J = 13.1$ Hz/ $J = 13.0$ Hz, 1H, CH_2CO), 2.16/2.22 (d, $J = 13.0$ Hz/ $J = 13.1$ Hz, 1H, CH_2CO), 4.28-4.35/5.35-5.43 (m, 1H, H1), 4.39/4.40 (d, $J = 15.3$ Hz/ $J = 17.8$ Hz, 1H, CH_2Ph), 4.48/4.61 (d, $J = 17.8$ Hz/ $J = 15.3$ Hz, 1H, CH_2Ph), 5.06-5.24/5.35-5.48 (m, 1H, H2), 5.68-5.78/5.79-5.89 (m, 1H, H3), 7.17-7.37 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ -0.7/-0.6 (q, $\text{Si}(\text{CH}_3)_3$), 21.6/21.8 (t, C5), 24.6/24.8 (t, C4), 26.0/26.8 (t, CH_2CO), 28.1/29.0 (t, C6), 46.2/48.1 (t, CH_2Ph), 51.4/56.4 (d, C1), 126.0/126.5 (d, CH_{Ar}), 127.1/127.3 (d, CH_{Ar}), 128.48/128.53 (d, C2), 128.8 (d, CH_{Ar}), 131.7/131.9 (d, C3), 139.3/140.2 (s, C_{Ar}), 173.3/174.0 (s, C=O).

General procedure for the tandem nucleophilic epoxide opening/Brook rearrangement/ α -oxygenation:

In a similar manner as described in [11] LiCl (252 mg, 6 mmol) was added to a round-bottomed flask containing a stirring bar, which was sealed with a septum, and dried under vacuum by a heat gun. Dry THF (8 mL) and the amide **8** (1.0 mmol) were added under argon. The mixture was cooled to 0 °C in an ice/water bath, *sec*-butyllithium (1.4 M solution in cyclohexane, 0.8 mL, 1.1 mmol) was added dropwise by syringe and the mixture was stirred at 0 °C for 15 min. Then, epoxide **7** (1.05 mmol) was added at once by syringe and the reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was cooled to –78 °C, diluted with dry THF (8 mL) and TEMPO (**3**; 164 mg, 1.05 mmol) was added as a solid in a single portion. Ferrocenium hexafluorophosphate (**4**; 397 mg, 1.2 mmol) was added in small portions with vigorous stirring until a dark blue-green color of the reaction mixture persisted for 20 min. The reaction mixture was quenched by saturated NH₄Cl solution (5 drops), diluted with diethyl ether (10 mL) and filtered through a pad of silica gel, which was washed with a fresh portion of diethyl ether. The filtrate was evaporated and the crude inhomogeneous mixture was purified by flash chromatography (gradient, hexanes/EtOAc 20:1 to 5:1) to give pure α -(aminoxy)amides **9**.

***N,N*-Diallyl-4-methyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (**9a**):**




Prepared according to the general procedure, yield 313 mg (61%).

[*R_f*(hexanes/EtOAc 10:1) = 0.41]; IR (film); ν [cm⁻¹]: 2972 (w), 2927 (m), 1655 (m), 1450 (w), 1415 (w), 1363 (w), 1249 (m), 1230 (w), 1179 (w), 1134 (m), 1033 (m), 988 (w), 921 (m), 863 (m), 838 (s), 753 (w), 684 (w); MS (+ESI) *m/z*, (%): 461 (60, [M+Na⁺]), 439 (100, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₄H₄₇N₂O₃Si⁺]: calcd. 439.3351; found 439.3354; ¹H NMR (400 MHz, CDCl₃): δ 0.08 (s, 9H, Si(CH₃)₃), 0.99 (s, 3H, NCCH₃), 1.04 (s, 3H, NCCH₃), 1.08 (s, 3H, CCH₃), 1.11 (s, 3H, NCCH₃), 1.22 (s, 3H, NCCH₃), 1.24-1.33 (m, 1H, piperidine-H₄), 1.29 (s, 3H, CCH₃), 1.35-1.48 (m, 4H, piperidine-H₃, H₅), 1.49-1.60 (m, 1H, piperidine-H₄), 1.96 (dd, *J*

= 13.4, 2.1 Hz, 1H, CH_2CHOTMP), 2.30 (dd, $J = 13.4, 10.6$ Hz, 1H, CH_2CHOTMP), 3.81-4.00 (m, 3H, $\text{CH}_2\text{CH=}$), 4.51-4.59 (m, 1H, $\text{CH}_2\text{CH=}$), 4.77 (dd, $J = 10.6, 2.1$ Hz, 1H, CHOTMP), 5.12-5.26 (m, 4H, CH=CH_2), 5.77 (ddt, $J = 16.9, 10.0, 6.6$ Hz, 1H, CH=CH_2), 6.03 (ddt, $J = 16.4, 10.1, 6.2$ Hz, 1H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ 2.7 (q, $\text{Si}(\text{CH}_3)_3$), 17.3 (t, piperidine-C4), 20.3 (q, NCCH_3), 20.6 (q, NCCH_3), 29.5 (q, CCH_3), 31.9 (q, CCH_3), 33.0 (q, NCCH_3), 33.9 (q, NCCH_3), 40.4 (t, piperidine-C3), 40.6 (t, piperidine-C5), 46.6 (t, CH_2CHOTMP), 48.1 (t, $\text{CH}_2\text{CH=}$), 49.5 (t, $\text{CH}_2\text{CH=}$), 59.4 (s, CNO), 60.6 (s, CNO), 72.8 (s, COTMS), 78.5 (d, CHOTMP), 118.1 (t, CH=CH_2), 118.3 (t, CH=CH_2), 133.2 (d, CH=CH_2), 134.3 (d, CH=CH_2), 172.8 (s, C=O).

***N,N*-Diallyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9b):**



Prepared according to the general procedure, yield 326 mg (77%) as an inseparable 1.1:1 mixture of diastereomers.


[R_f (hexanes/EtOAc 5:1) = 0.63]; IR (film); ν [cm^{-1}]: 2967 (w), 2955 (w), 1651 (s), 1461 (w), 1438 (w), 1411 (m), 1376 (w), 1281 (w), 1249 (m), 1215 (w), 1194 (w), 1137 (w), 1085 (m), 1047 (w), 1018 (w), 985 (m), 921 (m), 891 (w), 869 (w), 836 (s), 758 (m), 683 (w); MS (+ESI) m/z , (%): 447 (15, $[\text{M}+\text{Na}^+]$), 425 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{23}\text{H}_{45}\text{N}_2\text{O}_3\text{Si}^+$]: calcd. 425.3194; found 425.3193.

First diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.09 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.06 (s, 6H, NCCH_3), 1.11 (s, 3H, NCCH_3), 1.13 (s, 3H, NCCH_3), 1.19 (d, $J = 6.1$ Hz, 3H, CH_3CHOTMS), 1.24-1.34 (m, 1H, piperidine-H4), 1.35-1.49 (m, 4H, piperidine-H3, H5), 1.50-1.61 (m, 1H, piperidine-H4), 1.91-2.09 (m, 2H, CH_2CHOTMP), 3.70-3.77 (m, 1H, CHOTMS), 3.83-3.90 (m, 1H, $\text{CH}_2\text{CH=}$), 3.91-3.98 (m, 2H, $\text{CH}_2\text{CH=}$), 4.07 (dd, $J = 15.4, 6.0$ Hz, 1H, $\text{CH}_2\text{CH=}$), 4.61-4.72 (m, 1H, CHOTMP), 5.12-5.18 (m, 4H, CH=CH_2), 5.71-5.83 (m, 2H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ 0.4 (q, $\text{Si}(\text{CH}_3)_3$), 17.1 (t, piperidine-C4), 20.1 (q, 2C, NCCH_3), 24.6 (q,

$\underline{\text{CH}_3\text{CHOTMS}}$), 33.49 (q, $\text{NC}\underline{\text{CH}_3}$), 33.53 (q, $\text{NC}\underline{\text{CH}_3}$), 40.4 (t, piperidine-C3, C5), 47.7 (t, $\underline{\text{CH}_2\text{CH=}}$), 48.2 (t, $\underline{\text{CH}_2\text{CH=}}$), 59.3 (s, CNO), 60.6 (s, CNO), 65.7 (d, $\underline{\text{CHOTMS}}$), 78.7 (d, $\underline{\text{CHOTMP}}$), 118.0 (t, $\text{CH}=\underline{\text{CH}_2}$), 118.2 (t, $\text{CH}=\underline{\text{CH}_2}$), 133.07 (d, $\underline{\text{CH}}=\text{CH}_2$), 133.10 (d, $\underline{\text{CH}}=\text{CH}_2$), 172.6 (s, C=O).

Second diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.10 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.02 (s, 3H, NCCH_3), 1.03 (s, 3H, NCCH_3), 1.15 (d, $J = 6.2$ Hz, 3H, $\underline{\text{CH}_3\text{CHOTMS}}$), 1.20 (s, 3H, NCCH_3), 1.22 (s, 3H, NCCH_3), 1.24-1.34 (m, 1H, piperidine-H4), 1.35-1.49 (m, 4H, piperidine-H3, H5), 1.50-1.61 (m, 1H, piperidine-H4), 1.91-2.09 (m, 2H, $\underline{\text{CH}_2\text{CHOTMP}}$), 3.76-3.82 (m, 1H, $\underline{\text{CH}_2\text{CH=}}$), 3.87-3.92 (m, 1H, $\underline{\text{CHOTMS}}$), 3.99-4.11 (m, 1H, $\underline{\text{CH}_2\text{CH=}}$), 4.36 (dd, $J = 16.5, 6.0$ Hz, 1H, $\underline{\text{CH}_2\text{CH=}}$), 4.59 (dd, $J = 7.8, 5.9$ Hz, 1H, $\underline{\text{CHOTMP}}$), 4.62-4.71 (m, 1H, $\underline{\text{CH}_2\text{CH=}}$), 5.19-5.24 (m, 4H, $\text{CH}=\underline{\text{CH}_2}$), 5.84-6.01 (m, 2H, $\underline{\text{CH}}=\text{CH}_2$); ^{13}C NMR (101 MHz, CDCl_3): δ 0.6 (q, $\text{Si}(\text{CH}_3)_3$), 17.0 (t, piperidine-C4), 20.4 (q, $\text{NC}\underline{\text{CH}_3}$), 20.5 (q, $\text{NC}\underline{\text{CH}_3}$), 23.8 (q, $\underline{\text{CH}_3\text{CHOTMS}}$), 32.8 (q, $\text{NC}\underline{\text{CH}_3}$), 33.0 (q, $\text{NC}\underline{\text{CH}_3}$), 40.3 (t, piperidine-C3), 40.5 (t, piperidine-C3), 48.9 (t, $\underline{\text{CH}_2\text{CH=}}$), 49.1 (t, $\underline{\text{CH}_2\text{CH=}}$), 59.4 (s, CNO), 60.4 (s, CNO), 65.3 (d, $\underline{\text{CHOTMS}}$), 78.1 (d, $\underline{\text{CHOTMP}}$), 117.3 (t, $\text{CH}=\underline{\text{CH}_2}$), 117.6 (t, $\text{CH}=\underline{\text{CH}_2}$), 133.7 (d, $\underline{\text{CH}}=\text{CH}_2$), 134.1 (d, $\underline{\text{CH}}=\text{CH}_2$), 172.1 (s, C=O).

***N,N*-Diallyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)octanamide (9c):**




Prepared according to the general procedure, yield 336 mg (71%) as an inseparable 1:1 mixture of diastereomers.

[R_f (hexanes/EtOAc 10:1) = 0.42]; IR (film); ν [cm^{-1}]: 3007 (w), 2956 (m), 2930 (s), 2872 (m), 1653 (s), 1457 (m), 1418 (m), 1377 (m), 1362 (w), 1348 (w), 1250 (m), 1232 (w), 1184 (w), 1132 (w), 1061 (m), 990 (m), 956 (w), 921 (w), 840 (s), 754 (m), 714 (m), 684 (w), 613 (w); MS (+ESI) m/z , (%): 955 (35, $[2\text{M}+\text{Na}^+]$), 489 (100, $[\text{M}+\text{Na}^+]$), 467 (5, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{26}\text{H}_{50}\text{N}_2\text{O}_3\text{SiNa}^+$]: calcd. 489.3483; found 489.3484.

First diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.09 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.84-0.92 (m, 3H, CH_3CH_2), 1.01 (s, 3H, NCCH_3), 1.04 (s, 3H, NCCH_3), 1.12 (s, 6H, NCCH_3), 1.24-1.35 (m, 5H, $\text{CH}_3\text{CH}_2\text{CH}_2$, piperidine-H4), 1.40-1.50 (m, 6H, $\text{CH}_2\text{CH}_2\text{CHOTMS}$, piperidine-H3, H5), 1.53-1.60 (m, 1H, piperidine-H4), 1.95-2.10 (m, 2H, CH_2CHOTMP), 3.58-3.69 (m, 1H, CHOTMS), 3.80 (dd, $J = 14.4, 7.4$ Hz, 1H, $\text{CH}_2\text{CH=}$), 3.91-3.96 (m, 2H, $\text{CH}_2\text{CH=}$), 4.04 (dd, $J = 14.4, 6.0$ Hz, 1H, $\text{CH}_2\text{CH=}$), 4.62-4.66 (m, 1H, CHOTMP), 5.12-5.18 (m, 4H, CH=CH_2), 5.71-5.84 (m, 2H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ 0.8 (q, $\text{Si}(\text{CH}_3)_3$), 14.2 (q, CH_3CH_2), 17.18 (t, piperidine-C4), 20.2 (q, NCCH_3), 20.5 (q, NCCH_3), 22.89 (t, $\text{CH}_3\text{CH}_2\text{CH}_2$), 27.5 (t, $\text{CH}_3\text{CH}_2\text{CH}_2$), 33.0 (q, NCCH_3), 33.7 (q, NCCH_3), 37.8 (t, $\text{CH}_2\text{CH}_2\text{CHOTMS}$), 39.8 (t, CH_2CHOTMP), 40.5 (t, piperidine-C3, C5), 47.9 (t, $\text{CH}_2\text{CH=}$), 48.4 (t, $\text{CH}_2\text{CH=}$), 57.0 (s, CNO), 59.4 (s, CNO), 69.8 (d, CHOTMS), 79.2 (d, CHOTMP), 118.1 (t, CH=CH_2), 118.4 (t, CH=CH_2), 133.20 (d, CH=CH_2), 133.24 (d, CH=CH_2), 172.2 (s, C=O).

Second diastereomer: δ 0.10 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.84-0.92 (m, 3H, CH_3CH_2), 1.06 (s, 3H, NCCH_3), 1.07 (s, 3H, NCCH_3), 1.18 (s, 3H, NCCH_3), 1.21 (s, 3H, NCCH_3), 1.24-1.35 (m, 5H, $\text{CH}_3\text{CH}_2\text{CH}_2$, piperidine-H4), 1.36-1.40 (m, 2H, $\text{CH}_2\text{CH}_2\text{CHOTMS}$), 1.40-1.50 (m, 4H, piperidine-H3, H5), 1.53-1.60 (m, 1H, piperidine-H4), 1.95-2.10 (m, 2H, CH_2CHOTMP), 3.58-3.69 (m, 1H, CHOTMS), 3.87 (dd, $J = 16.0, 6.0$ Hz, 1H, $\text{CH}_2\text{CH=}$), 3.95-4.03 (m, 1H, $\text{CH}_2\text{CH=}$), 4.40 (dd, $J = 16.0, 6.0$ Hz, 1H, $\text{CH}_2\text{CH=}$), 4.58 (dd, $J = 8.2, 5.7$ Hz, 1H, CHOTMP), 4.64-4.70 (m, 1H, $\text{CH}_2\text{CH=}$), 5.19-5.23 (m, 4H, CH=CH_2), 5.85-5.98 (m, 2H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ 0.6 (q, $\text{Si}(\text{CH}_3)_3$), 14.1 (q, CH_3CH_2), 17.22 (t, piperidine-C4), 20.3 (q, NCCH_3), 20.6 (q, NCCH_3), 22.86 (t, $\text{CH}_3\text{CH}_2\text{CH}_2$), 27.9 (t, $\text{CH}_3\text{CH}_2\text{CH}_2$), 33.1 (q, NCCH_3), 33.6 (q, NCCH_3), 36.9 (t, $\text{CH}_2\text{CH}_2\text{CHOTMS}$), 40.2 (t, CH_2CHOTMP), 40.6 (t, piperidine-C3, C5), 49.1 (t, $\text{CH}_2\text{CH=}$), 49.2 (t, $\text{CH}_2\text{CH=}$), 57.1 (s, CNO), 59.6 (s, CNO), 69.5 (d, CHOTMS), 77.7 (d, CHOTMP), 117.4 (t, CH=CH_2), 117.6 (t, CH=CH_2), 133.9 (d, CH=CH_2), 134.2 (d, CH=CH_2), 172.7 (s, C=O).

***N,N*-Diallyl-4-phenyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)butanamide (9d):**



Prepared according to the general procedure, yield 265 mg (56%) as an inseparable 1.1:1 mixture of diastereomers.


[R_f (hexanes/EtOAc 10:1) = 0.51]; IR (film); ν [cm^{-1}]: 3084 (w), 3006 (w), 2930 (m), 2872 (w), 1654 (s), 1493 (w), 1453 (m), 1415 (m), 1377 (w), 1362 (w), 1250 (m), 1183 (w), 1133 (w), 1090 (m), 994 (w), 960 (w), 921 (w), 865 (m), 842 (s), 752 (m), 701 (m), 685 (w), 614 (w); MS (+ESI) m/z , (%): 509 (95, $[\text{M}+\text{Na}^+]$), 487 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{28}\text{H}_{46}\text{N}_2\text{O}_3\text{SiNa}^+$]: calcd. 509.3170; found 509.3167.

First diastereomer: ^1H NMR (400 MHz, CDCl_3): δ -0.05 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.06 (s, 12H, NCCH_3), 1.25-1.34 (m, 1H, piperidine-H4), 1.37-1.48 (m, 4H, piperidine-H3, H5), 1.49-1.56 (m, 1H, piperidine-H4), 2.21-2.39 (m, 2H, CH_2CHOTMP), 3.82 (dd, J = 16.0, 5.0 Hz, 1H, $\text{CH}_2\text{CH=}$), 4.11 (dd, J = 16.4, 5.7 Hz, 1H, $\text{CH}_2\text{CH=}$), 4.33 (dd, J = 16.4, 5.6 Hz, 1H, $\text{CH}_2\text{CH=}$), 4.38 (dd, J = 16.0, 5.0 Hz, 1H, $\text{CH}_2\text{CH=}$), 4.56 (dd, J = 9.7, 2.9 Hz, 1H, CHOTMS), 4.80 (dd, J = 10.6, 3.2 Hz, 1H, CHOTMP), 5.12-5.27 (m, 4H, CH=CH_2), 5.70-5.85 (m, 2H, CH=CH_2), 7.20-7.35 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.1 (q, $\text{Si}(\text{CH}_3)_3$), 16.9 (t, piperidine-C4), 20.0 (q, 2C, NCCH_3), 32.7 (q, 2C, NCCH_3), 40.2 (t, piperidine-C3, C5), 42.3 (t, CH_2CHOTMP), 48.8 (t, $\text{CH}_2\text{CH=}$), 49.1 (t, $\text{CH}_2\text{CH=}$), 59.2 (s, CNO), 60.1 (s, CNO), 71.9 (d, CHOTMS), 79.3 (d, CHOTMP), 117.8 (t, 2C, CH=CH_2), 126.1 (d, CH_{Ar}), 127.0 (d, CH_{Ar}), 127.9 (d, CH_{Ar}), 132.99 (d, CH=CH_2), 133.04 (d, CH=CH_2), 143.7 (s, C_{Ar}), 171.5 (s, C=O).

Second diastereomer: ^1H NMR (400 MHz, CDCl_3): δ -0.02 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.97 (s, 3H, NCCH_3), 1.10 (s, 3H, NCCH_3), 1.15 (s, 6H, NCCH_3), 1.25-1.34 (m, 1H, piperidine-H4), 1.37-1.48 (m, 4H, piperidine-H3, H5), 1.49-1.56 (m, 1H, piperidine-H4), 2.21-2.39 (m, 2H, CH_2CHOTMP), 3.86 (dd, J = 13.4, 6.6 Hz, 1H, $\text{CH}_2\text{CH=}$), 3.92 (dd, J = 13.4, 6.6 Hz, 1H, $\text{CH}_2\text{CH=}$), 3.95 (dd, J = 14.6, 6.7 Hz, 1H, $\text{CH}_2\text{CH=}$), 4.05 (dd, J = 14.6, 6.7 Hz, 1H, $\text{CH}_2\text{CH=}$), 4.45-4.50 (m, 1H, CHOTMP), 4.75 (t, J = 6.6 Hz, 1H, CHOTMS), 5.12-5.27 (m, 4H, CH=CH_2),

5.78-5.88 (m, 1H, $\text{CH}=\text{CH}_2$), 5.96 (ddt, $J = 17.6, 9.9, 6.5$ Hz, 1H, $\text{CH}=\text{CH}_2$), 7.20-7.35 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.2 (q, $\text{Si}(\text{CH}_3)_3$), 17.0 (t, piperidine-C4), 20.3 (q, NCCH_3), 20.4 (q, NCCH_3), 33.2 (q, NCCH_3), 33.4 (q, NCCH_3), 40.1 (t, piperidine-C3), 40.3 (t, piperidine-C5), 42.5 (t, CH_2CHOTMP), 47.4 (t, $\text{CH}_2\text{CH}=\text{}$), 47.7 (t, $\text{CH}_2\text{CH}=\text{}$), 59.4 (s, CNO), 60.4 (s, CNO), 72.0 (d, CHOTMS), 78.0 (d, CHOTMP), 117.4 (t, $\text{CH}=\text{CH}_2$), 118.0 (t, $\text{CH}=\text{CH}_2$), 126.7 (d, CH_{Ar}), 127.3 (d, CH_{Ar}), 128.0 (d, CH_{Ar}), 133.6 (d, $\text{CH}=\text{CH}_2$), 134.0 (d, $\text{CH}=\text{CH}_2$), 144.8 (s, C_{Ar}), 171.9 (s, $\text{C}=\text{O}$).

***N*-Allyl-*N*-methyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9e):**



Prepared according to the general procedure, yield 230 mg (68%) as a partly separable 1.1:1 mixture of diastereomers. Ratio of rotamers is 1.5:1 for each diastereomer.


[R_f (hexanes/EtOAc 5:1) = 0.51]; IR (film); ν [cm^{-1}]: 2967 (m), 2930 (m), 2873 (w), 1655 (s), 1456 (w), 1403 (w), 1376 (w), 1362 (w), 1250 (m), 1143 (w), 1134 (w), 1100 (w), 1083 (w), 1057 (w), 1021 (w), 990 (w), 974 (w), 956 (w), 922 (w), 899 (w), 841 (s), 750 (w), 708 (w); MS (+ESI) m/z , (%): 819 (20, $[2\text{M}+\text{Na}^+]$), 421 (100, $[\text{M}+\text{Na}^+]$), 399 (65, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{21}\text{H}_{42}\text{N}_2\text{O}_3\text{SiNa}^+$]: calcd. 421.2857; found 421.2856.

Less polar diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.06/0.07 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.00 (s, 3H, NCCH_3), 1.05 (s, 3H, NCCH_3), 1.10 (s, 3H, NCCH_3), 1.16 (d, $J = 6.1$ Hz, 3H, CH_3CHOTMS), 1.19/1.22 (s, 3H, NCCH_3), 1.24-1.33 (m, 1H, piperidine-H4), 1.35-1.47 (m, 4H, piperidine-H3, H5), 1.48-1.58 (m, 1H, piperidine-H4), 1.88-1.98/1.99-2.08 (m, 2H, CH_2CHOTMP), 2.85/3.14 (s, 3H, NCH_3), 3.66/3.73 (ddq, $J = 9.5, 6.1, 3.3$ Hz/ $J = 11.7, 6.0, 3.0$ Hz, 1H, CHOTMS), 3.91/4.06 (dd, $J = 14.4, 6.4$ Hz/ $J = 16.4, 5.9$ Hz, 1H, $\text{CH}_2\text{CH}=\text{}$), 4.03/4.37 (dd, $J = 14.4, 6.4$ Hz/ $J = 16.4, 5.9$ Hz, 1H, $\text{CH}_2\text{CH}=\text{}$), 4.67/4.75 (dd, $J = 10.0, 3.8$ Hz/ $J = 10.8, 3.4$ Hz, 1H, CHOTMP), 5.14-5.23 (m, 2H, $\text{CH}=\text{CH}_2$), 5.73/5.92 (ddt, $J = 16.6, 10.0, 6.4$ Hz, 1H, $\text{CH}=\text{CH}_2$); ^{13}C NMR (101 MHz, CDCl_3): δ 0.7 (q, $\text{Si}(\text{CH}_3)_3$), 17.24 (t, piperidine-C4), 20.1/20.24 (q, NCCH_3), 20.5/20.7 (q, NCCH_3), 24.6/24.8 (q, CH_3CHOTMS), 32.56/33.0 (q, NCCH_3), 33.4/35.0 (q,

NCH₃), 33.6/33.7 (q, NCCH₃), 40.4/40.59 (t, piperidine-C3, C5), 42.0/42.1 (t, CH₂CHOTMP), 50.6/52.6 (t, CH₂CH=), 59.3/59.52 (s, CNO), 60.5/60.59 (s, CNO), 65.8/65.9 (d, CHOTMS), 78.79/78.84 (d, CHOTMP), 117.9/118.08 (t, CH=CH₂), 133.2/134.0 (d, CH=CH₂), 172.6/172.7 (s, C=O).

More polar diastereomer: ¹H NMR (400 MHz, CDCl₃): δ 0.08/0.09 (s, 9H, Si(CH₃)₃), 0.97/1.00 (s, 3H, NCCH₃), 1.05 (s, 3H, NCCH₃), 1.10/1.11 (s, 3H, NCCH₃), 1.13/1.14 (d, *J* = 6.2 Hz, 3H, CH₃CHOTMS), 1.22 (s, 3H, NCCH₃), 1.24-1.31 (m, 1H, piperidine-H4), 1.35-1.47 (m, 4H, piperidine-H3, H5), 1.48-1.58 (m, 1H, piperidine-H4), 1.93-2.00/2.01-2.06 (m, 2H, CH₂CHOTMP), 2.85/3.14 (s, 3H, NCH₃), 3.79/3.82-3.87 (sext, *J* = 6.3 Hz/m, 1H, CHOTMS), 3.84/3.89 (dd, *J* = 17.0, 5.2 Hz/*J* = 14.5, 6.2 Hz, 1H, CH₂CH=), 4.02/4.70 (dd, *J* = 14.5, 6.5 Hz/*J* = 17.0, 5.4 Hz, 1H, CH₂CH=), 4.55-4.61 (m, 1H, CHOTMP), 5.13-5.23 (m, 2H, CH=CH₂), 5.74/5.88 (ddt, *J* = 16.6, 10.1, 6.5 Hz/*J* = 17.1, 10.5, 5.4 Hz, 1H, CH=CH₂); ¹³C NMR (101 MHz, CDCl₃): δ 0.3/0.6 (q, Si(CH₃)₃), 17.22 (t, piperidine-C4), 20.18/20.3 (q, NCCH₃), 20.56/20.63 (q, NCCH₃), 23.6/23.9 (q, CH₃CHOTMS), 32.63/33.2 (q, NCCH₃), 33.4/35.0 (q, NCH₃), 33.8/34.7 (q, NCCH₃), 40.5/40.57 (t, piperidine-C3), 40.61/40.7 (t, piperidine-C5), 42.2/42.5 (t, CH₂CHOTMP), 50.7/52.5 (t, CH₂CH=), 59.4/59.53 (s, CNO), 60.56/60.8 (s, CNO), 65.50/65.54 (d, CHOTMS), 78.3/80.7 (d, CHOTMP), 117.3/118.11 (t, CH=CH₂), 133.1/133.6 (d, CH=CH₂), 172.4/173.0 (s, C=O).

***N*-Benzyl-*N*-(2-methylallyl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9f):**



Prepared according to the general procedure, yield 170 mg (51%) as an inseparable 1:1 mixture of diastereomers. Ratio of rotamers is 1.9:1 for each diastereomer.


[*R*_f (hexanes/EtOAc 5:1) = 0.56]; IR (film); ν [cm⁻¹]: 2969 (m), 2930 (m), 1655 (s), 1495 (m), 1444 (m), 1376 (w), 1362 (w), 1250 (s), 1205 (w), 1182 (w), 1100 (m), 1080 (w), 1049 (w), 1013 (w), 992 (w), 958 (w), 895 (w), 840 (s), 748 (m), 702 (m); MS (+ESI) *m/z*, (%): 999 (30,

[2M+Na⁺]), 511 (100, [M+Na⁺]), 489 (40, [M+H⁺]); HRMS (+ESI) m/z [C₂₈H₄₈N₂O₃SiNa⁺]: calcd. 511.3326; found 511.3325.

First diastereomer: ¹H NMR (400 MHz, CDCl₃): δ 0.09 (s, 9H, Si(CH₃)₃), 1.05 (s, 3H, NCCH₃), 1.13 (s, 6H, NCCH₃), 1.16 (s, 3H, NCCH₃), 1.22 (d, *J* = 6.1 Hz, 3H, CH₃CHOTMS), 1.26-1.34 (m, 1H, piperidine-H₄), 1.36-1.51 (m, 4H, piperidine-H₃, H₅), 1.52-1.62 (m, 1H, piperidine-H₄), 1.75/1.76 (s, 3H, CH₃C=), 2.01-2.15 (m, 1H, CH₂CHOTMP), 2.22/2.30 (ddd, *J* = 13.6, 8.1, 4.0 Hz/*J* = 12.2, 9.7, 3.5 Hz, 1H, CH₂CHOTMP), 3.68/3.84 (d, *J* = 17.6 Hz/*J* = 18.3 Hz, 1H, NCH₂C=), 3.94-4.03 (m, 1H, CHOTMS), 4.20/4.40 (d, *J* = 14.1 Hz/*J* = 14.3 Hz, 1H, CH₂Ph), 4.42/4.68 (d, *J* = 18.3 Hz/*J* = 17.6 Hz, 1H, NCH₂C=), 4.64/4.91 (dd, *J* = 9.1, 4.0 Hz/*J* = 6.9, 3.5 Hz, 1H, CHOTMP), 4.77/4.89 (d, *J* = 14.1 Hz/*J* = 14.3 Hz, 1H, CH₂Ph), 4.79/4.82 (d, *J* = 1.2 Hz, 1H, C=CH₂), 4.93/4.99 (d, *J* = 1.2 Hz, 1H, C=CH₂), 7.28-7.45 (m, 5H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 0.01/0.03 (q, Si(CH₃)₃), 16.64/16.66 (t, piperidine-C₄), 19.7/19.9 (q, CH₃C=, NCCH₃), 23.4/23.6 (q, CH₃CHOTMS), 32.7 (q, NCCH₃), 33.1 (q, NCCH₃), 39.9 (t, piperidine-C₃, C₅), 40.2/40.8 (t, CH₂CHOTMP), 47.9/48.9 (t, CH₂Ph), 49.0/51.0 (t, NCH₂C=), 59.5 (s, 2C, CNO), 64.9/65.1 (d, CHOTMS), 77.8/78.0 (d, CHOTMP), 111.2/112.4 (t, C=CH₂), 126.8/126.93 (d, CH_{Ar}), 127.00/127.7 (d, CH_{Ar}), 128.1/128.7 (d, CH_{Ar}), 136.4/136.5 (s, C_{Ar}), 139.5/139.9 (s, C=CH₂), 171.1/172.7 (s, C=O).

Second diastereomer: ¹H NMR (400 MHz, CDCl₃): δ 0.11/0.13 (s, 9H, Si(CH₃)₃), 1.08 (s, 3H, NCCH₃), 1.10 (s, 3H, NCCH₃), 1.12 (s, 6H, NCCH₃), 1.18 (d, *J* = 6.1 Hz, 3H, CH₃CHOTMS), 1.26-1.34 (m, 1H, piperidine-H₄), 1.36-1.51 (m, 4H, piperidine-H₃, H₅), 1.52-1.62 (m, 1H, piperidine-H₄), 1.73 (s, 3H, CH₃C=), 1.98 (dt, *J* = 13.6, 6.7 Hz, 1H, CH₂CHOTMP), 2.01-2.15 (m, 1H, CH₂CHOTMP), 3.79/3.89 (d, *J* = 15.5 Hz/*J* = 14.9 Hz, 1H, NCH₂C=), 3.82-3.85 (m, 1H, CHOTMS), 4.02/4.09 (d, *J* = 14.8 Hz/*J* = 15.5 Hz, 1H, NCH₂C=), 4.58/4.82 (t, *J* = 6.7 Hz, 1H, CHOTMP), 4.63/4.75 (d, *J* = 17.0 Hz/*J* = 14.8 Hz, 1H, CH₂Ph), 4.87/4.98 (d, *J* = 14.8 Hz/*J* = 17.0 Hz, 1H, CH₂Ph), 4.89/4.92 (d, *J* = 1.4 Hz, 1H, C=CH₂), 4.91/5.00 (d, *J* = 1.4 Hz, 1H, C=CH₂), 7.28-7.45 (m, 5H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 0.1/0.2 (q, Si(CH₃)₃), 16.56/16.73 (t, piperidine-C₄), 20.0/20.2 (q, CH₃C=, NCCH₃), 24.1/24.2 (q, CH₃CHOTMS), 32.8 (q, NCCH₃), 33.1 (q, NCCH₃), 39.96 (t, piperidine-C₃), 40.03 (t, piperidine-C₅), 41.5/42.1 (t, CH₂CHOTMP), 48.5/49.2 (t, CH₂Ph), 49.9/51.2 (t, NCH₂C=), 59.0/59.2 (s, CNO), 59.8/60.0 (s, CNO), 65.3/65.6 (d, CHOTMS), 78.1/78.4 (d, CHOTMP), 111.3/112.9 (t, C=CH₂), 126.85/126.97 (d, CH_{Ar}), 127.2/127.8 (d, CH_{Ar}), 128.1/129.3 (d, CH_{Ar}), 136.56/136.63 (s, C_{Ar}), 139.7/140.2 (s, C=CH₂), 171.8/171.9 (s, C=O).

***N*-Benzyl-*N*-(3-methylbut-2-en-1-yl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9g):**



Prepared according to the general procedure, yield 271 mg (53%) as an inseparable 1:1 mixture of diastereomers. Ratio of rotamers is 1.2:1 for each diastereomer.


[R_f (hexanes/EtOAc 5:1) = 0.67]; IR (film); ν [cm^{-1}]: 2967 (m), 2929 (m), 1650 (s), 1495 (m), 1448 (m), 1376 (w), 1362 (w), 1250 (s), 1205 (w), 1133 (w), 1098 (m), 1079 (w), 1063 (w), 1020 (w), 990 (w), 973 (w), 957 (w), 892 (w), 840 (s), 748 (m), 701 (m); MS (+ESI) m/z , (%): 1027 (10, $[2M+Na^+]$), 525 (25, $[M+Na^+]$), 503 (100, $[M+H^+]$); HRMS (+ESI) m/z [$C_{29}H_{51}N_2O_3Si^+$]: calcd. 503.3664; found 503.3660.

First diastereomer: 1H NMR (400 MHz, $CDCl_3$): δ 0.03 (s, 9H, $Si(CH_3)_3$), 1.06 (s, 3H, $NCCH_3$), 1.07 (s, 3H, $NCCH_3$), 1.08 (s, 3H, $NCCH_3$), 1.10 (s, 3H, $NCCH_3$), 1.15/1.20 (d, $J = 6.1$ Hz, 3H, $CH_3CHOTMS$), 1.24-1.35 (m, 1H, piperidine- H_4), 1.36-1.45 (m, 4H, piperidine- H_3 , H_5), 1.46-1.53 (m, 1H, piperidine- H_4), 1.59/1.61 (s, 3H, $CH=C(CH_3)_2$), 1.73/1.74 (s, 3H, $CH=C(CH_3)_2$), 2.03-2.13 (m, 2H, $CH_2CHOTMP$), 3.85-3.90 (m, 1H, $CHOTMS$), 3.91/4.00 (dd, $J = 15.9$, 6.1 Hz, 1H, $CH_2CH=$), 4.07/4.25 (dd, $J = 15.9$, 6.8 Hz, 1H, $CH_2CH=$), 4.27/4.34 (d, $J = 14.4$ Hz/ $J = 16.9$ Hz, 1H, CH_2Ph), 4.63/4.74 (d, $J = 14.4$ Hz/ $J = 16.9$ Hz, 1H, CH_2Ph), 4.70-4.81 (m, 1H, $CHOTMP$), 5.15/5.31 (t, $J = 6.8$ Hz, 1H, $CH=C(CH_3)_2$), 7.19-7.36 (m, 5H, ArH); ^{13}C NMR (101 MHz, $CDCl_3$): δ 0.3/0.5 (q, $Si(CH_3)_3$), 17.1 (t, piperidine- C_4), 17.8/18.06 (q, $CH=C(CH_3)_2$), 20.2 (q, $NCCH_3$), 20.4 (q, $NCCH_3$), 23.7/23.9 (q, $CH_3CHOTMS$), 25.7/25.8 (q, $CH=C(CH_3)_2$), 33.1 (q, $NCCH_3$), 33.7 (q, $NCCH_3$), 40.37/40.44 (t, piperidine- C_3 , C_5), 41.9/42.1 (t, $CH_2CHOTMP$), 42.9/44.5 (t, $CH_2CH=$), 47.8/49.9 (t, CH_2Ph), 59.4 (s, 2C, CNO), 65.3/65.4 (d, $CHOTMS$), 77.3/77.8 (d, $CHOTMP$), 119.1/121.0 (d, $CH=C(CH_3)_2$), 127.0/127.1 (d, CH_{Ar}), 128.2 (d, CH_{Ar}), 128.6/128.8 (d, CH_{Ar}), 135.3/136.1 (s, $CH=C(CH_3)_2$), 137.4/137.6 (s, C_{Ar}), 172.2/172.4 (s, $C=O$).

Second diastereomer: 1H NMR (400 MHz, $CDCl_3$): δ 0.06/0.09 (s, 9H, $Si(CH_3)_3$), 0.99 (s, 3H, $NCCH_3$), 1.02 (d, $J = 6.1$ Hz, 3H, $CH_3CHOTMS$), 1.04 (s, 3H, $NCCH_3$), 1.08 (s, 3H, $NCCH_3$), 1.10 (s, 3H, $NCCH_3$), 1.24-1.35 (m, 1H, piperidine- H_4), 1.36-1.45 (m, 4H, piperidine- H_3 , H_5),

1.46-1.53 (m, 1H, piperidine-H4), 1.50/1.54 (s, 3H, CH=C(CH₃)₂), 1.67 (s, 3H, CH=C(CH₃)₂), 1.94-2.02 (m, 2H, CH₂CHOTMP), 3.70-3.79 (m, 1H, CHOTMS), 3.80-4.02 (m, 2H, CH₂CH=), 4.34/5.27 (d, $J = 14.2$ Hz/ $J = 16.9$ Hz, 1H, CH₂Ph), 4.61-4.69 (m, 1H, CHOTMP), 4.70/4.78 (d, $J = 16.9$ Hz/ $J = 14.2$ Hz, 1H, CH₂Ph), 5.18/5.40 (t, $J = 6.8$ Hz, 1H, CH=C(CH₃)₂), 7.19-7.36 (m, 5H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 0.6/0.7 (q, Si(CH₃)₃), 17.2 (t, piperidine-C4), 17.8/18.12 (q, CH=C(CH₃)₂), 20.2 (q, NCCH₃), 20.6 (q, NCCH₃), 24.4/24.8 (q, CH₃CHOTMS), 25.7/25.8 (q, CH=C(CH₃)₂), 32.9 (q, NCCH₃), 33.6 (q, NCCH₃), 40.5/40.6 (t, piperidine-C3, C5), 42.4/42.7 (t, CH₂CHOTMP), 43.3/44.3 (t, CH₂CH=), 48.3/49.8 (t, CH₂Ph), 59.49/59.53 (s, CNO), 60.3/60.5 (s, CNO), 65.7/65.9 (d, CHOTMS), 78.8/79.1 (d, CHOTMP), 119.3/121.1 (d, CH=C(CH₃)₂), 127.2/127.3 (d, CH_{Ar}), 128.3 (d, CH_{Ar}), 128.6/129.2 (d, CH_{Ar}), 135.4/136.1 (s, CH=C(CH₃)₂), 137.5/137.7 (s, C_{Ar}), 172.6/173.1 (s, C=O).

((4S)-N,N-Diallyl-5-(benzyloxy)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9h):



Prepared according to the general procedure, yield 300 mg (65%) as an inseparable 1.1:1 mixture of diastereomers.

[R_f (hexanes/EtOAc 5:1) = 0.62]; IR (film); ν [cm⁻¹]: 3084 (w), 2953 (w), 2862 (w), 1654 (s), 1454 (w), 1413 (m), 1378 (w), 1362 (w), 1251 (w), 1249 (w), 1211 (w), 1132 (m), 1094 (m), 991 (w), 922 (w), 876 (m), 841 (s), 751 (w), 713 (m), 698 (w), 612 (w); MS (+ESI) m/z , (%): 1083 (60, [2M+Na⁺]), 553 (100, [M+Na⁺]), 531 (10, [M+H⁺]); HRMS (+ESI) m/z [C₃₀H₅₀N₂O₄SiNa⁺]: calcd. 553.3613; found 553.3610.

First diastereomer: ¹H NMR (400 MHz, CDCl₃): δ 0.08 (s, 9H, Si(CH₃)₃), 1.00 (s, 3H, NCCH₃), 1.06 (s, 6H, NCCH₃), 1.18 (s, 3H, NCCH₃), 1.25-1.33 (m, 1H, piperidine-H4), 1.39-1.47 (m, 4H, piperidine-H3, H5), 1.48-1.56 (m, 1H, piperidine-H4), 2.03-2.11 (m, 2H, CH₂CHOTMP), 3.30-3.43 (m, 2H, CH₂OBn), 3.84-3.89 (m, 1H, CH₂CH=), 3.92-3.96 (m, 1H, CHOTMS), 4.07 (dd, $J = 16.5, 5.6$ Hz, 1H, CH₂CH=), 4.31 (dd, $J = 16.4, 6.1$ Hz, 1H, CH₂CH=), 4.49 (s, 2H, CH₂Ph),


4.56 (dd, $J = 16.1, 5.7$ Hz, 1H, $\text{CH}_2\text{CH=}$), 4.67-4.71 (m, 1H, CHOTMP), 5.10-5.20 (m, 4H, CH=CH_2), 5.82-5.92 (m, 2H, CH=CH_2), 7.24-7.36 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.8 (q, $\text{Si}(\text{CH}_3)_3$), 17.3 (t, piperidine-C4), 20.3 (q, NCCH_3), 20.5 (q, NCCH_3), 33.1 (q, NCCH_3), 33.8 (q, NCCH_3), 36.9 (t, CH_2CHOTMP), 40.6 (t, piperidine-C3, C5), 49.18 (t, $\text{CH}_2\text{CH=}$), 49.19 (t, $\text{CH}_2\text{CH=}$), 59.5 (s, CNO), 60.8 (s, CNO), 68.9 (d, CHOTMS), 73.4 (t, CH_2Ph), 75.3 (t, CH_2OBn), 79.5 (d, CHOTMP), 117.6 (t, CH=CH_2), 117.8 (t, CH=CH_2), 127.6 (d, CH_{Ar}), 127.83 (d, CH_{Ar}), 128.4 (d, CH_{Ar}), 134.0 (d, CH=CH_2), 134.3 (d, CH=CH_2), 138.4 (s, C_{Ar}), 171.9 (s, C=O).

Second diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.09 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.04 (s, 3H, NCCH_3), 1.09 (s, 3H, NCCH_3), 1.12 (s, 3H, NCCH_3), 1.21 (s, 3H, NCCH_3), 1.25-1.33 (m, 1H, piperidine-H4), 1.39-1.47 (m, 4H, piperidine-H3, H5), 1.48-1.56 (m, 1H, piperidine-H4), 1.93-2.02 (m, 1H, CH_2CHOTMP), 2.11-2.18 (m, 1H, CH_2CHOTMP), 3.30-3.43 (m, 2H, CH_2OBn), 3.75-3.80 (m, 2H, $\text{CH}_2\text{CH=}$, CHOTMS), 3.90-4.02 (m, 3H, $\text{CH}_2\text{CH=}$), 4.46 (d, $J = 12.2$ Hz, 1H, CH_2Ph), 4.51 (d, $J = 12.2$ Hz, 1H, CH_2Ph), 4.65-4.69 (m, 1H, CHOTMP), 5.10-5.20 (m, 4H, CH=CH_2), 5.70-5.81 (m, 2H, CH=CH_2), 7.24-7.36 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.7 (q, $\text{Si}(\text{CH}_3)_3$), 17.2 (t, piperidine-C4), 20.3 (q, NCCH_3), 20.5 (q, NCCH_3), 33.1 (q, NCCH_3), 33.8 (q, NCCH_3), 37.9 (t, CH_2CHOTMP), 40.7 (t, piperidine-C3, C5), 47.8 (t, $\text{CH}_2\text{CH=}$), 48.3 (t, $\text{CH}_2\text{CH=}$), 59.7 (s, CNO), 60.5 (s, CNO), 69.0 (d, CHOTMS), 73.3 (t, CH_2Ph), 75.1 (t, CH_2OBn), 77.4 (d, CHOTMP), 118.1 (t, CH=CH_2), 118.3 (t, CH=CH_2), 127.6 (d, CH_{Ar}), 127.84 (d, CH_{Ar}), 128.4 (d, CH_{Ar}), 133.3 (d, 2C, CH=CH_2), 138.5 (s, C_{Ar}), 172.7 (s, C=O).


(2*R*,4*S*)- and (2*S*,4*R*)- and (2*S*,4*S*)- and (2*R*,4*R*)-*N*-Allyl-*N*-((*S*)-1-phenylethyl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9i):

Prepared according to the general procedure from epoxides (*S*)-**7b** and (*R*)-**7b**, yield 312 mg (64%) as an inseparable 3:1 mixture of diastereomers and 307 mg (63%) as an inseparable 8:1 mixture of diastereomers. Ratio of rotamers is 1.5:1 for each diastereomer.

[R_f (hexanes/EtOAc 5:1) = 0.55]; IR (film); ν [cm^{-1}]: 2970 (w), 2931 (w), 1649 (s), 1453 (w), 1416 (w), 1376 (w), 1362 (w), 1250 (m), 1205 (w), 1179 (w), 1132 (w), 1116 (w), 1099 (w), 1061 (w), 1014 (w), 992 (w), 956 (w), 917 (w), 893 (w), 839 (s), 749 (w), 700 (m), 630 (w); MS (+ESI) m/z , (%): 999 (30, $[2\text{M}+\text{Na}^+]$), 511 (100, $[\text{M}+\text{Na}^+]$), 489 (40, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{28}\text{H}_{48}\text{N}_2\text{O}_3\text{SiNa}^+$]: calcd. 511.3326; found 511.3323.




(2R,4S)-Diastereomer *anti*-**9i**: ^1H NMR (400 MHz, CDCl_3): δ 0.00/0.10 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.10 (s, 3H, NCCH_3), 1.13 (s, 3H, NCCH_3), 1.16/1.22 (d, $J = 6.0$ Hz, 3H, CH_3CHOTMS), 1.17 (s, 6H, NCCH_3), 1.19-1.37 (m, 1H, piperidine-H4), 1.38-1.54 (m, 4H, piperidine-H3, H5), 1.49/1.71 (d, $J = 7.1$ Hz, 3H, PhCHCH_3), 1.51-1.59 (m, 1H, piperidine-H4), 1.92-2.13 (m, 2H, CH_2CHOTMP), 3.60/3.87 (dd, $J = 17.6, 5.8$ Hz/ $J = 17.0, 5.2$ Hz, 1H, $\text{CH}_2\text{CH=}$), 3.70-3.85/3.90-3.98 (m, 1H, CHOTMS), 4.03/4.64 (dd, $J = 17.0, 6.7$ Hz/ $J = 17.6, 4.6$ Hz, 1H, $\text{CH}_2\text{CH=}$), 4.70/4.86 (dd, $J = 9.8, 3.9$ Hz/ $J = 6.5$ Hz, 1H, CHOTMP), 4.87-5.13 (m, 2H, CH=CH_2), 5.76-5.95 (m, 1H, CH=CH_2), 5.87/5.98 (q, $J = 7.1$ Hz, 1H, PhCHCH_3), 7.21-7.51 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.5/0.8 (q, $\text{Si}(\text{CH}_3)_3$), 17.1/17.21 (t, piperidine-C4), 17.4/17.6 (q, PhCHCH_3), 20.2 (q, 2C, NCCH_3), 23.93/24.2 (q, CH_3CHOTMS), 33.4 (q, 2C, NCCH_3), 40.52 (t, piperidine-C3), 40.7 (t, piperidine-C5), 42.6/43.1 (t, CH_2CHOTMP), 46.10/46.11 (t, $\text{CH}_2\text{CH=}$), 51.8/52.4 (d, PhCHCH_3), 59.3/59.4 (s, CNO), 60.5/60.6 (s, CNO), 65.4/65.9 (d, CHOTMS), 76.4/78.52 (d, CHOTMP), 116.0/116.38 (t, CH=CH_2), 126.8/127.39 (d, CH_{Ar}), 128.1/128.34 (d, CH_{Ar}), 128.2/128.59 (d, CH_{Ar}), 136.6/136.9 (d, CH=CH_2), 140.5/141.1 (s, C_{Ar}), 173.2/173.3 (s, C=O).




(2S,4R)-Diastereomer *anti*-**9i**: ^1H NMR (400 MHz, CDCl_3): δ 0.10/0.11 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.07 (s, 3H, NCCH_3), 1.10 (s, 3H, NCCH_3), 1.13 (s, 3H, NCCH_3), 1.19 (s, 3H, NCCH_3), 1.22 (d, $J = 6.2$ Hz, 3H, CH_3CHOTMS), 1.25-1.31 (m, 1H, piperidine-H4), 1.33-1.46 (m, 5H, piperidine-H3, H4, H5), 1.50/1.72 (d, $J = 7.1$ Hz, 3H, PhCHCH_3), 1.95-2.05/2.07-2.12 (m, 2H, CH_2CHOTMP), 3.68/3.83-3.92 (dd, $J = 17.5, 6.1$ Hz/m, 1H, $\text{CH}_2\text{CH=}$), 3.79-3.91 (m, 1H, CHOTMS), 4.39-4.48 (m, 1H, $\text{CH}_2\text{CH=}$), 4.59/4.66 (dd, $J = 7.6, 5.9$ Hz/ $J = 8.3, 5.0$ Hz, 1H, CHOTMP), 4.80-4.95 (m, 1H, CH=CH_2), 4.96-5.07 (m, 1H, CH=CH_2), 5.46/5.62-5.74 (dddd, $J = 16.9, 11.1, 6.4, 4.8$ Hz/m,

^1H , $\text{CH}=\text{CH}_2$), 5.89/5.97 (q, $J = 6.7 \text{ Hz}/J = 7.0 \text{ Hz}$, 1H, PhCHCH_3), 7.22-7.40 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.5/0.86 (q, $\text{Si}(\text{CH}_3)_3$), 16.9/17.4 (q, PhCHCH_3), 17.19/17.31 (t, piperidine-C4), 20.2 (q, NCCH_3), 20.41 (q, NCCH_3), 24.2/24.8 (q, CH_3CHOTMS), 33.4 (q, NCCH_3), 33.6 (q, NCCH_3), 40.3/40.4 (t, piperidine-C3), 40.5/40.6 (t, piperidine-C5), 42.3/43.2 (t, CH_2CHOTMP), 45.7/46.0 (t, $\text{CH}_2\text{CH=}$), 52.0/52.1 (d, PhCHCH_3), 59.3 (s, CNO), 60.3 (s, CNO), 65.2/66.16 (d, CHOTMS), 77.7/78.50 (d, CHOTMP), 116.08/116.13 (t, $\text{CH}=\text{CH}_2$), 127.0/127.44 (d, CH_{Ar}), 128.2/128.33 (d, CH_{Ar}), 128.35/128.5 (d, CH_{Ar}), 136.0/136.9 (d, $\text{CH}=\text{CH}_2$), 140.5/140.9 (s, C_{Ar}), 172.7/173.5 (s, $\text{C}=\text{O}$).



(2*S*,4*S*)-Diastereomer *syn*-**9i**: ^1H NMR (400 MHz, CDCl_3): δ 0.05/0.11 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.04 (s, 3H, NCCH_3), 1.05 (s, 3H, NCCH_3), 1.16 (s, 3H, NCCH_3), 1.19 (s, 3H, NCCH_3), 1.20-1.37 (m, 1H, piperidine-H4), 1.22/1.24 (d, $J = 6.2 \text{ Hz}$, 3H, CH_3CHOTMS), 1.38-1.54 (m, 4H, piperidine-H3, H5), 1.47/1.63 (d, $J = 7.1 \text{ Hz}$, 3H, PhCHCH_3), 1.51-1.59 (m, 1H, piperidine-H4), 1.83-2.27 (m, 2H, CH_2CHOTMP), 3.86 (dd, $J = 13.0, 4.6 \text{ Hz}$, 1H, $\text{CH}_2\text{CH=}$), 3.88-3.96 (m, 1H, CHOTMS), 4.61 (dd, $J = 13.0, 4.6 \text{ Hz}$, 1H, $\text{CH}_2\text{CH=}$), 4.64/4.93 (t, $J = 6.6 \text{ Hz}$, 1H, CHOTMP), 4.81-5.13 (m, 2H, $\text{CH}=\text{CH}_2$), 5.83-5.93 (m, 2H, $\text{CH}=\text{CH}_2$, PhCHCH_3), 7.22-7.40 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.6/0.91 (q, $\text{Si}(\text{CH}_3)_3$), 17.24/17.29 (t, piperidine-C4), 19.3/19.5 (q, PhCHCH_3), 20.42 (q, NCCH_3), 20.5 (q, NCCH_3), 23.91/24.8 (q, CH_3CHOTMS), 33.2 (q, NCCH_3), 33.6 (q, NCCH_3), 40.46 (t, piperidine-C3), 40.8 (t, piperidine-C5), 41.0/42.4 (t, CH_2CHOTMP), 45.9/46.0 (t, $\text{CH}_2\text{CH=}$), 54.8/55.2 (d, PhCHCH_3), 59.5 (s, CNO), 60.7 (s, CNO), 65.5/66.22 (d, CHOTMS), 77.5/79.2 (d, CHOTMP), 116.12/116.43 (t, $\text{CH}=\text{CH}_2$), 127.42/127.7 (d, CH_{Ar}), 128.0/128.32 (d, CH_{Ar}), 128.4/128.63 (d, CH_{Ar}), 135.0/135.2 (d, $\text{CH}=\text{CH}_2$), 140.8/141.8 (s, C_{Ar}), 171.0/172.6 (s, $\text{C}=\text{O}$).




(2*R*,4*R*)-Diastereomer *syn*-**9i**: ^1H NMR (400 MHz, CDCl_3): δ 0.02/0.15 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.05 (s, 3H, NCCH_3), 1.06 (s, 3H, NCCH_3), 1.18 (s, 3H, NCCH_3), 1.21 (s, 3H, NCCH_3), 1.22-1.34 (m, 1H, piperidine-H4), 1.25 (d, $J = 6.1$ Hz, 3H, CH_3CHOTMS), 1.38-1.54 (m, 4H, piperidine-H3, H5), 1.55-1.59 (m, 1H, piperidine-H4), 1.61 (d, $J = 7.0$ Hz, 3H, PhCHCH_3), 1.87 (dt, $J = 13.8, 6.7$ Hz, 1H, CH_2CHOTMP), 2.11-2.23 (m, 1H, CH_2CHOTMP), 3.37/3.46 (dd, $J = 15.0, 6.7$ Hz/ $J = 15.3, 6.4$ Hz, 1H, $\text{CH}_2\text{CH=}$), 3.77-3.85 (m, 1H, CHOTMS), 4.02-4.13 (m, 1H, $\text{CH}_2\text{CH=}$), 4.83-4.90 (m, 2H, CHOTMP , CH=CH_2), 4.93-4.98 (m, 1H, CH=CH_2), 5.63-5.81 (m, 2H, PhCHCH_3 , CH=CH_2), 7.22-7.40 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.7/1.5 (q, $\text{Si}(\text{CH}_3)_3$), 17.1 (t, piperidine-C4), 19.0/19.4 (q, PhCHCH_3), 20.3 (q, NCCH_3), 20.6 (q, NCCH_3), 24.4/24.7 (q, CH_3CHOTMS), 33.1 (q, NCCH_3), 33.4 (q, NCCH_3), 40.96 (t, piperidine-C3), 40.97 (t, piperidine-C5), 41.4/42.7 (t, CH_2CHOTMP), 45.8/46.1 (t, $\text{CH}_2\text{CH=}$), 55.0 (d, PhCHCH_3), 59.5 (s, CNO), 60.8 (s, CNO), 65.8/66.4 (d, CHOTMS), 78.2/79.3 (d, CHOTMP), 115.9/116.5 (t, CH=CH_2), 126.7 (d, CH_{Ar}), 127.1/128.2 (d, CH_{Ar}), 128.6/128.8 (d, CH_{Ar}), 134.9/136.3 (d, CH=CH_2), 140.5/141.4 (s, C_{Ar}), 171.1/171.9 (s, C=O).


(2*R*,4*S*)- and (2*S*,4*S*)-*N*-Allyl-*N*-((*S*)-1-(naphthalen-2-yl)ethyl)-2-((2,2,6,6-tetramethyl-piperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9j**):**

Prepared according to the general procedure, yield 334 mg (62%) as an inseparable 3:1 mixture of diastereomers. Ratio of rotamers is 1.2:1 for each diastereomer. The silyl group in **9j** was deprotected (see p. S35) and hydroxy amide **S13** was transformed to hydrochloride **S13·HCl** (see p. S105). The major diastereomer of **S13·HCl** crystallized from MTBE with a few drops of CHCl_3 and its configuration was determined by X-ray crystallography.

[R_f (hexanes/EtOAc 5:1) = 0.60]; IR (film); ν [cm^{-1}]: 2970 (m), 2931 (m), 1647 (s), 1457 (m), 1438 (m), 1417 (m), 1376 (m), 1362 (m), 1249 (s), 1183 (m), 1131 (m), 1098 (w), 1060 (w), 1018 (w), 992 (w), 976 (w), 956 (w), 917 (w), 894 (w), 840 (s), 822 (w), 749 (m), 699 (w); MS (+ESI) m/z , (%): 561 (50, $[\text{M}+\text{Na}^+]$), 539 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{32}\text{H}_{51}\text{N}_2\text{O}_3\text{Si}^+$]: calcd. 539.3664; found 539.3661.



Major diastereomer *anti*-**9j**: ^1H NMR (400 MHz, CDCl_3): δ -0.03/0.09 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.94 (s, 3H, NCCH_3), 1.11 (s, 3H, NCCH_3), 1.14 (s, 3H, NCCH_3), 1.17 (s, 3H, NCCH_3), 1.21/1.29 (d, $J = 6.2$ Hz, 3H, CH_3CHOTMS), 1.28-1.40 (m, 1H, piperidine-H4), 1.41-1.55 (m, 4H, piperidine-H3, H5), 1.57-1.60 (m, 1H, piperidine-H4), 1.61 (d, $J = 7.1$ Hz, 3H, CH_3CHAr), 1.96-2.18 (m, 2H, CH_2CHOTMP), 3.61/3.73 (dd, $J = 15.3, 6.0$ Hz/ $J = 17.6, 6.4$ Hz, 1H, $\text{CH}_2\text{CH=}$), 3.78-3.86/3.91-4.02 (m, 1H, CHOTMS), 4.05/4.45 (dd, $J = 17.6, 5.7$ Hz/ $J = 15.3, 5.4$ Hz, 1H, $\text{CH}_2\text{CH=}$), 4.60-4.68/4.73 (m/dd, $J = 9.8, 3.9$ Hz, 1H, CHOTMP), 4.87-5.17 (m, 2H, CH=CH_2), 5.71-6.02 (m, 1H, CH=CH_2), 6.07/6.15 (q, $J = 7.2$ Hz, 1H, ArCHCH_3), 7.41-7.58 (m, 2H, ArH), 7.70-7.94 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.6/0.8 (q, $\text{Si}(\text{CH}_3)_3$), 17.1/17.26 (t, piperidine-C4), 17.5/17.6 (q, CH_3CHAr), 20.2 (q, NCCH_3), 20.44 (q, NCCH_3), 24.0/24.2 (q, CH_3CHOTMS), 33.5 (q, NCCH_3), 33.6 (q, NCCH_3), 40.5 (t, piperidine-C3), 40.7 (t, piperidine-C5), 42.7/43.2 (t, CH_2CHOTMP), 46.19/46.23 (t, $\text{CH}_2\text{CH=}$), 51.9/52.4 (d, ArCHCH_3), 59.4/59.5 (s, CNO), 60.62 (s, CNO), 65.4/65.9 (d, CHOTMS), 77.6/78.6 (d, CHOTMP), 116.2/116.5 (t, CH=CH_2), 125.4 (d, CHAr), 126.0 (d, CHAr), 126.3 (d, CHAr), 126.82 (d, CHAr), 127.34 (d, CHAr), 127.6 (d, CHAr), 127.8 (d, CHAr), 132.3 (s, CAr), 133.2/133.3 (s, CAr), 136.6/137.0 (d, CH=CH_2), 138.2/138.7 (s, CAr), 173.4/173.5 (s, C=O).




Minor diastereomer *syn*-**9j**: ^1H NMR (400 MHz, CDCl_3): δ 0.00/0.13 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.00 (s, 3H, NCCH_3), 1.08 (s, 3H, NCCH_3), 1.14 (s, 6H, NCCH_3), 1.25/1.31 (d, $J = 6.0$ Hz, 3H, CH_3CHOTMS), 1.28-1.40 (m, 1H, piperidine-H4), 1.41-1.55 (m, 4H, piperidine-H3, H5), 1.56-1.62 (m, 1H, piperidine-H4), 1.85/1.87 (d, $J = 6.4$ Hz, 3H, CH_3CHAr), 1.99-2.21 (m, 2H,

CH₂CHOTMP), 3.40/3.64 (dd, $J = 15.6, 5.4 \text{ Hz}/J = 17.3, 4.9 \text{ Hz}$, 1H, CH₂CH=), 3.48-3.56/4.05-4.12 (m, 1H, CH₂CH=), 3.92-4.00 (m, 1H, CHOTMS), 4.64-4.86 (m, 1H, CHOTMP), 4.87-5.17 (m, 2H, CH=CH₂), 5.45-5.56 (m, 1H, CH=CH₂), 6.13-6.26 (m, 1H, ArCHCH₃), 7.41-7.58 (m, 2H, ArH), 7.70-7.94 (m, 5H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 0.9/1.5 (q, Si(CH₃)₃), 17.2/17.29 (t, piperidine-C4), 19.3/19.5 (q, CH₃CHAr), 20.38 (q, NCCH₃), 20.6 (q, NCCH₃), 23.9/24.4 (q, CH₃CHOTMS), 33.3 (q, NCCH₃), 33.7 (q, NCCH₃), 40.4 (t, piperidine-C3), 41.0 (t, piperidine-C5), 41.5/42.5 (t, CH₂CHOTMP), 46.06/46.12 (t, CH₂CH=), 54.9/55.4 (d, ArCHCH₃), 59.7 (s, CNO), 60.63 (s, CNO), 65.3/65.6 (d, CHOTMS), 76.5/79.3 (d, CHOTMP), 116.6/116.8 (t, CH=CH₂), 124.6 (d, CHAr), 125.5 (d, CHAr), 126.1 (d, CHAr), 126.7 (d, CHAr), 126.80 (d, CHAr), 127.29 (d, CHAr), 127.9 (d, CHAr), 132.93 (s, CAr), 133.4 (s, CAr), 135.1/136.0 (d, CH=CH₂), 138.0/138.4 (s, CAr), 172.8/175.0 (s, C=O).

(2R,4S)- and (2S,4S)-N-Allyl-4-hydroxy-N-((S)-1-(naphthalen-2-yl)ethyl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentanamide (S13):


In a similar manner as described in [11] amide **9j** (619 mg, 1.15 mmol) was dissolved in dry THF (5 mL). The reaction mixture was cooled to 0 °C in an ice/water bath, tetrabutylammonium fluoride (1 M solution in THF, 1.4 mL, 1.4 mmol) was added and the mixture was stirred at 0 °C for 30 min. The reaction was quenched by saturated NH₄Cl solution and diluted with water (5 mL) and diethyl ether (5 mL), the organic layer was separated and the aqueous was extracted with diethyl ether (2 × 5 mL). The combined organic layers were dried over MgSO₄ and filtered. The crude mixture was purified by column chromatography (gradient, hexanes/EtOAc 10:1 to 1:1) to give 493 mg (92%) **S13** as an inseparable 3:1 mixture of diastereomers.

[R_f (hexanes/EtOAc 2:1) = 0.36]; IR (film); ν [cm⁻¹]: 3411 (br), 2970 (m), 2928 (s), 2873 (w), 1629 (s), 1455 (w), 1417 (w), 1377 (w), 1362 (w), 1321 (w), 1298 (w), 1258 (w), 1242 (w), 1131 (m), 1081 (w), 990 (w), 920 (w), 858 (w), 820 (w), 749 (w); MS (+ESI) m/z , (%): 955 (10, [2M+Na⁺], 489 (100, [M+Na⁺]); HRMS (+ESI) m/z [C₂₉H₄₂N₂O₃Na⁺]: calcd. 489.3088; found 489.3083.



(2*R*,4*S*)

Major diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 1.15 (s, 6H, NCCH_3), 1.16 (s, 3H, NCCH_3), 1.18 (s, 3H, NCCH_3), 1.24 (d, $J = 6.2$ Hz, 3H, CH_3CHOH), 1.31-1.40 (m, 1H, piperidine- H_4), 1.41-1.54 (m, 4H, piperidine- H_3 , H_5), 1.55-1.59 (m, 1H, piperidine- H_4), 1.60/1.61 (d, $J = 7.1$ Hz, 3H, ArCHCH_3), 2.08-2.18 (m, 3H, OH, CH_2CHOTMP), 3.85 (dd, $J = 17.4$, 4.6 Hz, 1H, $\text{CH}_2\text{CH=}$), 4.07-4.22 (m, 2H, CHOH , $\text{CH}_2\text{CH=}$), 4.70/4.76 (dd, $J = 7.2$, 4.5 Hz/ $J = 8.6$, 3.2 Hz, 1H, CHOTMP), 4.85-4.95/5.11-5.17 (m, 2H, CH=CH_2), 5.47/5.76-5.88 (dddd, $J = 17.2$, 10.6, 7.0, 4.5 Hz/m, 1H, CH=CH_2), 6.17/6.18 (q, $J = 7.1$ Hz/ $J = 6.8$ Hz, 1H, ArCHCH_3), 7.35-7.53 (m, 3H, ArH), 7.62-7.86 (m, 4H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.0/17.37 (q, ArCHCH_3), 17.1/17.2 (t, piperidine- C_4), 20.3/20.4 (q, NCCH_3), 20.5/20.6 (q, NCCH_3), 24.39/24.42 (q, CH_3CHOH), 33.5 (q, 2C, NCCH_3), 40.50 (t, piperidine- C_3), 40.53 (t, piperidine- C_5), 41.0/41.6 (t, CH_2CHOTMP), 46.0/46.1 (t, $\text{CH}_2\text{CH=}$), 51.9/52.1 (d, ArCHCH_3), 59.7 (s, CNO), 60.6 (s, CNO), 63.7/65.3 (d, CHOH), 79.3/80.1 (d, CHOTMP), 116.6/116.8 (t, CH=CH_2), 126.2 (d, CH_{Ar}), 126.34 (d, CH_{Ar}), 126.7 (d, CH_{Ar}), 127.10 (d, CH_{Ar}), 127.73 (d, CH_{Ar}), 128.12 (d, CH_{Ar}), 128.3 (d, CH_{Ar}), 132.92/132.94 (s, C_{Ar}), 133.26/133.28 (s, C_{Ar}), 136.0/136.4 (d, CH=CH_2), 138.0/138.1 (s, C_{Ar}), 173.7/175.0 (s, C=O).



(2*S*,4*S*)


Minor diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 1.08 (s, 3H, NCCH_3), 1.13 (s, 3H, NCCH_3), 1.16 (s, 3H, NCCH_3), 1.19 (s, 3H, NCCH_3), 1.25 (d, $J = 6.1$ Hz, 3H, CH_3CHOH), 1.31-1.40 (m, 1H, piperidine- H_4), 1.41-1.54 (m, 4H, piperidine- H_3 , H_5), 1.55-1.59 (m, 1H, piperidine- H_4), 1.79/1.83 (d, $J = 6.8$ Hz, 3H, ArCHCH_3), 1.96-2.06 (m, 3H, OH, CH_2CHOTMP), 3.62 (dd, $J = 17.9$, 5.0 Hz, 1H, $\text{CH}_2\text{CH=}$), 3.97-4.06 (m, 1H, CHOH), 4.40 (dd, $J = 17.9$, 5.2 Hz, 1H, CHOTMP), 4.85-4.95/5.11-5.17 (m, 2H, CH=CH_2), 5.47/5.76-5.88 (dddd, $J = 17.2$, 10.6, 7.0, 4.5 Hz/m, 1H, CH=CH_2), 6.17/6.18 (q, $J = 7.1$ Hz/ $J = 6.8$ Hz, 1H, ArCHCH_3), 7.35-7.53 (m, 3H, ArH), 7.62-7.86 (m, 4H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.0/17.37 (q, ArCHCH_3), 17.1/17.2 (t, piperidine- C_4), 20.3/20.4 (q, NCCH_3), 20.5/20.6 (q, NCCH_3), 24.39/24.42 (q, CH_3CHOH), 33.5 (q, 2C, NCCH_3), 40.50 (t, piperidine- C_3), 40.53 (t, piperidine- C_5), 41.0/41.6 (t, CH_2CHOTMP), 46.0/46.1 (t, $\text{CH}_2\text{CH=}$), 51.9/52.1 (d, ArCHCH_3), 59.7 (s, CNO), 60.6 (s, CNO), 63.7/65.3 (d, CHOH), 79.3/80.1 (d, CHOTMP), 116.6/116.8 (t, CH=CH_2), 126.2 (d, CH_{Ar}), 126.34 (d, CH_{Ar}), 126.7 (d, CH_{Ar}), 127.10 (d, CH_{Ar}), 127.73 (d, CH_{Ar}), 128.12 (d, CH_{Ar}), 128.3 (d, CH_{Ar}), 132.92/132.94 (s, C_{Ar}), 133.26/133.28 (s, C_{Ar}), 136.0/136.4 (d, CH=CH_2), 138.0/138.1 (s, C_{Ar}), 173.7/175.0 (s, C=O).

CH₂CH=), 4.86-4.95 (m, 1H, CHOTMP), 4.96-5.06/5.07-5.11 (m, 2H, CH=CH₂), 5.67-5.75/5.76-5.88 (m, 1H, CH=CH₂), 6.14-6.23 (m, 1H, ArCHCH₃), 7.35-7.53 (m, 3H, ArH), 7.62-7.86 (m, 4H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 17.3/17.44 (t, piperidine-C4), 19.4/19.5 (q, ArCHCH₃), 20.3/20.4 (q, NCCH₃), 20.5/20.6 (q, NCCH₃), 24.0/24.1 (q, CH₃CHOH), 33.6 (q, NCCH₃), 33.7 (q, NCCH₃), 40.0/41.3 (t, CH₂CHOTMP), 40.4 (t, piperidine-C3), 40.6 (t, piperidine-C5), 46.2/46.3 (t, CH₂CH=), 55.5/55.6 (d, ArCHCH₃), 59.8 (s, CNO), 60.7 (s, CNO), 64.6/65.7 (d, CHOH), 81.0/81.8 (d, CHOTMP), 116.7/116.9 (t, CH=CH₂), 125.2 (d, CH_{Ar}), 126.1 (d, CH_{Ar}), 126.29 (d, CH_{Ar}), 127.06 (d, CH_{Ar}), 127.68 (d, CH_{Ar}), 128.07 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 132.97/133.00 (s, C_{Ar}), 133.58/133.61 (s, C_{Ar}), 134.6/134.7 (d, CH=CH₂), 138.2/138.3 (s, C_{Ar}), 174.3/174.6 (s, C=O).

(2*R*,4*S*) and (2*S*,4*S*)-*N*-(3-Methylbut-2-en-1-yl)-*N*-((*S*)-1-phenylethyl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9k):


Prepared according to the general procedure, yield 315 mg (61%) as an inseparable 3:1 mixture of diastereomers. Ratio of rotamers is 1.2:1 for each diastereomer.

[*R*_f (hexanes/EtOAc 5:1) = 0.60]; IR (film); ν [cm⁻¹]: 2968 (m), 2930 (m), 1648 (s), 1495 (m), 1439 (m), 1376 (w), 1363 (w), 1309 (w), 1250 (s), 1208 (w), 1167 (m), 1133 (m), 1098 (w), 1064 (w), 1017 (w), 993 (w), 957 (w), 896 (w), 840 (s), 784 (w), 750 (w), 700 (m), 600 (w); MS (+ESI) *m/z*, (%): 539 (100, [M+Na⁺]), 517 (90, [M+H⁺]); HRMS (+ESI) *m/z* [C₃₀H₅₂N₂O₃SiNa⁺]: calcd. 539.3639; found 539.3638.



Major diastereomer *anti*-**9k**: ¹H NMR (400 MHz, CDCl₃): δ -0.03/0.11 (s, 9H, Si(CH₃)₃), 0.96/1.15 (d, *J* = 6.1 Hz, 3H, CH₃CHOTMS), 1.04 (s, 3H, NCCH₃), 1.10 (s, 3H, NCCH₃), 1.14 (s, 6H, NCCH₃), 1.25-1.36 (m, 1H, piperidine-H4), 1.37-1.51 (m, 4H, piperidine-H3, H5), 1.48/1.49 (d, *J* = 7.1 Hz, 3H, PhCHCH₃), 1.50 (s, 3H, CH=C(CH₃)₂), 1.52-1.57 (m, 1H, piperidine-H4), 1.53/1.67 (s, 3H, CH=C(CH₃)₂), 1.91-2.15 (m, 2H, CH₂CHOTMP), 3.61 (dd, *J* = 16.1, 4.0 Hz, 1H, CH₂CH=), 3.72-3.79/3.80-3.82 (m, 1H, CHOTMS), 3.83-3.90 (m, 1H, CH₂CH=), 4.56/4.71 (dd, *J* = 8.6, 5.1 Hz/*J* = 9.8, 3.6 Hz, 1H, CHOTMP), 5.10-5.20/5.48-5.55

(m, 1H, $\underline{\text{CH}}=\text{C}(\text{CH}_3)_2$), 5.87/6.02 (q, $J = 7.0$ Hz, 1H, $\text{PhCH}\underline{\text{H}}\text{CH}_3$), 7.20-7.41 (m, 5H, $\text{Ar}\underline{\text{H}}$); ^{13}C NMR (101 MHz, CDCl_3): δ 0.4/0.8 (q, $\text{Si}(\text{CH}_3)_3$), 16.1/17.0 (q, $\text{PhCH}\underline{\text{C}}\text{H}_3$), 17.1/17.24 (t, piperidine-C4), 18.1/18.3 (q, $\text{CH}=\text{C}(\underline{\text{C}}\text{H}_3)_2$), 20.1 (q, $\text{NC}\underline{\text{C}}\text{H}_3$), 20.4 (q, $\text{NC}\underline{\text{C}}\text{H}_3$), 23.9/25.6 (q, $\underline{\text{C}}\text{H}_3\text{CHOTMS}$), 25.47/25.53 (q, $\text{CH}=\text{C}(\underline{\text{C}}\text{H}_3)_2$), 33.3 (q, $\text{NC}\underline{\text{C}}\text{H}_3$), 33.4 (q, $\text{NC}\underline{\text{C}}\text{H}_3$), 40.46/40.70 (t, piperidine-C3), 40.50 (t, piperidine-C5), 41.6/41.8 (t, $\underline{\text{C}}\text{H}_2\text{CH}=\text{}$), 42.7/43.1 (t, $\underline{\text{C}}\text{H}_2\text{CHOTMP}$), 51.3/52.0 (d, $\text{Ph}\underline{\text{C}}\text{HCH}_3$), 59.3 (s, CNO), 60.49 (s, CNO), 65.3/65.9 (d, $\underline{\text{C}}\text{HOTMS}$), 78.0/78.6 (d, $\underline{\text{C}}\text{HOTMP}$), 124.0/124.3 (d, $\underline{\text{C}}\text{H}=\text{C}(\text{CH}_3)_2$), 126.7/127.3 (d, CH_{Ar}), 127.7/128.1 (d, CH_{Ar}), 128.4/128.5 (d, CH_{Ar}), 132.0/132.6 (s, $\text{CH}=\underline{\text{C}}(\text{CH}_3)_2$), 140.6/141.5 (s, C_{Ar}), 173.0/173.2 (s, $\text{C}=\text{O}$).




Minor diastereomer *syn*-**9k**: ^1H NMR (400 MHz, CDCl_3): δ 0.04/0.16 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.89 (s, 3H, NCCH_3), 1.04 (s, 3H, NCCH_3), 1.08 (s, 3H, NCCH_3), 1.12 (s, 3H, NCCH_3), 1.22/1.23 (d, $J = 6.1$ Hz, 3H, $\underline{\text{C}}\text{H}_3\text{CHOTMS}$), 1.25-1.36 (m, 1H, piperidine-H4), 1.37-1.51 (m, 4H, piperidine-H3, H5), 1.44/1.52 (d, $J = 7.2$ Hz, 3H, $\text{PhCH}\underline{\text{C}}\text{H}_3$), 1.45/1.61 (s, 3H, $\text{CH}=\text{C}(\underline{\text{C}}\text{H}_3)_2$), 1.53-1.57 (m, 1H, piperidine-H4), 1.65 (s, 3H, $\text{CH}=\text{C}(\underline{\text{C}}\text{H}_3)_2$), 1.85-2.30 (m, 2H, $\underline{\text{C}}\text{H}_2\text{CHOTMP}$), 3.96-4.31 (m, 2H, $\underline{\text{C}}\text{H}_2\text{CH}=\text{}$), 4.67-4.73 (m, 1H, $\underline{\text{C}}\text{HOTMP}$), 5.51 (dd, $J = 6.7, 5.2$ Hz, 1H, $\underline{\text{C}}\text{H}=\text{C}(\text{CH}_3)_2$), 5.87 (q, $J = 7.3$ Hz, 1H, $\text{PhCH}\underline{\text{H}}\text{CH}_3$), 7.20-7.41 (m, 5H, $\text{Ar}\underline{\text{H}}$); ^{13}C NMR (101 MHz, CDCl_3): δ 0.5/1.4 (q, $\text{Si}(\text{CH}_3)_3$), 15.3/15.9 (q, $\text{PhCH}\underline{\text{C}}\text{H}_3$), 17.18/17.3 (t, piperidine-C4), 17.6/17.7 (q, $\text{CH}=\text{C}(\underline{\text{C}}\text{H}_3)_2$), 20.2 (q, $\text{NC}\underline{\text{C}}\text{H}_3$), 20.5 (q, $\text{NC}\underline{\text{C}}\text{H}_3$), 24.3/24.9 (q, $\underline{\text{C}}\text{H}_3\text{CHOTMS}$), 24.8/25.7 (q, $\text{CH}=\text{C}(\underline{\text{C}}\text{H}_3)_2$), 33.1 (q, $\text{NC}\underline{\text{C}}\text{H}_3$), 33.5 (q, $\text{NC}\underline{\text{C}}\text{H}_3$), 40.4 (t, piperidine-C3), 40.72 (t, piperidine-C5), 40.9/41.3 (t, $\underline{\text{C}}\text{H}_2\text{CH}=\text{}$), 41.49/41.53 (t, $\underline{\text{C}}\text{H}_2\text{CHOTMP}$), 54.5/54.9 (d, $\text{Ph}\underline{\text{C}}\text{HCH}_3$), 59.2 (s, CNO), 60.53 (s, CNO), 65.5/66.2 (d, $\underline{\text{C}}\text{HOTMS}$), 76.6/79.5 (d, $\underline{\text{C}}\text{HOTMP}$), 122.3/123.2 (d, $\underline{\text{C}}\text{H}=\text{C}(\text{CH}_3)_2$), 127.2 (d, CH_{Ar}), 127.4 (d, CH_{Ar}), 128.6 (d, CH_{Ar}), 132.5/133.2 (s, $\text{CH}=\underline{\text{C}}(\text{CH}_3)_2$), 140.7/142.1 (s, C_{Ar}), 172.6/174.8 (s, $\text{C}=\text{O}$).


(*R)- and (*S**)-*N,N*-Diallyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-((1*R**,2*S**)-2-((trimethylsilyl)oxy)cyclohexyl)acetamide (9l):**

Prepared according to the general procedure, yield 292 mg (63%) as an inseparable 7:1 mixture of diastereomers.

[*R*_f (hexanes/EtOAc 10:1) = 0.63]; IR (film); ν [cm⁻¹]: 3006 (w), 2930 (m), 2857 (w), 1654 (s), 1447 (w), 1414 (w), 1378 (w), 1362 (w), 1250 (m), 1222 (w), 1202 (w), 1183 (w), 1133 (m), 1089 (w), 1058 (w), 989 (w), 941 (w), 920 (w), 881 (s), 839 (s), 792 (w), 709 (w), 689 (w); MS (+ESI) *m/z*, (%): 487 (15, [M+Na⁺]), 465 (100, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₆H₄₉N₂O₃Si⁺]: calcd. 465.3507; found 465.3508.




Major diastereomer: ¹H NMR (400 MHz, CDCl₃): δ 0.09 (s, 9H, Si(CH₃)₃), 1.04 (s, 3H, NCCH₃), 1.06-1.32 (m, 4H, H3, H4, H5, piperidine-H4), 1.09 (s, 3H, NCCH₃), 1.16 (s, 3H, NCCH₃), 1.19 (s, 3H, NCCH₃), 1.36-1.46 (m, 4H, piperidine-H3, H5), 1.47-1.51 (m, 2H, H1, H6), 1.52-1.57 (m, 1H, piperidine-H4), 1.60-1.74 (m, 2H, H4, H5), 1.95-2.04 (m, 1H, H3), 2.51-2.59 (m, 1H, H6), 3.73-3.80 (m, 2H, H2, CH₂CH=), 3.86 (dd, *J* = 16.9, 5.9 Hz, 1H, CH₂CH=), 4.01 (dd, *J* = 14.7, 6.1 Hz, 1H, CH₂CH=), 4.53 (dd, *J* = 16.9, 5.2 Hz, 1H, CH₂CH=), 5.06 (d, *J* = 3.3 Hz, 1H, CHOTMP), 5.10-5.13 (m, 1H, CH=CH₂), 5.14-5.16 (m, 2H, CH=CH₂), 5.17-5.20 (m, 1H, CH=CH₂), 5.72-5.83 (m, 1H, CH=CH₂), 5.90 (dddd, *J* = 17.5, 9.9, 5.9, 5.2 Hz, 1H, CH=CH₂); ¹³C NMR (101 MHz, CDCl₃): δ 1.2 (q, Si(CH₃)₃), 17.1 (t, piperidine-C4), 20.4 (q, NCCH₃), 20.6 (q, NCCH₃), 24.3 (t, C6), 25.0 (t, C4), 25.8 (t, C5), 33.4 (q, NCCH₃), 33.9 (q, NCCH₃), 36.8 (t, C3), 40.9 (t, piperidine-C3, C5), 47.8 (t, CH₂CH=), 49.1 (t, CH₂CH=), 51.2 (d, C1), 59.7 (s, CNO), 60.9 (s, CNO), 72.8 (d, C2), 74.8 (d, CHOTMP), 117.3 (t, CH=CH₂), 117.7 (t, CH=CH₂), 133.6 (d, CH=CH₂), 134.1 (d, CH=CH₂), 173.8 (s, C=O).



Minor diastereomer (detectable resonances): ^1H NMR (400 MHz, CDCl_3): δ 3.43 (td, $J = 9.6, 4.2$ Hz, 1H, CHOTMS), 3.53 (dd, $J = 14.8, 7.1$ Hz, 1H, $\text{CH}_2\text{CH=}$), 4.31 (dd, $J = 14.8, 5.4$ Hz, 1H, $\text{CH}_2\text{CH=}$), 4.40 (dd, $J = 16.3, 4.3$ Hz, 1H, $\text{CH}_2\text{CH=}$), 5.02 (d, $J = 4.2$ Hz, 1H, CHOTMP), 6.08-6.20 (m, 1H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ 1.4 (q, $\text{Si}(\text{CH}_3)_3$), 17.2 (t, piperidine-C4), 20.4 (q, NCCH_3), 20.6 (q, NCCH_3), 24.6 (t, C6), 24.7 (t, C4), 25.6 (t, C5), 33.4 (q, NCCH_3), 33.9 (q, NCCH_3), 36.4 (t, C3), 40.6 (t, piperidine-C3, C5), 47.0 (t, $\text{CH}_2\text{CH=}$), 49.7 (d, C1), 50.1 (t, $\text{CH}_2\text{CH=}$), 59.7 (s, CNO), 60.9 (s, CNO), 72.2 (d, C2), 78.2 (d, CHOTMP), 117.4 (t, CH=CH_2), 118.0 (t, CH=CH_2), 133.7 (d, CH=CH_2), 134.9 (d, CH=CH_2), 171.1 (s, C=O).

***N,N*-Diallyl-2-((1*R**,2*S**)-2-((trimethylsilyl)oxy)cyclohexyl)acetamide (S14):**




LiCl (252 mg, 6 mmol) was added to a round-bottomed flask containing a stirring bar, which was sealed with a septum, and dried under vacuum by a heat gun. Then, dry THF (8 mL) and amide **8a** (211 mg, 1.0 mmol) were added under argon. The mixture was cooled to 0 °C in an ice/water bath, *sec*-butyllithium (1.4 M solution in cyclohexane, 0.8 mL, 1.1 mmol) was added dropwise by syringe and the mixture was stirred at 0 °C for 15 min. The epoxide **7f** (102.9 mg, 1.05 mmol) was added at once by syringe and the reaction mixture was allowed to warm to room temperature and stirred at this temperature for 24 h. The reaction was quenched by saturated NH_4Cl solution and diluted with water (10 mL) and diethyl ether (10 mL). The organic layer was separated and the aqueous phase was extracted with diethyl ether (3×10 mL). The combined organic layers were dried over MgSO_4 and filtered. The filtrate was evaporated and the crude

product was purified by flash chromatography (gradient, hexanes/EtOAc 10:1 to 2:1) to give 247 mg (80%) pure amide **S14** as a single diastereomer.

[R_f (hexanes/EtOAc 10:1) = 0.41]; IR (film); ν [cm^{-1}]: 2929 (w), 2857 (w), 1642 (m), 1449 (w), 1411 (w), 1249 (w), 1083 (m), 992 (w), 949 (w), 919 (w), 887 (m), 838 (s), 750 (w), 690 (w); MS (+ESI) m/z , (%): 641 (30, $[2\text{M}+\text{Na}^+]$), 332 (100, $[\text{M}+\text{Na}^+]$); HRMS (+ESI) m/z [$\text{C}_{17}\text{H}_{31}\text{NO}_2\text{SiNa}^+$]: calcd. 332.2016; found 332.2014; ^1H NMR (400 MHz, CDCl_3): δ 0.09 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.89-1.04 (m, 1H, H5), 1.13-1.37 (m, 3H, H3, H4, H6), 1.56-1.63 (m, 1H, H6), 1.66-1.77 (m, 2H, H1, H4), 1.81-1.86 (m, 1H, H3), 1.87 (dd, $J = 14.3, 10.5$ Hz, 1H, CH_2CO), 1.92-1.99 (m, 1H, H5), 2.85 (dd, $J = 14.3, 2.7$ Hz, 1H, CH_2CO), 3.21 (td, $J = 10.1, 4.3$ Hz, 1H, H2), 3.77-3.87 (m, 2H, $\text{CH}_2\text{CH=}$), 3.98 (dd, $J = 17.5, 4.8$ Hz, 1H, $\text{CH}_2\text{CH=}$), 4.11 (dd, $J = 15.0, 5.8$ Hz, 1H, $\text{CH}_2\text{CH=}$), 5.10 (dd, $J = 15.5, 1.6$ Hz, 1H, CH=CH_2), 5.13 (dd, $J = 10.3, 1.6$ Hz, 1H, CH=CH_2), 5.14 (dd, $J = 15.4, 1.3$ Hz, 1H, CH=CH_2), 5.19 (dd, $J = 10.4, 1.3$ Hz, 1H, CH=CH_2), 5.69-5.81 (m, 2H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ 0.6 (q, $\text{Si}(\text{CH}_3)_3$), 25.2 (t, C4), 25.6 (t, C6), 31.1 (t, C5), 36.2 (t, C3), 36.7 (t, CH_2CO), 43.2 (d, C1), 47.8 (t, $\text{CH}_2\text{CH=}$), 49.3 (t, $\text{CH}_2\text{CH=}$), 75.2 (d, C2), 116.5 (t, CH=CH_2), 117.0 (t, CH=CH_2), 133.3 (d, CH=CH_2), 133.8 (d, CH=CH_2), 172.9 (s, C=O).

***N*-Benzyl-*N*-(cyclopent-1-en-1-ylmethyl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9m):**




Prepared according to the general procedure, yield 312 mg (61%) as an inseparable 1.2:1 mixture of diastereomers. Ratio of rotamers is 1.4:1 for each diastereomer.

[R_f (hexanes/EtOAc 5:1) = 0.63]; IR (film); ν [cm^{-1}]: 2930 (m), 2871 (m), 2847 (m), 1652 (s), 1448 (m), 1376 (w), 1362 (w), 1250 (s), 1205 (w), 1133 (w), 1079 (m), 1021 (w), 990 (w), 973 (w), 957 (w), 892 (w), 841 (s), 747 (m), 702 (m), 601 (w); MS (+ESI) m/z , (%): 1051 (20, $[2\text{M}+\text{Na}^+]$), 537 (100, $[\text{M}+\text{Na}^+]$), 515 (15, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{30}\text{H}_{50}\text{N}_2\text{O}_3\text{SiNa}^+$]: calcd. 537.3483; found 537.3483.

First diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.11 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.89/1.13 (s, 3H, NCCH_3), 1.07/1.15 (s, 6H, NCCH_3), 1.12 (d, $J = 6.0$ Hz, 3H, CH_3), 1.23 (s, 3H, NCCH_3), 1.29-1.35 (m, 1H, piperidine-H4), 1.37-1.54 (m, 4H, piperidine-H3, H5), 1.55-1.68 (m, 1H, piperidine-H4), 1.84-2.01 (m, 2H, H4), 2.02-2.17 (m, 2H, CH_2CHOTMP), 2.18-2.32 (m, 2H, H5), 2.33-2.44 (m, 2H, H3), 3.85 (d, $J = 17.6$ Hz, 1H, $\text{NCH}_2\text{C=}$), 3.93-4.04 (m, 1H, CHOTMS), 4.35/4.48 (d, $J = 13.9$ Hz/ $J = 14.0$ Hz, 1H, CH_2Ph), 4.72 (d, $J = 17.6$ Hz, 1H, $\text{NCH}_2\text{C=}$), 4.80/4.89 (d, $J = 14.0$ Hz/ $J = 13.9$ Hz, 1H, CH_2Ph), 5.50-5.61 (m, 1H, H2), 7.27-7.44 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.17 (q, $\text{Si}(\text{CH}_3)_3$), 16.5/16.6 (t, piperidine-C4), 19.5/19.85 (q, NCCH_3), 19.7/19.93 (q, NCCH_3), 22.78/22.85 (t, C4), 23.2/23.3 (q, CH_3), 31.6 (t, C3), 32.5 (q, NCCH_3), 32.6 (q, NCCH_3), 32.9/33.2 (t, C5), 39.7 (t, piperidine-C3), 39.8 (t, piperidine-C5), 41.7/41.9 (t, CH_2CHOTMP), 43.8/46.5 (t, $\text{NCH}_2\text{C=}$), 48.4/48.9 (t, CH_2Ph), 59.4 (s, CNO), 59.8 (s, CNO), 64.7/64.8 (d, CHOTMS), 78.7/79.5 (d, CHOTMP), 126.5/126.6 (d, CH_{Ar}), 127.5/127.88 (d, CH_{Ar}), 129.0 (d, CH_{Ar}), 136.5/136.58 (s, C_{Ar}), 139.36/139.39 (s, C1), 171.1/172.2 (s, C=O).

Second diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.15 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.97/1.15 (s, 3H, NCCH_3), 0.99/1.20 (s, 3H, NCCH_3), 1.23 (s, 6H, NCCH_3), 1.22 (d, $J = 6.1$ Hz, 3H, CH_3), 1.29-1.35 (m, 1H, piperidine-H4), 1.37-1.54 (m, 4H, piperidine-H3, H5), 1.55-1.68 (m, 1H, piperidine-H4), 1.84-2.01 (m, 2H, H4), 2.03-2.17 (m, 2H, CH_2CHOTMP), 2.18-2.32 (m, 2H, H5), 2.33-2.44 (m, 2H, H3), 3.80-3.92 (m, 1H, CHOTMS), 3.98 (d, $J = 17.5$ Hz, 1H, $\text{NCH}_2\text{C=}$), 4.44 (d, $J = 17.5$ Hz, 1H, $\text{NCH}_2\text{C=}$), 4.48/4.60 (d, $J = 14.0$ Hz/ $J = 16.6$ Hz, 1H, CH_2Ph), 4.70/5.10 (d, $J = 14.0$ Hz/ $J = 16.6$ Hz, 1H, CH_2Ph), 5.50-5.61 (m, 1H, H2), 7.27-7.44 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.14 (q, $\text{Si}(\text{CH}_3)_3$), 16.40/16.42 (t, piperidine-C4), 19.5/19.85 (q, NCCH_3), 19.7/19.93 (q, NCCH_3), 22.80/22.88 (t, C4), 23.9/24.0 (q, CH_3), 31.6 (t, C3), 32.5 (q, NCCH_3), 32.6 (q, NCCH_3), 33.0/33.5 (t, C5), 39.7 (t, piperidine-C3), 39.8 (t, piperidine-C5), 40.5/40.9 (t, CH_2CHOTMP), 44.5/46.2 (t, $\text{NCH}_2\text{C=}$), 47.8/49.3 (t, CH_2Ph), 59.3 (s, CNO), 59.8 (s, CNO), 65.2/65.3 (d, CHOTMS), 78.1/79.2 (d, CHOTMP), 126.7/126.8 (d, CH_{Ar}), 127.6/127.90 (d, CH_{Ar}), 128.5 (d, CH_{Ar}), 136.63/136.7 (s, C_{Ar}), 139.0/139.1 (s, C1), 171.5/171.8 (s, C=O).

***N*-Benzyl-*N*-(cyclohex-1-en-1-ylmethyl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9n):**



Prepared according to the general procedure, yield 327 mg (62%) as an inseparable 1.1:1 mixture of diastereomers. Ratio of rotamers is 1.5:1 for each diastereomer.


[R_f (hexanes/EtOAc 5:1) = 0.74]; IR (film); ν [cm^{-1}]: 2929 (m), 2873 (m), 1654 (s), 1445 (m), 1376 (w), 1362 (w), 1250 (m), 1205 (w), 1133 (w), 1100 (w), 1081 (w), 1013 (w), 957 (w), 894 (w), 840 (s), 750 (w), 701 (w), 613 (w); MS (+ESI) m/z , (%): 529 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{31}\text{H}_{53}\text{N}_2\text{O}_3\text{Si}^+$]: calcd. 529.3820; found 529.3819.

First diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.060/0.064 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.85 (s, 3H, NCCH_3), 1.09 (s, 6H, NCCH_3), 1.11 (s, 3H, NCCH_3), 1.19 (d, $J = 6.1$ Hz, 3H, CH_3), 1.24-1.30 (m, 1H, piperidine-H4), 1.33-1.49 (m, 4H, piperidine-H3, H5), 1.50-1.54 (m, 1H, piperidine-H4), 1.55-1.65 (m, 4H, H4, H5), 1.82-1.94 (m, 2H, H6), 1.96-2.07 (m, 3H, H3, CH_2CHOTMP), 2.08-2.15 (m, 1H, CH_2CHOTMP), 3.63/3.67 (d, $J = 16.8$ Hz/ $J = 14.5$ Hz, 1H, CH_2Ph), 3.78-3.85 (m, 1H, CHOTMS), 4.05/4.52 (d, $J = 14.5$ Hz/ $J = 16.8$ Hz, 1H, CH_2Ph), 4.27/4.54 (d, $J = 14.1$ Hz/ $J = 16.6$ Hz, 1H, $\text{NCH}_2\text{C=}$), 4.65/4.84 (dd, $J = 9.0$, 4.1 Hz/ $J = 10.0$, 3.4 Hz, 1H, CHOTMP), 4.71/5.05 (d, $J = 14.1$ Hz/ $J = 16.6$ Hz, 1H, $\text{NCH}_2\text{C=}$), 5.43-5.47/5.49 (m/dd, $J = 3.4$, 1.8 Hz, 1H, H2), 7.20-7.41 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.57 (q, $\text{Si}(\text{CH}_3)_3$), 17.23 (t, piperidine-C4), 20.3/20.6 (q, NCCH_3), 20.5/20.7 (q, NCCH_3), 22.4/22.49 (t, C5), 22.50/22.7 (t, C4), 24.7/24.8 (q, CH_3), 25.0/25.2 (t, C3), 26.7/26.82 (t, C6), 33.3/33.4 (q, NCCH_3), 33.65/33.73 (q, NCCH_3), 40.5/40.6 (t, piperidine-C3, C5), 42.3/42.6 (t, CH_2CHOTMP), 49.0/49.4 (t, $\text{NCH}_2\text{C=}$), 50.3/52.4 (t, CH_2Ph), 59.5/60.1 (s, 2C, CNO), 65.9/66.1 (d, CHOTMS), 78.8/79.0 (d, CHOTMP), 123.6/125.3 (d, C2), 127.20/128.2 (d, CH_{Ar}), 127.4/127.7 (d, CH_{Ar}), 128.6/129.7 (d, CH_{Ar}), 132.77/133.1 (s, C1), 137.3/137.45 (s, C_{Ar}), 171.9/173.1 (s, C=O).

Second diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.07/0.10 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.97 (s, 3H, NCCH_3), 1.03 (s, 3H, NCCH_3), 1.06/1.16 (d, $J = 6.1$ Hz, 3H, CH_3), 1.10 (s, 3H, NCCH_3), 1.19 (s, 3H, NCCH_3), 1.24-1.30 (m, 1H, piperidine-H4), 1.33-1.49 (m, 4H, piperidine-H3, H5), 1.50-

1.54 (m, 1H, piperidine-H4), 1.55-1.65 (m, 4H, H4, H5), 1.82-1.94 (m, 2H, H6), 1.95-2.09 (m, 3H, H3, CH₂CHOTMP), 2.18-2.28 (m, 1H, CH₂CHOTMP), 3.79 (s, 2H, CH₂Ph)/3.82 (d, *J* = 16.8 Hz, 1H, CH₂Ph)/4.16 (d, *J* = 16.8 Hz, 1H, CH₂Ph), 3.89-3.98 (m, 1H, CHOTMS), 4.49 (d, *J* = 14.4 Hz, 1H, NCH₂C=), 4.57 (d, *J* = 14.4 Hz, 1H, NCH₂C=), 4.58-4.61/4.72-4.76 (m, 1H, CHOTMP), 5.43-5.47/5.51-5.55 (m, 1H, H2), 7.20-7.41 (m, 5H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 0.61 (q, Si(CH₃)₃), 17.16/17.3 (t, piperidine-C4), 20.3/20.6 (q, NCCH₃), 20.5/20.7 (q, NCCH₃), 22.3/22.48 (t, C5), 22.53/22.6 (t, C4), 23.97/24.03 (q, CH₃), 25.0/25.3 (t, C3), 26.79/27.1 (t, C6), 33.3/33.4 (q, NCCH₃), 33.65/33.73 (q, NCCH₃), 40.5/40.6 (t, piperidine-C3, C5), 41.0/41.6 (t, CH₂CHOTMP), 48.4/49.8 (t, NCH₂C=), 51.3/52.1 (t, CH₂Ph), 60.0/60.5 (s, 2C, CNO), 65.5/65.6 (d, CHOTMS), 77.7/77.9 (d, CHOTMP), 123.9/125.9 (d, C2), 127.24/128.3 (d, CH_{Ar}), 127.3/127.5 (d, CH_{Ar}), 128.6/129.2 (d, CH_{Ar}), 132.80/133.5 (s, C1), 137.51/137.6 (s, C_{Ar}), 172.5/172.7 (s, C=O).

***N*-Benzyl-*N*-(cyclopent-2-en-1-yl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9o):**



Prepared according to the general procedure, yield 340 mg (68%) as an inseparable 2:2:1:1 mixture of diastereomers. Ratio of rotamers is 1.3:1 for each diastereomer.

[*R_f* (hexanes/EtOAc 5:1) = 0.64]; IR (film); ν [cm⁻¹]: 2966 (w), 2930 (m), 2871 (w), 1651 (s), 1453 (w), 1439 (w), 1376 (w), 1362 (w), 1250 (m), 1133 (m), 1098 (w), 1078 (w), 1060 (w), 1015 (w), 990 (w), 957 (w), 892 (w), 840 (s), 748 (w), 726 (m), 699 (m), 605 (w); MS (+ESI) *m/z*, (%): 523 (65, [M+Na⁺]), 501 (100, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₉H₄₉N₂O₃Si⁺]: calcd. 501.3507; found 501.3506.


Major diastereomers: ¹H NMR (400 MHz, CDCl₃): δ -0.04/0.06 (s, 9H, Si(CH₃)₃), 0.08 (s, 9H, Si(CH₃)₃), 0.90/1.16 (d, *J* = 6.1 Hz, 3H, CH₃), 0.95/1.17 (d, *J* = 6.0 Hz, 3H, CH₃), 1.07 (s, 6H, NCCH₃), 1.10 (s, 6H, NCCH₃), 1.11 (s, 6H, NCCH₃), 1.12 (s, 6H, NCCH₃), 1.26-1.35 (m, 2H, piperidine-H4), 1.37-1.49 (m, 8H, piperidine-H3, H5), 1.50-1.70 (m, 4H, H5, piperidine-H4),

2.02-2.15 (m, 3H, CH_2CHOTMP), 2.16-2.26 (m, 4H, H4, CH_2CHOTMP), 2.27-2.50 (m, 3H, H4, H5), 3.76 (ddq, $J = 9.2, 6.1, 3.0$ Hz, 1H, CHOTMS), 3.81-3.87 (m, 1H, CHOTMS), 4.19 (d, $J = 14.9$ Hz, 1H, CH_2Ph), 4.27 (d, $J = 16.9$ Hz, 1H, CH_2Ph), 4.36-4.51 (m, 1H, CHOTMP), 4.55 (d, $J = 14.9$ Hz, 1H, CH_2Ph), 4.87 (dd, $J = 10.5, 5.7$ Hz, 1H, CHOTMP), 5.09 (d, $J = 16.9$ Hz, 1H, CH_2Ph), 5.43-5.48 (m, 1H, H2), 5.54-5.57 (m, 1H, H1), 5.58-5.63 (m, 2H, H1, H2), 5.77-5.83 (m, 1H, H3), 5.84-5.87 (m, 1H, H3), 7.14-7.34 (m, 10H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.36/0.40 (q, $\text{Si}(\text{CH}_3)_3$), 0.61/0.64 (q, $\text{Si}(\text{CH}_3)_3$), 17.2 (t, 2C, piperidine-C4), 20.2 (q, 2C, NCCH_3), 20.3 (q, 2C, NCCH_3), 23.6/24.0 (q, CH_3), 23.9 (q, CH_3), 27.4/27.8 (t, C5), 28.3/28.8 (t, C5), 31.40 (t, C4), 31.42/31.47 (t, C4), 33.27 (q, 2C, NCCH_3), 33.32 (q, NCCH_3), 33.5 (q, NCCH_3), 40.31/40.4 (t, piperidine-C3, C5), 40.34/40.5 (t, piperidine-C3, C5), 41.0 (t, CH_2CHOTMP), 41.6/42.6 (t, CH_2CHOTMP), 45.57/45.62 (t, CH_2Ph), 45.7/45.8 (t, CH_2Ph), 59.4 (s, CNO), 59.5 (s, CNO), 60.0 (s, CNO), 60.5 (s, CNO), 61.1/61.6 (d, C1), 61.2/61.8 (d, C1), 65.08/65.11 (d, CHOTMS), 65.47/65.54 (d, CHOTMS), 77.0 (d, CHOTMP), 77.9/78.2 (d, CHOTMP), 126.1 (d, CH_{Ar}), 126.2 (d, CH_{Ar}), 126.9 (d, CH_{Ar}), 127.6 (d, CH_{Ar}), 128.3 (d, CH_{Ar}), 128.6 (d, CH_{Ar}), 130.17/130.5 (d, C3), 130.24/130.6 (d, C3), 134.7/134.8 (d, C2), 134.9 (d, C2), 139.2/139.3 (s, C_{Ar}), 139.38/139.39 (s, C_{Ar}), 171.6/172.1 (s, C=O), 172.5/172.6 (s, C=O).

Minor diastereomers: ^1H NMR (400 MHz, CDCl_3): δ 0.05/0.06 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.07/0.10 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.96/1.21 (d, $J = 6.1$ Hz, 3H, CH_3), 1.03/1.22 (d, $J = 6.1$ Hz, 3H, CH_3), 1.08 (s, 6H, NCCH_3), 1.09 (s, 6H, NCCH_3), 1.12 (s, 12H, NCCH_3), 1.26-1.35 (m, 2H, piperidine-H4), 1.37-1.49 (m, 8H, piperidine-H3, H5), 1.50-1.70 (m, 4H, H5, piperidine-H4), 1.72-1.91 (m, 4H, H5, CH_2CHOTMP), 1.94-2.02 (m, 4H, H4, CH_2CHOTMP), 2.26-2.51 (m, 2H, H4), 3.79-4.00 (m, 2H, CHOTMS), 4.28 (d, $J = 15.2$ Hz, 1H, CH_2Ph), 4.35 (d, $J = 16.7$ Hz, 1H, CH_2Ph), 4.36-4.51 (m, 1H, CHOTMP), 4.81 (dd, $J = 7.8, 6.1$ Hz, 1H, CHOTMP), 5.10 (d, $J = 15.2$ Hz, 1H, CH_2Ph), 5.20 (d, $J = 16.7$ Hz, 1H, CH_2Ph), 5.49-5.53 (m, 1H, H2), 5.64-5.71 (m, 2H, H1, H2), 5.72-5.78 (m, 1H, H1), 5.89-6.01 (m, 2H, H3), 7.14-7.34 (m, 10H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.5 (q, $\text{Si}(\text{CH}_3)_3$), 0.7 (q, $\text{Si}(\text{CH}_3)_3$), 17.3 (t, 2C, piperidine-C4), 20.1 (q, 2C, NCCH_3), 20.7 (q, 2C, NCCH_3), 24.4/24.5 (q, CH_3), 24.88/24.92 (q, CH_3), 28.4/29.2 (t, C5), 28.9/29.4 (t, C5), 31.53/31.61 (t, C4), 31.63 (t, C4), 33.58 (q, NCCH_3), 33.64 (q, NCCH_3), 33.9 (q, NCCH_3), 34.1 (q, NCCH_3), 40.6/40.7 (t, piperidine-C3, C5), 40.76/40.79 (t, piperidine-C3, C5), 42.7/43.4 (t, CH_2CHOTMP), 42.8/43.5 (t, CH_2CHOTMP), 46.6/46.68 (t, CH_2Ph), 46.70 (t, CH_2Ph), 59.7 (s, CNO), 59.8 (s, CNO), 60.6 (s, CNO), 60.8 (s, CNO), 63.6 (d, C1), 63.7/63.8 (d, C1), 65.6/66.0 (d, CHOTMS), 66.1 (d, CHOTMS), 78.6/79.2 (d, CHOTMP), 78.7/80.4 (d,

CHOTMP), 126.3 (d, CH_{Ar}), 126.5 (d, CH_{Ar}), 126.8 (d, CH_{Ar}), 127.7 (d, CH_{Ar}), 128.1 (d, CH_{Ar}), 128.5 (d, CH_{Ar}), 130.7/131.0 (d, C3), 131.1/131.2 (d, C3), 134.96/135.00 (d, C2), 135.1/135.4 (d, C2), 139.6/139.69 (s, C_{Ar}), 139.70/139.8 (s, C_{Ar}), 173.7/173.8 (s, C=O), 174.4/174.5 (s, C=O).

***N*-Benzyl-*N*-((*R*)-cyclohex-2-en-1-yl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9p):**



Prepared according to the general procedure, yield 323 mg (63%) as an inseparable 2:2:1:1 mixture of diastereomers. Ratio of rotamers is 1.5:1 for each diastereomer.

[R_f (hexanes/EtOAc 5:1) = 0.54]; IR (film); ν [cm⁻¹]: 3005 (m), 2930 (s), 2872 (m), 1647 (s), 1452 (m), 1376 (w), 1362 (w), 1250 (s), 1099 (w), 1078 (m), 1057 (w), 1016 (w), 989 (w), 957 (w), 897 (w), 840 (s), 729 (m), 698 (m), 615 (w); MS (+ESI) m/z, (%): 1051 (30, [2M+Na⁺], 537 (100, [M+Na⁺]), 515 (90, [M+H⁺]); HRMS (+ESI) m/z [C₃₀H₅₀N₂O₃SiNa⁺]: calcd. 537.3480; found 537.3479.

Major diastereomers: ¹H NMR (400 MHz, CDCl₃): δ -0.05/-0.03 (s, 9H, Si(CH₃)₃), 0.06/0.07 (s, 9H, Si(CH₃)₃), 0.89 (d, *J* = 6.1 Hz, 3H, CH₃), 0.96/1.16 (d, *J* = 6.1 Hz, 3H, CH₃), 1.07 (s, 3H, NCCH₃), 1.08 (s, 6H, NCCH₃), 1.09 (s, 6H, NCCH₃), 1.10 (s, 9H, NCCH₃), 1.24-1.34 (m, 2H, piperidine-H4), 1.36-1.48 (m, 10H, H4, piperidine-H3, H5), 1.49-1.65 (m, 6H, H4, H6, piperidine-H4), 1.68-1.83 (m, 2H, H6), 1.84-1.90 (m, 2H, CH₂CHOTMP), 1.91-2.04 (m, 6H, H5, CH₂CHOTMP), 3.70-3.79 (m, 2H, CHOTMS), 4.16 (d, *J* = 15.0 Hz, 1H, CH₂Ph), 4.25 (d, *J* = 15.4 Hz, 1H, CH₂Ph), 4.40-4.55 (m, 2H, CHOTMP), 4.45 (d, *J* = 15.4 Hz, 1H, CH₂Ph), 4.78 (d, *J* = 15.0 Hz, 1H, CH₂Ph), 5.04-5.17 (m, 2H, H1), 5.37-5.55 (m, 1H, H2), 5.60-5.68 (m, 1H, H2), 5.69-5.81 (m, 1H, H3), 5.82-5.96 (m, 1H, H3), 7.15-7.37 (m, 10H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 0.4/0.5 (q, Si(CH₃)₃), 0.6/0.8 (q, Si(CH₃)₃), 17.19 (t, piperidine-C4), 17.23 (t, piperidine-C4), 20.2 (q, 2C, NCCH₃), 20.25 (q, NCCH₃), 20.29 (q, NCCH₃), 21.47/21.53 (t, C6), 21.6/21.8 (t, C6), 23.8/23.9 (q, CH₃), 24.09/24.12 (q, CH₃), 24.66 (t, 2C, C5), 26.7/27.73 (t, C4), 27.0/27.68 (t, C4), 33.28 (q, NCCH₃), 33.32 (q, NCCH₃), 33.4 (q, 2C, NCCH₃), 40.4 (t,

piperidine-C3), 40.5 (t, piperidine-C3), 40.6 (t, 2C, piperidine-C5), 41.0 (t, $\underline{\text{CH}_2\text{CHOTMP}}$), 42.7/42.8 (t, $\underline{\text{CH}_2\text{CHOTMP}}$), 46.2/46.33 (t, $\underline{\text{CH}_2\text{Ph}}$), 46.27 (t, $\underline{\text{CH}_2\text{Ph}}$), 51.9/52.0 (d, C1), 52.5/52.6 (d, C1), 59.4 (s, CNO), 60.0 (s, CNO), 60.5 (s, CNO), 60.7 (s, CNO), 65.1/65.2 (d, $\underline{\text{CHOTMS}}$), 65.60/65.71 (d, $\underline{\text{CHOTMS}}$), 77.7/78.1 (d, $\underline{\text{CHOTMP}}$), 78.2/78.6 (d, $\underline{\text{CHOTMP}}$), 126.19/126.23 (d, CH_{Ar}), 126.48/126.53 (d, CH_{Ar}), 127.6/127.7 (d, CH_{Ar}), 128.0/128.08 (d, CH_{Ar}), 128.12 (d, 2C, CH_{Ar}), 128.45/128.54 (d, C2), 128.51/128.53 (d, C2), 131.3/131.36 (d, C3), 131.41/131.44 (d, C3), 139.4 (s, C_{Ar}), 139.5 (s, C_{Ar}), 173.8 (s, C=O), 174.4 (s, C=O).

Minor diastereomers: ^1H NMR (400 MHz, CDCl_3): δ 0.076/0.077 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 0.09/0.16 (s, 9H, $\text{Si}(\text{CH}_3)_3$), 1.02/1.17 (d, $J = 6.2$ Hz, 3H, CH_3), 1.03/1.21 (d, $J = 6.2$ Hz, 3H, CH_3), 1.12 (s, 6H, NCCH_3), 1.13 (s, 6H, NCCH_3), 1.14 (s, 6H, NCCH_3), 1.15 (s, 6H, NCCH_3), 1.24-1.34 (m, 2H, piperidine-H4), 1.36-1.48 (m, 8H, piperidine-H3, H5), 1.49-1.65 (m, 6H, H4, H6, piperidine-H4), 1.83-1.90 (m, 5H, H4, H6, $\underline{\text{CH}_2\text{CHOTMP}}$), 1.91-2.04 (m, 7H, H4, H5, $\underline{\text{CH}_2\text{CHOTMP}}$), 3.87-4.03 (m, 2H, $\underline{\text{CHOTMS}}$), 4.33 (d, $J = 16.4$ Hz, 1H, $\underline{\text{CH}_2\text{Ph}}$), 4.39 (d, $J = 17.5$ Hz, 1H, $\underline{\text{CH}_2\text{Ph}}$), 4.56 (d, $J = 17.5$ Hz, 1H, $\underline{\text{CH}_2\text{Ph}}$), 4.73-4.85 (m, 2H, $\underline{\text{CHOTMP}}$), 4.82 (d, $J = 16.4$ Hz, 1H, $\underline{\text{CH}_2\text{Ph}}$), 5.18-5.35 (m, 2H, H1), 5.37-5.55 (m, 2H, H2), 5.81-5.96 (m, 2H, H3), 7.15-7.37 (m, 10H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 0.7 (q, $\text{Si}(\text{CH}_3)_3$), 1.4 (q, $\text{Si}(\text{CH}_3)_3$), 17.24 (t, piperidine-C4), 17.3 (t, piperidine-C4), 20.4 (q, NCCH_3), 20.45 (q, NCCH_3), 20.49 (q, 2C, NCCH_3), 21.87/22.0 (t, C6), 21.90 (t, C6), 24.45/24.53 (q, CH_3), 24.6/24.73 (t, C5), 24.8 (t, C5), 25.0 (q, CH_3), 29.40/29.6 (t, C4), 29.42/29.7 (t, C4), 33.2 (q, NCCH_3), 33.6 (q, NCCH_3), 33.7 (q, 2C, NCCH_3), 40.4 (t, piperidine-C3), 40.5 (t, piperidine-C3), 40.7 (t, piperidine-C5), 40.8 (t, piperidine-C5), 42.9/43.4 (t, $\underline{\text{CH}_2\text{CHOTMP}}$), 43.5/43.9 (t, $\underline{\text{CH}_2\text{CHOTMP}}$), 47.1/47.3 (t, $\underline{\text{CH}_2\text{Ph}}$), 47.4/47.5 (t, $\underline{\text{CH}_2\text{Ph}}$), 54.62 (d, C1), 54.63/54.8 (d, C1), 59.4 (s, CNO), 60.0 (s, CNO), 60.8 (s, CNO), 60.9 (s, CNO), 65.63/65.69 (d, $\underline{\text{CHOTMS}}$), 66.1/66.2 (d, $\underline{\text{CHOTMS}}$), 78.8 (d, $\underline{\text{CHOTMP}}$), 78.9/79.5 (d, $\underline{\text{CHOTMP}}$), 125.9/126.0 (d, CH_{Ar}), 126.3/126.4 (d, CH_{Ar}), 126.8/126.9 (d, CH_{Ar}), 127.0 (d, CH_{Ar}), 127.80/127.84 (d, CH_{Ar}), 128.2 (d, CH_{Ar}), 128.6/128.8 (d, C2), 128.7/128.9 (d, C2), 131.60/131.63 (d, C3), 132.1/132.5 (d, C3), 139.77 (s, C_{Ar}), 139.84 (s, C_{Ar}), 174.5 (s, C=O), 174.8 (s, C=O).

General procedure for the thermal radical cyclization of compounds **9** and subsequent deprotection:

The α -(aminoxy)amide **9** (0.65 mmol) was heated in *t*-BuOH (6 mL) in a microwave reactor at 150 °C for 1 h. The reaction mixture was diluted with diethyl ether (5 mL), transferred into a round-bottomed Schlenk flask and evaporated. The crude residue was dissolved in dry THF (5 mL), the reaction mixture was cooled to 0 °C in an ice/water bath, tetrabutylammonium fluoride (1 M solution in THF, 0.96 mL, 0.96 mmol) was added and the mixture was stirred at this temperature for 30 min. The reaction was quenched by saturated NH₄Cl solution and diluted with water (5 mL) and diethyl ether (5 mL), the organic layer was separated and the aqueous phase was extracted with diethyl ether (2 × 5 mL). The combined organic layers were dried over MgSO₄, filtered and evaporated. The crude mixture was purified by column chromatography (gradient, hexanes/EtOAc 5:1 to 1:1) to give pure lactams **12** as diastereomeric mixtures. Their configuration was deducted from the base-mediated *cis*–*trans* isomerization (vide infra) and from NOE measurement of the derived alcohol oxidation products (see pp. S79–S97).

Equilibration of lactams **12**:


A solution of KO^{*t*}-Bu (1 M in THF, 0.25 mL, 0.25 mmol) was added to a stirred solution of hydroxy lactam **12** (0.50 mmol) in *t*-BuOH (3 mL) at room temperature and the reaction mixture was stirred for 24 h. The reaction was quenched by saturated NH₄Cl solution and diluted with water (3 mL) and diethyl ether (5 mL). The organic layer was separated and the aqueous phase was extracted with diethyl ether (3 × 5 mL). The combined organic layers were dried over MgSO₄ and filtered. The filtrate was evaporated and the diastereomeric ratio was determined by ¹H NMR spectroscopy. The crude mixture was purified by flash chromatography (gradient, hexanes/EtOAc 10:1 to 1:1) to give lactam *trans*-**12**.

(3*R**,4*R**)- and (3*S**,4*R**)-1-Allyl-3-(2-hydroxy-2-methylpropyl)-4-(((2,2,6,6-tetramethyl-piperidin-1-yl)oxy)methyl)pyrrolidin-2-one (**12a**):


Prepared according to the general procedure, yield 270 mg (91%) as an inseparable 2(*trans*):1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-**12a** increased to 17(*trans*):1(*cis*).

[R_f (hexanes/EtOAc 1:1) = 0.29]; IR (film); ν [cm⁻¹]: 3327 (br), 2970 (m), 2930 (m), 2872 (w), 1667 (s), 1469 (w), 1450 (w), 1418 (w), 1375 (w), 1360 (w), 1263 (w), 1155 (w), 1133 (w), 1046

(w), 993 (w), 923 (w), 787 (w), 719 (w), 636 (w); MS (+ESI) m/z , (%): 389 (25, $[M+Na^+]$), 367 (100, $[M+H^+]$); HRMS (+ESI) m/z $[C_{21}H_{39}N_2O_3^+]$: calcd. 367.2955; found 367.2954.



Major diastereomer: 1H NMR (400 MHz, $CDCl_3$): δ 1.09 (s, 6H, $NCCH_3$), 1.14 (s, 6H, $NCCH_3$), 1.26 (s, 3H, CH_3), 1.27 (s, 3H, CH_3), 1.30-1.37 (m, 1H, piperidine- H_4), 1.41-1.48 (m, 4H, piperidine- H_3 , H_5), 1.49-1.56 (m, 1H, piperidine- H_4), 1.74 (dd, $J = 14.3, 3.7$ Hz, 1H, CH_2C), 1.85 (dd, $J = 14.3, 9.2$ Hz, 1H, CH_2C), 2.19-2.30 (m, 1H, H_4), 2.73 (ddd, $J = 10.1, 9.2, 3.7$ Hz, 1H, H_3), 3.22 (t, $J = 9.2$ Hz, 1H, H_5), 3.42 (t, $J = 9.2$ Hz, 1H, H_5), 3.79-3.87 (m, 3H, CH_2OTMP , $CH_2CH=$), 3.95 (dd, $J = 15.1, 5.9$ Hz, 1H, $CH_2CH=$), 5.11-5.25 (m, 2H, $CH=CH_2$), 5.66-5.74 (m, 1H, $CH=CH_2$), 5.76 (s, 1H, OH); ^{13}C NMR (101 MHz, $CDCl_3$): δ 17.1 (t, piperidine- C_4), 20.31 (q, 2C, $NCCH_3$), 28.5 (q, CH_3), 31.9 (q, CH_3), 33.3 (q, 2C, $NCCH_3$), 39.2 (d, C_4), 39.8 (t, piperidine- C_3 , C_5), 42.1 (d, C_3), 44.6 (t, CH_2C), 45.7 (t, $CH_2CH=$), 48.9 (t, C_5), 60.1 (s, 2C, CNO), 69.06 (s, COH), 76.8 (t, CH_2OTMP), 118.4 (t, $CH=CH_2$), 132.0 (d, $CH=CH_2$), 177.4 (s, C_2).




Minor diastereomer: 1H NMR (400 MHz, $CDCl_3$, detectable signals): δ 1.11 (s, 6H, $NCCH_3$), 1.29 (s, 6H, CH_3), 1.61 (dd, $J = 14.5, 4.2$ Hz, 1H, CH_2C), 1.79-1.86 (m, 1H, CH_2C), 2.61-2.69 (m, 1H, H_4), 2.85-2.96 (m, 1H, H_3), 3.35 (dd, $J = 10.3, 2.4$ Hz, 1H, H_5), 3.39-3.45 (m, 1H, H_5), 3.66 (t, $J = 9.2$ Hz, 1H, CH_2OTMP), 3.76 (dd, $J = 9.0, 5.7$ Hz, 1H, CH_2OTMP); ^{13}C NMR (101 MHz, $CDCl_3$): δ 17.2 (t, piperidine- C_4), 20.26 (q, $NCCH_3$), 20.4 (q, $NCCH_3$), 28.4 (q, CH_3), 31.8 (q, CH_3), 33.1 (q, $NCCH_3$), 33.4 (q, $NCCH_3$), 36.3 (d, C_4), 39.0 (t, CH_2C), 39.8 (t,

piperidine-C3, C5), 41.3 (d, C3), 45.8 (t, $\underline{\text{C}}\text{H}_2\text{CH=}$), 48.8 (t, C5), 60.1 (s, 2C, CNO), 69.11 (s, $\underline{\text{C}}\text{OH}$), 75.0 (t, $\underline{\text{C}}\text{H}_2\text{OTMP}$), 118.8 (t, $\text{CH}=\underline{\text{C}}\text{H}_2$), 132.2 (d, $\underline{\text{C}}\text{H}=\text{CH}_2$), 177.1 (s, C2).

(3*R,4*R**)- and (3*S**,4*R**)-1-Allyl-3-(2-hydroxypropyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12b):**

Prepared according to the general procedure, yield 200 mg (87%) as an inseparable 2.5:2.5(*trans*):1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-**12b** increased to 12:12(*trans*):1:1(*cis*).


[*R*_f (hexanes/EtOAc 1:1) = 0.51]; IR (film); ν [cm^{-1}]: 3356 (br), 2975 (w), 2928 (m), 2870 (w), 1666 (s), 1492 (w), 1470 (m), 1453 (w), 1416 (w), 1374 (w), 1359 (w), 1262 (m), 1244 (w), 1133 (w), 1047 (w), 1029 (w), 993 (w), 924 (w), 788 (w), 720 (w), 654 (w); MS (+ESI) *m/z*, (%): 727 (40, [2M+Na⁺], 375 (100, [M+Na⁺]), 353 (60, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₀H₃₆N₂O₃Na⁺]: calcd. 375.2618; found 375.2620.



(3*R**,4*R**)

Major diastereomers: ¹H NMR (400 MHz, CDCl₃): δ 1.07 (s, 9H, NCCH₃), 1.08 (s, 6H, NCCH₃), 1.11 (s, 6H, NCCH₃), 1.13 (s, 3H, NCCH₃), 1.20 (d, *J* = 6.2 Hz, 3H, CH₃), 1.22 (d, *J* = 6.4 Hz, 3H, CH₃), 1.27-1.35 (m, 2H, piperidine-H₄), 1.39-1.46 (m, 8H, piperidine-H₃, H₅), 1.47-1.59 (m, 2H, piperidine-H₄), 1.60-1.69 (m, 1H, $\underline{\text{C}}\text{H}_2\text{CHOH}$), 1.70-1.81 (m, 2H, $\underline{\text{C}}\text{H}_2\text{CHOH}$), 1.90 (ddd, *J* = 14.3, 8.5, 3.4 Hz, 1H, $\underline{\text{C}}\text{H}_2\text{CHOH}$), 2.17-2.28 (m, 1H, H₄), 2.29-2.40 (m, 1H, H₄), 2.56 (td, *J* = 9.8, 3.2 Hz, 1H, H₃), 2.63 (td, *J* = 8.5, 4.9 Hz, 1H, H₃), 3.12-3.20 (m, 2H, H₅), 3.41 (dd, *J* = 11.7, 8.4 Hz, 1H, H₅), 3.42 (dd, *J* = 10.9, 7.5 Hz, 1H, H₅), 3.78-3.86 (m, 6H, $\underline{\text{C}}\text{H}_2\text{OTMP}$, $\underline{\text{C}}\text{H}_2\text{CH=}$), 3.89-3.97 (m, 3H, $\underline{\text{C}}\text{HOH}$, $\underline{\text{C}}\text{H}_2\text{CH=}$), 4.03-4.13 (m, 1H, $\underline{\text{C}}\text{HOH}$), 4.31 (br. s, 2H, OH), 5.14-5.23 (m, 4H, $\text{CH}=\underline{\text{C}}\text{H}_2$), 5.70 (ddt, *J* = 16.5, 10.4, 6.1 Hz, 2H, $\underline{\text{C}}\text{H}=\text{CH}_2$); ¹³C NMR (101 MHz, CDCl₃): δ 17.1 (t, 2C, piperidine-C₄), 20.3 (q, 4C, NCCH₃), 23.1 (q, CH₃), 24.3 (q, CH₃), 33.3 (q, 4C, NCCH₃), 38.0 (d, C₄), 38.9 (d, C₄), 39.3 (t, $\underline{\text{C}}\text{H}_2\text{CHOH}$), 39.7 (t, piperidine-C₃, C₅), 39.8 (t, piperidine-C₃, C₅), 40.8 (t, $\underline{\text{C}}\text{H}_2\text{CHOH}$), 42.2 (d, C₃), 45.56 (t, $\underline{\text{C}}\text{H}_2\text{CH=}$), 45.7 (t, $\underline{\text{C}}\text{H}_2\text{CH=}$), 45.83 (d, C₃), 48.7 (t, C₅), 48.81 (t, C₅), 60.11 (s, 2C, CNO),

60.13 (s, 2C, CNO), 66.0 (d, CHOH), 68.2 (d, CHOH), 76.8 (t, $\underline{\text{CH}_2\text{OTMP}}$), 77.4 (t, $\underline{\text{CH}_2\text{OTMP}}$), 118.3 (t, $\text{CH}=\underline{\text{CH}_2}$), 118.4 (t, $\text{CH}=\underline{\text{CH}_2}$), 131.9 (d, $\underline{\text{CH}}=\text{CH}_2$), 132.14 (d, $\underline{\text{CH}}=\text{CH}_2$), 176.8 (s, C2), 177.4 (s, C2).




Minor diastereomers: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 1.59-1.66 (m, 2H, $\underline{\text{CH}_2\text{CHOH}}$), 1.79-1.87 (m, 2H, $\underline{\text{CH}_2\text{CHOH}}$), 2.64-2.73 (m, 2H, H4), 2.74-2.82 (m, 1H, H3), 2.83-2.89 (m, 1H, H3), 3.30 (dd, $J = 10.0, 3.9$ Hz, 1H, H5), 3.36 (dd, $J = 10.1, 2.7$ Hz, 1H, H5), 3.39-3.43 (m, 1H, H5), 3.63-3.70 (m, 3H, $\underline{\text{CH}_2\text{OTMP}}$), 3.74 (dd, $J = 9.2, 5.4$ Hz, 1H, $\underline{\text{CH}_2\text{OTMP}}$), 4.03-4.14 (m, 2H, $\underline{\text{CHOH}}$), 4.66 (br. s, 1H, OH), 5.41 (br. s, 1H, OH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.1 (t, 2C, piperidine-C4), 20.2 (q, 2C, $\text{NC}\underline{\text{CH}_3}$), 20.3 (q, 2C, $\text{NC}\underline{\text{CH}_3}$), 23.2 (q, CH_3), 24.5 (q, CH_3), 33.1 (q, $\text{NC}\underline{\text{CH}_3}$), 33.16 (q, $\text{NC}\underline{\text{CH}_3}$), 33.22 (q, $\text{NC}\underline{\text{CH}_3}$), 33.5 (q, $\text{NC}\underline{\text{CH}_3}$), 34.3 (t, $\underline{\text{CH}_2\text{CHOH}}$), 35.8 (t, $\underline{\text{CH}_2\text{CHOH}}$), 35.9 (d, 2C, C4), 39.7 (t, piperidine-C3, C5), 39.8 (t, piperidine-C3, C5), 41.2 (d, C3), 44.8 (d, C3), 45.61 (t, $\underline{\text{CH}_2\text{CH=}}$), 45.81 (t, $\underline{\text{CH}_2\text{CH=}}$), 48.80 (t, C5), 48.9 (t, C5), 59.98 (s, 2C, CNO), 60.04 (s, 2C, CNO), 66.0 (d, CHOH), 68.3 (d, CHOH), 74.6 (t, $\underline{\text{CH}_2\text{OTMP}}$), 75.3 (t, $\underline{\text{CH}_2\text{OTMP}}$), 118.5 (t, $\text{CH}=\underline{\text{CH}_2}$), 118.8 (t, $\text{CH}=\underline{\text{CH}_2}$), 132.11 (d, $\underline{\text{CH}}=\text{CH}_2$), 132.4 (d, $\underline{\text{CH}}=\text{CH}_2$), 176.4 (s, C2), 177.0 (s, C2).

(3R*,4R*)- and (3S*,4R*)-1-Allyl-3-(2-hydroxyhexyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12c):


Prepared according to the general procedure, yield 220 mg (86%) as an inseparable 2:2(*trans*):1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-**12c** increased to 16:16(*trans*):1:1(*cis*).

[R_f (hexanes/EtOAc 1:1) = 0.56]; IR (film); ν [cm^{-1}]: 3366 (br), 2930 (s), 2871 (m), 1670 (s), 1490 (w), 1448 (m), 1417 (w), 1374 (w), 1359 (w), 1262 (m), 1208 (w), 1185 (w), 1113 (w), 1046 (w), 994 (w), 972 (w), 956 (w), 925 (w), 790 (w), 717 (w), 620 (w), 605 (w); MS (+ESI)

m/z, (%): 811 (60, [2M+Na⁺], 417 (100, [M+Na⁺]), 395 (90, [M+H⁺]); HRMS (+ESI) m/z [C₂₃H₄₂N₂O₃Na⁺]; calcd. 417.3088; found 417.3084.



Major diastereomers: ¹H NMR (400 MHz, CDCl₃): δ 0.89 (t, *J* = 7.1 Hz, 6H, CH₃), 1.09 (s, 12H, NCCH₃), 1.13 (s, 3H, NCCH₃), 1.14 (s, 9H, NCCH₃), 1.28-1.37 (m, 8H, CH₃CH₂CH₂, piperidine-H4), 1.39-1.47 (m, 12H, CH₃CH₂CH₂CH₂, piperidine-H3, H5), 1.49-1.60 (m, 4H, CH₃CH₂CH₂CH₂, piperidine-H4), 1.61-1.72 (m, 2H, CHCH₂CH), 1.73-1.84 (m, 1H, CHCH₂CH), 1.89 (ddd, *J* = 14.5, 8.7, 3.4 Hz, 1H, CHCH₂CH), 2.19-2.29 (m, 1H, H4), 2.30-2.43 (m, 1H, H4), 2.53-2.66 (m, 2H, H3), 3.11-3.23 (m, 2H, H5), 3.41 (dd, *J* = 12.9, 8.8 Hz, 1H, H5), 3.42 (dd, *J* = 11.6, 6.7 Hz, 1H, H5), 3.69-3.78 (m, 1H, CHOH), 3.80-3.87 (m, 7H, CH₂CH=, CH₂OTMP, CHOH), 3.95 (dd, *J* = 15.6, 6.1 Hz, 2H, CH₂CH=), 4.05 (br. s, 1H, OH), 5.15-5.24 (m, 4H, CH=CH₂), 5.60 (br. s, 1H, OH), 5.72 (ddt, *J* = 16.5, 10.3, 6.1 Hz, 2H, CH=CH₂); ¹³C NMR (101 MHz, CDCl₃): δ 14.20 (q, CH₃), 14.22 (q, CH₃), 17.1 (t, 2C, piperidine-C4), 20.34 (q, 4C, NCCH₃), 22.90 (t, CH₃CH₂), 22.94 (t, CH₃CH₂), 28.1 (t, CH₃CH₂CH₂), 28.4 (t, CH₃CH₂CH₂), 33.21 (q, NCCH₃), 33.29 (q, 2C, NCCH₃), 33.31 (q, NCCH₃), 37.0 (t, CH₃CH₂CH₂CH₂), 37.8 (t, CHCH₂CH), 38.06 (d, C4), 38.09 (t, CH₃CH₂CH₂CH₂), 38.9 (t, CHCH₂CH), 39.1 (d, C4), 39.7 (t, piperidine-C3, C5), 39.8 (t, piperidine-C3, C5), 42.4 (d, C3), 45.5 (t, CH₂CH=), 45.62 (d, C3), 45.7 (t, CH₂CH=), 48.7 (t, C5), 48.79 (t, C5), 60.1 (s, 4C, CNO), 69.9 (d, CHOH), 71.9 (d, CHOH), 76.8 (t, CH₂OTMP), 77.6 (t, CH₂OTMP), 118.2 (t, CH=CH₂), 118.37 (t, CH=CH₂), 132.0 (d, CH=CH₂), 132.2 (d, CH=CH₂), 176.86 (s, C2), 177.4 (s, C2).




Minor diastereomers: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 2.62-2.71 (m, 2H, H4), 2.74 (td, $J = 9.2, 4.1$ Hz, 1H, H3), 2.83 (td, $J = 9.3, 4.5$ Hz, 1H, H3), 3.26 (dd, $J = 10.0, 4.0$ Hz, 1H, H5), 3.57-3.68 (m, 3H, CH_2OTMP), 3.69-3.74 (m, 1H, CHOH), 3.71 (dd, $J = 9.3, 5.5$ Hz, 1H, CH_2OTMP); ^{13}C NMR (101 MHz, CDCl_3): δ 14.20 (q, CH_3), 14.22 (q, CH_3), 17.1 (t, 2C, piperidine-C4), 20.2 (q, NCCCH_3), 20.29 (q, NCCCH_3), 20.34 (q, 2C, NCCCH_3), 22.90 (t, CH_3CH_2), 22.94 (t, CH_3CH_2), 28.0 (t, $\text{CH}_3\text{CH}_2\text{CH}_2$), 28.3 (t, $\text{CH}_3\text{CH}_2\text{CH}_2$), 32.7 (t, $\text{CH}_3\text{CH}_2\text{CH}_2\text{CH}_2$), 33.1 (q, NCCCH_3), 33.17 (q, NCCCH_3), 33.22 (q, NCCCH_3), 33.30 (q, NCCCH_3), 34.0 (t, $\text{CH}_3\text{CH}_2\text{CH}_2\text{CH}_2$), 36.0 (d, 2C, C4), 37.1 (t, CHCH_2CH), 38.3 (t, CHCH_2CH), 39.7 (t, piperidine-C3, C5), 39.8 (t, piperidine-C3, C5), 41.1 (d, C3), 44.7 (d, C3), 45.59 (t, $\text{CH}_2\text{CH=}$), 45.8 (t, $\text{CH}_2\text{CH=}$), 48.76 (t, C5), 48.9 (t, C5), 59.99 (s, 2C, CNO), 60.04 (s, 2C, CNO), 69.9 (d, CHOH), 72.0 (d, CHOH), 74.8 (t, CH_2OTMP), 75.3 (t, CH_2OTMP), 118.42 (t, CH=CH_2), 118.7 (t, CH=CH_2), 132.2 (d, CH=CH_2), 132.4 (d, CH=CH_2), 176.90 (s, C2), 177.1 (s, C2).

(3*R,4*R**)- and (3*S**,4*R**)-1-Allyl-3-(2-hydroxy-2-phenylethyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12d):**


Prepared according to the general procedure, yield 231 mg (86%) as an inseparable 3:3(*trans*):1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-**12d** increased to 13:13(*trans*):1:1(*cis*).

[R_f (hexanes/EtOAc 1:1) = 0.49]; IR (film); ν [cm^{-1}]: 3276 (br), 2974 (w), 2930 (m), 2871 (w), 1667 (s), 1492 (w), 1451 (m), 1418 (w), 1374 (w), 1360 (w), 1262 (w), 1133 (w), 1047 (w), 993 (w), 926 (w), 757 (w), 701 (m), 669 (w), 627 (w); MS (+ESI) m/z , (%): 851 (20, $[2\text{M}+\text{Na}^+]$), 437 (60, $[\text{M}+\text{Na}^+]$), 415 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{25}\text{H}_{39}\text{N}_2\text{O}_3^+$]: calcd. 415.2955; found 415.2951.



(3*R**,4*R**)

Major diastereomers: ^1H NMR (400 MHz, CDCl_3): δ 0.95 (s, 6H, NCCH_3), 1.03 (s, 3H, NCCH_3), 1.06 (s, 3H, NCCH_3), 1.10 (s, 3H, NCCH_3), 1.11 (s, 3H, NCCH_3), 1.15 (s, 3H, NCCH_3), 1.16 (s, 3H, NCCH_3), 1.24-1.36 (m, 2H, piperidine-H4), 1.37-1.48 (m, 8H, piperidine-H3, H5), 1.49-1.59 (m, 2H, piperidine-H4), 1.89-2.03 (m, 2H, CH_2CHOH), 2.10 (ddd, $J = 14.5$, 5.7, 3.7 Hz, 1H, CH_2CHOH), 2.15-2.33 (m, 3H, H4, CH_2CHOH), 2.39 (td, $J = 9.5$, 3.7 Hz, 1H, H3), 2.80 (td, $J = 9.7$, 3.7 Hz, 1H, H3), 3.15 (dd, $J = 9.9$, 8.2 Hz, 1H, H5), 3.25 (dd, $J = 9.9$, 8.8 Hz, 1H, H5), 3.39 (dd, $J = 14.5$, 3.5 Hz, 1H, H5), 3.44 (dd, $J = 14.5$, 3.9 Hz, 1H, H5), 3.60 (dd, $J = 9.2$, 6.2 Hz, 1H, CH_2OTMP), 3.66 (dd, $J = 9.2$, 5.3 Hz, 1H, CH_2OTMP), 3.82 (dd, $J = 15.2$, 6.2 Hz, 1H, $\text{CH}_2\text{CH=}$), 3.85 (d, $J = 5.6$ Hz, 2H, CH_2OTMP), 3.87 (dd, $J = 14.9$, 5.9 Hz, 1H, $\text{CH}_2\text{CH=}$), 3.92-4.05 (m, 2H, $\text{CH}_2\text{CH=}$), 4.88 (dd, $J = 9.1$, 3.7 Hz, 1H, CHOH), 5.09-5.11 (m, 1H, CHOH), 5.16-5.25 (m, 4H, CH=CH_2), 5.65-5.81 (m, 2H, CH=CH_2), 6.34 (br. s, 2H, OH), 7.18-7.25 (m, 2H, ArH), 7.29-7.35 (m, 6H, ArH), 7.36-7.43 (m, 2H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.10 (t, piperidine-C4), 17.14 (t, piperidine-C4), 20.2 (q, NCCH_3), 20.3 (q, NCCH_3), 20.42 (q, 2C, NCCH_3), 33.18 (q, NCCH_3), 33.23 (q, NCCH_3), 33.3 (q, NCCH_3), 33.4 (q, NCCH_3), 38.7 (d, C4), 39.2 (d, C4), 39.5 (t, CH_2CHOH), 39.7 (t, 4C, piperidine-C3, C5), 41.8 (d, C3), 42.0 (t, CH_2CHOH), 45.67 (d, C3), 45.70 (t, $\text{CH}_2\text{CH=}$), 45.76 (t, $\text{CH}_2\text{CH=}$), 48.81 (t, C5), 49.1 (t, C5), 60.00 (s, 2C, CNO), 60.2 (s, 2C, CNO), 72.0 (d, CHOH), 74.7 (d, CHOH), 76.3 (t, CH_2OTMP), 76.7 (t, CH_2OTMP), 118.4 (t, CH=CH_2), 118.6 (t, CH=CH_2), 125.8 (d, CH_{Ar}), 125.9 (d, CH_{Ar}), 126.9 (d, CH_{Ar}), 127.2 (d, CH_{Ar}), 128.38 (d, CH_{Ar}), 128.43 (d, CH_{Ar}), 131.9 (d, CH=CH_2), 132.0 (d, CH=CH_2), 144.53 (s, C_{Ar}), 145.7 (s, C_{Ar}), 177.00 (s, C2), 177.4 (s, C2).




Minor diastereomers: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 1.01 (s, 3H, NCCH_3), 2.46 (dq, $J = 8.4, 4.7$ Hz, 1H, H4), 2.55-2.62 (m, 1H, H3), 2.64-2.70 (m, 1H, H4), 2.91 (ddd, $J = 9.9, 7.6, 3.3$ Hz, 1H, H3), 3.73 (dd, $J = 9.2, 5.3$ Hz, 1H, CH_2OTMP), 4.78-4.83 (m, 1H, CHOH), 5.96 (br. s, 2H, OH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.13 (t, 2C, piperidine-C4), 20.2 (q, NCCH_3), 20.3 (q, NCCH_3), 20.37 (q, NCCH_3), 20.44 (q, NCCH_3), 33.0 (q, NCCH_3), 33.08 (q, NCCH_3), 33.12 (q, NCCH_3), 33.5 (q, NCCH_3), 34.4 (t, CH_2CHOH), 35.9 (d, C4), 36.1 (d, C4), 36.9 (t, CH_2CHOH), 39.8 (t, 4C, piperidine-C3, C5), 41.0 (d, C3), 44.8 (d, C3), 45.81 (t, $\text{CH}_2\text{CH=}$), 45.9 (t, $\text{CH}_2\text{CH=}$), 48.76 (t, C5), 48.82 (t, C5), 59.9 (s, 2C, CNO), 60.03 (s, 2C, CNO), 71.8 (d, CHOH), 74.5 (t, CH_2OTMP), 74.78 (d, CHOH), 74.83 (t, CH_2OTMP), 118.8 (t, CH=CH_2), 118.9 (t, CH=CH_2), 125.9 (d, CH_{Ar}), 126.0 (d, CH_{Ar}), 127.0 (d, CH_{Ar}), 127.3 (d, CH_{Ar}), 128.38 (d, CH_{Ar}), 128.43 (d, CH_{Ar}), 132.1 (d, CH=CH_2), 132.2 (d, CH=CH_2), 144.51 (s, C_{Ar}), 145.5 (s, C_{Ar}), 176.97 (s, C2), 177.2 (s, C2).

(3*R,4*R**)- and (3*S**,4*R**)-3-(2-Hydroxypropyl)-1-methyl-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12e):**


Prepared according to the general procedure, yield 214 mg (82%) as an inseparable 2:2(*trans*):1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-**12e** increased to 4:4(*trans*):1:1(*cis*).

[R_f (hexanes/EtOAc 1:1) = 0.25]; IR (film); ν [cm^{-1}]: 3351 (br), 2970 (w), 2928 (m), 2871 (w), 1669 (s), 1501 (w), 1468 (w), 1453 (w), 1404 (w), 1373 (w), 1359 (w), 1263 (w), 1245 (w), 1133 (w), 1096 (w), 1078 (w), 1046 (w), 994 (w), 793 (w), 721 (w), 636 (w); MS (+ESI) m/z , (%): 349 (100, $[\text{M}+\text{Na}^+]$), 327 (10, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{18}\text{H}_{34}\text{N}_2\text{O}_3\text{Na}^+$]: calcd. 349.2462; found 349.2460.



(3*R**,4*R**)

Major diastereomers: ^1H NMR (400 MHz, CDCl_3): δ 1.09 (s, 12H, NCCH_3), 1.14 (s, 12H, NCCH_3), 1.21 (d, $J = 6.6$ Hz, 3H, CHCH_3), 1.23 (d, $J = 6.2$ Hz, 3H, CHCH_3), 1.28-1.36 (m, 2H, piperidine-H4), 1.40-1.47 (m, 8H, piperidine-H3, H5), 1.50-1.58 (m, 2H, piperidine-H4), 1.59-1.67 (m, 1H, CH_2CHOH), 1.68-1.80 (m, 2H, CH_2CHOH), 1.90 (ddd, $J = 14.5, 8.7, 3.6$ Hz, 1H, CH_2CHOH), 2.16-2.24 (m, 1H, H4), 2.28-2.42 (m, 1H, H4), 2.53 (td, $J = 9.8, 3.2$ Hz, 1H, H3), 2.62 (td, $J = 8.7, 5.0$ Hz, 1H, H3), 2.85 (s, 3H, NCH_3), 2.86 (s, 3H, NCH_3), 3.21 (dd, $J = 9.1, 4.5$ Hz, 1H, H5), 3.23 (dd, $J = 13.2, 7.9$ Hz, 1H, H5), 3.43 (dd, $J = 9.1, 8.2$ Hz, 1H, H5), 3.44 (dd, $J = 13.2, 3.5$ Hz, 1H, H5), 3.79-3.84 (m, 4H, CH_2OTMP), 3.88-4.02 (m, 1H, CHOH), 4.04-4.12 (m, 1H, CHOH), 5.82 (br. s, 2H, OH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.1 (t, 2C, piperidine-C4), 20.3 (q, 4C, NCCH_3), 23.0 (q, CHCH_3), 24.3 (q, CHCH_3), 30.2 (q, NCH_3), 31.4 (q, NCH_3), 33.1 (q, NCCH_3), 33.39 (q, NCCH_3), 33.42 (q, NCCH_3), 33.5 (q, NCCH_3), 34.3 (t, CH_2CHOH), 35.86 (t, CH_2CHOH), 35.88 (d, C4), 35.93 (d, C4), 39.7 (t, 2C, piperidine-C3), 39.8 (t, 2C, piperidine-C5), 40.8 (d, C3), 44.6 (d, C3), 51.62 (t, C5), 51.7 (t, C5), 59.96 (s, CNO), 59.97 (s, CNO), 59.99 (s, CNO), 60.01 (s, CNO), 65.9 (d, CHOH), 68.3 (d, CHOH), 74.9 (t, CH_2OTMP), 75.3 (t, CH_2OTMP), 177.08 (s, C2), 177.6 (s, C2).



(3*S**,4*R**)


Minor diastereomers: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 1.11 (s, 12H, NCCH_3), 1.13 (s, 12H, NCCH_3), 1.80-1.85 (m, 1H, CH_2CHOH), 2.65-2.70 (m, 2H, H4), 2.74 (td, $J = 8.7, 4.6$ Hz, 1H, H3), 2.78-2.86 (m, 1H, H3), 2.87 (s, 3H, NCH_3), 3.32 (dd, $J = 9.9, 3.9$ Hz, 1H, H5), 3.37 (dd, $J = 10.1, 2.6$ Hz, 1H, H5), 3.67 (dd, $J = 9.2, 6.0$ Hz, 1H, CH_2OTMP), 3.74 (dd, $J = 9.1, 5.3$ Hz, 1H, CH_2OTMP), 3.82-3.92 (m, 1H, CHOH), 4.38 (br. s, 1H, OH), 5.54 (br. s, 1H, OH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.1 (t, 2C, piperidine-C4), 20.3 (q, 4C, NCCH_3), 23.1 (q, CHCH_3), 24.4 (q, CHCH_3), 30.0 (q, NCH_3), 30.1 (q, NCH_3), 33.2 (q, 2C, NCCH_3), 33.3 (q, 2C, NCCH_3).

NCCH₃), 38.1 (d, C4), 38.9 (d, C4), 39.4 (t, CH₂CHOH), 39.7 (t, 2C, piperidine-C3), 39.8 (t, 2C, piperidine-C5), 40.9 (t, CH₂CHOH), 41.9 (d, C3), 45.6 (d, C3), 51.5 (t, C5), 51.56 (t, C5), 60.1 (s, 2C, CNO), 60.2 (s, 2C, CNO), 66.0 (d, CHOH), 68.2 (d, CHOH), 76.9 (t, CH₂OTMP), 77.4 (t, CH₂OTMP), 177.12 (s, C2), 177.6 (s, C2).

(3*R,4*R**)- and (3*S**,4*R**)-1-Benzyl-3-(2-hydroxypropyl)-4-methyl-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12f):**


Prepared according to the general procedure, yield 178 mg (66%) as an inseparable 3:3(*trans*):1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-**12f** did not change.

[*R_f* (hexanes/EtOAc 1:1) = 0.56]; IR (film); ν [cm⁻¹]: 3341 (br), 2969 (m), 2928 (m), 2872 (m), 1667 (s), 1490 (w), 1452 (m), 1373 (w), 1359 (w), 1322 (w), 1260 (w), 1208 (w), 1153 (w), 1132 (w), 1054 (w), 1030 (m), 994 (w), 954 (w), 925 (w), 726 (w), 701 (w), 646 (w), 620 (w); MS (+ESI) *m/z*, (%): 417 (100, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₅H₄₁N₂O₃⁺]: calcd. 417.3112; found 417.3111.



Major diastereomers: ¹H NMR (400 MHz, CDCl₃): δ 0.89 (s, 3H, CCH₃), 0.92 (s, 3H, CCH₃), 1.03 (s, 3H, NCCH₃), 1.04 (s, 3H, NCCH₃), 1.07 (s, 18H, NCCH₃), 1.23 (d, *J* = 6.5 Hz, 6H, CHCH₃), 1.25-1.33 (m, 2H, piperidine-H4), 1.34-1.44 (m, 8H, piperidine-H3, H5), 1.46-1.51 (m, 2H, piperidine-H4), 1.57-1.62 (m, 1H, CH₂CHOH), 1.63-1.68 (m, 2H, CH₂CHOH), 1.88 (ddd, *J* = 14.7, 11.4, 3.5 Hz, 1H, CH₂CHOH), 2.78 (d, *J* = 9.5 Hz, 1H, H5), 2.79-2.83 (m, 1H, H3), 2.81 (d, *J* = 9.7 Hz, 1H, H5), 2.92 (dd, *J* = 9.8, 6.5 Hz, 1H, H3), 3.39 (d, *J* = 9.5 Hz, 1H, H5), 3.43 (d, *J* = 9.7 Hz, 1H, H5), 3.57 (d, *J* = 9.0 Hz, 1H, CH₂OTMP), 3.58 (d, *J* = 9.1 Hz, 1H, CH₂OTMP), 3.61 (d, *J* = 9.0 Hz, 1H, CH₂OTMP), 3.62 (d, *J* = 9.1 Hz, 1H, CH₂OTMP), 3.89-3.98 (m, 1H, CHOH), 4.16-4.26 (m, 1H, CHOH), 4.23 (d, *J* = 14.7 Hz, 1H, CH₂Ph), 4.24 (d, *J* = 14.9 Hz, 1H, CH₂Ph), 4.66 (d, *J* = 14.7 Hz, 1H, CH₂Ph), 4.67 (d, *J* = 14.9 Hz, 1H, CH₂Ph), 6.13 (br. s, 2H, OH), 7.20-7.37 (m, 10H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 17.04 (t, piperidine-C4), 17.07

(t, piperidine-C4), 18.9 (q, 2C, CCH₃), 20.3 (q, NCCH₃), 20.4 (q, NCCH₃), 20.48 (q, NCCH₃), 20.53 (q, NCCH₃), 22.8 (q, CHCH₃), 24.7 (q, CHCH₃), 33.17 (q, NCCH₃), 33.24 (q, NCCH₃), 33.3 (q, NCCH₃), 33.4 (q, NCCH₃), 33.6 (t, CH₂CHOH), 35.3 (t, CH₂CHOH), 39.8 (t, piperidine-C3, C5), 39.9 (t, piperidine-C3, C5), 41.1 (s, C4), 41.4 (s, C4), 43.9 (d, C3), 46.98 (t, C5), 47.04 (t, C5), 49.2 (d, C3), 55.2 (t, CH₂Ph), 55.3 (t, CH₂Ph), 60.3 (s, 4C, CNO), 65.2 (d, CHOH), 68.76 (d, CHOH), 79.9 (t, CH₂OTMP), 80.2 (t, CH₂OTMP), 127.8 (d, CH_{Ar}), 127.9 (d, CH_{Ar}), 128.28 (d, CH_{Ar}), 128.29 (d, CH_{Ar}), 128.88 (d, CH_{Ar}), 128.89 (d, CH_{Ar}), 136.04 (s, C_{Ar}), 136.3 (s, C_{Ar}), 176.9 (s, C2), 177.4 (s, C2).




Minor diastereomers: ¹H NMR (400 MHz, CDCl₃, detectable signals): δ 0.86 (s, 3H, CCH₃), 0.98 (s, 3H, NCCH₃), 0.99 (s, 3H, NCCH₃), 1.13 (s, 3H, NCCH₃), 1.19 (d, *J* = 6.1 Hz, 3H, CHCH₃), 1.21 (d, *J* = 6.2 Hz, 3H, CHCH₃), 1.80 (ddd, *J* = 14.7, 11.0, 3.7 Hz, 1H, CH₂CHOH), 2.33-2.44 (m, 1H, H3), 2.54 (dd, *J* = 11.0, 3.2 Hz, 1H, H3), 2.93 (d, *J* = 9.8 Hz, 1H, H5), 3.03 (d, *J* = 9.7 Hz, 1H, H5), 3.44 (d, *J* = 9.8 Hz, 1H, H5), 3.49 (d, *J* = 9.7 Hz, 1H, CH₂OTMP), 3.51 (d, *J* = 9.7 Hz, 1H, H5), 3.57 (d, *J* = 9.9 Hz, 1H, CH₂OTMP), 3.83-3.89 (m, 1H, CHOH), 4.27 (d, *J* = 14.3 Hz, 1H, CH₂Ph), 4.28 (d, *J* = 14.4 Hz, 1H, CH₂Ph), 4.57 (d, *J* = 14.4 Hz, 1H, CH₂Ph), 4.58 (d, *J* = 14.3 Hz, 1H, CH₂Ph), 5.97 (br. s, 2H, OH); ¹³C NMR (101 MHz, CDCl₃): δ 17.00 (t, piperidine-C4), 17.13 (t, piperidine-C4), 20.3 (q, NCCH₃), 20.4 (q, NCCH₃), 20.48 (q, NCCH₃), 20.53 (q, NCCH₃), 22.0 (q, CHCH₃), 22.3 (q, CHCH₃), 22.7 (q, CCH₃), 22.9 (q, CCH₃), 32.6 (t, CH₂CHOH), 33.17 (q, NCCH₃), 33.24 (q, NCCH₃), 33.3 (q, NCCH₃), 33.4 (q, NCCH₃), 34.2 (t, CH₂CHOH), 39.8 (t, piperidine-C3, C5), 39.9 (t, piperidine-C3, C5), 41.0 (s, C4), 41.2 (s, C4), 47.3 (t, C5), 47.4 (t, C5), 48.0 (d, C3), 48.7 (d, C3), 54.6 (t, CH₂Ph), 54.7 (t, CH₂Ph), 59.0 (s, 4C, CNO), 65.0 (d, CHOH), 68.84 (d, CHOH), 77.1 (t, CH₂OTMP), 77.3 (t, CH₂OTMP), 127.7 (d, CH_{Ar}), 128.0 (d, CH_{Ar}), 128.4 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 128.8 (d, CH_{Ar}), 129.0 (d, CH_{Ar}), 136.00 (s, C_{Ar}), 136.1 (s, C_{Ar}), 177.2 (s, C2), 177.3 (s, C2).

(3*R,4*S**)- and (3*S**,4*S**)-1-Benzyl-3-(2-hydroxypropyl)-4-(prop-1-en-2-yl)pyrrolidin-2-one (12g):**


Prepared according to the general procedure, yield 165 mg (93%) as an inseparable 2:2(*trans*):1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-12g increased to 7:7(*trans*):1:0(*cis*).

[*R*_f (hexanes/EtOAc 1:1) = 0.43]; IR (film); ν [cm⁻¹]: 3367 (br), 3076 (w), 3031 (w), 2966 (w), 2926 (w), 1666 (s), 1495 (w), 1435 (m), 1376 (w), 1321 (w), 1255 (m), 1202 (w), 1138 (w), 1079 (w), 1057 (w), 1029 (w), 939 (w), 899 (w), 820 (w), 750 (w), 701 (m), 646 (w); MS (+ESI) *m/z*, (%): 569 (30, [2*M*+Na⁺]), 296 (100, [*M*+Na⁺]), 274 (30, [*M*+H⁺]); HRMS (+ESI) *m/z* [C₁₇H₂₃NO₂Na⁺]: calcd. 296.1621; found 296.1619.



(3*R**,4*S**)

Major diastereomers: ¹H NMR (400 MHz, CDCl₃): δ 1.22 (d, *J* = 6.2 Hz, 6H, CHCH₃), 1.62-1.72 (m, 3H, CH₂CHOH), 1.68 (s, 6H, =CCH₃), 1.87 (ddd, *J* = 14.5, 9.1, 3.5 Hz, 1H, CH₂CHOH), 2.57-2.72 (m, 3H, H3, H4), 2.77 (td, *J* = 9.7, 3.9 Hz, 1H, H3), 3.08 (dd, *J* = 9.8, 4.2 Hz, 1H, H5), 3.10 (dd, *J* = 9.5, 4.7 Hz, 1H, H5), 3.29 (dd, *J* = 9.5, 8.4 Hz, 1H, H5), 3.30 (dd, *J* = 9.8, 8.2 Hz, 1H, H5), 3.95 (sext, *J* = 6.0 Hz, 1H, CHOH), 4.08-4.20 (m, 1H, CHOH), 4.39 (d, *J* = 14.5 Hz, 1H, CH₂Ph), 4.40 (d, *J* = 14.7 Hz, 1H, CH₂Ph), 4.51 (d, *J* = 14.7 Hz, 1H, CH₂Ph), 4.52 (d, *J* = 14.5 Hz, 1H, CH₂Ph), 4.82 (d, *J* = 1.7 Hz, 1H, C=CH₂), 4.83 (d, *J* = 1.7 Hz, 1H, C=CH₂), 4.85 (d, *J* = 1.5 Hz, 1H, C=CH₂), 4.86 (d, *J* = 1.5 Hz, 1H, C=CH₂), 5.71 (br. s, 2H, OH), 7.20-7.25 (m, 4H, ArH), 7.28-7.36 (m, 6H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 19.5 (q, CHCH₃), 19.6 (q, CHCH₃), 23.1 (q, =CCH₃), 24.4 (q, =CCH₃), 38.2 (t, CH₂CHOH), 40.0 (t, CH₂CHOH), 42.0 (d, C4), 45.9 (d, C4), 46.8 (d, C3), 46.94 (t, CH₂Ph), 47.1 (t, CH₂Ph), 47.6 (d, C3), 49.87 (t, C5), 49.94 (t, C5), 65.3 (d, CHOH), 68.0 (d, CHOH), 113.4 (t, C=CH₂), 113.9 (t, C=CH₂), 127.86 (d, CH_{Ar}), 127.94 (d, CH_{Ar}), 128.25 (d, CH_{Ar}), 128.28 (d, CH_{Ar}), 128.90 (d, CH_{Ar}), 128.94 (d, CH_{Ar}), 136.0 (s, C_{Ar}), 136.17 (s, C_{Ar}), 142.1 (s, C=CH₂), 142.6 (s, C=CH₂), 176.9 (s, C2), 177.3 (s, C2).




(3*S**,4*S**)

Minor diastereomers: ^1H NMR (400 MHz, CDCl_3): δ 1.20 (d, $J = 6.4$ Hz, 3H, CHCH_3), 1.21 (d, $J = 6.1$ Hz, 3H, CHCH_3), 1.38-1.46 (m, 1H, CH_2CHOH), 1.49 (s, 3H, $=\text{CCH}_3$), 1.52-1.56 (m, 2H, CH_2CHOH), 1.57 (s, 3H, $=\text{CCH}_3$), 1.60-1.68 (m, 1H, CH_2CHOH), 2.76-2.83 (m, 1H, H4), 2.86-2.93 (m, 1H, H4), 2.94-3.05 (m, 2H, H3), 3.13 (dd, $J = 10.5, 3.2$ Hz, 1H, H5), 3.20 (dd, $J = 10.0, 5.7$ Hz, 1H, H5), 3.32 (dd, $J = 10.5, 5.7$ Hz, 1H, H5), 3.41 (dd, $J = 10.0, 6.8$ Hz, 1H, H5), 3.89-4.00 (m, 1H, CHOH), 4.03-4.10 (m, 1H, CHOH), 4.45 (s, 2H, CH_2Ph), 4.46 (s, 2H, CH_2Ph), 4.65 (d, $J = 1.7$ Hz, 1H, $\text{C}=\text{CH}_2$), 4.68 (d, $J = 1.7$ Hz, 1H, $\text{C}=\text{CH}_2$), 4.79 (d, $J = 1.5$ Hz, 1H, $\text{C}=\text{CH}_2$), 4.80-4.83 (m, 1H, $\text{C}=\text{CH}_2$), 5.21 (br. s, 2H, OH); ^{13}C NMR (101 MHz, CDCl_3): δ 20.1 (q, CHCH_3), 21.1 (q, CHCH_3), 22.9 (q, $=\text{CCH}_3$), 24.4 (q, $=\text{CCH}_3$), 34.3 (t, CH_2CHOH), 35.9 (t, CH_2CHOH), 41.0 (d, C4), 43.7 (d, C3), 43.8 (d, C3), 45.0 (d, C4), 46.92 (t, CH_2Ph), 47.2 (t, CH_2Ph), 48.9 (t, C5), 49.7 (t, C5), 65.5 (d, CHOH), 68.3 (d, CHOH), 113.4 (t, $\text{C}=\text{CH}_2$), 114.5 (t, $\text{C}=\text{CH}_2$), 127.89 (d, CH_{Ar}), 128.0 (d, CH_{Ar}), 128.5 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 128.87 (d, 2C, CH_{Ar}), 135.9 (s, C_{Ar}), 136.20 (s, C_{Ar}), 142.8 (s, $\text{C}=\text{CH}_2$), 143.1 (s, $\text{C}=\text{CH}_2$), 176.8 (s, C2), 177.5 (s, C2).


(3*R*,4*R*)- and (3*S*,4*S*)- and (3*R*,4*S*)- and (3*S*,4*R*)-1-Allyl-3-((*S*)-3-(benzyloxy)-2-hydroxypropyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12h):

Prepared according to the general procedure, yield 214 mg (72%) as an inseparable 4:4(*trans*):1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-**12h** increased to 17:17(*trans*):1:1(*cis*).

[R_f (hexanes/EtOAc 1:1) = 0.61]; IR (film); ν [cm^{-1}]: 3295 (br), 2974 (w), 2929 (m), 2869 (w), 1667 (s), 1493 (w), 1452 (m), 1418 (w), 1374 (w), 1359 (w), 1262 (m), 1208 (w), 1185 (w), 1132 (m), 1101 (m), 1046 (w), 1029 (w), 993 (w), 971 (w), 956 (w), 925 (w), 736 (w), 698 (w), 606 (w); MS (+ESI) m/z , (%): 939 (50, $[2\text{M}+\text{Na}^+]$), 481 (100, $[\text{M}+\text{Na}^+]$), 459 (65, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{27}\text{H}_{42}\text{N}_2\text{O}_4\text{Na}^+$]: calcd. 481.3037; found 481.3033.



Major diastereomers: ^1H NMR (400 MHz, CDCl_3): δ 1.07 (s, 12H, NCCH_3), 1.12 (s, 12H, NCCH_3), 1.28-1.36 (m, 2H, piperidine- H_4), 1.39-1.47 (m, 8H, piperidine- H_3 , H_5), 1.48-1.61 (m, 2H, piperidine- H_4), 1.67 (dt, $J = 14.5, 10.0$ Hz, 1H, CH_2CHOH), 1.87 (t, $J = 6.1$ Hz, 2H, CH_2CHOH), 1.99 (ddd, $J = 14.5, 3.4, 2.1$ Hz, 1H, CH_2CHOH), 2.21-2.31 (m, 1H, H_4), 2.32-2.41 (m, 1H, H_4), 2.52-2.62 (m, 2H, H_3), 3.17 (dd, $J = 10.5, 7.5$ Hz, 1H, H_5), 3.20 (dd, $J = 17.9, 9.3$ Hz, 1H, H_5), 3.38-3.44 (m, 3H, CHCH_2O , H_5), 3.47 (dd, $J = 9.3, 3.3$ Hz, 1H, CHCH_2O), 3.50 (dd, $J = 9.3, 4.2$ Hz, 1H, CHCH_2O), 3.55 (dd, $J = 9.5, 5.3$ Hz, 1H, CHCH_2O), 3.78 (dd, $J = 9.0, 7.1$ Hz, 1H, CH_2OTMP), 3.81-3.88 (m, 5H, CH_2OTMP , $\text{CH}_2\text{CH=}$), 3.89-3.99 (m, 3H, $\text{CH}_2\text{CH=}$, CHOH), 4.11 (quint, $J = 5.5$ Hz, 1H, CHOH), 4.54 (d, $J = 12.0$ Hz, 1H, CH_2Ph), 4.55 (d, $J = 12.0$ Hz, 1H, CH_2Ph), 4.56 (d, $J = 12.4$ Hz, 1H, CH_2Ph), 4.58 (d, $J = 12.4$ Hz, 1H, CH_2Ph), 5.15-5.24 (m, 4H, CH=CH_2), 5.65 (br. s, 2H, OH), 5.73 (ddt, $J = 16.4, 10.4, 6.2$ Hz, 2H, CH=CH_2), 7.26-7.37 (m, 10H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.14 (t, piperidine- C_4), 17.15 (t, piperidine- C_4), 20.3 (q, 4C, NCCH_3), 33.3 (q, 2C, NCCH_3), 33.4 (q, 2C, NCCH_3), 34.4 (t, CH_2CHOH), 35.6 (t, CH_2CHOH), 38.1 (d, C_4), 39.0 (d, C_4), 39.7 (t, piperidine- C_3 , C_5), 39.8 (t, piperidine- C_3 , C_5), 42.1 (d, C_3), 45.1 (d, C_3), 45.5 (t, $\text{CH}_2\text{CH=}$), 45.7 (t, $\text{CH}_2\text{CH=}$), 48.9 (t, C_5), 49.0 (t, C_5), 60.04 (s, 2C, CNO), 60.1 (s, 2C, CNO), 68.6 (d, CHOH), 70.7 (d, CHOH), 73.45 (t, CH_2Ph), 73.47 (t, CH_2Ph), 73.9 (t, CHCH_2O), 74.73 (t, CHCH_2O), 76.7 (t, CH_2OTMP), 77.6 (t, CH_2OTMP), 118.2 (t, CH=CH_2), 118.4 (t, CH=CH_2), 127.6 (d, CH_{Ar}), 127.72 (d, CH_{Ar}), 127.76 (d, CH_{Ar}), 127.84 (d, CH_{Ar}), 128.4 (d, CH_{Ar}), 128.52 (d, CH_{Ar}), 132.0 (d, CH=CH_2), 132.23 (d, CH=CH_2), 138.4 (s, C_{Ar}), 138.6 (s, C_{Ar}), 176.6 (s, C_2), 177.2 (s, C_2).




Minor diastereomers: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 1.78 (ddd, $J = 12.8, 9.3, 3.4$ Hz, 1H, CH_2CHOH), 2.63-2.71 (m, 2H, H4), 2.80 (dt, $J = 8.9, 4.6$ Hz, 1H, H3), 2.87 (dd, $J = 9.7, 2.1$ Hz, 1H, H5), 2.97 (dd, $J = 18.3, 4.7$ Hz, 1H, H5), 3.10 (dd, $J = 18.3, 4.8$ Hz, 1H, H5), 3.11 (dd, $J = 9.7, 4.4$ Hz, 1H, H5), 3.31-3.40 (m, 1H, CHCH_2O), 3.64 (dd, $J = 9.5, 6.1$ Hz, 1H, CH_2OTMP), 3.66 (dd, $J = 9.5, 6.2$ Hz, 1H, CH_2OTMP), 4.09-4.16 (m, 2H, CH_2OTMP), 4.56 (d, $J = 11.8$ Hz, 1H, CH_2Ph), 4.62 (d, $J = 11.8$ Hz, 1H, CH_2Ph), 5.42 (br. s, 2H, OH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.2 (t, 2C, piperidine-C4), 20.20 (q, NCCH_3), 20.22 (q, NCCH_3), 20.39 (q, NCCH_3), 20.41 (q, NCCH_3), 29.2 (t, CH_2CHOH), 30.9 (t, CH_2CHOH), 33.08 (q, NCCH_3), 33.11 (q, NCCH_3), 33.4 (q, NCCH_3), 33.5 (q, NCCH_3), 35.8 (d, C4), 35.9 (d, C4), 39.7 (t, piperidine-C3, C5), 39.8 (t, piperidine-C3, C5), 41.1 (d, C3), 44.3 (d, C3), 45.6 (t, $\text{CH}_2\text{CH=}$), 45.9 (t, $\text{CH}_2\text{CH=}$), 48.6 (t, C5), 48.8 (t, C5), 59.98 (s, CNO), 60.01 (s, CNO), 60.19 (s, CNO), 60.21 (s, CNO), 68.8 (d, CHOH), 70.8 (d, CHOH), 73.4 (t, CH_2Ph), 73.6 (t, CH_2Ph), 73.8 (t, CHCH_2O), 74.69 (t, CHCH_2O), 75.0 (t, CH_2OTMP), 75.2 (t, CH_2OTMP), 118.5 (t, CH=CH_2), 118.8 (t, CH=CH_2), 127.74 (d, CH_{Ar}), 127.81 (d, CH_{Ar}), 127.89 (d, CH_{Ar}), 127.94 (d, CH_{Ar}), 128.54 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 132.16 (d, CH=CH_2), 132.4 (d, CH=CH_2), 138.3 (s, C_{Ar}), 138.5 (s, C_{Ar}), 176.9 (s, C2), 177.0 (s, C2).

(3*R*,4*R*)- and (3*S*,4*S*)- and (3*R*,4*S*)- and (3*S*,4*R*)-3-((*S*)-2-Hydroxypropyl)-1-((*S*)-1-phenylethyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12i**):**


Prepared according to the general procedure, yield 228 mg (82%) as an inseparable 2:2(*trans*):1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-**12i** increased to 1:1(*trans*):0:0(*cis*).

[*R*_f (hexanes/EtOAc 1:1) = 0.42]; IR (film); ν [cm⁻¹]: 3352 (br), 2973 (m), 2931 (m), 2873 (w), 1652 (s), 1493 (w), 1452 (m), 1430 (m), 1374 (w), 1359 (w), 1263 (w), 1245 (w), 1209 (w), 1186 (w), 1133 (w), 1048 (w), 994 (w), 956 (w), 786 (w), 746 (w), 699 (m), 637 (w); MS (+ESI) *m/z*, (%): 439 (100, [M+Na⁺]), 417 (30, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₅H₄₀N₂O₃Na⁺]: calcd. 439.2931; found 439.2931.



Major diastereomers: ¹H NMR (400 MHz, CDCl₃): δ 0.98 (s, 9H, NCCH₃), 1.04 (s, 3H, NCCH₃), 1.05 (s, 6H, NCCH₃), 1.09 (s, 3H, NCCH₃), 1.11 (s, 3H, NCCH₃), 1.21 (d, *J* = 6.5 Hz, 3H, CHOHCH₃), 1.22 (d, *J* = 6.2 Hz, 3H, CHOHCH₃), 1.28-1.35 (m, 2H, piperidine-H₄), 1.37-1.46 (m, 8H, piperidine-H₃, H₅), 1.47-1.50 (m, 2H, piperidine-H₄), 1.51 (d, *J* = 7.3 Hz, 3H, PhCHCH₃), 1.52 (d, *J* = 7.0 Hz, 3H, PhCHCH₃), 1.62-1.82 (m, 3H, CH₂CHOH), 1.91 (ddd, *J* = 14.3, 8.8, 3.5 Hz, 1H, CH₂CHOH), 2.06-2.13 (m, 1H, H₄), 2.24-2.38 (m, 1H, H₄), 2.58-2.65 (m, 2H, H₃), 2.75 (dd, *J* = 9.8, 7.4 Hz, 1H, H₅), 3.04 (dd, *J* = 10.1, 5.3 Hz, 1H, H₅), 3.13 (dd, *J* = 9.8, 2.3 Hz, 1H, H₅), 3.38 (dd, *J* = 10.1, 8.6 Hz, 1H, H₅), 3.65 (d, *J* = 6.4 Hz, 2H, CH₂OTMP), 3.78 (d, *J* = 6.2 Hz, 2H, CH₂OTMP), 3.93-4.02 (m, 1H, CHOH), 4.10 (ddq, *J* = 9.9, 6.5, 3.3 Hz, 1H, CHOH), 5.45 (q, *J* = 7.2 Hz, 2H, PhCHCH₃), 5.86 (br. s, 2H, OH), 7.23-7.37 (m, 10H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 16.1 (q, PhCHCH₃), 16.4 (q, PhCHCH₃), 17.10 (t, piperidine-C₄), 17.12 (t, piperidine-C₄), 20.26 (q, 2C, NCCH₃), 20.31 (q, 2C, NCCH₃), 23.1 (q, CHOHCH₃), 24.4 (q, CHOHCH₃), 33.2 (q, 4C, NCCH₃), 37.8 (d, C₄), 38.9 (d, C₄), 39.4 (t, CH₂CHOH), 39.70 (t, piperidine-C₃, C₅), 39.8 (t, piperidine-C₃, C₅), 40.9 (t, CH₂CHOH), 42.7 (d, C₃), 44.16 (t, C₅), 44.22 (t, C₅), 46.3 (d, C₃), 49.4 (d, PhCHCH₃), 49.5 (d, PhCHCH₃), 60.0 (s, 2C, CNO), 60.1 (s, 2C, CNO), 66.1 (d, CHOH), 68.2 (d, CHOH), 76.8 (t, CH₂OTMP), 77.3 (t,

$\underline{\text{CH}_2\text{OTMP}}$), 126.9 (d, CH_{Ar}), 127.1 (d, CH_{Ar}), 127.57 (d, CH_{Ar}), 127.62 (d, CH_{Ar}), 128.60 (d, CH_{Ar}), 128.64 (d, CH_{Ar}), 139.6 (s, C_{Ar}), 139.7 (s, C_{Ar}), 176.6 (s, C2), 177.0 (s, C2).




Minor diastereomers: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 2.80-2.84 (m, 1H, H3), 2.97 (dd, $J = 10.0, 2.1$ Hz, 1H, H5), 2.99 (dd, $J = 9.4, 3.2$ Hz, 1H, H5), 3.27 (dd, $J = 10.0, 3.5$ Hz, 1H, H5), 3.55 (dd, $J = 9.4, 5.1$ Hz, 1H, H5), 3.64 (dd, $J = 6.2, 3.0$ Hz, 1H, $\underline{\text{CH}_2\text{OTMP}}$), 3.88-3.95 (m, 1H, $\underline{\text{CHOH}}$), 5.08 (br. s, 2H, OH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.2 (q, $\text{PhCH}\underline{\text{CH}_3}$), 16.5 (q, $\text{PhCH}\underline{\text{CH}_3}$), 17.2 (t, 2C, piperidine-C4), 20.1 (q, 2C, $\text{NC}\underline{\text{CH}_3}$), 20.4 (q, 2C, $\text{NC}\underline{\text{CH}_3}$), 23.2 (q, $\text{CHOH}\underline{\text{CH}_3}$), 24.3 (q, $\text{CHOH}\underline{\text{CH}_3}$), 33.2 (q, 3C, $\text{NC}\underline{\text{CH}_3}$), 33.3 (q, $\text{NC}\underline{\text{CH}_3}$), 34.2 (t, $\underline{\text{CH}_2\text{CHOH}}$), 35.71 (d, C4), 35.74 (d, C4), 35.8 (t, $\underline{\text{CH}_2\text{CHOH}}$), 39.71 (t, piperidine-C3, C5), 39.74 (t, piperidine-C3, C5), 41.5 (d, C3), 42.4 (t, C3), 48.3 (t, C5), 48.6 (t, C5), 49.1 (d, $\text{PhCH}\underline{\text{CH}_3}$), 49.2 (d, $\text{PhCH}\underline{\text{CH}_3}$), 59.8 (s, 2C, CNO), 59.96 (s, 2C, CNO), 66.0 (d, $\underline{\text{CHOH}}$), 68.3 (d, $\underline{\text{CHOH}}$), 74.3 (t, $\underline{\text{CH}_2\text{OTMP}}$), 75.0 (t, $\underline{\text{CH}_2\text{OTMP}}$), 127.2 (d, CH_{Ar}), 127.4 (d, CH_{Ar}), 127.58 (d, CH_{Ar}), 127.63 (d, CH_{Ar}), 128.57 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 140.1 (s, C_{Ar}), 140.4 (s, C_{Ar}), 176.0 (s, C2), 176.3 (s, C2).


(3R,4R)- and (3S,4S)- and (3R,4S)- and (3S,4R)-3-((S)-2-Hydroxypropyl)-1-((S)-1-(naphthalen-2-yl)ethyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12j):

Prepared according to the general procedure, yield 233 mg (77%) as an inseparable 2:2(*trans*):1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-**12j** increased to 4:4(*trans*):1:1(*cis*).

[R_f (hexanes/EtOAc 1:1) = 0.51]; IR (film); ν [cm^{-1}]: 3374 (br), 2972 (m), 2931 (m), 2873 (w), 1661 (s), 1508 (w), 1489 (w), 1456 (m), 1430 (m), 1374 (w), 1360 (w), 1263 (w), 1132 (w), 1046 (w), 989 (w), 903 (w), 821 (w), 752 (w), 693 (w); MS (+ESI) m/z , (%): 489 (20, $[\text{M}+\text{Na}^+]$), 467 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{29}\text{H}_{43}\text{N}_2\text{O}_3^+$]: calcd. 467.3268; found 467.3260.



Major diastereomers: ^1H NMR (400 MHz, CDCl_3): δ 1.06 (s, 12H, NCCH_3), 1.12 (s, 12H, NCCH_3), 1.26 (d, $J = 6.4$ Hz, 3H, CHOHCH_3), 1.27 (d, $J = 6.4$ Hz, 3H, CHOHCH_3), 1.33-1.42 (m, 2H, piperidine-H4), 1.43-1.49 (m, 8H, piperidine-H3, H5), 1.50-1.59 (m, 2H, piperidine-H4), 1.65 (d, $J = 6.8$ Hz, 3H, ArCHCH_3), 1.66 (d, $J = 7.1$ Hz, 3H, ArCHCH_3), 1.68-1.88 (m, 4H, CH_2CHOH), 2.02-2.13 (m, 1H, H4), 2.29-2.36 (m, 1H, H4), 2.56 (td, $J = 9.5, 3.5$ Hz, 1H, H3), 2.64 (td, $J = 9.6, 4.3$ Hz, 1H, H3), 2.74 (dd, $J = 9.2, 5.3$ Hz, 1H, H5), 2.76 (dd, $J = 8.9, 3.1$ Hz, 1H, H5), 3.06 (dd, $J = 8.9, 5.3$ Hz, 1H, H5), 3.40 (dd, $J = 9.2, 4.9$ Hz, 1H, H5), 3.61 (d, $J = 5.9$ Hz, 2H, CH_2OTMP), 3.78 (d, $J = 6.1$ Hz, 2H, CH_2OTMP), 3.96-4.04 (m, 1H, CHOH), 4.07-4.18 (m, 1H, CHOH), 5.64 (q, $J = 7.1$ Hz, 2H, ArCHCH_3), 5.88 (br. s, 2H, OH), 7.35-7.44 (m, 2H, ArH), 7.45-7.53 (m, 4H, ArH), 7.71-7.78 (m, 2H, ArH), 7.79-7.88 (m, 6H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.2 (q, ArCHCH_3), 16.3 (q, ArCHCH_3), 17.1 (t, 2C, piperidine-C4), 20.2 (q, 2C, NCCH_3), 20.3 (q, 2C, NCCH_3), 23.1 (q, CHOHCH_3), 24.3 (q, CHOHCH_3), 33.04 (q, 2C, NCCH_3), 33.3 (q, 2C, NCCH_3), 37.7 (d, C4), 38.7 (d, C4), 39.4 (t, CH_2CHOH), 39.6 (t, piperidine-C3, C5), 39.7 (t, piperidine-C3, C5), 40.9 (t, CH_2CHOH), 42.6 (d, C3), 44.1 (t, C5), 44.3 (t, C5), 46.3 (d, C3), 49.3 (d, ArCHCH_3), 49.7 (d, ArCHCH_3), 59.9 (s, 2C, CNO), 60.0 (s, 2C, CNO), 66.1 (d, CHOH), 68.2 (d, CHOH), 76.9 (t, CH_2OTMP), 77.5 (t, CH_2OTMP), 125.32 (d, CH_{Ar}), 125.41 (d, CH_{Ar}), 125.6 (d, CH_{Ar}), 125.8 (d, CH_{Ar}), 126.2 (d, CH_{Ar}), 126.28 (d, CH_{Ar}), 126.33 (d, CH_{Ar}), 126.4 (d, CH_{Ar}), 127.6 (d, CH_{Ar}), 127.68 (d, CH_{Ar}), 127.71 (d, CH_{Ar}), 128.12 (d, CH_{Ar}), 128.62 (d, CH_{Ar}), 128.73 (d, CH_{Ar}), 132.87 (s, C_{Ar}), 132.92 (s, C_{Ar}), 133.26 (s, C_{Ar}), 133.32 (s, C_{Ar}), 137.12 (s, C_{Ar}), 137.3 (s, C_{Ar}), 176.6 (s, C2), 177.2 (s, C2).




Minor diastereomers: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 2.84 (td, $J = 8.1, 5.3$ Hz, 1H, H3), 2.96 (dd, $J = 10.3, 6.7$ Hz, 1H, H5), 2.98 (dd, $J = 10.1, 6.6$ Hz, 1H, H5), 3.23-3.38 (m, 2H, CH_2OTMP), 4.32-4.43 (m, 2H, CHOH), 5.05 (br. s, 1H, OH), 5.08 (br. s, 1H, OH); ^{13}C NMR (101 MHz, CDCl_3): δ 15.9 (q, ArCHCH_3), 16.4 (q, ArCHCH_3), 17.0 (t, piperidine-C4), 17.12 (t, piperidine-C4), 20.1 (q, 2C, NCCH_3), 20.4 (q, 2C, NCCH_3), 23.2 (q, CHOHCH_3), 24.5 (q, CHOHCH_3), 29.4 (d, C4), 30.4 (d, C4), 33.03 (q, 2C, NCCH_3), 33.4 (q, 2C, NCCH_3), 34.1 (t, CH_2CHOH), 34.2 (t, CH_2CHOH), 39.46 (t, piperidine-C3, C5), 39.48 (t, piperidine-C3, C5), 41.4 (d, C3), 41.5 (d, C3), 44.2 (t, C5), 44.3 (t, C5), 49.3 (d, ArCHCH_3), 49.6 (d, ArCHCH_3), 59.6 (s, 2C, CNO), 59.7 (s, 2C, CNO), 66.0 (d, CHOH), 68.3 (d, CHOH), 74.1 (t, CH_2OTMP), 75.0 (t, CH_2OTMP), 125.31 (d, CH_{Ar}), 125.43 (d, CH_{Ar}), 125.7 (d, CH_{Ar}), 126.0 (d, CH_{Ar}), 126.1 (d, CH_{Ar}), 126.31 (d, CH_{Ar}), 126.5 (d, CH_{Ar}), 127.2 (d, CH_{Ar}), 128.14 (d, CH_{Ar}), 128.2 (d, CH_{Ar}), 128.56 (d, CH_{Ar}), 128.64 (d, CH_{Ar}), 128.74 (d, CH_{Ar}), 128.8 (d, CH_{Ar}), 132.88 (s, C_{Ar}), 133.0 (s, C_{Ar}), 133.25 (s, C_{Ar}), 133.32 (s, C_{Ar}), 137.10 (s, C_{Ar}), 137.3 (s, C_{Ar}), 176.8 (s, C2), 177.1 (s, C2).

(3R,4S)- and (3S,4R)- and (3R,4R)- and (3S,4S)-3-((S)-2-Hydroxypropyl)-1-((S)-1-phenylethyl)-4-(prop-1-en-2-yl)pyrrolidin-2-one (12k):


Prepared according to the general procedure, yield 170 mg (92%) **12k** as a partly separable 2:2(*trans*):1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *trans*-**12k** increased to 1:1(*trans*):0:0(*cis*). The minor more polar diastereomer of **12k** crystallized from hexane with a few drops of DCM and its configuration was determined by X-ray crystallography.

$[\text{R}_f(\text{hexanes}/\text{EtOAc } 1:1) = 0.36]$; IR (film); ν [cm^{-1}]: 3354 (br), 3031 (w), 2969 (w), 2930 (w), 1656 (s), 1494 (w), 1429 (m), 1377 (w), 1342 (w), 1253 (m), 1187 (w), 1136 (w), 1077 (w), 1053 (w), 1028 (w), 939 (w), 897 (w), 786 (w), 753 (w), 700 (m), 637 (w); MS (+ESI) m/z , (%):

597 (10, [2M+Na⁺]), 310 (100, [M+Na⁺]), 288 (15, [M+H⁺]); HRMS (+ESI) m/z [C₁₈H₂₅NO₂Na⁺]: calcd. 310.1778; found 310.1779.




Major diastereomers: ¹H NMR (400 MHz, CDCl₃): δ 1.21 (d, *J* = 6.4 Hz, 3H, CHOHCH₃), 1.22 (d, *J* = 6.2 Hz, 3H, CHOHCH₃), 1.51-1.56 (m, 2H, CH₂CHOH), 1.52 (d, *J* = 7.1 Hz, 3H, PhCHCH₃), 1.54 (d, *J* = 7.2 Hz, 3H, PhCHCH₃), 1.60 (s, 3H, =CCH₃), 1.61-1.69 (m, 1H, CH₂CHOH), 1.70 (s, 3H, =CCH₃), 1.86 (ddd, *J* = 14.5, 9.0, 3.7 Hz, 1H, CH₂CHOH), 2.42-2.54 (m, 1H, H4), 2.59-2.70 (m, 1H, H3), 2.71-2.79 (m, 3H, H3, H4, H5), 3.06 (dd, *J* = 9.7, 8.3 Hz, 1H, H5), 3.13 (dd, *J* = 9.7, 4.0 Hz, 1H, H5), 3.37 (dd, *J* = 9.5, 4.0 Hz, 1H, H5), 3.91-3.99 (m, 1H, CHOH), 4.08-4.17 (m, 1H, CHOH), 4.79 (d, *J* = 1.7 Hz, 1H, C=CH₂), 4.81 (d, *J* = 1.5 Hz, 1H, C=CH₂), 4.83 (d, *J* = 1.7 Hz, 1H, C=CH₂), 4.88 (d, *J* = 1.5 Hz, 1H, C=CH₂), 5.47 (q, *J* = 6.9 Hz, 1H, PhCHCH₃), 5.49 (q, *J* = 7.0 Hz, 1H, PhCHCH₃), 5.64 (br. s, 2H, OH), 7.25-7.37 (m, 10H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 16.2 (q, PhCHCH₃), 16.4 (q, PhCHCH₃), 19.5 (q, =CCH₃), 19.6 (q, =CCH₃), 23.1 (q, CHOHCH₃), 24.4 (q, CHOHCH₃), 38.2 (t, CH₂CHOH), 40.0 (t, CH₂CHOH), 42.4 (d, C4), 45.7 (t, C5), 45.8 (t, C5), 46.3 (d, C3), 46.9 (d, C3), 47.7 (d, C4), 49.5 (d, PhCHCH₃), 49.6 (d, PhCHCH₃), 65.3 (d, CHOH), 68.1 (d, CHOH), 113.4 (t, C=CH₂), 114.0 (t, C=CH₂), 127.1 (d, CH_{Ar}), 127.3 (d, CH_{Ar}), 127.83 (d, 2C, CH_{Ar}), 128.78 (d, CH_{Ar}), 128.82 (d, CH_{Ar}), 139.72 (s, C_{Ar}), 139.9 (s, C_{Ar}), 142.1 (s, C=CH₂), 142.7 (s, C=CH₂), 176.5 (s, C2), 176.82 (s, C2).



(3*R*,4*R*)

Less polar minor diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 1.22 (d, $J = 6.1$ Hz, 3H, CHOHCH_3), 1.39-1.46 (m, 1H, CH_2CHOH), 1.55 (d, $J = 7.1$ Hz, 3H, PhCHCH_3), 1.61-1.69 (m, 1H, CH_2CHOH), 1.70 (s, 3H, $=\text{CCH}_3$), 2.84-2.94 (m, 2H, H3, H4), 3.03 (dd, $J = 10.0, 6.7$ Hz, 1H, H5), 3.27 (dd, $J = 10.0, 6.2$ Hz, 1H, H5), 4.01-4.12 (m, 1H, CHOH), 4.69 (d, $J = 1.6$ Hz, 1H, $\text{C}=\text{CH}_2$), 4.87 (d, $J = 1.6$ Hz, 1H, $\text{C}=\text{CH}_2$), 5.53 (q, $J = 7.1$ Hz, 1H, PhCHCH_3), 5.82 (br. s, 1H, OH), 7.27-7.37 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.2 (q, PhCHCH_3), 19.8 (q, $=\text{CCH}_3$), 21.2 (q, $=\text{CCH}_3$), 22.9 (q, CHOHCH_3), 34.3 (t, CH_2CHOH), 41.3 (d, C3), 43.5 (d, C4), 44.6 (t, C5), 49.4 (d, PhCHCH_3), 65.6 (d, CHOH), 113.3 (t, $\text{C}=\text{CH}_2$), 127.2 (d, CH_{Ar}), 127.78 (d, CH_{Ar}), 128.81 (d, CH_{Ar}), 139.66 (s, C_{Ar}), 142.8 (s, $\text{C}=\text{CH}_2$), 176.84 (s, C2).




(3*S*,4*S*)

More polar minor diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 1.20 (d, $J = 6.1$ Hz, 3H, CHOHCH_3), 1.22 (dd, $J = 1.5, 0.9$ Hz, 3H, $=\text{CCH}_3$), 1.48-1.51 (m, 2H, CH_2CHOH), 1.53 (d, $J = 7.2$ Hz, 3H, PhCHCH_3), 2.80 (td, $J = 8.6, 5.2$ Hz, 1H, H3), 2.89 (dd, $J = 10.1, 3.1$ Hz, 1H, H5), 2.95-3.00 (m, 1H, H4), 3.48 (dd, $J = 10.1, 6.9$ Hz, 1H, H5), 3.87-3.97 (m, 1H, CHOH), 4.59 (d, $J = 1.7$ Hz, 1H, $\text{C}=\text{CH}_2$), 4.68 (d, $J = 1.7$ Hz, 1H, $\text{C}=\text{CH}_2$), 5.51 (q, $J = 7.1$ Hz, 1H, PhCHCH_3), 5.74 (br. s, 1H, OH), 7.27-7.37 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 15.8 (q, PhCHCH_3), 19.7 (q, $=\text{CCH}_3$), 24.4 (q, CHOHCH_3), 35.8 (t, CH_2CHOH), 43.6 (d, C4), 45.3 (t, C5), 45.5 (d, C3), 49.8 (d, PhCHCH_3), 68.4 (d, CHOH), 114.5 (t, $\text{C}=\text{CH}_2$), 127.84 (d, CH_{Ar}), 128.1 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 140.0 (s, C_{Ar}), 143.4 (s, $\text{C}=\text{CH}_2$), 176.9 (s, C2).


(3*R,4*S**)- and (3*S**,4*R**)- and (3*R**,4*R**)-(1-Allyl-3-((1*S**,2*R**)-2-hydroxycyclohexyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12I):**

Prepared according to the general procedure, yield 214 mg (84%) as an inseparable 10:8.5(*trans*):1(*cis*) mixture of diastereomers.

[*R*_f (hexanes/EtOAc 1:1) = 0.52]; IR (film); ν [cm⁻¹]: 3424 (br), 2974 (w), 2928 (s), 2856 (w), 1671 (s), 1489 (w), 1448 (m), 1417 (w), 1374 (w), 1359 (w), 1264 (m), 1245 (w), 1186 (w), 1132 (w), 1049 (m), 993 (w), 956 (w), 924 (w), 791 (w), 732 (w), 712 (w), 656 (w), 635 (w), 610 (w); MS (+ESI) *m/z*, (%): 807 (60, [2*M*+Na⁺]), 415 (90, [*M*+Na⁺]), 393 (100, [*M*+H⁺]); HRMS (+ESI) *m/z* [C₂₃H₄₁N₂O₃⁺]: calcd. 393.3112; found 393.3108.



Major diastereomers **12IA,B**: ¹H NMR (400 MHz, CDCl₃): δ 0.92-1.05 (m, 1H, H10), 1.09 (s, 6H, NCCH₃), 1.10 (s, 6H, NCCH₃), 1.15 (s, 6H, NCCH₃), 1.16 (s, 6H, NCCH₃), 1.20-1.28 (m, 4H, H7, H9, H10), 1.29-1.37 (m, 3H, H8, piperidine-H4), 1.40-1.50 (m, 8H, piperidine-H3, H5), 1.51-1.63 (m, 3H, H7, piperidine-H4), 1.64-1.71 (m, 5H, H7, H8), 1.72-1.80 (m, 2H, H9), 1.81-1.92 (m, 2H, H6), 1.96-2.09 (m, 2H, H10), 2.45-2.54 (m, 3H, H3, H4), 2.82 (t, *J* = 4.6 Hz, 1H, H3), 2.98 (dd, *J* = 10.2, 3.7 Hz, 1H, H5), 3.14 (dd, *J* = 9.8, 4.6 Hz, 1H, H5), 3.35-3.39 (m, 1H, H11), 3.40 (dd, *J* = 10.2, 8.7 Hz, 1H, H5), 3.42 (dd, *J* = 9.8, 6.3 Hz, 1H, H5), 3.59-3.72 (m, 1H, H11), 3.73-3.81 (m, 4H, CH₂OTMP), 3.82-3.90 (m, 3H, CH₂CH=), 3.95 (dd, *J* = 15.1, 6.1 Hz, 1H, CH₂CH=), 5.14-5.26 (m, 6H, OH, CH=CH₂), 5.64-5.78 (m, 2H, CH=CH₂); ¹³C NMR (101 MHz, CDCl₃): δ 17.19 (q, piperidine-C4), 17.20 (q, piperidine-C4), 20.2 (q, NCCH₃), 20.3 (q, NCCH₃), 20.5 (q, NCCH₃), 20.7 (q, NCCH₃), 25.3 (t, C9), 25.7 (t, C9), 25.9 (t, C8), 26.0 (t, C8), 26.8 (t, C7), 29.2 (t, C7), 31.6 (d, C4), 33.2 (q, 2C, NCCH₃), 33.3 (q, 2C, NCCH₃), 33.4 (d, C4), 35.2 (t, C10), 36.5 (t, C10), 39.8 (t, piperidine-C3, C5), 39.9 (t, piperidine-C3), 40.0 (t, piperidine-C5), 45.5 (t, 2C, CH₂CH=), 46.7 (d, 2C, C3, C6), 47.0 (d, C6), 47.1 (d, C3), 49.0 (t, C5), 49.2 (t, C5), 60.1 (s, 2C, CNO), 60.20 (s, 2C, CNO), 72.16 (d, C11), 72.18 (d, C11), 79.0 (t, CH₂OTMP), 79.8 (t, CH₂OTMP), 117.9 (t, CH=CH₂), 118.29 (t, CH=CH₂), 132.5 (d, CH=CH₂), 132.6 (d, CH=CH₂), 176.3 (s, C2), 176.9 (s, C2).




Minor *cis*-diastereomer: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 3.15-3.24 (m, 1H, H5), 3.60-3.70 (m, 1H, CH_2OH); ^{13}C NMR (101 MHz, CDCl_3 , detectable signals): δ 25.0 (t, C9), 27.9 (t, C8), 28.0 (t, C7), 35.1 (d, C4), 36.2 (t, C10), 45.3 (t, $\text{CH}_2\text{CH=}$), 50.8 (t, C5), 60.0 (s, CNO), 60.16 (s, CNO), 71.1 (d, C11), 75.4 (t, CH_2OTMP), 118.26 (t, CH=CH_2), 132.7 (d, CH=CH_2), 176.1 (s, C2).

(4S*,5S*,6R*)- and (4S*,5S*,6S*)- and (4R*,5S*,6R*)- and (4R*,5S*,6S*)-2-Benzyl-4-(2-hydroxypropyl)-6-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-azaspiro[4.4]nonan-3-one (12m):


Prepared according to the general procedure, yield 198 mg (69%) as an inseparable 9:9:5:5(*trans*):2:2:1:1(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *equil*-**12m** increased to 11:11:6:6(*trans*):3:3:1:1(*cis*).

[R_f (hexanes/EtOAc 2:1) = 0.24]; IR (film); ν [cm^{-1}]: 3336 (br), 2966 (m), 2930 (m), 2874 (w), 1668 (s), 1493 (w), 1453 (m), 1375 (w), 1360 (w), 1319 (w), 1259 (w), 1208 (w), 1180 (w), 1133 (w), 1081 (w), 1030 (w), 975 (w), 955 (w), 736 (w), 701 (m), 606 (w); MS (+ESI) m/z , (%): 907 (35, $[2\text{M}+\text{Na}^+]$), 465 (100, $[\text{M}+\text{Na}^+]$), 443 (15, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{26}\text{H}_{41}\text{N}_2\text{O}_3\text{Na}^+$]: calcd. 465.3088; found 465.3088.



(4S*,5S*,6R*)

12mA




(4S*,5S*,6S*)

12mB


Major diastereomers **12mA,B**: ^1H NMR (400 MHz, CDCl_3): δ 1.00 (s, 6H, NCCH_3), 1.05 (s, 6H, NCCH_3), 1.07 (s, 9H, NCCH_3), 1.11 (s, 9H, NCCH_3), 1.12 (s, 9H, NCCH_3), 1.15 (s, 9H, NCCH_3), 1.22-1.34 (m, 4H, piperidine-H4), 1.24 (d, $J = 6.2$ Hz, 6H, CH_3), 1.25 (d, $J = 6.2$ Hz, 3H, CH_3), 1.26 (d, $J = 6.4$ Hz, 3H, CH_3), 1.36-1.48 (m, 16H, piperidine-H3, H5), 1.49-1.65 (m, 20H, H7, H8, H9, CH_2CHOH , piperidine-H4), 1.66-1.75 (m, 8H, H7, H8, H9, CH_2CHOH), 1.76-1.87 (m, 2H, CH_2CHOH), 1.89-1.97 (m, 1H, H7), 1.98-2.06 (m, 1H, H7), 2.75 (d, $J = 9.4$ Hz, 1H, H1), 2.82 (d, $J = 9.4$ Hz, 1H, H1), 2.92-3.05 (m, 4H, H4), 2.96 (d, $J = 10.0$ Hz, 1H, H1), 2.99 (d, $J = 10.1$ Hz, 1H, H1), 3.60 (d, $J = 9.4$ Hz, 1H, H1), 3.67 (d, $J = 9.4$ Hz, 1H, H1), 3.68 (d, $J = 10.0$ Hz, 1H, H1), 3.72 (d, $J = 10.1$ Hz, 1H, H1), 3.90-4.08 (m, 4H, H6, CHOH), 4.14-4.24 (m, 4H, H6, CHOH), 4.17 (d, $J = 14.3$ Hz, 1H, CH_2Ph), 4.18 (d, $J = 14.5$ Hz, 1H, CH_2Ph), 4.20 (d, $J = 14.4$ Hz, 1H, CH_2Ph), 4.21 (d, $J = 13.0$ Hz, 1H, CH_2Ph), 4.72 (d, $J = 13.0$ Hz, 1H, CH_2Ph), 4.73 (d, $J = 14.4$ Hz, 1H, CH_2Ph), 4.76 (d, $J = 14.3$ Hz, 1H, CH_2Ph), 4.97 (d, $J = 14.5$ Hz, 1H, CH_2Ph), 5.72 (br. s, 1H, OH), 6.31 (br. s, 3H, OH), 7.19-7.26 (m, 8H, ArH), 7.27-7.37 (m, 12H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.2 (t, 3C, piperidine-C4), 17.3 (t, piperidine-C4), 18.1 (t, C8), 18.8 (t, C8), 19.4 (t, C8), 19.97 (t, C8), 20.57 (q, NCCH_3), 20.59 (q, NCCH_3), 20.61 (q, NCCH_3), 20.63 (q, NCCH_3), 20.64 (q, NCCH_3), 20.68 (q, NCCH_3), 20.71 (q, NCCH_3), 20.8 (q, NCCH_3), 22.8 (q, 2C, CH_3), 24.6 (q, CH_3), 24.7 (q, CH_3), 28.1 (t, C7), 28.7 (t, C7), 28.9 (t, C7), 29.5 (t, C7), 34.0 (t, 2C, CH_2CHOH), 34.17 (q, NCCH_3), 34.24 (q, NCCH_3), 34.5 (q, NCCH_3), 34.6 (q, NCCH_3), 34.7 (q, NCCH_3), 34.8 (q, NCCH_3), 34.87 (q, NCCH_3), 34.94 (q, NCCH_3), 35.1 (t, CH_2CHOH), 35.3 (t, CH_2CHOH), 35.7 (t, C9), 36.2 (t, C9), 37.0 (t, 2C, C9), 40.49 (t, piperidine-C3, C5), 40.53 (t, piperidine-C3, C5), 40.6 (t, piperidine-C3, C5), 40.7 (t, piperidine-C3, C5), 42.8 (d, C4), 46.8 (d, C4), 46.88 (d, C4), 47.0 (t, 2C, CH_2Ph), 47.1 (t, 2C, CH_2Ph), 50.7 (d, C4), 51.20 (t, C1), 51.5 (t, C1), 53.3 (t, C1), 53.7 (t, C1), 56.5 (s, 2C, C5), 57.1

(s, 2C, C5), 59.2 (s, CNO), 59.28 (s, CNO), 59.31 (s, CNO), 59.4 (s, CNO), 61.10 (s, CNO), 61.12 (s, CNO), 61.16 (s, CNO), 61.19 (s, CNO), 64.9 (d, CHOH), 65.2 (d, CHOH), 68.6 (d, CHOH), 68.7 (d, CHOH), 82.7 (d, C6), 83.8 (d, C6), 84.1 (d, C6), 84.6 (d, C6), 127.74 (d, CH_{Ar}), 127.81 (d, CH_{Ar}), 128.11 (d, 2C, CH_{Ar}), 128.14 (d, CH_{Ar}), 128.17 (d, 2C, CH_{Ar}), 128.3 (d, CH_{Ar}), 128.86 (d, 4C, CH_{Ar}), 136.1 (s, C_{Ar}), 136.3 (s, C_{Ar}), 136.4 (s, C_{Ar}), 136.5 (s, C_{Ar}), 176.8 (s, C3), 177.2 (s, C3), 177.7 (s, C3), 177.8 (s, C3).



(4*R**,5*S**,6*R**)

12mC



(4*R**,5*S**,6*S**)

12mD


Minor diastereomers **12mC,D**: ¹H NMR (400 MHz, CDCl₃, detectable signals): δ 2.43 (d, *J* = 11.3 Hz, 1H, H1), 2.44 (d, *J* = 11.3 Hz, 1H, H1), 2.50 (d, *J* = 11.9 Hz, 1H, H1), 2.51 (d, *J* = 11.9 Hz, 1H, H1), 2.66 (d, *J* = 11.9 Hz, 1H, H1), 2.68 (d, *J* = 11.9 Hz, 1H, H1), 2.81 (d, *J* = 13.7 Hz, 1H, H1), 2.84 (d, *J* = 13.7 Hz, 1H, H1), 3.10-3.18 (m, 3H, H4), 3.32 (dd, *J* = 9.4, 6.2 Hz, 1H, H4), 4.06-4.16 (m, 1H, CHOH), 4.29 (d, *J* = 14.4 Hz, 1H, CH₂Ph), 4.33 (d, *J* = 14.4 Hz, 1H, CH₂Ph), 4.35 (d, *J* = 14.7 Hz, 1H, CH₂Ph), 4.36 (d, *J* = 14.4 Hz, 1H, CH₂Ph), 4.55 (d, *J* = 14.4 Hz, 1H, CH₂Ph), 4.57 (d, *J* = 14.4 Hz, 1H, CH₂Ph), 4.62 (d, *J* = 14.4 Hz, 1H, CH₂Ph), 4.97 (d, *J* = 14.7 Hz, 1H, CH₂Ph), 5.16 (br. s, 1H, OH), 6.27 (br. s, 3H, OH); ¹³C NMR (101 MHz, CDCl₃): δ 17.2 (t, 3C, piperidine-C4), 17.3 (t, piperidine-C4), 18.8 (t, C8), 20.00 (t, C8), 20.2 (t, C8), 20.5 (t, C8), 20.57 (q, NCCH₃), 20.59 (q, NCCH₃), 20.61 (q, NCCH₃), 20.63 (q, NCCH₃), 20.64 (q, NCCH₃), 20.68 (q, NCCH₃), 20.71 (q, NCCH₃), 20.8 (q, NCCH₃), 22.7 (q, 2C, CH₃), 22.9 (q, CH₃), 24.3 (q, CH₃), 28.3 (t, C7), 28.5 (t, C7), 29.4 (t, C7), 30.4 (t, C7), 34.0 (t, CH₂CHOH), 34.17 (q, NCCH₃), 34.24 (q, NCCH₃), 34.5 (q, NCCH₃), 34.6 (q, NCCH₃), 34.7 (q, NCCH₃), 34.8 (q, NCCH₃), 34.87 (q, NCCH₃), 34.94 (q, NCCH₃), 35.1 (t, CH₂CHOH), 35.2 (t, CH₂CHOH), 35.9 (t, CH₂CHOH), 36.5 (t, C9), 37.0 (t, 2C, C9), 37.9 (t, C9), 40.77 (t, piperidine-C3, C5), 40.83 (t, piperidine-C3, C5), 41.0 (t, piperidine-C3, C5), 41.1 (t, piperidine-C3, C5),

41.6 (d, C4), 42.8 (d, C4), 46.7 (d, C4), 46.93 (t, 2C, $\underline{\text{CH}}_2\text{Ph}$), 47.3 (t, 2C, $\underline{\text{CH}}_2\text{Ph}$), 51.0 (t, C1), 51.1 (t, C1), 51.17 (t, C1), 51.38 (t, C1), 51.43 (d, C4), 54.7 (s, 2C, C5), 55.7 (s, 2C, C5), 59.2 (s, CNO), 59.28 (s, CNO), 59.31 (s, CNO), 59.4 (s, CNO), 61.10 (s, CNO), 61.12 (s, CNO), 61.16 (s, CNO), 61.19 (s, CNO), 65.4 (d, CHOH), 65.5 (d, CHOH), 68.8 (d, CHOH), 69.0 (d, CHOH), 87.2 (d, C6), 88.0 (d, C6), 88.7 (d, C6), 89.5 (d, C6), 127.73 (d, CH_{Ar}), 127.78 (d, CH_{Ar}), 127.9 (d, CH_{Ar}), 128.14 (d, CH_{Ar}), 128.24 (d, CH_{Ar}), 128.3 (d, CH_{Ar}), 128.36 (d, CH_{Ar}), 128.43 (d, CH_{Ar}), 128.86 (d, 3C, CH_{Ar}), 128.92 (d, CH_{Ar}), 136.1 (s, C_{Ar}), 136.3 (s, C_{Ar}), 136.4 (s, C_{Ar}), 136.5 (s, C_{Ar}), 177.2 (s, C3), 177.58 (s, C3), 177.63 (s, C3), 177.8 (s, C3).

(4*S,5*S**,6*R**)- and (4*S**,5*S**,6*S**)- and (4*R**,5*S**,6*R**)-2-Benzyl-4-(2-hydroxypropyl)-6-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-azaspiro[4.5]decan-3-one (12n):**

Prepared according to the general procedure, yield 196 mg (66%) as an inseparable 4:4:1:1(*trans*):2:2(*cis*) mixture of diastereomers. After equilibration the diastereomeric ratio for *equil*-**12n** increased to 5:5:1:1(*trans*):1:1(*cis*).


[R_f (hexanes/EtOAc 2:1) = 0.35]; IR (film); ν [cm^{-1}]: 3320 (br), 2928 (m), 2857 (w), 1664 (s), 1493 (w), 1450 (m), 1375 (w), 1360 (w), 1256 (w), 1133 (w), 1081 (w), 1039 (w), 991 (w), 913 (w), 878 (w), 842 (w), 790 (w), 730 (m), 700 (m), 645 (w); MS (+ESI) m/z , (%): 457 (100, [$\text{M}+\text{H}^+$]); HRMS (+ESI) m/z [$\text{C}_{28}\text{H}_{45}\text{N}_2\text{O}_3^+$]: calcd. 457.3425; found 457.3420.



(4*S**,5*S**,6*R**)

Major diastereomers **12nA**: ^1H NMR (400 MHz, CDCl_3): δ 0.96 (s, 6H, NCCH_3), 0.98 (s, 6H, NCCH_3), 0.99-1.05 (m, 4H, H7, H8), 1.08 (s, 6H, NCCH_3), 1.12-1.22 (m, 2H, H9), 1.15 (s, 6H, NCCH_3), 1.17 (d, $J = 6.4$ Hz, 3H, CH_3), 1.23-1.33 (m, 4H, H10, piperidine-H4), 1.25 (d, $J = 6.2$ Hz, 3H, CH_3), 1.34-1.49 (m, 12H, H9, H10, piperidine-H3, H5), 1.50-1.61 (m, 6H, $\underline{\text{CH}}_2\text{CHOH}$, piperidine-H4), 1.62-1.75 (m, 2H, H8), 2.29-2.40 (m, 3H, H4, H7), 2.44-2.48 (m, 1H, H4), 2.98 (d, $J = 9.9$ Hz, 1H, H1), 3.02 (d, $J = 10.2$ Hz, 1H, H1), 3.48 (d, $J = 9.9$ Hz, 1H, H1), 3.51 (d, $J =$

10.2 Hz, 1H, H1), 3.65 (dd, $J = 11.6, 3.7$ Hz, 1H, H6), 3.67-3.71 (m, 1H, H6), 3.72 (d, $J = 14.9$ Hz, 1H, $\underline{\text{CH}_2\text{Ph}}$), 3.96 (tq, $J = 6.2, 3.1$ Hz, 1H, $\underline{\text{CHOH}}$), 4.23 (tq, $J = 6.2, 2.9$ Hz, 1H, $\underline{\text{CHOH}}$), 4.36 (d, $J = 14.8$ Hz, 1H, $\underline{\text{CH}_2\text{Ph}}$), 4.59 (d, $J = 14.8$ Hz, 1H, $\underline{\text{CH}_2\text{Ph}}$), 5.24 (d, $J = 14.9$ Hz, 1H, $\underline{\text{CH}_2\text{Ph}}$), 6.44 (br. s, 1H, OH), 6.50 (br. s, 1H, OH), 7.20-7.25 (m, 4H, ArH), 7.27-7.36 (m, 6H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.3 (t, piperidine-C4), 17.37 (t, piperidine-C4), 20.7 (q, 2C, NCCH_3), 21.3 (q, 2C, NCCH_3), 21.7 (t, C9), 22.0 (t, C9), 22.98 (q, CH_3), 24.6 (t, 2C, C8), 24.8 (q, CH_3), 28.0 (t, C7), 28.2 (t, C7), 29.3 (t, C10), 30.2 (t, C10), 33.0 (t, $\underline{\text{CH}_2\text{CHOH}}$), 33.9 (q, 2C, NCCH_3), 34.1 (q, 2C, NCCH_3), 34.5 (t, $\underline{\text{CH}_2\text{CHOH}}$), 40.56 (t, piperidine-C3, C5), 40.60 (t, piperidine-C3, C5), 42.2 (d, 2C, C4), 45.8 (s, C5), 46.3 (s, C5), 46.98 (t, $\underline{\text{CH}_2\text{Ph}}$), 47.01 (t, $\underline{\text{CH}_2\text{Ph}}$), 48.2 (t, C1), 48.6 (t, C1), 59.19 (s, CNO), 59.23 (s, CNO), 60.9 (s, CNO), 61.2 (s, CNO), 65.3 (d, $\underline{\text{CHOH}}$), 68.8 (d, $\underline{\text{CHOH}}$), 79.0 (d, C6), 80.0 (d, C6), 127.7 (d, CH_{Ar}), 128.11 (d, 2C, CH_{Ar}), 128.86 (d, 2C, CH_{Ar}), 128.87 (d, CH_{Ar}), 136.2 (s, C_{Ar}), 136.36 (s, C_{Ar}), 177.21 (s, C3), 177.7 (s, C3).




(4S*,5S*,6S*)

Diastereomers **12nB**: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 2.18 (dd, $J = 14.0, 9.7$ Hz, 1H, H4), 2.49-2.57 (m, 2H, H7), 2.80 (d, $J = 12.6$ Hz, 1H, H1), 2.93 (d, $J = 9.8$ Hz, 1H, H1), 3.25 (d, $J = 9.8$ Hz, 1H, H1), 3.29 (d, $J = 9.8$ Hz, 1H, H1), 4.08-4.15 (m, 1H, $\underline{\text{CHOH}}$), 5.10 (d, $J = 14.7$ Hz, 1H, $\underline{\text{CH}_2\text{Ph}}$), 5.20 (d, $J = 14.3$ Hz, 1H, $\underline{\text{CH}_2\text{Ph}}$), 5.63 (br. s, 1H, OH), 6.44 (br. s, 1H, OH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.37 (t, piperidine-C4), 17.43 (t, piperidine-C4), 20.7 (q, NCCH_3), 20.9 (q, NCCH_3), 21.1 (q, NCCH_3), 21.3 (q, NCCH_3), 22.4 (q, CH_3), 22.8 (t, C9), 23.6 (t, C9), 23.9 (t, C8), 24.3 (t, C8), 24.7 (q, CH_3), 26.79 (t, C7), 26.83 (t, C7), 32.5 (t, C10), 32.7 (t, C10), 33.9 (q, NCCH_3), 34.1 (q, NCCH_3), 34.5 (q, NCCH_3), 34.8 (q, NCCH_3), 35.6 (t, $\underline{\text{CH}_2\text{CHOH}}$), 37.0 (t, $\underline{\text{CH}_2\text{CHOH}}$), 41.0 (d, C4), 41.36 (t, piperidine-C3, C5), 41.43 (t, piperidine-C3, C5), 45.8 (s, C5), 46.0 (s, C5), 46.8 (t, $\underline{\text{CH}_2\text{Ph}}$), 46.9 (t, $\underline{\text{CH}_2\text{Ph}}$), 46.99 (d, C4), 58.3 (t, C1),

(3*R,3*aR**,4*R**,6*aR**)- and (3*S**,3*aR**,4*R**,6*aR**)-1-Benzyl-3-(2-hydroxypropyl)-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)hexahydrocyclopenta[*b*]pyrrol-2(1*H*)-one (12o):**


Prepared according to the general procedure, yield 228 mg (82%) as an inseparable 4:4(*trans*):1:1(*cis*) mixture of diastereomers.

[*R*_f (hexanes/EtOAc 1:1) = 0.31]; IR (film); ν [cm⁻¹]: 3386 (br), 2966 (w), 2930 (m), 2871 (w), 1659 (s), 1449 (m), 1434 (m), 1374 (w), 1359 (m), 1299 (w), 1254 (m), 1182 (w), 1133 (m), 1080 (w), 1030 (w), 961 (m), 732 (m), 701 (m), 645 (w), 618 (w); MS (+ESI) *m/z*, (%): 451 (25, [M+Na⁺]), 429 (100, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₆H₄₁N₂O₃⁺]: calcd. 429.3112; found 429.3106.



(3*R**,3*aR**,4*R**,6*aR**)

Major diastereomers **12oA**: ¹H NMR (400 MHz, CDCl₃): δ 1.04 (s, 6H, NCCH₃), 1.08 (s, 12H, NCCH₃), 1.14 (s, 6H, NCCH₃), 1.24 (d, *J* = 6.2 Hz, 3H, CH₃), 1.26 (d, *J* = 6.1 Hz, 3H, CH₃), 1.29-1.36 (m, 2H, piperidine-H4), 1.41-1.48 (m, 8H, piperidine-H3, H5), 1.49-1.56 (m, 2H, piperidine-H4), 1.59-1.74 (m, 5H, H5, H6, CH₂CHOH), 1.75-1.81 (m, 4H, H6, CH₂CHOH), 1.82-2.09 (m, 3H, H5, CH₂CHOH), 2.29-2.42 (m, 2H, H3), 2.56 (ddd, *J* = 8.7, 4.6, 1.7 Hz, 1H, H3a), 2.80-2.91 (m, 1H, H3a), 3.84-3.90 (m, 2H, H6a), 3.95 (d, *J* = 14.8 Hz, 2H, CH₂Ph), 3.96-4.05 (m, 1H, CHOH), 4.06-4.12 (m, 1H, CHOH), 4.15 (q, *J* = 2.3 Hz, 1H, H4), 4.19 (dt, *J* = 4.6, 2.4 Hz, 1H, H4), 4.92 (d, *J* = 14.9 Hz, 2H, CH₂Ph), 5.31 (br. s, 2H, OH), 7.19-7.25 (m, 4H, ArH), 7.27-7.37 (m, 6H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 17.2 (t, piperidine-C4), 17.27 (t, piperidine-C4), 20.5 (q, 2C, NCCH₃), 20.7 (q, 2C, NCCH₃), 23.51 (q, CH₃), 24.3 (q, CH₃), 28.20 (t, C6), 28.24 (t, C6), 29.68 (t, C5), 29.73 (t, C5), 34.6 (q, 2C, NCCH₃), 35.0 (q, 2C, NCCH₃), 40.2 (t, piperidine-C3, C5), 40.3 (t, piperidine-C3, C5), 41.5 (t, CH₂CHOH), 43.0 (t, CH₂CHOH), 45.2 (d, C3), 45.3 (t, CH₂Ph), 45.6 (t, CH₂Ph), 47.1 (d, C3a), 47.3 (d, C3), 49.0 (d, C3a), 60.3 (s, 4C, CNO), 60.7 (d, C6a), 60.79 (d, C6a), 66.7 (d, CHOH), 67.9 (d, CHOH), 90.78 (d, C4), 90.82 (d, C4), 127.72 (d, CH_{Ar}), 127.8 (d, CH_{Ar}), 128.2 (d, CH_{Ar}), 128.3 (d, CH_{Ar}), 128.86 (d, CH_{Ar}), 128.91 (d, CH_{Ar}), 136.2 (s, C_{Ar}), 136.5 (s, C_{Ar}), 176.6 (s, C2), 177.25 (s, C2).




(3S*,3aR*,4R*,6aR*)

Minor diastereomers **12oB**: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 2.80 (td, $J = 7.9$, 4.5 Hz, 1H, H3a), 2.96 (ddd, $J = 10.1$, 7.9, 5.7 Hz, 1H, H3a), 3.93 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 3.94 (d, $J = 14.6$ Hz, 1H, CH_2Ph), 4.30 (dt, $J = 9.0$, 5.7 Hz, 1H, H4), 4.31 (dt, $J = 9.6$, 4.5 Hz, 1H, H4), 4.91 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 4.95 (d, $J = 14.6$ Hz, 1H, CH_2Ph), 5.81 (br. s, 1H, OH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.31 (t, 2C, piperidine-C4), 20.5 (q, 2C, NCCCH_3), 20.7 (q, 2C, NCCCH_3), 23.49 (q, CH_3), 24.4 (q, CH_3), 27.7 (t, C6), 27.8 (t, C6), 29.8 (t, C5), 30.0 (t, C5), 34.6 (q, 2C, NCCCH_3), 35.0 (q, 2C, NCCCH_3), 36.1 (t, CH_2CHOH), 37.8 (t, CH_2CHOH), 40.2 (t, piperidine-C3, C5), 40.3 (t, piperidine-C3, C5), 40.6 (d, C3), 43.8 (d, C3), 44.8 (t, CH_2Ph), 45.0 (t, CH_2Ph), 46.5 (d, C3a), 46.6 (d, C3a), 60.3 (s, 4C, CNO), 60.81 (d, C6a), 61.0 (d, C6a), 66.8 (d, CHOH), 68.3 (d, CHOH), 85.0 (d, C4), 85.1 (d, C4), 127.74 (d, CH_{Ar}), 127.8 (d, CH_{Ar}), 128.39 (d, CH_{Ar}), 128.41 (d, CH_{Ar}), 128.8 (d, CH_{Ar}), 128.86 (d, CH_{Ar}), 136.1 (s, C_{Ar}), 136.4 (s, C_{Ar}), 177.32 (s, C2), 177.6 (s, C2).

(3R,3aR,4R,7aR)-1-Benzyl-3-(2-hydroxypropyl)-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)octahydro-2H-indol-2-one (12pA):

Prepared according to the general procedure, yield 233 mg (81%) as an inseparable 1:1 mixture of *trans*-diastereomers.

[R_f (hexanes/EtOAc 1:1) = 0.35]; IR (film); ν [cm^{-1}]: 3406 (br), 2965 (m), 2931 (s), 2869 (m), 1666 (s), 1496 (w), 1450 (m), 1375 (m), 1360 (m), 1311 (w), 1298 (w), 1258 (m), 1241 (w), 1207 (w), 1182 (w), 1132 (m), 1078 (w), 1045 (w), 1030 (w), 958 (w), 702 (m), 637 (w), 609 (w); MS (+ESI) m/z , (%): 465 (25, $[\text{M}+\text{Na}^+]$), 443 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{27}\text{H}_{43}\text{N}_2\text{O}_3^+$]: calcd. 443.3268; found 443.3268.



^1H NMR (400 MHz, CDCl_3): δ 1.07 (s, 12H, NCCH_3), 1.10 (s, 12H, NCCH_3), 1.25 (d, $J = 6.4$ Hz, 6H, CH_3), 1.27-1.37 (m, 4H, H6, H7, piperidine-H4), 1.40-1.47 (m, 8H, piperidine-H3, H5), 1.48-1.60 (m, 6H, H5, H6, H7, piperidine-H4), 1.61-1.70 (m, 2H, H6, H7), 1.71-1.75 (m, 5H, H5, CH_2CHOH), 1.76-1.84 (m, 2H, H5, H7), 1.86-1.92 (m, 1H, CH_2CHOH), 2.21-2.33 (m, 2H, H3a), 2.58 (td, $J = 9.0, 5.1$ Hz, 1H, H3), 2.73 (q, $J = 6.9$ Hz, 1H, H3), 3.53 (q, $J = 7.1$ Hz, 1H, H7a), 3.58 (q, $J = 6.4$ Hz, 1H, H7a), 3.81-3.86 (m, 1H, H4), 3.87-3.90 (m, 1H, H4), 3.93-3.99 (m, 1H, CHOH), 4.00 (d, $J = 15.2$ Hz, 1H, CH_2Ph), 4.03 (d, $J = 15.0$ Hz, 1H, CH_2Ph), 4.13-4.20 (m, 1H, CHOH), 4.88 (d, $J = 15.0$ Hz, 1H, CH_2Ph), 4.91 (d, $J = 15.2$ Hz, 1H, CH_2Ph), 5.27 (br. s, 1H, OH), 5.68 (br. s, 1H, OH), 7.18-7.24 (m, 4H, ArH), 7.27-7.36 (m, 6H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.26 (t, piperidine-C4), 17.31 (t, piperidine-C4), 17.6 (t, C6), 18.0 (t, C6), 20.3 (q, NCCH_3), 20.4 (q, NCCH_3), 20.5 (q, NCCH_3), 20.6 (q, NCCH_3), 23.0 (q, CH_3), 24.3 (q, CH_3), 27.02 (t, C5), 27.04 (t, C5), 27.4 (t, C7), 27.8 (t, C7), 34.59 (q, NCCH_3), 34.64 (q, NCCH_3), 34.7 (q, NCCH_3), 34.8 (q, NCCH_3), 37.5 (t, CH_2CHOH), 39.1 (t, CH_2CHOH), 40.5 (t, piperidine-C3, C5), 40.6 (t, piperidine-C3, C5), 42.5 (d, C3), 43.5 (d, C3a), 43.9 (d, C3a), 44.4 (t, CH_2Ph), 44.7 (t, CH_2Ph), 44.8 (d, C3), 54.8 (d, C7a), 55.0 (d, C7a), 59.5 (s, CNO), 59.8 (s, CNO), 60.1 (s, CNO), 60.2 (s, CNO), 66.5 (d, CHOH), 68.0 (d, CHOH), 78.8 (d, C4), 79.5 (d, C4), 127.65 (d, CH_{Ar}), 127.73 (d, CH_{Ar}), 127.9 (d, CH_{Ar}), 128.0 (d, CH_{Ar}), 128.82 (d, CH_{Ar}), 128.84 (d, CH_{Ar}), 136.6 (s, C_{Ar}), 136.7 (s, C_{Ar}), 177.7 (s, C2), 177.9 (s, C2).


General procedure for the Dess–Martin oxidation of hydroxy lactams **12**:

A solution of hydroxy lactam **12** or *trans*-**12** (0.7 mmol) in dichloromethane (4 mL) was added to a stirred solution of Dess–Martin periodinane (386 mg, 0.9 mmol) and *t*-BuOH (0.1 mL, 1.1 mmol) in dichloromethane (4 mL) at room temperature. After 30 min, saturated Na₂CO₃ solution (2 mL) and saturated Na₂S₂O₃ solution (2 mL) were added. After 5 min of vigorous stirring, the mixture was diluted with dichloromethane (10 mL), the organic layer was separated, washed with brine, dried over MgSO₄, and filtered. The filtrate was evaporated and the crude mixture was purified by column chromatography (gradient, hexanes/EtOAc 10:1 to 1:1) to give keto lactam **13**.

(3*R**,4*R**)- and (3*S**,4*R**)-1-Allyl-3-(2-oxopropyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (**13b**):


Prepared according to the general procedure from lactam *trans*-**12b**, yield 216 mg (88%) as a single diastereomer, and from lactam **12b**, yield 211 mg (86%) as a separable 2.5:1 mixture of diastereomers.

[*R*_f (hexanes/EtOAc 1:1) = 0.41]; IR (film); ν [cm⁻¹]: 2974 (w), 2930 (m), 2871 (w), 1709 (m), 1692 (s), 1490 (w), 1417 (w), 1374 (w), 1359 (w), 1286 (w), 1263 (w), 1244 (w), 1209 (w), 1185 (w), 1163 (w), 1133 (w), 1046 (w), 1016 (w), 993 (w), 956 (w), 925 (w), 707 (w), 614 (w); MS (+ESI) *m/z*, (%): 723 (40, [2*M*+Na⁺]), 373 (100, [*M*+Na⁺]), 351 (30, [*M*+H⁺]); HRMS (+ESI) *m/z* [C₂₀H₃₄N₂O₃Na⁺]: calcd. 373.2462; found 373.2465.



Major *trans*-diastereomer: ¹H NMR (400 MHz, CDCl₃): δ 1.06 (s, 6H, NCCH₃), 1.12 (s, 6H, NCCH₃), 1.24-1.35 (m, 1H, piperidine-H₄), 1.39-1.46 (m, 4H, piperidine-H₃, H₅), 1.47-1.60 (m, 1H, piperidine-H₄), 2.18 (s, 3H, CH₃), 2.36 (ttd, *J* = 8.6, 7.2, 6.4 Hz, 1H, H₄), 2.66-2.73 (m, 1H, H₃), 2.74-2.78 (m, 1H, CH₂CO), 2.88-2.94 (m, 1H, CH₂CO), 3.11 (dd, *J* = 9.8, 7.2 Hz, 1H, H₅), 3.42 (dd, *J* = 9.8, 8.6 Hz, 1H, H₅), 3.79 (dd, *J* = 8.9, 6.3 Hz, 1H, CH₂OTMP), 3.81 (dd, *J* = 8.9,

6.2 Hz, 1H, CH_2OTMP), 3.82 (dd, $J = 15.5, 6.1$ Hz, 1H, $\text{CH}_2\text{CH=}$), 3.95 (dd, $J = 15.5, 5.9$ Hz, 1H, $\text{CH}_2\text{CH=}$), 5.19 (dd, $J = 10.1, 1.3$ Hz, 1H, CH=CH_2), 5.22 (dd, $J = 17.2, 1.3$ Hz, 1H, CH=CH_2), 5.73 (ddt, $J = 17.2, 10.1, 6.0$ Hz, 1H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ 17.2 (t, piperidine-C4), 20.23 (q, NCCH_3), 20.27 (q, NCCH_3), 30.4 (q, CH_3), 33.26 (q, 2C, NCCH_3), 37.4 (d, C4), 37.9 (t, piperidine-C3, C5), 41.5 (d, C3), 43.7 (t, CH_2CO), 45.5 (t, $\text{CH}_2\text{CH=}$), 48.32 (t, C5), 60.03 (s, 2C, CNO), 78.1 (t, CH_2OTMP), 118.0 (t, CH=CH_2), 132.4 (d, CH=CH_2), 175.0 (s, C2), 206.8 (s, C=O).




Minor *cis*-diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 1.05 (s, 6H, NCCH_3), 1.08 (s, 6H, NCCH_3), 1.22-1.34 (m, 1H, piperidine-H4), 1.39-1.46 (m, 4H, piperidine-H3, H5), 1.47-1.60 (m, 1H, piperidine-H4), 2.18 (s, 3H, CH_3), 2.55 (dd, $J = 18.5, 9.8$ Hz, 1H, CH_2CO), 2.76-2.86 (m, 1H, H4), 2.99 (dd, $J = 18.5, 4.3$ Hz, 1H, CH_2CO), 3.07 (ddd, $J = 9.8, 8.1, 4.3$ Hz, 1H, H3), 3.28 (dd, $J = 10.1, 1.7$ Hz, 1H, H5), 3.39 (dd, $J = 10.1, 6.5$ Hz, 1H, H5), 3.53 (dd, $J = 9.1, 5.1$ Hz, 1H, CH_2OTMP), 3.57 (dd, $J = 9.1, 4.2$ Hz, 1H, CH_2OTMP), 3.81 (dd, $J = 15.0, 6.1$ Hz, 1H, $\text{CH}_2\text{CH=}$), 3.94 (dd, $J = 15.0, 6.0$ Hz, 1H, $\text{CH}_2\text{CH=}$), 5.19 (dd, $J = 9.7, 1.4$ Hz, 1H, CH=CH_2), 5.20 (dd, $J = 17.5, 1.4$ Hz, 1H, CH=CH_2), 5.70 (ddt, $J = 17.5, 9.7, 6.0$ Hz, 1H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ 17.1 (t, piperidine-C4), 20.21 (q, NCCH_3), 20.33 (q, NCCH_3), 30.2 (q, CH_3), 33.0 (q, NCCH_3), 33.34 (q, NCCH_3), 34.2 (d, C4), 39.7 (t, piperidine-C3), 39.8 (t, piperidine-C5), 40.1 (d, C3), 40.2 (t, CH_2CO), 45.6 (t, $\text{CH}_2\text{CH=}$), 48.31 (t, C5), 59.98 (s, CNO), 60.01 (s, CNO), 75.3 (t, CH_2OTMP), 118.5 (t, CH=CH_2), 132.5 (d, CH=CH_2), 174.6 (s, C2), 206.9 (s, C=O).

(3*R,4*R**)-1-Allyl-3-(2-oxohexyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13c):**

Prepared according to the general procedure, yield 238 mg (87%) as a single diastereomer.

[*R*_f (hexanes/EtOAc 2:1) = 0.40]; IR (film); ν [cm⁻¹]: 2973 (w), 2930 (m), 2872 (w), 1708 (m), 1685 (m), 1693 (s), 1489 (w), 1440 (w), 1416 (w), 1374 (w), 1359 (w), 1263 (w), 1208 (w), 1185 (w), 1132 (w), 1046 (w), 993 (w), 957 (w), 708 (w), 615 (w); MS (+ESI) *m/z*, (%): 807 (20, [2*M*+Na⁺]), 415 (65, [*M*+Na⁺]), 393 (100, [*M*+H⁺]); HRMS (+ESI) *m/z* [C₂₃H₄₁N₂O₃⁺]: calcd. 393.3112; found 393.3108.




¹H NMR (400 MHz, CDCl₃): δ 0.89 (t, *J* = 7.3 Hz, 3H, CH₃), 1.06 (s, 6H, NCCH₃), 1.12 (s, 6H, NCCH₃), 1.25-1.29 (m, 1H, piperidine-H₄), 1.30 (sext, *J* = 7.3 Hz, 2H, CH₃CH₂), 1.39-1.45 (m, 4H, piperidine-H₃, H₅), 1.46-1.50 (m, 1H, piperidine-H₄), 1.56 (quint, *J* = 7.4 Hz, 2H, CH₃CH₂CH₂), 2.29-2.42 (m, 1H, H₄), 2.43 (t, *J* = 7.4 Hz, 1H, CH₃CH₂CH₂CH₂), 2.44 (t, *J* = 7.6 Hz, 1H, CH₃CH₂CH₂CH₂), 2.68-2.71 (m, 1H, H₃), 2.73 (dd, *J* = 15.0, 6.2 Hz, 1H, CHCH₂CO), 2.89 (dd, *J* = 15.0, 2.7 Hz, 1H, CHCH₂CO), 3.11 (dd, *J* = 9.8, 7.2 Hz, 1H, H₅), 3.42 (dd, *J* = 9.8, 8.5 Hz, 1H, H₅), 3.78 (dd, *J* = 9.1, 6.2 Hz, 1H, CH₂OTMP), 3.81 (dd, *J* = 9.1, 5.3 Hz, 1H, CH₂OTMP), 3.83 (dd, *J* = 15.3, 6.1 Hz, 1H, CH₂CH=), 3.94 (dd, *J* = 15.3, 5.9 Hz, 1H, CH₂CH=), 5.16-5.20 (m, 1H, CH=CH₂), 5.21-5.26 (m, 1H, CH=CH₂), 5.73 (ddt, *J* = 16.1, 10.1, 6.0 Hz, 1H, CH=CH₂); ¹³C NMR (101 MHz, CDCl₃): δ 14.0 (q, CH₃), 17.2 (t, piperidine-C₄), 20.2 (q, NCCH₃), 20.3 (q, NCCH₃), 22.5 (t, CH₃CH₂), 26.0 (t, CH₃CH₂CH₂), 33.26 (q, NCCH₃), 33.29 (q, NCCH₃), 37.5 (d, C₄), 39.7 (t, piperidine-C₃, C₅), 41.5 (d, C₃), 42.8 (t, CHCH₂CO), 43.0 (t, CH₃CH₂CH₂CH₂), 45.5 (t, CH₂CH=), 48.4 (t, C₅), 60.0 (s, 2C, CNO), 78.2 (t, CH₂OTMP), 118.0 (t, CH=CH₂), 132.6 (d, CH=CH₂), 175.1 (s, C₂), 209.2 (s, C=O).

(3*R,4*R**)-1-Allyl-3-(2-oxo-2-phenylethyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13d):**

Prepared according to the general procedure, yield 231 mg (80%) as a single diastereomer.

[*R*_f (hexanes/EtOAc 2:1) = 0.46]; IR (film); ν [cm⁻¹]: 2974 (w), 2929 (w), 2871 (w), 1683 (s), 1598 (w), 1490 (w), 1448 (w), 1416 (w), 1380 (w), 1373 (w), 1360 (w), 1289 (w), 1263 (w), 1221 (w), 1183 (w), 1133 (w), 1046 (w), 995 (w), 925 (w), 755 (w), 691 (w); MS (+ESI) *m/z*, (%): 847 (20, [2M+Na⁺]), 435 (65, [M+Na⁺]), 413 (100, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₅H₃₇N₂O₃⁺]: calcd. 413.2799; found 413.2795.




¹H NMR (400 MHz, CDCl₃): δ 1.02 (s, 6H, NCCH₃), 1.10 (s, 3H, NCCH₃), 1.11 (s, 3H, NCCH₃), 1.26-1.33 (m, 1H, piperidine-H₄), 1.37-1.45 (m, 4H, piperidine-H₃, H₅), 1.46-1.57 (m, 1H, piperidine-H₄), 2.40-2.51 (m, 1H, H₄), 2.89 (td, *J* = 7.6, 4.0 Hz, 1H, H₃), 3.19 (dd, *J* = 9.8, 6.6 Hz, 1H, H₅), 3.24 (dd, *J* = 17.5, 7.6 Hz, 1H, CH₂CO), 3.49 (dd, *J* = 9.8, 6.7 Hz, 1H, H₅), 3.57 (dd, *J* = 17.5, 4.0 Hz, 1H, CH₂CO), 3.82 (dd, *J* = 8.9, 6.6 Hz, 1H, CH₂OTMP), 3.85 (dd, *J* = 8.9, 6.6 Hz, 1H, CH₂OTMP), 3.89 (dd, *J* = 15.2, 6.0 Hz, 1H, CH₂CH=), 3.97 (dd, *J* = 15.2, 6.0 Hz, 1H, CH₂CH=), 5.19-5.22 (m, 1H, CH=CH₂), 5.24-5.28 (m, 1H, CH=CH₂), 5.76 (ddt, *J* = 16.1, 10.1, 6.0 Hz, 1H, CH=CH₂), 7.42-7.47 (m, 2H, ArH), 7.52-7.59 (m, 1H, ArH), 7.94-8.00 (m, 2H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 17.2 (t, piperidine-C₄), 20.2 (q, 2C, NCCH₃), 33.2 (q, NCCH₃), 33.3 (q, NCCH₃), 37.5 (d, C₄), 39.3 (t, CH₂CO), 39.7 (t, piperidine-C₃, C₅), 41.6 (d, C₃), 45.6 (t, CH₂CH=), 48.5 (t, C₅), 60.0 (s, 2C, CNO), 78.2 (t, CH₂OTMP), 118.0 (t, CH=CH₂), 128.2 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 132.5 (d, CH=CH₂), 133.2 (d, CH_{Ar}), 136.9 (s, C_{Ar}), 175.1 (s, C₂), 198.2 (s, C=O).


(3*R,4*R**)- and (3*S**,4*R**)-1-Benzyl-4-methyl-3-(2-oxopropyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13f):**

Prepared according to the general procedure, yield 261 mg (90%) as a partly separable 3:1 mixture of diastereomers.

[*R*_f (hexanes/EtOAc 1:1) = 0.42]; IR (film); ν [cm⁻¹]: 2971 (w), 2928 (m), 2873 (w), 1717 (m), 1690 (s), 1488 (w), 1430 (m), 1373 (m), 1359 (m), 1323 (w), 1295 (w), 1261 (w), 1244 (w), 1165 (w), 1133 (w), 1060 (w), 994 (w), 971 (w), 957 (w), 925 (w), 750 (w), 701 (m), 642 (w); MS (+ESI) *m/z*, (%): 415 (100, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₅H₃₉N₂O₃⁺]: calcd. 415.2955; found 415.2954.



Major *trans*-diastereomer: ¹H NMR (400 MHz, CDCl₃): δ 0.96 (s, 3H, CCH₃), 1.03 (s, 3H, NCCH₃), 1.08 (s, 6H, NCCH₃), 1.10 (s, 3H, NCCH₃), 1.25-1.33 (m, 1H, piperidine-H4), 1.37-1.45 (m, 4H, piperidine-H3, H5), 1.46-1.58 (m, 1H, piperidine-H4), 2.27 (s, 3H, COCH₃), 2.49 (dd, *J* = 17.0, 5.2 Hz, 1H, CH₂CO), 2.80 (d, *J* = 9.7 Hz, 1H, H5), 2.83 (dd, *J* = 17.0, 7.9 Hz, 1H, CH₂CO), 3.20 (dd, *J* = 7.9, 5.2 Hz, 1H, H3), 3.30 (d, *J* = 9.7 Hz, 1H, H5), 3.64 (d, *J* = 8.8 Hz, 1H, CH₂OTMP), 3.67 (d, *J* = 8.8 Hz, 1H, CH₂OTMP), 4.25 (d, *J* = 14.8 Hz, 1H, CH₂Ph), 4.57 (d, *J* = 14.8 Hz, 1H, CH₂Ph), 7.21-7.36 (m, 5H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 17.1 (t, piperidine-C4), 19.2 (q, CCH₃), 20.3 (q, NCCH₃), 20.4 (q, NCCH₃), 30.7 (q, COCH₃), 33.2 (q, NCCH₃), 33.3 (q, NCCH₃), 39.8 (t, piperidine-C3), 39.88 (t, CH₂CO, piperidine-C5), 40.5 (s, C4), 45.1 (d, C3), 46.9 (t, CH₂Ph), 55.2 (t, C5), 60.2 (s, 2C, CNO), 81.7 (t, CH₂OTMP), 127.7 (d, CH_{Ar}), 128.3 (d, CH_{Ar}), 128.8 (d, CH_{Ar}), 136.5 (s, C_{Ar}), 175.0 (s, C2), 206.8 (s, C=O).




Minor *cis*-diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.87 (s, 3H, NCCH_3), 0.99 (s, 3H, NCCH_3), 1.06 (s, 3H, NCCH_3), 1.11 (s, 3H, NCCH_3), 1.23 (s, 3H, CCH_3), 1.25-1.33 (m, 1H, piperidine-H4), 1.37-1.45 (m, 4H, piperidine-H3, H5), 1.46-1.58 (m, 1H, piperidine-H4), 2.26 (s, 3H, COCH_3), 2.39 (dd, $J = 17.1, 6.3$ Hz, 1H, CH_2CO), 2.86 (dd, $J = 17.1, 6.7$ Hz, 1H, CH_2CO), 2.91 (d, $J = 10.5$ Hz, 1H, H5), 2.96 (t, $J = 6.5$ Hz, 1H, H3), 3.406 (d, $J = 10.5$ Hz, 1H, H5), 3.415 (d, $J = 8.4$ Hz, 1H, CH_2OTMP), 3.54 (d, $J = 8.4$ Hz, 1H, CH_2OTMP), 4.25 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 4.57 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 7.21-7.36 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.0 (t, piperidine-C4), 20.3 (q, NCCH_3), 20.4 (q, NCCH_3), 22.6 (q, CCH_3), 30.8 (q, COCH_3), 33.1 (q, NCCH_3), 33.2 (q, NCCH_3), 38.7 (t, CH_2CO), 39.88 (t, piperidine-C3), 39.92 (t, piperidine-C5), 40.6 (s, C4), 47.2 (t, CH_2Ph), 47.9 (d, C3), 54.2 (t, C5), 60.2 (s, 2C, CNO), 78.0 (t, CH_2OTMP), 127.8 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 128.9 (d, CH_{Ar}), 136.4 (s, C_{Ar}), 176.9 (s, C2), 207.0 (s, C=O).

(3*R*,4*R*)- and (3*S*,4*S*)-3-(2-Oxopropyl)-1-((*S*)-1-phenylethyl)-4-(((2,2,6,6-tetramethyl-piperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13i):

Prepared according to the general procedure, yield 223 mg (77%) as a partly separable 1:1 mixture of diastereomers.

[R_f (hexanes/EtOAc 1:1) = 0.24]; IR (film); ν [cm^{-1}]: 2973 (w), 2930 (w), 2872 (w), 1717 (m), 1682 (s), 1488 (w), 1450 (w), 1430 (m), 1373 (m), 1358 (m), 1261 (w), 1244 (w), 1185 (w), 1162 (w), 1133 (w), 1047 (w), 1029 (w), 993 (w), 972 (w), 956 (w), 924 (w), 786 (w), 746 (w), 700 (m), 632 (w); MS (+ESI) m/z , (%): 437 (65, $[\text{M}+\text{Na}^+]$), 415 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{25}\text{H}_{39}\text{N}_2\text{O}_3^+$]: calcd. 415.2955; found 415.2953.




Less polar diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 1.05 (s, 6H, NCCH_3), 1.11 (s, 6H, NCCH_3), 1.28-1.35 (m, 1H, piperidine-H4), 1.38-1.47 (m, 4H, piperidine-H3, H5), 1.48-1.52 (m, 1H, piperidine-H4), 1.53 (d, $J = 7.3$ Hz, 3H, PhCHCH_3), 2.20 (s, 3H, COCH_3), 2.22-2.34 (m, 1H, H4), 2.72-2.81 (m, 2H, H3, CH_2CO), 2.94 (dd, $J = 19.2, 6.6$ Hz, 1H, CH_2CO), 3.04 (dd, $J = 9.4, 4.2$ Hz, 1H, H5), 3.08 (dd, $J = 9.4, 5.1$ Hz, 1H, H5), 3.78 (d, $J = 6.4$ Hz, 2H, CH_2OTMP), 5.48 (q, $J = 7.3$ Hz, 1H, PhCHCH_3), 7.26-7.40 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.3 (q, PhCHCH_3), 17.2 (t, piperidine-C4), 20.25 (q, NCCH_3), 20.34 (q, NCCH_3), 30.4 (q, COCH_3), 33.3 (q, 2C, NCCH_3), 37.2 (d, C4), 39.74 (t, piperidine-C3, C5), 42.02 (d, C3), 43.5 (t, CH_2CO), 43.7 (t, C5), 49.1 (d, PhCHCH_3), 60.0 (s, 2C, CNO), 78.1 (t, CH_2OTMP), 127.1 (d, CH_{Ar}), 127.51 (d, CH_{Ar}), 128.67 (d, CH_{Ar}), 140.3 (s, C_{Ar}), 174.7 (s, C2), 206.6 (s, C=O).

More polar diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 0.97 (s, 9H, NCCH_3), 1.05 (s, 3H, NCCH_3), 1.23-1.33 (m, 1H, piperidine-H4), 1.35-1.43 (m, 4H, piperidine-H3, H5), 1.44-1.52 (m, 1H, piperidine-H4), 1.54 (d, $J = 7.2$ Hz, 3H, PhCHCH_3), 2.19 (s, 3H, COCH_3), 2.23-2.38 (m, 1H, H4), 2.67 (ddd, $J = 7.8, 6.4, 4.8$ Hz, 1H, H3), 2.72 (dd, $J = 9.8, 6.5$ Hz, 1H, H5), 2.78 (dd, $J = 17.6, 6.4$ Hz, 1H, CH_2CO), 2.93 (dd, $J = 17.6, 4.8$ Hz, 1H, CH_2CO), 3.38 (dd, $J = 9.8, 8.4$ Hz, 1H, H5), 3.65 (dd, $J = 9.0, 6.7$ Hz, 1H, CH_2OTMP), 3.68 (dd, $J = 9.0, 6.5$ Hz, 1H, CH_2OTMP), 5.46 (q, $J = 7.2$ Hz, 1H, PhCHCH_3), 7.21-7.37 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.1 (q, PhCHCH_3), 17.1 (t, piperidine-C4), 20.1 (q, NCCH_3), 20.2 (q, NCCH_3), 30.3 (q, COCH_3), 33.1 (q, 2C, NCCH_3), 37.1 (d, C4), 39.68 (t, piperidine-C3, C5), 42.00 (d, C3), 43.8 (t, CH_2CO), 43.9 (t, C5), 49.4 (d, PhCHCH_3), 59.9 (s, 2C, CNO), 78.0 (t, CH_2OTMP), 127.2 (d, CH_{Ar}), 127.54 (d, CH_{Ar}), 128.65 (d, CH_{Ar}), 140.0 (s, C_{Ar}), 174.8 (s, C2), 206.8 (s, C=O).

(3*R*,4*R*)- and (3*S*,4*S*)- and (3*S*,4*R*)- and (3*R*,4*S*)-1-((*S*)-1-(Naphthalen-2-yl)ethyl)-3-(2-oxopropyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13j):


Prepared according to the general procedure, yield 255 mg (81%) as a partly separable 4:4:1:1 mixture of diastereomers. The minor diastereomer (3*S*,4*R*)-**13j** crystallized from hexane with a few drops of DCM and its configuration was determined by X-ray crystallography.

[*R*_f (hexanes/EtOAc 2:1) = 0.36]; IR (film); ν [cm⁻¹]: 2973 (w), 2930 (w), 2872 (w), 1716 (m), 1681 (s), 1486 (w), 1469 (w), 1427 (m), 1373 (m), 1359 (w), 1261 (w), 1245 (w), 1163 (w), 1131 (w), 1047 (w), 993 (w), 972 (w), 956 (w), 923 (w), 858 (w), 821 (w), 751 (m), 731 (m), 673 (w), 645 (w); MS (+ESI) *m/z*, (%): 951 (5, [2*M*+Na⁺]), 487 (45, [*M*+Na⁺]), 465 (100, [*M*+H⁺]); HRMS (+ESI) *m/z* [C₂₉H₄₁N₂O₃⁺]: calcd. 465.3112; found 465.3112.



Major *trans*-diastereomers: ¹H NMR (400 MHz, CDCl₃): δ 0.88 (s, 6H, NCCH₃), 0.92 (s, 6H, NCCH₃), 1.03 (s, 3H, NCCH₃), 1.04 (s, 3H, NCCH₃), 1.10 (s, 3H, NCCH₃), 1.11 (s, 3H, NCCH₃), 1.22-1.29 (m, 2H, piperidine-H₄), 1.30-1.39 (m, 8H, piperidine-H₃, H₅), 1.40-1.44 (m, 2H, piperidine-H₄), 1.64 (d, *J* = 7.1 Hz, 3H, ArCHCH₃), 1.67 (d, *J* = 7.1 Hz, 3H, ArCHCH₃), 2.21 (s, 6H, COCH₃), 2.23-2.37 (m, 2H, H₄), 2.68-2.75 (m, 1H, H₃), 2.72 (dd, *J* = 9.8, 6.7 Hz, 1H, H₅), 2.76-2.80 (m, 1H, H₃), 2.78 (dd, *J* = 12.8, 6.1 Hz, 1H, CH₂CO), 2.82 (dd, *J* = 17.5, 6.4 Hz, 1H, CH₂CO), 2.95 (dd, *J* = 17.5, 4.9 Hz, 1H, CH₂CO), 2.96 (dd, *J* = 12.8, 5.2 Hz, 1H, CH₂CO), 3.03 (dd, *J* = 9.7, 8.4 Hz, 1H, H₅), 3.09 (dd, *J* = 9.7, 7.6 Hz, 1H, H₅), 3.42 (dd, *J* = 9.8, 8.4 Hz, 1H, H₅), 3.62 (dd, *J* = 9.0, 6.7 Hz, 1H, CH₂OTMP), 3.66 (dd, *J* = 9.0, 5.6 Hz, 1H, CH₂OTMP), 3.77 (d, *J* = 6.4 Hz, 2H, CH₂OTMP), 5.64 (q, *J* = 7.1 Hz, 2H, ArCHCH₃), 7.38 (dd, *J* = 8.6, 1.8 Hz, 2H, ArH), 7.43-7.52 (m, 4H, ArH), 7.71-7.88 (m, 8H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 16.0 (q, ArCHCH₃), 16.1 (q, ArCHCH₃), 17.1 (t, piperidine-C₄), 17.2 (t, piperidine-C₄), 20.08 (q, NCCH₃), 20.13 (q, NCCH₃), 20.27 (q, NCCH₃), 20.33 (q, NCCH₃), 30.39 (q, COCH₃), 30.44 (q, COCH₃), 33.0 (q, 2C, NCCH₃), 33.17 (q, NCCH₃), 33.24 (q,

NCCH₃), 37.1 (d, C₄), 37.2 (d, C₄), 39.66 (t, piperidine-C3, C5), 39.72 (t, piperidine-C3, C5), 42.07 (d, C3), 42.12 (d, C3), 43.4 (t, CH₂CO), 43.7 (t, C5), 43.8 (t, CH₂CO), 43.89 (t, C5), 49.1 (d, ArCHCH₃), 49.5 (d, ArCHCH₃), 59.9 (s, 2C, CNO), 60.02 (s, 2C, CNO), 78.0 (t, CH₂OTMP), 78.1 (t, CH₂OTMP), 125.4 (d, CH_{Ar}), 125.6 (d, CH_{Ar}), 125.9 (d, CH_{Ar}), 126.0 (d, CH_{Ar}), 126.11 (d, CH_{Ar}), 126.3 (d, 2C, CH_{Ar}), 127.69 (d, 2C, CH_{Ar}), 127.72 (d, CH_{Ar}), 128.11 (d, CH_{Ar}), 128.13 (d, CH_{Ar}), 128.51 (d, CH_{Ar}), 128.53 (d, CH_{Ar}), 132.87 (s, C_{Ar}), 132.92 (s, C_{Ar}), 133.3 (s, C_{Ar}), 133.38 (s, C_{Ar}), 137.61 (s, C_{Ar}), 137.9 (s, C_{Ar}), 174.85 (s, C2), 174.89 (s, C2), 206.6 (s, C=O), 206.8 (s, C=O).




Minor *cis*-diastereomers: ¹H NMR (400 MHz, CDCl₃): δ 0.91 (s, 3H, NCCH₃), 0.96 (s, 3H, NCCH₃), 1.04 (s, 6H, NCCH₃), 1.08 (s, 9H, NCCH₃), 1.12 (s, 3H, NCCH₃), 1.28-1.38 (m, 2H, piperidine-H₄), 1.39-1.47 (m, 8H, piperidine-H₃, H₅), 1.48-1.54 (m, 2H, piperidine-H₄), 1.65 (d, *J* = 7.1 Hz, 3H, ArCHCH₃), 1.67 (d, *J* = 7.1 Hz, 3H, ArCHCH₃), 2.19 (s, 3H, COCH₃), 2.21 (s, 3H, COCH₃), 2.50 (dd, *J* = 18.6, 10.1 Hz, 1H, CH₂CO), 2.51-2.64 (m, 1H, H₄), 2.68-2.79 (m, 2H, H₃, H₄), 2.96 (dd, *J* = 10.1, 6.4 Hz, 1H, H₅), 3.00-3.10 (m, 4H, H₅, CH₂CO), 3.15 (ddd, *J* = 10.3, 4.9, 2.6 Hz, 1H, H₃), 3.19 (dd, *J* = 8.7, 6.9 Hz, 1H, CH₂OTMP), 3.30 (dd, *J* = 10.1, 2.7 Hz, 1H, H₅), 3.31 (dd, *J* = 8.7, 5.5 Hz, 1H, CH₂OTMP), 3.41 (dd, *J* = 9.8, 3.6 Hz, 1H, H₅), 3.55 (dd, *J* = 8.9, 6.1 Hz, 1H, CH₂OTMP), 3.60 (dd, *J* = 8.9, 5.7 Hz, 1H, CH₂OTMP), 5.65 (q, *J* = 7.1 Hz, 2H, ArCHCH₃), 7.36 (dd, *J* = 8.6, 2.0 Hz, 1H, ArH), 7.41 (dd, *J* = 8.4, 2.1 Hz, 1H, ArH), 7.45-7.50 (m, 4H, ArH), 7.71-7.88 (m, 8H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 16.2 (q, ArCHCH₃), 16.3 (q, ArCHCH₃), 17.0 (t, piperidine-C₄), 17.2 (t, piperidine-C₄), 20.2 (q, 2C, NCCH₃), 20.4 (q, 2C, NCCH₃), 30.2 (q, COCH₃), 30.5 (q, COCH₃), 32.9 (q, 2C, NCCH₃), 33.4 (q, 2C, NCCH₃), 33.9 (d, C₄), 34.0 (d, C₄), 39.69 (t, piperidine-C3, C5), 39.8 (t, piperidine-C3, C5), 40.07 (t, CH₂CO), 40.10 (t, CH₂CO), 40.5 (d, C3), 40.6 (d, C3), 43.7 (t, C5), 43.92 (t, C5),

49.2 (d, ArCHCH₃), 49.4 (d, ArCHCH₃), 59.98 (s, 2C, CNO), 60.00 (s, 2C, CNO), 74.8 (t, CH₂OTMP), 75.2 (t, CH₂OTMP), 125.5 (d, CH_{Ar}), 125.7 (d, CH_{Ar}), 125.8 (d, 2C, CH_{Ar}), 126.11 (d, 2C, CH_{Ar}), 126.14 (d, CH_{Ar}), 126.2 (d, CH_{Ar}), 126.4 (d, CH_{Ar}), 127.65 (d, CH_{Ar}), 127.74 (d, CH_{Ar}), 128.11 (d, CH_{Ar}), 128.6 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 132.85 (s, C_{Ar}), 132.91 (s, C_{Ar}), 133.36 (s, C_{Ar}), 133.37 (s, C_{Ar}), 137.5 (s, C_{Ar}), 137.60 (s, C_{Ar}), 174.1 (s, C2), 174.5 (s, C2), 206.88 (s, C=O), 206.93 (s, C=O).

(3*R,4*S**)- and (3*S**,4*R**)- and (3*R**,4*R**)-1-Allyl-3-((*R**)-2-oxocyclohexyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13l):**

Prepared according to the general procedure, yield 229 mg (81%) as a partly separable 10:8.5(*trans*):1(*cis*) mixture of diastereomers.


[*R*_f (hexanes/EtOAc 1:1) = 0.44]; IR (film); ν [cm⁻¹]: 2973 (w), 2931 (m), 2868 (w), 1722 (m), 1688 (s), 1488 (w), 1447 (w), 1373 (w), 1359 (w), 1307 (w), 1269 (w), 1132 (w), 1047 (w), 995 (w), 924 (w), 756 (w), 691 (w); MS (+ESI) *m/z*, (%): 803 (40, [2M+Na⁺]), 413 (85, [M+Na⁺]), 391 (100, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₃H₃₉N₂O₃⁺]: calcd. 391.2955; found 391.2953.



(3*R**,4*S**)


Less polar *trans*-diastereomer **13IA**: ¹H NMR (400 MHz, CDCl₃): δ 1.07 (s, 6H, NCCH₃), 1.15 (s, 6H, NCCH₃), 1.27-1.36 (m, 1H, piperidine-H4), 1.39-1.52 (m, 4H, piperidine-H3, H5), 1.53-1.61 (m, 1H, piperidine-H4), 1.62-1.75 (m, 2H, H8, H9), 1.83-2.00 (m, 3H, H7, H8), 2.01-2.11 (m, 1H, H9), 2.24-2.46 (m, 3H, H4, H10), 2.64 (dd, *J* = 6.8, 2.4 Hz, 1H, H3), 2.86-2.95 (m, 1H, H6), 3.19 (dd, *J* = 9.8, 5.4 Hz, 1H, H5), 3.35-3.42 (m, 1H, H5), 3.79-3.91 (m, 3H, CH₂CH=, CH₂OTMP), 3.96 (dd, *J* = 15.2, 5.9 Hz, 1H, CH₂CH=), 5.16-5.29 (m, 2H, CH=CH₂), 5.68-5.81 (m, 1H, CH=CH₂); ¹³C NMR (101 MHz, CDCl₃): δ 17.21 (t, piperidine-C4), 20.24 (q, NCCH₃), 20.3 (q, NCCH₃), 25.42 (t, C8), 27.27 (t, C9), 30.3 (t, C7), 33.27 (q, NCCH₃), 33.40 (q, NCCH₃),

35.0 (d, C4), 39.81 (t, piperidine-C3, C5), 42.2 (t, C10), 45.4 (d, C3), 45.5 (t, $\underline{\text{C}}\text{H}_2\text{CH=}$), 49.0 (t, C5), 51.8 (d, C6), 60.06 (s, 2C, CNO), 78.6 (t, $\underline{\text{C}}\text{H}_2\text{OTMP}$), 118.0 (t, $\text{CH}=\underline{\text{C}}\text{H}_2$), 132.6 (d, $\underline{\text{C}}\text{H}=\text{CH}_2$), 175.2 (s, C2), 210.8 (s, C11).



(3*S**,4*R**)

More polar *trans*-diastereomer **13IB**: ^1H NMR (400 MHz, CDCl_3): δ 1.07 (s, 6H, NCCH_3), 1.15 (s, 6H, NCCH_3), 1.27-1.36 (m, 1H, piperidine-H4), 1.40-1.47 (m, 4H, piperidine-H3, H5), 1.51-1.64 (m, 1H, piperidine-H4), 1.65-1.76 (m, 3H, H7, H8), 1.87-1.99 (m, 1H, H8), 2.01-2.13 (m, 2H, H9), 2.26-2.43 (m, 4H, H3, H4, H10), 3.01-3.09 (m, 1H, H6), 3.11 (dd, $J = 9.5, 3.9$ Hz, 1H, H5), 3.63 (t, $J = 9.4$ Hz, 1H, H5), 3.69 (dd, $J = 9.1, 3.8$ Hz, 1H, $\underline{\text{C}}\text{H}_2\text{OTMP}$), 3.74 (dd, $J = 9.1, 4.1$ Hz, 1H, $\underline{\text{C}}\text{H}_2\text{OTMP}$), 3.85 (dd, $J = 15.3, 6.1$ Hz, 1H, $\underline{\text{C}}\text{H}_2\text{CH=}$), 3.95 (dd, $J = 15.3, 5.9$ Hz, 1H, $\underline{\text{C}}\text{H}_2\text{CH=}$), 5.19 (dd, $J = 10.1, 1.5$ Hz, 1H, $\text{CH}=\underline{\text{C}}\text{H}_2$), 5.26 (dd, $J = 17.2, 1.5$ Hz, 1H, $\text{CH}=\underline{\text{C}}\text{H}_2$), 5.77 (ddt, $J = 17.2, 10.1, 6.0$ Hz, 1H, $\underline{\text{C}}\text{H}=\text{CH}_2$); ^{13}C NMR (101 MHz, CDCl_3): δ 17.17 (t, piperidine-C4), 20.43 (q, 2C, $\text{NC}\underline{\text{C}}\text{H}_3$), 25.43 (t, C8), 27.30 (t, C9), 32.1 (t, C7), 33.34 (q, $\text{NC}\underline{\text{C}}\text{H}_3$), 33.41 (d, C4), 39.80 (t, piperidine-C3, C5), 42.3 (t, C10), 45.6 (t, $\underline{\text{C}}\text{H}_2\text{CH=}$), 46.6 (d, C3), 49.3 (t, C5), 51.6 (d, C6), 60.14 (s, 2C, CNO), 79.6 (t, $\underline{\text{C}}\text{H}_2\text{OTMP}$), 117.7 (t, $\text{CH}=\underline{\text{C}}\text{H}_2$), 132.71 (d, $\underline{\text{C}}\text{H}=\text{CH}_2$), 174.8 (s, C2), 211.2 (s, C11).




cis-Diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 1.04 (s, 3H, NCCH_3), 1.05 (s, 6H, NCCH_3), 1.08 (s, 3H, NCCH_3), 1.27-1.33 (m, 1H, piperidine-H4), 1.37-1.45 (m, 5H, H7, piperidine-H3, H5), 1.48-1.57 (m, 1H, piperidine-H4), 1.60-1.72 (m, 2H, H8, H9), 1.84-1.90 (m, 1H, H8), 2.06-2.14 (m, 1H, H9), 2.31-2.38 (m, 2H, H10), 2.67 (ddd, $J = 12.2, 9.1, 5.1$ Hz, 1H, H6), 2.75 (dd, $J = 9.0, 7.9$ Hz, 1H, H3), 2.95-3.02 (m, 1H, H4), 3.09-3.19 (m, 1H, H7), 3.29-3.35 (m, 2H, H5), 3.44 (dd, $J = 8.6, 4.5$ Hz, 1H, CH_2OTMP), 3.55 (dd, $J = 10.4, 8.6$ Hz, 1H, CH_2OTMP), 3.78 (dd, $J = 15.0, 6.3$ Hz, 1H, $\text{CH}_2\text{CH=}$), 3.94 (dd, $J = 15.0, 6.0$ Hz, 1H, $\text{CH}_2\text{CH=}$), 5.18 (dd, $J = 10.1, 1.9$ Hz, 1H, CH=CH_2), 5.21 (dd, $J = 16.6, 1.9$ Hz, 1H, CH=CH_2), 5.71 (ddt, $J = 16.6, 10.1, 6.2$ Hz, 1H, CH=CH_2); ^{13}C NMR (101 MHz, CDCl_3): δ 17.1 (t, piperidine-C4), 20.16 (q, NCCH_3), 20.38 (q, NCCH_3), 25.5 (t, C8), 29.0 (t, C9), 32.8 (q, NCCH_3), 33.2 (t, C7), 33.43 (q, NCCH_3), 34.8 (d, C4), 39.6 (t, piperidine-C3), 39.7 (t, piperidine-C5), 42.7 (t, C10), 43.4 (d, C3), 45.5 (t, $\text{CH}_2\text{CH=}$), 48.0 (t, C5), 49.5 (d, C6), 59.9 (s, CNO), 60.0 (s, CNO), 75.1 (t, CH_2OTMP), 118.4 (t, CH=CH_2), 132.66 (d, CH=CH_2), 174.6 (s, C2), 212.0 (s, C11).

(4S*,5S*,6R*)- and (4S*,5S*,6S*)- and (4R*,5S*,6R*)- and (4R*,5S*,6S*)-2-Benzyl-4-(2-oxopropyl)-6-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-azaspiro[4.4]nonan-3-one (13m):


Prepared according to the general procedure, yield 262 mg (81%) as a partly separable 11:6(*trans*):3:1(*cis*) mixture of diastereomers.

[R_f (hexanes/EtOAc 1:1) = 0.25]; IR (film); ν [cm^{-1}]: 2927 (w), 2871 (m), 1720 (m), 1689 (s), 1487 (w), 1429 (m), 1359 (m), 1284 (w), 1259 (w), 1238 (w), 1163 (w), 1133 (w), 1080 (w), 1029 (w), 975 (w), 910 (w), 731 (m), 701 (m), 645 (w); MS (+ESI) m/z , (%): 903 (10, $[2\text{M}+\text{Na}^+]$), 463 (30, $[\text{M}+\text{Na}^+]$), 441 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{27}\text{H}_{41}\text{N}_2\text{O}_3^+$]: calcd. 441.3112; found 441.3111.



(4S*,5S*,6R*)


Major diastereomer **13mA**: ^1H NMR (400 MHz, CDCl_3): δ 1.09 (s, 6H, NCCH_3), 1.15 (s, 6H, NCCH_3), 1.24-1.33 (m, 1H, piperidine- H_4), 1.35-1.47 (m, 7H, H_9 , H_8 , piperidine- H_3 , H_5), 1.48-1.60 (m, 2H, H_8 , piperidine- H_4), 1.61-1.70 (m, 1H, H_7), 1.88-1.98 (m, 1H, H_7), 2.27 (s, 3H, COCH_3), 2.39 (dd, $J = 17.1, 5.1$ Hz, 1H, CH_2CO), 2.75 (d, $J = 9.3$ Hz, 1H, H_1), 2.82 (dd, $J = 17.1, 7.9$ Hz, 1H, CH_2CO), 3.39 (dd, $J = 7.9, 5.1$ Hz, 1H, H_4), 3.64 (d, $J = 9.3$ Hz, 1H, H_1), 4.01-4.15 (m, 1H, H_6), 4.23 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 4.67 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 7.21-7.35 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.31 (t, piperidine- C_4), 18.8 (t, C_8), 20.6 (q, NCCH_3), 20.8 (q, NCCH_3), 29.1 (t, C_7), 30.0 (t, C_9), 30.7 (q, COCH_3), 34.3 (q, NCCH_3), 34.80 (q, NCCH_3), 40.1 (t, CH_2CO), 40.5 (t, piperidine- C_3 , C_5), 43.4 (d, C_4), 46.9 (t, CH_2Ph), 50.2 (s, C_5), 51.4 (t, C_1), 59.27 (s, CNO), 61.2 (s, CNO), 84.67 (d, C_6), 127.59 (d, CHAr), 128.2 (d, CHAr), 128.76 (d, CHAr), 136.61 (s, CAr), 175.4 (s, C_3), 206.7 (s, C=O).




(4S*,5S*,6S*)

Diastereomer **13mB**: ^1H NMR (400 MHz, CDCl_3): δ 0.97 (s, 6H, NCCH_3), 1.05 (s, 3H, NCCH_3), 1.16 (s, 3H, NCCH_3), 1.24-1.33 (m, 1H, piperidine- H_4), 1.35-1.47 (m, 4H, piperidine- H_3 , H_5), 1.48-1.60 (m, 3H, H_8 , piperidine- H_4), 1.61-1.70 (m, 1H, H_9), 1.76-1.86 (m, 2H, H_9 , H_7), 2.06 (ddt, $J = 13.6, 9.5, 6.5$ Hz, 1H, H_7), 2.24 (s, 3H, COCH_3), 2.67 (dd, $J = 18.4, 8.9$ Hz, 1H,

CH₂CO), 2.88-2.99 (m, 2H, CH₂CO, H4), 2.94 (d, *J* = 9.9 Hz, 1H, H1), 3.68 (d, *J* = 9.9 Hz, 1H, H1), 4.01-4.15 (m, 1H, H6), 4.04 (d, *J* = 14.7 Hz, 1H, CH₂Ph), 4.91 (d, *J* = 14.7 Hz, 1H, CH₂Ph), 7.21-7.35 (m, 5H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 17.2 (t, piperidine-C4), 19.6 (t, C8), 20.6 (q, NCCH₃), 20.8 (q, NCCH₃), 28.3 (t, C7), 30.59 (q, COCH₃), 34.5 (q, NCCH₃), 34.7 (q, NCCH₃), 36.6 (t, C9), 40.78 (t, piperidine-C3), 40.92 (t, piperidine-C5), 41.1 (t, CH₂CO), 46.2 (d, C4), 47.1 (t, CH₂Ph), 50.7 (s, C5), 53.1 (t, C1), 59.4 (s, CNO), 60.9 (s, CNO), 84.72 (d, C6), 127.61 (d, CH_{Ar}), 128.3 (d, CH_{Ar}), 128.79 (d, CH_{Ar}), 136.64 (s, C_{Ar}), 175.3 (s, C3), 207.1 (s, C=O).



Diastereomer **13mC**: ¹H NMR (400 MHz, CDCl₃): δ 1.11 (s, 12H, NCCH₃), 1.23-1.34 (m, 1H, piperidine-H4), 1.35-1.50 (m, 5H, H7, piperidine-H3, H5), 1.51-1.67 (m, 3H, H9, H7, piperidine-H4), 1.71-1.84 (m, 1H, H8), 1.85-1.90 (m, 1H, H9), 2.02-2.12 (m, 1H, H8), 2.27 (s, 3H, COCH₃), 2.94 (dd, *J* = 7.4, 5.3 Hz, 1H, H4), 2.99 (d, *J* = 9.6 Hz, 1H, H1), 3.10 (dd, *J* = 17.4, 5.3 Hz, 1H, CH₂CO), 3.14 (d, *J* = 9.6 Hz, 1H, H1), 3.23 (dd, *J* = 17.4, 7.4 Hz, 1H, CH₂CO), 4.09 (d, *J* = 14.5 Hz, 1H, CH₂Ph), 4.16 (t, *J* = 6.2 Hz, 1H, H6), 4.80 (d, *J* = 14.5 Hz, 1H, CH₂Ph), 7.19-7.36 (m, 5H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 17.26 (t, piperidine-C4), 20.0 (t, C8), 21.1 (q, 2C, NCCH₃), 30.56 (q, COCH₃), 30.59 (t, C7), 34.21 (q, NCCH₃), 34.4 (q, NCCH₃), 35.2 (t, C9), 40.7 (t, piperidine-C3), 40.89 (t, piperidine-C5), 41.86 (t, CH₂CO), 46.6 (d, C4), 47.0 (t, CH₂Ph), 51.0 (s, C5), 57.1 (t, C1), 59.34 (s, CNO), 61.14 (s, CNO), 90.1 (d, C6), 127.70 (d, CH_{Ar}), 128.4 (d, CH_{Ar}), 128.81 (d, CH_{Ar}), 136.53 (s, C_{Ar}), 175.5 (s, C3), 207.9 (s, C=O).




Diastereomer **13mD**: ^1H NMR (400 MHz, CDCl_3): δ 1.00 (s, 3H, NCCH_3), 1.04 (s, 3H, NCCH_3), 1.07 (s, 3H, NCCH_3), 1.11 (s, 3H, NCCH_3), 1.22-1.33 (m, 1H, piperidine- H_4), 1.35-1.58 (m, 7H, H_7 , H_8 , H_9 , piperidine- H_3 , H_5), 1.60-1.71 (m, 3H, H_7 , H_9 , piperidine- H_4), 2.17-2.25 (m, 1H, H_8), 2.27 (s, 3H, COCH_3), 2.78 (dd, $J = 15.0, 2.4$ Hz, 1H, CH_2CO), 2.82 (d, $J = 9.5$ Hz, 1H, H_1), 2.95 (d, $J = 9.5$ Hz, 1H, H_1), 3.58-3.63 (m, 2H, H_4 , CH_2CO), 4.10-4.15 (m, 1H, H_6), 4.36 (d, $J = 14.7$ Hz, 1H, CH_2Ph), 4.49 (d, $J = 14.7$ Hz, 1H, CH_2Ph), 7.19-7.36 (m, 5H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.31 (t, piperidine- C_4), 20.3 (t, C_8), 20.7 (q, NCCH_3), 21.2 (q, NCCH_3), 28.4 (t, C_7), 30.5 (q, COCH_3), 33.9 (q, NCCH_3), 34.76 (q, NCCH_3), 35.3 (t, C_9), 40.6 (t, piperidine- C_3), 40.77 (t, piperidine- C_5), 41.91 (t, CH_2CO), 42.4 (d, C_4), 46.8 (t, CH_2Ph), 51.5 (s, C_5), 56.2 (t, C_1), 59.34 (s, CNO), 61.13 (s, CNO), 89.7 (d, C_6), 127.68 (d, CH_{Ar}), 128.3 (d, CH_{Ar}), 128.80 (d, CH_{Ar}), 136.51 (s, C_{Ar}), 175.9 (s, C_3), 206.9 (s, C=O).


(4*S,5*S**,6*R**)- and (4*R**,5*S**,6*R**)- and (4*S**,5*S**,6*S**)-2-Benzyl-4-(2-oxopropyl)-6-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-azaspiro[4.5]decan-3-one (13n):**

Prepared according to the general procedure, yield 273 mg (88%) as a partly separable 5(*trans*):1(*cis*):1(*trans*) mixture of diastereomers. The major diastereomer **13nA** was transformed to the hydrochloride **13nA**·HCl (see p. S105), which crystallized from hexane with a few drops of DCM and its configuration was determined by X-ray crystallography.

[R_f (hexanes/EtOAc 1:1) = 0.38]; IR (film); ν [cm^{-1}]: 2927 (m), 2855 (w), 1719 (m), 1694 (s), 1486 (w), 1448 (m), 1432 (w), 1375 (m), 1359 (w), 1311 (w), 1270 (w), 1250 (w), 1166 (w), 1134 (w), 1080 (w), 1041 (w), 959 (w), 937 (w), 747 (w), 712 (m), 700 (w), 644 (w); MS (+ESI) m/z , (%): 931 (10, $[2\text{M}+\text{Na}^+]$), 477 (80, $[\text{M}+\text{Na}^+]$), 455 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{28}\text{H}_{43}\text{N}_2\text{O}_3^+$]: calcd. 455.3268; found 455.3267.




Major diastereomer **13nA**: ^1H NMR (400 MHz, CDCl_3): δ 0.96 (s, 6H, NCCH_3), 1.00-1.13 (m, 4H, H7, H8, H9, H10), 1.17 (s, 3H, NCCH_3), 1.23 (s, 3H, NCCH_3), 1.24-1.32 (m, 1H, piperidine-H4), 1.33-1.50 (m, 6H, H9, H10, piperidine-H3, H5), 1.51-1.61 (m, 1H, piperidine-H4), 1.62-1.72 (m, 1H, H8), 2.29 (s, 3H, COCH_3), 2.31-2.38 (m, 1H, H7), 2.35 (dd, $J = 16.6, 5.4$ Hz, 1H, CH_2CO), 2.80 (dd, $J = 16.6, 8.6$ Hz, 1H, CH_2CO), 2.89 (d, $J = 9.7$ Hz, 1H, H1), 3.50 (d, $J = 9.7$ Hz, 1H, H1), 3.75 (dd, $J = 10.9, 3.6$ Hz, 1H, H6), 3.94 (dd, $J = 8.6, 5.4$ Hz, 1H, H4), 4.31 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 4.60 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 7.21-7.28 (m, 3H, ArH), 7.29-7.36 (m, 2H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.4 (t, piperidine-C4), 20.73 (q, NCCH_3), 21.0 (q, NCCH_3), 22.0 (t, C9), 24.5 (t, C8), 28.2 (t, C7), 30.9 (q, COCH_3), 31.10 (t, C10), 34.5 (q, NCCH_3), 34.7 (q, NCCH_3), 39.6 (t, CH_2CO), 40.60 (t, piperidine-C3), 41.0 (t, piperidine-C5), 43.3 (d, C4), 44.6 (s, C5), 46.86 (t, CH_2Ph), 48.7 (t, C1), 59.25 (s, CNO), 61.2 (s, CNO), 80.7 (d, C6), 127.57 (d, CH_{Ar}), 128.2 (d, CH_{Ar}), 128.77 (d, CH_{Ar}), 136.6 (s, C_{Ar}), 175.5 (s, C3), 207.2 (s, C=O).



(4*S**,5*S**,6*S**)

Diastereomer **13nB**: ^1H NMR (400 MHz, CDCl_3): δ 0.96 (s, 6H, NCCH_3), 1.02-1.16 (m, 2H, H9, H10), 1.17 (s, 3H, NCCH_3), 1.23 (s, 3H, NCCH_3), 1.24-1.32 (m, 1H, piperidine-H4), 1.33-1.50 (m, 7H, H7, H8, H9, piperidine-H3, H5), 1.51-1.61 (m, 1H, piperidine-H4), 1.62-1.72 (m, 1H, H10), 1.73-1.79 (m, 1H, H8), 2.24-2.31 (m, 1H, H7), 2.26 (s, 3H, COCH_3), 2.76 (dd, $J = 13.5$, 7.7 Hz, 1H, CH_2CO), 2.86 (d, $J = 9.4$ Hz, 1H, H1), 3.36-3.38 (m, 2H, H4, CH_2CO), 3.39 (d, $J = 9.4$ Hz, 1H, H1), 3.69-3.73 (m, 1H, H6), 4.09 (d, $J = 14.3$ Hz, 1H, CH_2Ph), 4.86 (d, $J = 14.3$ Hz, 1H, CH_2Ph), 7.21-7.28 (m, 3H, ArH), 7.29-7.36 (m, 2H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.4 (t, piperidine-C4), 20.73 (q, NCCH_3), 20.94 (q, NCCH_3), 23.5 (t, C9), 24.4 (t, C8), 27.0 (t, C7), 30.5 (q, COCH_3), 33.3 (t, C10), 34.5 (q, NCCH_3), 34.7 (q, NCCH_3), 40.60 (t, piperidine-C3), 41.0 (t, piperidine-C5), 42.0 (d, C4), 42.2 (t, CH_2CO), 43.4 (s, C5), 46.93 (t, CH_2Ph), 58.0 (t, C1), 59.25 (s, CNO), 61.2 (s, CNO), 86.7 (t, C6), 127.57 (d, CH_{Ar}), 128.5 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 136.6 (s, C_{Ar}), 175.5 (s, C3), 207.2 (s, C=O).



(4*R**,5*S**,6*R**)


Diastereomer **13nC**: ^1H NMR (400 MHz, CDCl_3): δ 0.95-1.07 (m, 2H, H7, H8), 0.99 (s, 3H, NCCH_3), 1.09 (s, 3H, NCCH_3), 1.20 (s, 3H, NCCH_3), 1.22 (s, 3H, NCCH_3), 1.24-1.33 (m, 1H, piperidine-H4), 1.34-1.51 (m, 7H, H7, H8, H9, H10, piperidine-H3, H5), 1.52-1.62 (m, 2H, H10,

piperidine-H4), 1.67-1.75 (m, 1H, H8), 2.32 (s, 3H, COCH₃), 2.49-2.56 (m, 1H, H9), 2.62 (dd, $J = 16.9, 5.9$ Hz, 1H, CH₂CO), 2.92 (t, $J = 6.4$ Hz, 1H, H4), 2.97 (d, $J = 10.3$ Hz, 1H, H1), 3.33 (dd, $J = 16.9, 7.0$ Hz, 1H, CH₂CO), 3.53 (d, $J = 10.3$ Hz, 1H, H1), 3.70 (dd, $J = 11.7, 3.8$ Hz, 1H, H6), 3.71 (d, $J = 14.4$ Hz, 1H, CH₂Ph), 5.23 (d, $J = 14.4$ Hz, 1H, CH₂Ph), 7.20-7.24 (m, 2H, ArH), 7.26-7.36 (m, 3H, ArH); ¹³C NMR (101 MHz, CDCl₃): δ 17.2 (t, piperidine-C4), 20.66 (q, NCCH₃), 20.91 (q, NCCH₃), 23.2 (t, C9), 24.8 (t, C8), 26.3 (t, C7), 31.11 (q, COCH₃), 34.0 (q, NCCH₃), 34.2 (q, NCCH₃), 38.0 (t, C10), 39.3 (t, CH₂CO), 40.57 (t, piperidine-C3), 41.4 (t, piperidine-C5), 45.8 (s, C5), 47.4 (t, CH₂Ph), 48.3 (d, C4), 52.3 (t, C1), 59.33 (s, CNO), 60.8 (s, CNO), 83.6 (d, C6), 127.59 (d, CH_{Ar}), 128.4 (d, CH_{Ar}), 128.80 (d, CH_{Ar}), 136.8 (s, C_{Ar}), 174.9 (s, C3), 208.3 (s, C=O).

(3*R,3*aR**,4*R**,6*aR**)- and (3*S**,3*aR**,4*R**,6*aR**)-1-Benzyl-3-(2-oxopropyl)-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)hexahydrocyclopenta[*b*]pyrrol-2(1*H*)-one (13o):**

Prepared according to the general procedure, yield 265 mg (89%) as a partly separable 4:1 mixture of diastereomers.


[*R*_f (hexanes/EtOAc 1:1) = 0.29]; IR (film); ν [cm⁻¹]: 2971 (w), 2932 (m), 2867 (w), 1717 (m), 1684 (s), 1432 (m), 1359 (m), 1256 (w), 1182 (w), 1166 (w), 1133 (w), 1083 (w), 1029 (w), 962 (m), 740 (w), 700 (m), 646 (w); MS (+ESI) *m/z*, (%): 875 (20, [2*M*+Na⁺]), 449 (10, [*M*+Na⁺]), 427 (100, [*M*+H⁺]); HRMS (+ESI) *m/z* [C₂₆H₃₉N₂O₃⁺]: calcd. 427.2955; found 427.2956.



(3*R**,3*aR**,4*R**,6*aR**)

Major diastereomer **13oA**: ¹H NMR (400 MHz, CDCl₃): δ 1.02 (s, 6H, NCCH₃), 1.10 (s, 3H, NCCH₃), 1.12 (s, 3H, NCCH₃), 1.23-1.34 (m, 1H, piperidine-H4), 1.39-1.46 (m, 4H, piperidine-H3, H5), 1.47-1.54 (m, 1H, piperidine-H4), 1.55-1.61 (m, 1H, H5), 1.62-1.66 (m, 1H, H6), 1.68-1.75 (m, 1H, H6), 1.87-2.00 (m, 1H, H5), 2.19 (s, 3H, COCH₃), 2.46 (td, $J = 6.6, 4.0$ Hz, 1H, H3), 2.58-2.62 (m, 1H, H3a), 2.86 (dd, $J = 17.7, 6.6$ Hz, 1H, CH₂CO), 2.96 (dd, $J = 17.7, 4.0$ Hz, 1H, CH₂CO), 3.86-3.95 (m, 1H, H6a), 3.98 (d, $J = 15.3$ Hz, 1H, CH₂Ph), 4.13-4.18 (m, 1H, H4),


4.93 (d, $J = 15.3$ Hz, 1H, CH_2Ph), 7.27-7.30 (m, 3H, ArH), 7.32-7.36 (m, 2H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.27 (t, piperidine-C4), 20.3 (q, 2C, NCCH_3), 27.9 (t, C6), 29.6 (t, C5), 30.4 (q, CH_3), 34.6 (q, NCCH_3), 35.0 (q, NCCH_3), 40.31 (t, piperidine-C3, C5), 42.8 (d, C3), 45.0 (t, CH_2CO), 45.6 (t, CH_2Ph), 47.9 (d, C3a), 59.5 (s, CNO), 60.1 (s, CNO), 60.5 (d, C6a), 90.6 (d, C4), 127.6 (d, CH_{Ar}), 128.33 (d, CH_{Ar}), 128.7 (d, CH_{Ar}), 136.6 (s, C_{Ar}), 175.3 (s, C2), 206.4 (s, C=O).



(3*S**,3*aR**,4*R**,6*aR**)

Minor diastereomer **13oB**: ^1H NMR (400 MHz, CDCl_3): δ 0.98 (s, 3H, NCCH_3), 1.05 (s, 3H, NCCH_3), 1.06 (s, 3H, NCCH_3), 1.09 (s, 3H, NCCH_3), 1.27-1.33 (m, 1H, piperidine-H4), 1.36-1.47 (m, 4H, piperidine-H3, H5), 1.48-1.56 (m, 1H, piperidine-H4), 1.63-1.71 (m, 2H, H5, H6), 1.73-1.82 (m, 1H, H6), 1.96-2.06 (m, 1H, H5), 2.24 (s, 3H, COCH_3), 2.78 (dd, $J = 18.2, 8.8$ Hz, 1H, CH_2CO), 2.84 (ddd, $J = 10.1, 7.4, 4.6$ Hz, 1H, H3a), 3.07 (dd, $J = 18.2, 4.4$ Hz, 1H, CH_2CO), 3.30 (ddd, $J = 10.1, 8.8, 4.4$ Hz, 1H, H3), 3.82-3.88 (m, 1H, H6a), 3.89 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 4.08 (q, $J = 5.0$ Hz, 1H, H4), 4.97 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 7.17-7.23 (m, 2H, ArH), 7.24-7.35 (m, 3H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 17.30 (t, piperidine-C4), 20.4 (q, NCCH_3), 20.6 (q, NCCH_3), 27.1 (t, C6), 30.0 (t, C5), 30.3 (q, CH_3), 34.46 (q, NCCH_3), 34.52 (q, NCCH_3), 39.3 (d, C3), 40.26 (t, piperidine-C3), 40.33 (t, piperidine-C5), 41.4 (t, CH_2CO), 45.4 (d, C3a), 59.3 (s, CNO), 60.0 (d, C6a), 60.3 (s, CNO), 85.2 (d, C4), 127.7 (d, CH_{Ar}), 128.34 (d, CH_{Ar}), 128.8 (d, CH_{Ar}), 136.4 (s, C_{Ar}), 175.1 (s, C2), 206.6 (s, C=O).


(3*R,4*R**)-1-Allyl-4-(hydroxymethyl)-3-(2-hydroxypropyl)pyrrolidin-2-one (*trans*-14):**



Lactam *trans*-**12b** (100 mg, 0.28 mmol), acetic acid (2 mL), water (1 mL), THF (1 mL), and zinc dust (740 mg, 11.4 mmol) were heated to 60 °C for 2 h. The reaction mixture was diluted with diethyl ether and filtered through a plug of silica gel. The solvent was evaporated, the crude product was dissolved in diethyl ether, washed with brine, dried over MgSO₄, and filtered. The filtrate was evaporated and the crude mixture was purified by column chromatography (gradient, hexanes/EtOAc 1:1 to pure EtOAc) to give 51 mg (82%) *trans*-**14** as an inseparable 1:1 mixture of diastereomers.

[*R*_f (EtOAc/MeOH 40:1) = 0.45]; IR (film); ν [cm⁻¹]: 3371 (br), 2966 (w), 2929 (w), 1659 (s), 1494 (w), 1453 (w), 1419 (w), 1375 (w), 1270 (w), 1135 (w), 1056 (w), 1029 (w), 994 (w), 937 (w), 686 (w), 621 (w); MS (+ESI) *m/z*, (%): 449 (10, [2M+Na⁺]), 236 (100, [M+Na⁺]); HRMS (+ESI) *m/z* [C₁₁H₁₉NO₃Na⁺]: calcd. 236.1257; found 236.1255; ¹H NMR (400 MHz, CDCl₃): δ 1.22 (d, *J* = 6.2 Hz, 6H, CH₃), 1.54-1.63 (m, 1H, CH₂CHOH), 1.64 (ddd, *J* = 14.3, 5.6, 2.7 Hz, 1H, CH₂CHOH), 1.77 (ddd, *J* = 14.4, 9.7, 8.5 Hz, 1H, CH₂CHOH), 1.96 (ddd, *J* = 14.3, 6.3, 3.2 Hz, 1H, CH₂CHOH), 2.19-2.28 (m, 1H, H₄), 2.29-2.39 (m, 1H, H₄), 2.53-2.60 (m, 2H, H₃), 3.08 (dd, *J* = 10.0, 7.0 Hz, 1H, H₅), 3.16 (dd, *J* = 10.0, 7.5 Hz, 1H, H₅), 3.32 (br. s, 4H, OH), 3.40 (dd, *J* = 10.0, 5.7 Hz, 1H, H₅), 3.42 (dd, *J* = 10.0, 5.8 Hz, 1H, H₅), 3.63-3.73 (m, 4H, CH₂OH), 3.85-3.90 (m, 4H, CH₂CH=), 3.93-4.00 (m, 1H, CHOH), 4.06-4.14 (m, 1H, CHOH), 5.14-5.22 (m, 4H, CH=CH₂), 5.63-5.78 (m, 2H, CH=CH₂); ¹³C NMR (101 MHz, CDCl₃): δ 23.6 (q, CH₃), 24.1 (q, CH₃), 40.0 (t, CH₂CHOH), 40.7 (t, CH₂CHOH), 40.9 (d, C₄), 41.0 (d, C₄), 42.6 (d, C₃), 44.1 (d, C₃), 45.6 (t, CH₂CH=), 45.7 (t, CH₂CH=), 48.2 (t, C₅), 48.5 (t, C₅), 63.4 (t, CH₂OH), 64.0 (t, CH₂OH), 67.0 (d, CHOH), 67.2 (d, CHOH), 118.3 (t, CH=CH₂), 118.5 (t, CH=CH₂), 131.9 (d, CH=CH₂), 132.1 (d, CH=CH₂), 176.7 (s, C₂), 177.1 (s, C₂).

((3*R,4*R**)-1-Allyl-3-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)-4-(2-hydroxypropyl)pyrrolidine (*trans*-15):**




Lithium aluminum hydride solution (1 M in THF, 1.7 mL, 1.7 mmol) was added dropwise by syringe to dry THF (4.5 mL). A solution of lactam *trans*-**12b** (200 mg, 0.57 mmol) in dry THF (3 mL) was added dropwise by syringe at 0 °C and the reaction mixture was stirred for 1 h. The reaction was quenched by methanol (2 mL), diluted with ethyl acetate (10 mL), and filtered through a pad of silica gel, which was washed with a fresh portion of ethyl acetate. The filtrate was evaporated and the crude mixture was purified by flash chromatography (gradient, CHCl₃/MeOH 50:1 to 10:1) to give 190 mg (95%) *trans*-**15** as an inseparable 1:1 mixture of diastereomers.

[R_f(EtOAc) = 0.22]; IR (film); ν [cm⁻¹]: 3355 (br), 2967 (m), 2927 (s), 2871 (w), 1470 (w), 1452 (w), 1373 (m), 1359 (m), 1262 (w), 1244 (w), 1208 (w), 1184 (w), 1133 (s), 1046 (s), 994 (m), 955 (m), 923 (m), 874 (m), 788 (w), 715 (w), 645 (w), 605 (w); MS (+ESI) *m/z*, (%): 361 (10, [M+Na⁺]), 339 (100, [M+H⁺]); HRMS (+ESI) *m/z* [C₂₀H₃₉N₂O₂⁺]: calcd. 339.3006; found 339.3006; ¹H NMR (400 MHz, CDCl₃): δ 1.08 (s, 12H, NCCH₃), 1.13 (s, 12H, NCCH₃), 1.18 (d, *J* = 6.4 Hz, 3H, CH₃), 1.20 (d, *J* = 6.4 Hz, 3H, CH₃), 1.26-1.34 (m, 2H, piperidine-H₄), 1.40-1.48 (m, 8H, piperidine-H₃, H₅), 1.49-1.58 (m, 4H, CH₂CHOH, piperidine-H₄), 1.59-1.64 (m, 1H, CH₂CHOH), 1.72 (ddd, *J* = 13.8, 6.0, 3.9 Hz, 1H, CH₂CHOH), 2.15-2.27 (m, 2H, H₃, H₄), 2.28-2.37 (m, 2H, H₃, H₄), 2.47 (dd, *J* = 10.6, 7.3 Hz, 1H, H₅), 2.59 (dd, *J* = 10.0, 8.6 Hz, 1H, H₅), 2.78-2.90 (m, 3H, H₂), 3.05-3.15 (m, 2H, H₂, H₅), 3.19 (dd, *J* = 10.0, 7.7 Hz, 1H, H₅), 3.23-3.41 (m, 4H, CH₂CH=), 3.70-3.84 (m, 4H, CH₂OTMP), 3.85-3.89 (m, 1H, CHOH), 3.90-3.96 (m, 1H, CHOH), 5.22-5.35 (m, 4H, CH=CH₂), 5.54 (br. s, 2H, OH), 5.89-6.08 (m, 2H, CH=CH₂); ¹³C NMR (101 MHz, CDCl₃): δ 17.2 (t, 2C, piperidine-C₄), 20.4 (q, 3C, NCCH₃), 20.5 (q, NCCH₃), 23.9 (q, CH₃), 24.1 (q, CH₃), 33.2 (q, NCCH₃), 33.3 (q, 3C, NCCH₃), 38.2 (d, C₄), 38.6 (d, C₄), 39.79 (t, piperidine-C₃, C₅), 39.83 (t, piperidine-C₃, C₅), 42.0 (d, C₃), 42.9 (d, C₃), 43.1 (t, CH₂CHOH), 43.3 (t, CH₂CHOH), 55.9 (t, C₅), 56.6 (t, C₅), 58.4 (t, 2C, CH₂CH=), 59.1 (t, C₂), 59.3 (t, C₂), 60.1 (s, 4C, CNO), 65.6 (d, CHOH), 66.7 (d, CHOH), 78.1

(t, $\underline{\text{CH}_2\text{OTMP}}$), 78.2 (t, $\underline{\text{CH}_2\text{OTMP}}$), 120.4 (t, $\text{CH}=\underline{\text{CH}_2}$), 121.1 (t, $\text{CH}=\underline{\text{CH}_2}$), 131.5 (d, $\underline{\text{CH}}=\text{CH}_2$), 132.2 (d, $\underline{\text{CH}}=\text{CH}_2$).

(3aR*,4R*,6aR*)-6-Allyl-2-methyl-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)hexahydro-2H-furo[2,3-b]pyrrole (16):




Sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al, 70% solution in toluene, 246 mg, 0.85 mmol) was added dropwise by syringe to a stirred solution of lactam *trans*-**12b** (100 mg, 0.28 mmol) and *t*-BuOK (6.5 mg, 0.06 mmol) in dry THF (2 mL) at $-10\text{ }^{\circ}\text{C}$ and the reaction mixture was stirred at this temperature for 1 h. The reaction was quenched by saturated NH_4Cl solution and diluted with water (5 mL) and diethyl ether (5 mL). The organic layer was separated and the aqueous phase was extracted with diethyl ether ($3 \times 5\text{ mL}$). The combined organic layers were dried over MgSO_4 and filtered. The filtrate was evaporated and the crude product was purified by flash chromatography (gradient, hexanes/EtOAc 50:1 to 20:1) to give 79 mg (83%) **16** as an inseparable 1:1 mixture of diastereomers.

[R_f (hexanes/EtOAc 10:1) = 0.44]; IR (film); ν [cm^{-1}]: 3004 (s), 2930 (s), 2871 (s), 1470 (w), 1448 (w), 1419 (w), 1373 (w), 1359 (w), 1335 (w), 1262 (w), 1245 (w), 1208 (w), 1171 (w), 1133 (w), 1083 (m), 1047 (w), 1013 (w), 994 (w), 957 (w), 918 (w), 859 (w), 710 (w); MS (+ESI) m/z , (%): 359 (15, $[\text{M}+\text{Na}^+]$), 337 (100, $[\text{M}+\text{H}^+]$); HRMS (+ESI) m/z [$\text{C}_{20}\text{H}_{37}\text{N}_2\text{O}_2^+$]: calcd. 337.2850; found 337.2846; ^1H NMR (400 MHz, CDCl_3): δ 1.08 (s, 12H, NCCH_3), 1.13 (s, 6H, NCCH_3), 1.14 (s, 6H, NCCH_3), 1.21-1.29 (m, 1H, H3), 1.24 (d, $J = 6.0\text{ Hz}$, 3H, CH_3), 1.27 (d, $J = 6.1\text{ Hz}$, 3H, CH_3), 1.30-1.35 (m, 2H, piperidine-H4), 1.39-1.46 (m, 8H, piperidine-H3, H5), 1.47-1.52 (m, 2H, piperidine-H4), 1.53 (ddd, $J = 12.2, 10.8, 8.1\text{ Hz}$, 1H, H3), 1.84 (dd, $J = 12.3, 4.5\text{ Hz}$, 1H, H3), 2.03-2.15 (m, 2H, H4), 2.22 (ddd, $J = 12.2, 9.3, 5.8\text{ Hz}$, 1H, H3), 2.35-2.50 (m, 3H, H3a, H5), 2.70 (dd, $J = 9.0, 4.5\text{ Hz}$, 1H, H5), 2.85-3.05 (m, 2H, H5), 3.21-3.53 (m, 4H, $\underline{\text{CH}_2\text{CH=}}$), 3.61-3.76 (m, 4H, $\underline{\text{CH}_2\text{OTMP}}$), 3.80-3.96 (m, 1H, H2), 4.10 (tq, $J = 10.7, 5.9\text{ Hz}$, 1H, H2), 4.82 (d, $J = 4.4\text{ Hz}$, 1H, H6a), 4.83 (d, $J = 3.8\text{ Hz}$, 1H, H6a), 5.04-5.25 (m, 4H, $\text{CH}=\underline{\text{CH}_2}$), 5.81-5.98 (m, 2H, $\underline{\text{CH}}=\text{CH}_2$); ^{13}C NMR (101 MHz, CDCl_3): δ 17.2 (t, 2C, piperidine-C4), 20.26 (q, 4C, $\text{NC}\underline{\text{CH}_3}$), 20.31 (q, CH_3), 20.8 (q, CH_3), 33.3 (q, 4C, $\text{NC}\underline{\text{CH}_3}$), 39.7 (t, 2C,

piperidine-C3), 39.8 (t, 2C, piperidine-C5), 40.5 (t, C3), 40.9 (t, C3), 43.1 (d, C4), 45.0 (d, C4), 46.3 (d, C3a), 46.7 (d, C3a), 52.9 (t, C5), 53.6 (t, $\underline{\text{CH}}_2\text{CH=}$), 54.4 (t, C5), 55.1 (t, $\underline{\text{CH}}_2\text{CH=}$), 59.92 (s, 2C, CNO), 59.94 (s, 2C, CNO), 73.7 (d, C2), 74.5 (d, C2), 78.5 (t, $\underline{\text{CH}}_2\text{OTMP}$), 78.9 (t, $\underline{\text{CH}}_2\text{OTMP}$), 98.9 (d, C6a), 99.1 (d, C6a), 116.4 (t, $\text{CH}=\underline{\text{CH}}_2$), 116.7 (t, $\text{CH}=\underline{\text{CH}}_2$), 136.0 (d, $\underline{\text{CH}}=\text{CH}_2$), 136.5 (d, $\underline{\text{CH}}=\text{CH}_2$).

(3*R,4*R**)-3-(2-Hydroxypropyl)-1-((*E*)-prop-1-en-1-yl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (S15):**




$\text{ClRh}(\text{PPh}_3)_3$ (52 mg, 0.06 mmol) was added to a solution of lactam *trans*-**12b** (250 mg, 0.7 mmol) in dry toluene (1.5 mL). The reaction mixture was heated at 120 °C for 14 h, cooled to room temperature, diluted with diethyl ether (5 mL), and filtered through a pad of silica gel, which was washed with a fresh portion of diethyl ether. The filtrate was evaporated and the crude product **S15** was used in the next step without further purification. Yield 195 mg (78%) as an inseparable 1:1 mixture of diastereomers.

[R_f (hexanes/EtOAc 1:1) = 0.46]; IR (film); ν [cm^{-1}]: 3373 (br), 2971 (m), 2929 (m), 1666 (s), 1454 (w), 1415 (m), 1375 (m), 1359 (w), 1332 (w), 1281 (w), 1244 (w), 1209 (w), 1185 (w), 1133 (w), 1047 (w), 953 (w), 790 (w), 724 (w), 695 (w), 623 (w); MS (+ESI) m/z , (%): 727 (25, [2M+Na⁺]), 375 (100, [M+Na⁺]), 353 (65, [M+H⁺]); HRMS (+ESI) m/z [$\text{C}_{20}\text{H}_{36}\text{N}_2\text{O}_3\text{Na}^+$]: calcd. 375.2618; found 375.2615; ^1H NMR (400 MHz, CDCl_3): δ 1.10 (s, 12H, NCCH_3), 1.14 (s, 6H, NCCH_3), 1.15 (s, 6H, NCCH_3), 1.23 (d, J = 6.4 Hz, 3H, CHOHCH_3), 1.24 (d, J = 6.0 Hz, 3H, CHOHCH_3), 1.29-1.37 (m, 2H, piperidine-H4), 1.40-1.50 (m, 8H, piperidine-H3, H5), 1.51-1.61 (m, 2H, piperidine-H4), 1.65-1.84 (m, 3H, $\underline{\text{CH}}_2\text{CHOH}$), 1.73 (d, J = 7.3 Hz, 6H, $\underline{\text{CH}}_3\text{CH=}$), 1.91 (ddd, J = 14.7, 8.1, 3.4 Hz, 1H, $\underline{\text{CH}}_2\text{CHOH}$), 2.24-2.35 (m, 1H, H4), 2.37-2.48 (m, 1H, H4), 2.64 (dt, J = 9.4, 3.5 Hz, 1H, H3), 2.69 (dt, J = 10.2, 5.8 Hz, 1H, H3), 3.24 (dd, J = 10.0, 6.4 Hz, 1H, H5), 3.25 (dd, J = 10.2, 8.0 Hz, 1H, H5), 3.60 (dd, J = 10.2, 3.2 Hz, 1H, H5), 3.62 (dd, J = 10.0, 3.3 Hz, 1H, H5), 3.82 (dd, J = 17.0, 6.2 Hz, 2H, $\underline{\text{CH}}_2\text{OTMP}$), 3.88 (dd, J = 17.0, 5.7 Hz, 2H, $\underline{\text{CH}}_2\text{OTMP}$), 3.92-4.02 (m, 1H, $\underline{\text{CHOH}}$), 4.06-4.14 (m, 1H, $\underline{\text{CHOH}}$), 5.02 (dq, J = 14.2, 7.3 Hz,

2H, CH₃CH=), 5.25 (br. s, 2H, OH), 6.85 (d, *J* = 14.2 Hz, 2H, CH=CHCH₃); ¹³C NMR (101 MHz, CDCl₃): δ 15.32 (q, CH₃CH=), 15.34 (q, CH₃CH=), 17.2 (t, 2C, piperidine-C4), 20.4 (q, 4C, NCCH₃), 23.26 (q, CHOHCH₃), 23.30 (q, CHOHCH₃), 33.2 (q, NCCH₃), 33.4 (q, 3C, NCCH₃), 37.6 (d, C4), 38.5 (d, C4), 39.5 (t, CH₂CHOH), 39.76 (t, piperidine-C3, C5), 39.82 (t, piperidine-C3, C5), 40.7 (t, CH₂CHOH), 42.9 (d, C3), 45.9 (d, C3), 47.3 (t, C5), 47.4 (t, C5), 60.17 (s, 2C, CNO), 60.19 (s, 2C, CNO), 66.1 (d, CHOH), 68.0 (d, CHOH), 76.9 (t, CH₂OTMP), 77.6 (t, CH₂OTMP), 107.9 (d, CH₃CH=), 108.4 (d, CH₃CH=), 124.2 (d, CH=CHCH₃), 124.4 (d, CH=CHCH₃), 174.8 (s, C2), 175.3 (s, C2).

(3*R,4*R**)-3-(2-Hydroxypropyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (*trans*-17):**



OsO₄ (2.5% solution in *t*-BuOH, 380 mg, 0.04 mmol) was added by syringe to a stirred solution of lactam **S15** (195 mg, 0.55 mmol) in THF (3 mL) at room temperature. After 5 min, a solution of NaIO₄ (179 mg, 0.88 mmol) in water (5 mL) was added by syringe and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (5 mL) and dichloromethane (10 mL). The organic layer was separated and the aqueous was extracted with dichloromethane (3 × 5 mL). The combined organic layers were dried over MgSO₄ and filtered. The filtrate was evaporated and the crude product was purified by flash chromatography (gradient, CHCl₃/MeOH 30:1 to 5:1) to give 130 mg (80%) *trans*-17 as an inseparable 1:1 mixture of diastereomers.


[*R*_f(EtOAc) = 0.26]; IR (film); ν [cm⁻¹]: 3344 (br), 2972 (m), 2929 (s), 1669 (s), 1487 (w), 1436 (m), 1374 (m), 1360 (m), 1261 (m), 1208 (w), 1133 (m), 994 (m), 938 (w), 793 (w), 719 (w), 690 (w), 624 (w); MS (+ESI) *m/z*, (%): 335 (100, [M+Na⁺]), 313 (35, [M+H⁺]); HRMS (+ESI) *m/z* [C₁₇H₃N₂O₃Na⁺]: calcd. 335.2305; found 335.2305; ¹H NMR (400 MHz, CDCl₃): δ 1.08 (s, 12H, NCCH₃), 1.14 (s, 12H, NCCH₃), 1.21 (d, *J* = 6.7 Hz, 6H, CH₃), 1.28-1.36 (m, 2H, piperidine-H4), 1.41-1.48 (m, 8H, piperidine-H3, H5), 1.49-1.59 (m, 2H, piperidine-H4), 1.60-1.74 (m, 2H, CH₂CHOH), 1.75-1.83 (m, 1H, CH₂CHOH), 1.84-1.94 (m, 1H, CH₂CHOH), 2.19-2.35 (m, 2H, H4), 2.53-2.67 (m, 2H, H3), 3.35-3.42 (m, 2H, H5), 3.60-3.68 (m, 2H, H5), 3.78-3.87 (m, 4H, CH₂OTMP), 3.92-4.00 (m, 2H, CHOH), 4.82 (br. s, 1H, OH), 4.85 (br. s, 1H, OH), 5.34 (br. s,

1H, NH), 5.40 (br. s, 1H, NH); ¹³C NMR (101 MHz, CDCl₃): δ 17.1 (t, 2C, piperidine-C4), 20.4 (br. q, 4C, NCCH₃), 24.2 (q, CHOHCH₃), 24.3 (q, CHOHCH₃), 33.2 (q, 2C, NCCH₃), 33.3 (q, 2C, NCCH₃), 39.1 (d, C4), 39.4 (d, C4), 39.7 (t, piperidine-C3, C5), 39.8 (t, piperidine-C3, C5), 40.2 (t, CH₂CHOH), 40.4 (t, CH₂CHOH), 46.2 (d, C3), 46.5 (d, C3), 46.9 (t, C5), 47.3 (t, C5), 60.1 (s, 4C, CNO), 67.5 (d, CHOH), 68.1 (d, CHOH), 76.6 (t, CH₂OTMP), 76.8 (t, CH₂OTMP), 178.7 (s, C2), 179.4 (s, C2).

(3*R,3*aR**,6*aR**)- and (3*S**,3*aR**,6*aR**)-1-Benzyl-3-(2-hydroxypropyl)hexahydrocyclopenta[*b*]pyrrole-2,4-dione (18):**


mCPBA (75 mg, 0.30 mmol) was added to a solution of lactam **12o** (100 mg, 0.23 mmol) in dry DCM (5 mL) at 0 °C under an argon atmosphere. The reaction mixture was stirred for 15 min and saturated Na₂SO₃ solution (5 mL) was added. The organic layer was separated and the aqueous phase was extracted with dichloromethane (3 × 5 mL). The combined organic layers were dried over MgSO₄ and filtered. The filtrate was evaporated and the crude product was purified by flash chromatography (gradient, hexane/EtOAc 3:1 to 1:4) to give 54 mg (81%) **18** as an inseparable 4:4:1:1 mixture of diastereomers.

[R_f(EtOAc) = 0.45]; IR (film); ν [cm⁻¹]: 3414 (br), 2965 (w), 2928 (w), 1741 (s), 1667 (s), 1440 (m), 1358 (w), 1344 (w), 1313 (w), 1264 (w), 1204 (w), 1182 (w), 1150 (w), 1132 (w), 1083 (w), 1056 (w), 1007 (w), 949 (w), 732 (w), 705 (m), 669 (w); MS (+ESI) m/z, (%): 310 (100, [M+Na⁺]), 288 (40, [M+H⁺]); HRMS (+ESI) m/z [C₁₇H₂₁NO₃Na⁺]: calcd. 310.1414; found 310.1411.



(3*R**,3*aR**,6*aR**)

Major diastereomers **18A**: ^1H NMR (400 MHz, CDCl_3): δ 1.25 (d, $J = 6.2$ Hz, 3H, CH_3), 1.27 (d, $J = 6.2$ Hz, 3H, CH_3), 1.60-1.74 (m, 2H, CH_2CHOH), 1.76-1.88 (m, 4H, CH_2CHOH), 1.95-2.09 (m, 4H, H6), 2.17-2.33 (m, 4H, H5), 2.55 (dd, $J = 7.3, 3.7$ Hz, 1H, H3a), 2.73-2.85 (m, 3H, H3, H3a), 4.00-4.11 (m, 2H, CHOH), 4.12-4.17 (m, 2H, H6a), 4.18 (d, $J = 14.9$ Hz, 1H, CH_2Ph), 4.20 (d, $J = 14.9$ Hz, 1H, CH_2Ph), 4.84 (d, $J = 14.9$ Hz, 1H, CH_2Ph), 4.86 (d, $J = 14.9$ Hz, 1H, CH_2Ph), 7.21-7.27 (m, 4H, ArH), 7.28-7.39 (m, 6H, ArH); ^{13}C NMR (101 MHz, CDCl_3): δ 23.6 (q, CH_3), 23.8 (q, CH_3), 25.3 (t, 2C, C6), 35.7 (t, C5), 35.8 (t, C5), 40.83 (t, CH_2CHOH), 41.8 (t, CH_2CHOH), 43.4 (d, C3), 44.2 (d, C3), 45.07 (t, CH_2Ph), 45.11 (t, CH_2Ph), 50.7 (d, C3a), 51.3 (d, C3a), 58.48 (d, C6a), 58.53 (d, C6a), 66.9 (d, CHOH), 67.1 (d, CHOH), 128.0 (d, CH_{Ar}), 128.1 (d, CH_{Ar}), 128.2 (d, CH_{Ar}), 128.27 (d, CH_{Ar}), 129.0 (d, CH_{Ar}), 129.1 (d, CH_{Ar}), 135.9 (s, C_{Ar}), 136.13 (s, C_{Ar}), 175.84 (s, C2), 176.58 (s, C2), 217.38 (s, C4), 218.28 (s, C4).



(3*S**,3*aR**,6*aR**)

Minor diastereomers **18B**: ^1H NMR (400 MHz, CDCl_3 , detectable signals): δ 1.21 (d, $J = 6.2$ Hz, 3H, CH_3), 1.24 (d, $J = 6.1$ Hz, 3H, CH_3), 1.44-1.54 (m, 2H, CH_2CHOH), 2.33-2.53 (m, 2H, H3), 2.89-2.97 (m, 1H, H3a), 3.54-3.62 (m, 1H, CHOH), 3.89-3.99 (m, 1H, CHOH), 4.85 (d, $J = 14.7$ Hz, 1H, CH_2Ph), 4.95 (d, $J = 15.0$ Hz, 1H, CH_2Ph); ^{13}C NMR (101 MHz, CDCl_3): δ 21.8 (q, CH_3), 22.3 (q, CH_3), 26.1 (t, C6), 27.8 (t, C6), 29.2 (t, C5), 29.5 (t, C5), 36.9 (d, C3), 39.0 (d, C3), 40.2 (t, 2C, CH_2CHOH), 40.77 (d, C3a), 41.1 (d, C3a), 44.7 (t, CH_2Ph), 44.8 (t, CH_2Ph), 60.2 (d, C6a), 61.5 (d, C6a), 64.8 (d, CHOH), 66.4 (d, CHOH), 127.7 (d, CH_{Ar}), 127.8 (d, CH_{Ar}),


128.32 (d, CH_{Ar}), 128.4 (d, CH_{Ar}), 128.8 (d, CH_{Ar}), 128.9 (d, CH_{Ar}), 136.0 (s, C_{Ar}), 136.10 (s, C_{Ar}), 175.80 (s, C2), 176.56 (s, C2), 217.39 (s, C4), 218.27 (s, C4).

Preparation of the hydrochloride adduct of S13 and 13n

Compound **S13** or **13n** (0.5 mmol) was dissolved in a round-bottomed flask in diethyl ether (5 mL). The solution was cooled to 0 °C and HCl solution (0.5 mL, 1.0 mmol, 2 M in Et₂O) was added dropwise. The mixture was stirred for 10 min when a white precipitate formed. The solvent was removed carefully under reduced pressure to give a quantitative yield of the HCl salt as an off-white solid. The solid salt **S13·HCl** was crystallized from MTBE with a few drops of CHCl₃ and salt **13nA·HCl** was crystallized from hexane with a few drops of DCM to give crystals suitable for X-ray analysis. After X-ray analysis, the crystal of **S13·HCl** was redissolved in CDCl₃ and the ¹H NMR spectrum was recorded. The comparison of the ¹H NMR spectrum of the crystal and the ¹H NMR spectrum of the diastereomeric mixture of the salt **S13·HCl** showed that the measured crystal was a crystal of the major diastereomer (see section ¹H and ¹³C NMR spectra, p. S202).


1-(((2*R*,4*S*)- and (2*R*,4*S*)-1-(Allyl((*S*)-1-(naphthalen-2-yl)ethyl)amino)-4-hydroxy-1-oxopentan-2-yl)oxy)-2,2,6,6-tetramethylpiperidin-1-ium chloride (S13·HCl):

IR (film); ν [cm⁻¹]: 3550-3250 (br), 2945 (w), 2926 (w), 2500-2000 (br), 1631 (m), 1507 (w), 1451 (w), 1418 (w), 1378 (w), 1362 (w), 1321 (w), 1242 (w), 1182 (w), 1128 (w), 1091 (w), 958 (m), 908 (w), 727 (s), 644 (w); MS (+ESI) *m/z*, (%): 467 (100, [M-HCl+H⁺]); HRMS (+ESI) *m/z* [C₂₉H₄₃N₂O₃⁺]: calcd. 467.3268; found 467.3269.



(2R,4S)

Major diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 1.21/1.25 (d, $J = 6.2$ Hz, 3H, CH_3CHOH), 1.46 (s, 6H, NCCH_3), 1.47 (s, 6H, NCCH_3), 1.58-1.77 (m, 6H, piperidine-H3, H4, H5), 1.64/1.68 (d, $J = 7.0$ Hz, 3H, ArCHCH_3), 2.23-2.29 (m, 1H, CH_2CHOTMP), 2.30-2.58 (m, 2H, OH, CH_2CHOTMP), 3.66/3.81 (dd, $J = 15.1, 6.7$ Hz/ $J = 15.8, 3.2$ Hz, 1H, $\text{CH}_2\text{CH=}$), 4.16-4.22/4.25-4.30 (m, 1H, CHOH), 4.31-4.40 (m, 1H, $\text{CH}_2\text{CH=}$), 4.92-5.16 (m, 2H, CH=CH_2), 5.24-5.51 (m, 1H, CH=CH_2), 6.03/6.12 (q, $J = 7.0/J = 7.2$ Hz, 1H, ArCHCH_3), 6.15-6.20/6.25-6.33 (m, 1H, CHOTMP), 7.32-7.54 (m, 3H, ArH), 7.76-7.87 (m, 4H, ArH), 13.54/13.63 (br. s, 1H, NH); ^{13}C NMR (101 MHz, CDCl_3): δ 15.86/15.91 (t, piperidine-C4), 15.89/17.1 (q, ArCHCH_3), 21.26 (q, NCCH_3), 21.29 (q, NCCH_3), 22.9/24.2 (q, CH_3CHOH), 28.5 (q, NCCH_3), 29.0 (q, NCCH_3), 37.4 (t, piperidine-C3, C5), 42.1 (t, CH_2CHOTMP), 46.5/46.59 (t, $\text{CH}_2\text{CH=}$), 52.8/53.2 (d, ArCHCH_3), 59.7 (s, CNO), 60.2 (s, CNO), 62.3/63.5 (d, CHOH), 79.1/81.2 (d, CHOTMP), 117.8/118.4 (t, CH=CH_2), 124.7/125.3 (d, CH_{Ar}), 126.27/126.32 (d, CH_{Ar}), 126.4/126.47 (d, CH_{Ar}), 126.52/126.87 (d, CH_{Ar}), 127.7/127.8 (d, CH_{Ar}), 128.14/128.2 (d, CH_{Ar}), 128.4/128.6 (d, CH_{Ar}), 132.9/133.0 (s, C_{Ar}), 133.27/133.31 (s, C_{Ar}), 134.0/134.4 (d, CH=CH_2), 137.5 (s, C_{Ar}), 173.6/175.1 (s, C=O).



(2S,4S)

Minor diastereomer: ^1H NMR (400 MHz, CDCl_3): δ 1.00 (d, $J = 6.3$ Hz, 3H, CH_3CHOH), 1.49 (s, 6H, NCCH_3), 1.51 (s, 3H, NCCH_3), 1.53 (s, 3H, NCCH_3), 1.58-1.77 (m, 7H, OH, piperidine-H3, H4, H5), 1.79/1.94 (d, $J = 6.8$ Hz, 3H, ArCHCH_3), 1.84-2.00 (m, 2H, CH_2CHOTMP), 2.30-2.58 (m, 1H, OH), 3.93-4.00 (m, 1H, $\text{CH}_2\text{CH=}$), 4.08-4.15 (m, 1H, CHOH), 4.62-4.71 (m, 1H,

$\text{CH}_2\text{CH=}$), 4.92-5.16 (m, 2H, CH=CH_2), 5.24-5.51 (m, 1H, CH=CH_2), 5.66-5.85 (m, 1H, ArCHCH_3), 6.60-6.65 (m, 1H, CHOTMP), 7.32-7.54 (m, 3H, ArH), 7.76-7.87 (m, 4H, ArH), 13.77 (br. s, 1H, NH); ^{13}C NMR (101 MHz, CDCl_3): δ 16.0 (t, piperidine-C4), 20.5 (q, ArCHCH_3), 21.1 (q, 2C, NCCH_3), 22.6 (q, CH_3CHOH), 29.2 (q, NCCH_3), 29.3 (q, NCCH_3), 37.9 (t, piperidine-C3, C5), 43.6 (t, CH_2CHOTMP), 46.62 (t, $\text{CH}_2\text{CH=}$), 55.7 (d, ArCHCH_3), 59.7 (s, CNO), 60.2 (s, CNO), 64.0 (d, CHOH), 81.3 (d, CHOTMP), 119.8 (t, CH=CH_2), 125.1 (d, CH_{Ar}), 126.2 (d, CH_{Ar}), 126.7 (d, CH_{Ar}), 126.90 (d, CH_{Ar}), 127.9 (d, CH_{Ar}), 128.07 (d, CH_{Ar}), 128.8 (d, CH_{Ar}), 132.7 (s, C_{Ar}), 133.4 (s, C_{Ar}), 136.9 (d, CH=CH_2), 138.3 (s, C_{Ar}), 175.6 (s, C=O).

2. X-Ray crystallography

The crystallographic data for **12k**, **13j**, **13nA·HCl**, and **S13·HCl** were collected on a Bruker D8 VENTURE Kappa Duo diffractometer equipped with a PHOTON III detector, and an X-ray source I μ S micro-focus sealed tube using CuK α (λ = 1.54178 Å) radiation at a temperature 120(2) K. The structures were solved by direct methods (XT)^{12a} and refined by full matrix least squares based on F^2 (SHELXL2018).^{12b} The hydrogen atoms on carbon were fixed into idealized positions (riding model) and assigned temperature factors either $H_{iso}(H) = 1.2 U_{eq}(\text{pivot atom})$ or $H_{iso}(H) = 1.5 U_{eq}(\text{pivot atom})$ for methyl groups. The hydrogen atoms of –N-H groups were found on the difference Fourier maps and refined under rigid body assumption with assigned temperature factors $H_{iso}(H) = 1.2 U_{eq}(\text{pivot atom})$. The absolute configuration for compounds **12k**, **13j**, and **S13·HCl** was confirmed by anomalous scattering of N and O and Cl atoms. The crystallographic data are summarized in Table S1.

Table S1: Crystallographic data, data collection, and structure refinement parameters for compounds **S13·HCl**, **12k**, **13j**, and **13nA·HCl**.

Compound	S13·HCl	12k	13j	13nA·HCl
CCDC entry	2040885	2040886	2040887	2040888
Formula	C ₃₀ H ₄₄ Cl ₄ N ₂ O ₃	C ₁₈ H ₂₅ NO ₂	C ₂₉ H ₄₀ N ₂ O ₃	C ₂₈ H ₄₃ ClN ₂ O ₃
<i>M</i> (g mol ⁻¹)	622.47	287.39	464.63	491.09
Crystal size (mm)	0.22 × 0.14 × 0.097	0.42 × 0.24 × 0.17	0.29 × 0.055 × 0.048	0.29 × 0.11 × 0.076
Crystal system	orthorhombic	monoclinic	monoclinic	monoclinic
Space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁	<i>C</i> 2	<i>P</i> 2 ₁ / <i>c</i>
<i>a</i> (Å)	8.4685(4)	10.9324(8)	21.9325(9)	11.4050(4)
<i>b</i> (Å)	12.8323(7)	5.7722(4)	6.0099(3)	21.9241(8)
<i>c</i> (Å)	30.4621(16)	13.1448(9)	22.1042(10)	11.7015(4)
<i>α</i> (°)	90	90	90	90
<i>β</i> (°)	90	93.122(2)	114.102(2)	113.5230(10)
<i>γ</i> (°)	90	90	90	90
<i>V</i> (Å ³)	3310.3(3)	828.26(10)	2659.6(2)	2682.75(16)
<i>Z</i>	4	2	4	4
<i>D</i> _{calc} (mg m ⁻³)	1.249	1.152	1.160	1.216
<i>μ</i> (Mo Kα) (mm ⁻¹)	3.497	0.58	0.59	1.50
2θ(max) (°)	72.4	72.2	72.1	72.2
Number of reflections	34067	14442	14851	45024
Unique reflections / <i>R</i> _{int} ^a	6521/0.044	3177/0.021	5107/0.044	5275/0.034
<i>R</i> 1 (<i>F</i> ² > 2σ(<i>F</i>)) ^b	0.037	0.030	0.042	0.036
w <i>R</i> 2 ^c	0.094	0.076	0.114	0.097
<i>GOF</i> ^d	1.05	1.06	1.05	1.03
min/max Δρ(e Å ⁻³)	-0.44/0.49	-0.12/0.23	-0.19/0.17	-0.23/0.34
Flack parameter	0.015(5)	0.06(5)	-0.1(2)	-

^a *R*_{int} = Σ|*F*_o² - *F*_o²_{mean}|/Σ*F*_o², ^b *R*(*F*) = Σ||*F*_o|| - ||*F*_c||/Σ||*F*_o||, ^c w*R*(*F*²) = [Σ(w(*F*_o² - *F*_c²)²)/Σ(*F*_o²)²]^{1/2},

weighting scheme: *w* = [σ²(*F*_o²) + (*w*₁*P*)² + *w*₂*P*²]⁻¹, where *P* = [max(*F*_o², 0) + 2*F*_c²]^{1/3},


^d *S* = [Σ(w(*F*_o² - *F*_c²)²)/N_{diffs} - N_{params}]^{1/2}.

3. References



1. L. J. Peterson, J. Luo, J. P. Wolfe, *Org. Lett.* **2017**, *19*, 2817-2820.
2. F. Xu, S. A. Shuler, D. A. Watson, *Angew. Chem. Int. Ed.* **2018**, *57*, 12081-12085.
3. S. Kerres, E. Plut, S. Malcherek, J. Rehbein, O. Reiser, *Adv. Synth. Catal.* **2019**, *361*, 1400-1407.
4. M. T. Flynn, R. Stott, V. L. Blair, P. C. Andrews, *Organometallics* **2016**, *35*, 2707-2714.
5. J. Balsells, A. Moyano, A. Riera, M. A. Pericas, *Org. Lett.* **1999**, *1*, 1981-1984.
6. D. Just, D. Hernandez-Guerra, S. Kritsch, R. Pohl, I. Císařová, P. G. Jones, R. Mackman, G. Bahador, U. Jahn, *Eur. J. Org. Chem.* **2018**, 5213-5221.
7. S. Krompiec, M. Pigulla, N. Kuznik, M. Krompiec, B. Marciniec, D. Chadyniak, J. Kasperczyk, *J. Mol. Catal. A: Chem.* **2005**, *225*, 91-101.
8. N. Ohmura, A. Nakamura, A. Hamasaki, M. Tokunaga, *Eur. J. Org. Chem.* **2008**, 5042-5045.
9. R. Tamura, L. S. Hegedus, *J. Am. Chem. Soc.* **1982**, *104*, 3727-3729.
10. A. L. Bartuschat, K. Wicht, M. R. Heinrich, *Angew. Chem. Int. Ed.* **2015**, *54*, 10294-10298.
11. M. K. Klychnikov, R. Pohl, I. Císařová, U. Jahn, *Eur. J. Org. Chem.* **2020**, 2854–2866
12. a) SHELXT: G. M. Sheldrick, *Acta Cryst.* **2015**, *A71*, 3-8; b) SHELXT: G. M. Sheldrick, *Acta Cryst.* **2015**, *C71*, 3-8.

4. ^1H and ^{13}C NMR spectra



(S)-N-Allyl-N-(1-(naphthalen-2-yl)ethyl)amine (S10)





***N*-Benzyl-*N*-(cyclopent-1-en-1-ylmethyl)amine (S11)**





(S)-3-Methyl-N-(1-phenylethyl)but-2-en-1-amine (S12)





***N*-Benzyl-*N*-(2-methylallyl)acetamide (11c)**





***N*-Benzyl-*N*-(3-methylbut-2-en-1-yl)acetamide (11d)**





(S)-N-Allyl-N-(1-phenylethyl)acetamide (11e)





(S)-N-Allyl-N-(1-(naphthalen-2-yl)ethyl)acetamide (11f)




(S)-N-(3-Methylbut-2-en-1-yl)-N-(1-phenylethyl)acetamide (11g)





(S)-N-(2-Methylallyl)-N-(1-phenylethyl)acetamide (11h)





(S)-N-(Cyclopent-1-en-1-ylmethyl)-N-(1-phenylethyl)acetamide (11i)





N-Benzyl-N-(cyclopent-1-en-1-ylmethyl)acetamide (11j)



***N*-Benzyl-*N*-(cyclohex-1-en-1-ylmethyl)acetamide (11k)**



***N*-Benzyl-*N*-(cyclopent-2-en-1-yl)acetamide (11l)**





CC(=O)N[C@H](Cc1ccccc1)c2ccccc2



¹H NMR spectrum (CDCl₃) of (S)-1-(benzyl(phenyl)amino)ethan-1-one. The spectrum displays peaks from -1.37 to 7.37 ppm. Key features include a carbonyl singlet at 2.00 ppm, aromatic signals between 7.2 and 7.4 ppm, a methine doublet at 4.5 ppm, a methylene doublet at 2.8 ppm, and a benzyl multiplet at 1.5 ppm. Integration values are provided below the baseline.





***N,N*-Diallyl-2-(trimethylsilyl)acetamide (8a)**



***N*-Allyl-*N*-methyl-2-(trimethylsilyl)acetamide (8b)**



***N*-Benzyl-*N*-(2-methylallyl)-2-(trimethylsilyl)acetamide (8c)**





Chemical structure of N-benzyl-N-(2-methylbut-3-en-1-yl)benzamide is shown. The structure consists of a benzamide core where the nitrogen is substituted with a benzyl group and a 2-methylbut-3-en-1-yl group.

The ^1H NMR spectrum (400 MHz, CDCl_3) displays the following peaks and integrations:



- Aromatic region (7.2-7.4 ppm): Multiple peaks with integrations 2.04, 2.66, 4.08, and 2.07.
- Vinyl region (4.7-5.1 ppm): Peaks with integrations 1.10 and 1.26.
- Allylic region (3.7-4.1 ppm): Peaks with integrations 2.74, 2.00, 2.00, and 2.75.
- Aliphatic region (1.4-2.1 ppm): Peaks with integrations 2.65, 2.09, 4.32, 3.10, 4.09, and 3.08.
- Dimethylsilane (DMS) peak at 0.1 ppm: Integration 11.30.
- Reference peak at 0 ppm: Integration 8.71.




(S)-N-Allyl-N-(1-phenylethyl)-2-(trimethylsilyl)acetamide (8e)



(S)-N-Allyl-N-(1-(naphthalen-2-yl)ethyl)-2-(trimethylsilyl)acetamide (8f)



(S)-N-(3-Methylbut-2-en-1-yl)-N-(1-phenylethyl)-2-(trimethylsilyl)acetamide (8g)





Chemical structure: CC(C)=CCN(C(=O)C[Si](C)(C)C)C(C)C1=CC=CC=C1

¹H NMR spectrum (CDCl₃) showing peaks and integration values:



Chemical Shift (ppm)	Integration
7.26	29.27
6.14	3.85
4.79	10.3
3.51	0.90
1.61	10.8
0.11	2.95, 3.89, 1.00



(S)-N-(Cyclopent-1-en-1-ylmethyl)-N-(1-phenylethyl)-2-(trimethylsilyl)acetamide (8i)



***N*-Benzyl-*N*-(cyclopent-1-en-1-ylmethyl)-2-(trimethylsilyl)acetamide (8j)**





Chemical structure: CC(C)(C)C(=O)N(Cc1ccccc1)Cc2ccccc2

¹H NMR spectrum (400 MHz, CDCl₃) data:



Chemical Shift (ppm)	Integration
7.1 - 7.4 (m)	2.08, 3.68, 4.44, 1.97
5.4 (m)	1.50, 1.00
4.4 (d)	3.02, 2.02
3.6 (d)	1.98
3.5 (s)	2.99
1.5 - 2.1 (m)	10.12, 2.05, 3.03, 10.31
0.1 (s)	8.74, 13.25





***N*-Benzyl-*N*-(cyclopent-2-en-1-yl)-2-(trimethylsilyl)acetamide (8l)**





(R)-N-Benzyl-N-(cyclohex-2-en-1-yl)-2-(trimethylsilyl)acetamide (8m)




***N,N*-Diallyl-4-methyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-
((trimethylsilyl)oxy)pentanamide (9a)**





***N,N*-Diallyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide
(9b)**





***N,N*-Diallyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)octanamide (9c)**





***N,N*-Diallyl-4-phenyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-
((trimethylsilyl)oxy)butanamide (9d)**





***N*-Allyl-*N*-methyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-
((trimethylsilyl)oxy)pentanamide (9e)**





***N*-Benzyl-*N*-(2-methylallyl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9f)**



***N*-Benzyl-*N*-(3-methylbut-2-en-1-yl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9g)**



(4S)-N,N-Diallyl-5-(benzyloxy)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9h)



[illegible]

Chemical structure of the major diastereomer (2R,4S) and the minor diastereomer (2S,4S) are shown. The major diastereomer (2R,4S) is the top structure, and the minor diastereomer (2S,4S) is the bottom structure. The ¹H NMR spectrum (400 MHz, CDCl₃) is displayed below the structures, showing peaks from 0.00 to 7.94 ppm. The spectrum includes integration values and peak lists.

Major diastereomer (2R,4S)

Minor diastereomer (2S,4S)



1H NMR Spectrum (400 MHz, CDCl₃)

Chemical shift (ppm): 7.94, 7.83, 7.83, 7.83, 7.82, 7.81, 7.80, 7.79, 7.78, 7.75, 7.74, 7.52, 7.50, 7.50, 7.49, 7.48, 7.47, 7.47, 7.46, 7.46, 7.45, 7.40, 7.40, 7.38, 7.38, 5.13, 5.12, 5.09, 4.96, 4.93, 4.93, 4.93, 4.91, 4.88, 4.88, 4.88, 4.86, 4.66, 4.64, 4.63, 3.95, 3.94, 3.93, 3.93, 2.09, 2.07, 2.07, 2.06, 2.06, 2.06, 2.04, 2.04, 2.00, 2.00, 1.83, 1.83, 1.81, 1.78, 1.76, 1.62, 1.52, 1.23, 1.17, 1.14, 1.11, 1.04, 0.13, 0.09, 0.00, 0.03.

Integration values: 12.52, 8.87, 2.24, 3.41, 1.97, 4.54, 1.00, 1.95, 4.25, 1.38, 1.63, 0.37, 0.34, 3.77, 3.21, 0.78, 6.63, 21.31, 49.75, 12.61, 12.75.





(2*R*,4*S*)- and (2*S*,4*S*)-*N*-Allyl-4-hydroxy-*N*-((*S*)-1-(naphthalen-2-yl)ethyl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)pentanamide (S13)




[illegible]



(*R)- and (*S**)-*N,N*-Diallyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-((1*R**,2*S**)-2-((trimethylsilyl)oxy)cyclohexyl)acetamide (9l)**




***N,N*-Diallyl-2-((1*R**,2*S**)-2-((trimethylsilyl)oxy)cyclohexyl)acetamide (S14)**




***N*-Benzyl-*N*-(cyclopent-1-en-1-ylmethyl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9m)**





[illegible]



***N*-Benzyl-*N*-((*R*)-cyclohex-2-en-1-yl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-4-((trimethylsilyl)oxy)pentanamide (9p)**



(3*R,4*R**)- and (3*S**,4*R**)-1-Allyl-3-(2-hydroxy-2-methylpropyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12a).** Spectral data for compound *trans*-12a are identical, only signals of the major diastereomers are more intense.



Chemical structure of (3*R**,4*R**)-2-(2,2,6,6-tetramethyl-1,3-dioxane-5-yloxy)-N-(3-methylbut-3-en-1-yl)pyrrolidine-2-carboxamide is shown. The structure is labeled as (3*R**,4*R**) and Major diastereomers.



Chemical structure of (3*S**,4*R**)-2-(2,2,6,6-tetramethyl-1,3-dioxane-5-yloxy)-N-(3-methylbut-3-en-1-yl)pyrrolidine-2-carboxamide is shown. The structure is labeled as (3*S**,4*R**) and Minor diastereomers.

¹H NMR spectrum (CDCl₃) showing peaks from 1.08 to 7.26 ppm. The spectrum is labeled with chemical shifts (ppm) and integrations.





(3*R,4*R**)-** and **(3*S**,4*R**)-1-Allyl-3-(2-hydroxy-2-phenylethyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12d).** Spectral data for compound *trans*-12d are identical, only signals of the major diastereomers are more intense.





Chemical structures of the diastereomers are shown on the left. The major diastereomer is (3R*,4R*) and the minor diastereomer is (3S*,4R*). The ¹H NMR spectrum is displayed on the right, showing peaks from 0 to 11 ppm. The spectrum includes chemical structures, peak assignments, and integration values.

Chemical structures of the diastereomers are shown on the left. The major diastereomer is (3R*,4R*) and the minor diastereomer is (3S*,4R*). The ¹H NMR spectrum is displayed on the right, showing peaks from 0 to 11 ppm. The spectrum includes chemical structures, peak assignments, and integration values.



(3*R,4*R**)- and (3*S**,4*R**)-1-Benzyl-3-(2-hydroxypropyl)-4-methyl-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12f)**



(3*R,4*S**)**
Major diastereomers

(3*S,4*S**)**
Minor diastereomers


1H NMR spectrum (400 MHz, CDCl₃) of (3*R**,4*S**)-1-methyl-1-phenyl-2-oxo-2-(2-methylbutan-3-yl)pyrrolidine. The spectrum shows peaks from 1.0 to 7.5 ppm. The x-axis is labeled 'f1 (ppm)' with values from 10.5 to -1.0. The y-axis is labeled 'intensity' with values from 0 to 10000. The spectrum is divided into two regions: 'Major diastereomers' (3*R**,4*S**) and 'Minor diastereomers' (3*S**,4*S**). The major diastereomers region shows a large peak at 7.3 ppm (integration 35.14) and a smaller peak at 7.1 ppm (integration 1.79). The minor diastereomers region shows a large peak at 7.3 ppm (integration 1.06) and a smaller peak at 7.1 ppm (integration 1.05). The spectrum also shows peaks at 5.5 ppm (integration 1.79), 4.5 ppm (integration 1.05), 4.3 ppm (integration 1.06), 4.1 ppm (integration 1.05), 3.9 ppm (integration 1.06), 3.7 ppm (integration 1.05), 3.5 ppm (integration 1.06), 3.3 ppm (integration 1.05), 3.1 ppm (integration 1.06), 2.9 ppm (integration 1.05), 2.7 ppm (integration 1.06), 2.5 ppm (integration 1.05), 2.3 ppm (integration 1.06), 2.1 ppm (integration 1.05), 1.9 ppm (integration 1.06), 1.7 ppm (integration 1.05), 1.5 ppm (integration 1.06), 1.3 ppm (integration 1.05), 1.1 ppm (integration 1.06), and 0.9 ppm (integration 1.05).







(3*R*,4*R*)- and (3*S*,4*S*)- and (3*R*,4*S*)- and (3*S*,4*R*)-3-((*S*)-2-Hydroxypropyl)-1-((*S*)-1-phenylethyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12i).

Spectral data for compound *trans*-12i are identical, only signals of the major diastereomers are more intense.



(3*R*,4*R*)- and (3*S*,4*S*)- and (3*R*,4*S*)- and (3*S*,4*R*)-3-((*S*)-2-Hydroxypropyl)-1-((*S*)-1-(naphthalen-2-yl)ethyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (**12j**). Spectral data for compound *trans*-**12j** are identical, only signals of the major diastereomers are more intense.







Chemical structure of the less polar *trans*-diastereomer is shown. The structure is a substituted pyrrolidine-2-one with a phenyl group, a methyl group, and a 1-hydroxyethyl group.

1H NMR spectrum (CDCl3) of the less polar *trans*-diastereomer. The spectrum shows peaks in the aromatic region (7.2-7.4 ppm), a broad peak for the hydroxyl group (7.2-7.4 ppm), a multiplet for the methine proton (4.8-5.0 ppm), a doublet for the methyl group (3.9-4.0 ppm), a multiplet for the methylene protons (2.6-2.7 ppm), and a sharp peak for the methyl group (1.6 ppm). Integration values are provided below the peaks.


1H NMR spectrum (CDCl3) of the less polar *trans*-diastereomer. The spectrum shows peaks in the aromatic region (7.2-7.4 ppm), a broad peak for the hydroxyl group (7.2-7.4 ppm), a multiplet for the methine proton (4.8-5.0 ppm), a doublet for the methyl group (3.9-4.0 ppm), a multiplet for the methylene protons (2.6-2.7 ppm), and a sharp peak for the methyl group (1.6 ppm). Integration values are provided below the peaks.










(3*R,4*S**)- and (3*S**,4*R**)- and (3*R**,4*R**)-(1-Allyl-3-((1*S**,2*R**)-2-hydroxycyclohexyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (12l)**





(4*S**,5*S**,6*R**)- and (4*S**,5*S**,6*S**)- and (4*R**,5*S**,6*R**)- and (4*R**,5*S**,6*S**)-2-Benzyl-4-(2-hydroxypropyl)-6-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-azaspiro[4.4]nonan-3-one (12*m*). Spectral data for compound *equil*-12*m* are identical, only signals of the major diastereomers are more intense.





(4*S**,5*S**,6*R**)- and (4*S**,5*S**,6*S**)- and (4*R**,5*S**,6*R**)-2-Benzyl-4-(2-hydroxypropyl)-6-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-azaspiro[4.5]decan-3-one (12n). Spectral data for compound *equil*-12n are identical, only signals of the major diastereomers are more intense.





(3*R,3*aR**,4*R**,6*aR**)- and (3*S**,3*aR**,4*R**,6*aR**)-1-Benzyl-3-(2-hydroxypropyl)-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)hexahydrocyclopenta[*b*]pyrrol-2(1*H*)-one (12o):**





(3*R*,3*aR*,4*R*,7*aR*)-1-Benzyl-3-(2-hydroxypropyl)-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)octahydro-2*H*-indol-2-one (12pA):





(3*R,4*R**)- and (3*S**,4*R**)-1-Allyl-3-(2-oxopropyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13b)**






(3*R,4*R**)-1-Allyl-3-(2-oxohexyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13c)**



(3*R,4*R**)-1-Allyl-3-(2-oxo-2-phenylethyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13d)**



Chemical structure of (3*R**,4*R**)-1-benzyl-2-acetyl-4-(4,4,4-trimethyl-2-oxo-1,3-dioxane-1-yl)pyrrolidine (Major diastereomer):

CC(=O)C[C@H]1C[C@@H](Cc2ccccc2)N1C3CC(C)(C)OC3(C)C

(3*R**,4*R**)

Major diastereomer

Chemical structure of (3*S**,4*R**)-1-benzyl-2-acetyl-4-(4,4,4-trimethyl-2-oxo-1,3-dioxane-1-yl)pyrrolidine (Minor diastereomer):



CC(=O)C[C@H]1C[C@@H](Cc2ccccc2)N1C3CC(C)(C)OC3(C)C



(3*S**,4*R**)

Minor diastereomer







(3*R*,4*R*)- and (3*S*,4*S*)-3-(2-Oxopropyl)-1-((*S*)-1-phenylethyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13i)









(3*R*,4*R*)- and (3*S*,4*S*)- and (3*S*,4*R*)- and (3*R*,4*S*)-1-((*S*)-1-(Naphthalen-2-yl)ethyl)-3-(2-oxopropyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13j)









(3*R,4*S**)- and (3*S**,4*R**)- and (3*R**,4*R**)-1-Allyl-3-((*R**)-2-oxocyclohexyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (13l)**













(4*S,5*S**,6*R**)- and (4*S**,5*S**,6*S**)- and (4*R**,5*S**,6*R**)- and (4*R**,5*S**,6*S**)-2-Benzyl-4-(2-oxopropyl)-6-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-azaspiro[4.4]nonan-3-one (13m)**













(4*S,5*S**,6*R**)- and (4*R**,5*S**,6*R**)- and (4*S**,5*S**,6*S**)-2-Benzyl-4-(2-oxopropyl)-6-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-2-azaspiro[4.5]decan-3-one (13n)**







(3*R,3*aR**,4*R**,6*aR**)- and (3*S**,3*aR**,4*R**,6*aR**)-1-Benzyl-3-(2-oxopropyl)-4-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)hexahydrocyclopenta[*b*]pyrrol-2(1*H*)-one (13o)**









(3*R,4*R**)-1-Allyl-4-(hydroxymethyl)-3-(2-hydroxypropyl)pyrrolidin-2-one (*trans*-14)**





((3*R,4*R**)-1-Allyl-3-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)-4-(2-hydroxypropyl)pyrrolidine (*trans*-15)**





(3aR*,4R*,6aR*)-6-Allyl-2-methyl-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)hexahydro-2H-furo[2,3-b]pyrrole (16)



(3*R,4*R**)-3-(2-Hydroxypropyl)-1-((*E*)-prop-1-en-1-yl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (S15)**



(3*R,4*R**)-3-(2-Hydroxypropyl)-4-(((2,2,6,6-tetramethylpiperidin-1-yl)oxy)methyl)pyrrolidin-2-one (*trans*-17)**



(3*R,3*aR**,6*aR**)**
Major diastereomers

(3*S,3*aR**,6*aR**)**
Minor diastereomers

Integration values: 6.33, 4.78, 0.15, 1.84, 0.88, 2.11, 0.53, 0.19, 0.44, 2.69, 1.00, 0.56, 4.16, 2.37, 6.33, 0.57



1-(((2*R*,4*S*)- and (2*R*,4*S*)-1-(Allyl(*S*)-1-(naphthalen-2-yl)ethyl)amino)-4-hydroxy-1-oxo-pentan-2-yl)oxy)-2,2,6,6-tetramethylpiperidin-1-ium chloride (S13·HCl):

